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Abstract 
 
Antibiotic resistance poses a major risk to modern medicine, therefore finding new 
antimicrobial compounds is vital.  Most currently used antibiotics originate from 
actinomycetes discovered more than half a century ago.  Previous work from the 
Hutchings laboratory led to the isolation of a new Streptomyces species named S. 
formicae from the African fungus-farming plant-ant, Tetraponera penzigi.  S. 
formicae produces novel pentacyclic polyketides, the formicamycins, that have 
potent antibacterial activity against drug-resistant pathogens including methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).  
During this work, the genes responsible for formicamycin biosynthesis in the native 
producer were identified and characterised in detail using CRISPR/Cas9-mediated 
genome editing.  In addition, we used cappable RNA- and ChIP-sequencing to 
determine the transcriptional organisation of the pathway and study the regulatory 
cascade controlling the production of- and host resistance to- these potent 
antimicrobials.  We exploited this information to generate multiple mutants of S. 
formicae that overproduce formicamycins as well as various biosynthetic 
intermediates and shunt metabolites, some of which also have bioactivity.  Attempts 
to understand the evolutionary origins of the biosynthetic pathway and the mode of 
action of these novel compounds are also presented.  Furthermore, the potential for 
novel chemistry from S. formicae is not limited to the formicamycin pathway; 
antiSMASH analysis shows this talented strain contains at least 45 secondary 
metabolite biosynthetic gene clusters (BGCs).  Under standard laboratory conditions, 
wild-type S. formicae also exhibits antifungal activity against the drug-resistant 
Lomentospora prolificans, and when the formicamycin BGC is deleted, the strain 
produces additional compounds with potent antibacterial activity against MRSA.  
Overall, this work demonstrates that searching under-explored environments for 
new species combined with genome editing is a promising route towards finding new 
anti-infectives. 
 
This thesis is 305 pages and 79 298 words in length 
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1 Introduction 
 
1.1 Antibiotics 
 
The use of antimicrobials in the treatment and prevention of disease was one of the 
most revolutionary interventions to be introduced into modern medicine.  
Antibiotics are compounds that either inhibit the growth of, or directly kill, bacterial 
cells.  They act by targeting essential cell processes within microbial cells, such as 
inhibiting biosynthesis of the cell wall (e.g. the b-lactams), preventing protein 
synthesis usually by interacting with ribosomal subunits (e.g. chloramphenicol, the 
aminoglycosides),  interacting with nucleic acids or their repair machinery (e.g. the 
fluoroquinolones, rifampicin), interfering with metabolic pathways such as fatty acid 
biosynthesis (e.g. isoniazid) or folic acid synthesis (e.g. the sulphonamides), or by 
disrupting the structure of the membrane (e.g. daptomycin) (Sultan et al., 2018).  By 
selectively targeting biochemical differences between prokaryotic and eukaryotic 
cells, antibiotics are less harmful to the host and cause relatively fewer side effects 
compared to other medicinal compounds.  In fact, antibiotics are unique amongst 
pharmaceutical agents as they can cure disease rather than simply alleviating the 
symptoms (Demain, 2009).  Most of the antibiotics that we currently use in the clinic 
were discovered more than half a century ago.  Since the beginning of this ‘antibiotic 
era’, antibiotics have been used to rapidly treat infectious diseases that were once 
commonplace, such as cholera and typhoid fever, as well as wound infections that 
might once have proved fatal.  In addition, the use of antibiotics has enabled more 
complex interventions such as organ transplant surgery and chemotherapy to be 
developed, as these immunocompromised patients can be protected from the 
potentially serious complications that could arise from infection (Livermore, 2004).   
Approximately two thirds of all the antibiotics and chemotherapeutic agents 
currently used in the clinic are derived from the natural products of soil dwelling 
actinomycetes, most notably Streptomyces bacteria (Manteca and Yagüe, 2018).  
These microorganisms are constantly having to adapt to rapidly changing 
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environments to compete for nutrients and other resources and they produce these 
molecules as part of their secondary metabolism.  Though costly, the production of 
antimicrobial secondary metabolites can provide a significant survival advantage 
over neighbouring bacteria in the competition for resources (Barke et al., 2010).  One 
of the earliest and most well publicised descriptions of an antibiotic produced 
naturally by a microorganism was in 1929 when Alexander Fleming observed an 
inhibitory substance originating from a contaminating mould that was lysing the 
bacterial cells it encountered (Fleming, 1929).  Now known as penicillin, this finding 
was the primary initiator of the ‘Golden Age’ of antibiotic discovery.  During the 
1940s and 50s, almost all currently known classes of antibacterials were discovered, 
with between 70 and 80% being isolated from Streptomyces species (Bérdy, 2005).  
The first well characterised Streptomyces natural product was streptomycin, 
described in 1943, isolated from Streptomyces griseus.  This became the first 
commercially available treatment for tuberculosis and is still used in the treatment 
of tuberculosis patients today (Ohnishi et al., 2008).  Chloramphenicol, now 
commonly used as a treatment for eye infections, was subsequently discovered from 
Streptomyces venezuelae in 1947 and is now made synthetically.  Over 9000 bioactive 
molecules have been isolated from actinomycete bacteria since the 1940s and 
around 60 are still in clinical use today (Demain, 2009).   
Despite this success, the discovery of new strains and bioactive molecules peaked in 
the 1950s due to high rates of rediscovery of already characterised compounds 
(Hover et al., 2018).  Instead, the focus turned to rational target-based design of 
synthetic compounds by pharmaceutical companies, an approach which was also 
largely unsuccessful (Peláez, 2006).  Companies came to the realisation that it was 
more profitable to invest in the development of drugs that are administered longer 
term, like statins or chemotherapeutic agents, rather than anti-infectives that are 
often only required for a few days at a time.  Furthermore, due to increasing concerns 
about antibiotic resistance, governments began restricting the use of new antibiotics 
for extreme cases of infection only, reducing potential profits from any 
developments even further (Demain, 2009).  As a result, interest in antibiotic 
development by large pharmaceutical companies has plummeted, with just four 
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companies still actively engaged in antibiotic development today (Nature 
Biotechnology, 2018).  The numbers of antibiotics approved by the Food and Drug 
Administration (FDA) in the US over the last 20 years has fallen by 56% and only three 
new antibacterial classes, including lipopeptides like daptomycin, have been 
introduced into the clinic since the 1970s (Butler and Buss, 2006).  With no new 
compounds available to treat infectious disease and pathogens rapidly developing 
resistance to the antibiotics we have available, the treatment of bacterial infections 
is becoming increasingly challenging once again. 
1.2 Antimicrobial resistance (AMR) 
 
The huge success of antimicrobial therapy in the late 1900s led to the widespread 
distribution and use of these compounds, not just in a clinical setting, but also in 
veterinary medicine and agriculture.  This extensive use means antibiotics have 
accumulated in the environment, resulting in extreme selection pressure for 
resistance to develop (Sultan et al., 2018).  Bacteria and other microorganisms can 
acquire or evolve mechanisms to resist antimicrobial toxicity by increasing the 
expression of efflux pumps to prevent accumulation of the compound in the cell, 
modifying the target so that the compound is no longer functional, or inactivating 
the antibiotic enzymatically, as in the case of the beta-lactamases (Kapoor, Saigal and 
Elongavan, 2017).  These adaptations can occur spontaneously through mutation and 
are frequently shared between bacterial species on mobile genetic elements such as 
plasmids.  This ability to undergo horizontal gene transfer, together with the 
relatively short generation times, means bacteria and other microorganisms are 
capable of evolving resistance much faster than we can generate new drugs (Ventola, 
2015).  Furthermore, antimicrobials are produced by bacteria and fungi as a part of 
their normal secondary metabolism, meaning their associated resistance genes are a 
naturally occurring phenomenon and exist in the environment all the time (Davies 
and Davies, 2010).  Resistance genes are now alarmingly widespread in the 
environment.  A global metagenomics survey found antibiotic resistance gene 
determinants (ARGDs) in all of the 71 different environments selected for testing, 
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including a secluded cave and frozen rock sediments that had likely not been exposed 
to human activity for thousands of years (Nesme et al., 2014).   
The ability of pathogenic bacteria to acquire and disseminate resistance genes 
significantly compromises the therapeutic potential of our available antibiotics.  As a 
result, we are increasingly unable to treat diseases caused by drug-resistant strains 
of bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and 
Mycobacterium tuberculosis, the causative agent of tuberculosis.  M. tuberculosis 
(also known as the tubercle bacillus or TB) often becomes multidrug-resistant (MDR-
TB) because a combination of antibiotics are usually required for substantial lengths 
of time, from six months to up to two years, and strains of extensively drug-resistant 
(XDR) TB are becoming increasingly common (Davies and Davies, 2010).  As well as 
Gram-positive bacterial pathogens, high rates of resistance to third generation 
antibiotics have been reported in Escherichia coli and Klebsiella pneumoniae isolates.  
The recent emergence of MCR-1 mediated colistin resistance in E. coli was especially 
shocking as these compounds were the last remaining antibiotics that did not appear 
to select for resistance and were therefore seen as the last resort treatment for 
persistent drug-resistant infection by Gram-negative pathogens (Liu et al., 2016).  In 
addition, it is not just bacterial pathogens that develop resistance; systemic 
infections with drug-resistant fungi also represent a major clinical challenge.  
Although mostly documented in Candida isolates, multidrug-resistance is also 
becoming a problem in many Aspergillus strains as well as in emerging human 
pathogens such as Lomentospora (formerly Scedosporium) (Wiederhold, 2017).   
One of the main drivers of AMR is the overuse of antibiotics.  Treatment by antibiotics 
is effective at removing antibiotic-sensitive bacteria from a community involved in 
infection, but resistant isolates will be left behind, meaning that during subsequent 
infections, patients are likely to be primarily colonized by bacteria that are already 
resistant to the frontline antibiotic (Ventola, 2015).  The dangers of overusing and 
misusing antibiotics have been well-known for many years; in his Nobel Prize 
acceptance speech in 1945, Fleming warned that the inappropriate use of penicillin 
would lead to more serious, drug-resistant infections that could be passed on 
through the community (Alanis, 2005).  Nevertheless, antibiotics continue to be 
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overprescribed in many countries and elsewhere remain unregulated and easily 
available both over the counter and online (Ventola, 2015).  The overuse of 
antibiotics by clinicians is reflective of the lack of available diagnostic tests at the 
point of care.  Without any information about the causative agent and the 
antimicrobial susceptibility profile, clinicians often have to use multiple antibiotics in 
the hope that one will be effective at treating the disease.  Whilst assuring better 
patient outcomes, this approach drives the development of resistance in the clinic 
(Michael, Dominey-Howes and Labbate, 2014).  Furthermore, when antibiotics are 
consumed, a large portion of the required dose is excreted in the active form and 
therefore enters waste water as sewage. Wastewater treatment plants are effective 
at removing living microorganisms from sewage but undegraded antimicrobials and 
the genetic material from treated pathogens remain.  Similarly, when farm animals 
are treated with antimicrobials, the AMR genes generated during this selection will 
enter sludge, some of which is later spread on the land and used as crop fertilizer.  
All these practices have the potential to spread ever greater quantities of AMR genes 
in the environment, contributing to the rapid spread of drug-resistant pathogens 
(Singer et al., 2016).   
AMR is generally accepted as one of the greatest threats to modern healthcare.  
Without the means to treat infections we risk entering a post-antibiotic era, where 
minor infections become fatal once again and surgical interventions cannot take 
place due to the lack of available antibiotic prophylaxis.  The 2014 report led by 
economist Lord Jim O’Neil predicted that if current rates of resistance continue, more 
than 10 million people could die from an antibiotic-resistant infection every year by 
2050, making it a bigger killer than cancer.  If AMR is not effectively controlled, it 
could also have significant economic impacts.  It is estimated that $100 trillion USD 
of economic output will be lost every year and each person in the world will be 
$10,000 USD worse off by 2050.  In order to combat this, 10 key areas were 
highlighted in the report as research priorities for the future, including better 
surveillance of resistant infections, developing rapid and accurate diagnostic tests for 
clinical use and finding new drugs with activity against resistant pathogens (O’Neil, 
2016).   
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1.3 Natural products 
 
Research has returned to natural products in an effort to discover new compounds 
with novel mechanisms of action that may be effective at treating drug-resistant 
infections.  Natural products are predicted to be better candidates for the 
development of new antimicrobials than synthetic molecules as millions of years of 
evolutionary adaptation ensures that secondary metabolites provide the greatest 
selective advantage to the producing organism.  As such they are often more 
effective at crossing the cell membranes of other bacteria and interacting with 
specific intracellular targets (Butler, Blaskovich and Cooper, 2013).  Natural products 
are often large, highly decorated molecules generated by multi-enzyme complexes, 
such as polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS), 
although some small molecules like terpenes and alkaloids also poses antimicrobial 
activity (Demain, 2009).  The genes required for making natural products are often 
clustered together in the genome of the producing organism, with the core enzyme 
machinery being adjacent to accessory enzymes, transporters and regulatory 
elements.  These biosynthetic gene clusters (BGCs) vary in size from a few thousand 
base pairs (bp) to over 100 kb (Bibb, 2005). 
1.3.1 Polyketides 
 
PKS gene clusters give rise to a large class of structurally diverse molecules, such as 
macrolides, aromatic compounds and polyenes (Hofeditz et al., 2018).  Many 
products of PKS BGCs are used as commercial antibiotics, such as erythromycin, or 
are used as a basis for the development of semi-synthetic molecules like doxycycline 
(Ward and Allenby, 2018).  Polyketides are derived from the successive 
decarboxylative condensation of multiple extender units, usually malonyl-
CoenzymeA (CoA) or methylmalonyl-CoA, to generate an elongated carbon chain of 
pre-determined length upon the incorporation of an initiating starter unit (Fischbach 
and Walsh, 2006; Rutledge and Challis, 2015).  The chain length, as well as the 
extensive modifications to the oxidation state and stereochemistry of the resulting 
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keto groups on these compounds, contribute to the high degree of structural and 
chemical diversity of polyketides (Ray and Moore, 2002).     
PKS enzymes can be classified into three distinct groups; type 1, type 2 and type 3.  
Type 1 PKS enzymes are large enzymes with distinct catalytic domains, known as 
modules, each responsible for the addition of a single extender unit and any 
modification of the associated b-keto group.  Each module therefore elongates the 
product by 2 carbons using an acyltransferase domain (AT) that loads the acyl carrier 
protein (ACP) with a single extender unit, on which the ketosynthase (KS) can then 
act to form a carbon-carbon bond between the extender unit and the growing 
product (Wang, Yuan and Zheng, 2019).  This modular architecture of T1PKSs means 
that the chain length of the final product often corresponds with the number of 
modules present in the PKS (Rutledge and Challis, 2015).  Modules may also contain 
domains that modify the b-keto group to either a hydroxyl group by the action of a 
ketoreductase (KR), to a carbon-carbon double bond by the action of a dehydratase 
(DH) or to a single carbon-carbon bond by an enoylreductase (ER) (Dutta et al., 2014).  
Analysis of the catalytic domains can predict the b-keto group modifications that will 
be incorporated, making it possible to estimate the structure of a natural product 
from the architecture of the predicted T1PKS encoded in a genome sequence 
(Rutledge and Challis, 2015).  Once the chain is extended to the pre-determined 
length (i.e. once it reaches the final module in the PKS), the ACP transfers the 
polyketide to the thioesterase (TE) unit for release from the PKS by hydrolysis before 
further modifications by accessory enzymes take place (Dutta et al., 2014).   
A good example of this modular system is the biosynthesis of erythromycin A.  The 
PKS for erythromycin A biosynthesis consists of a loading module and six extender 
modules.  The loading module is responsible for loading one propionyl-CoA starter 
unit onto the ACP.  The six extender modules then each add a single methylmalonyl-
CoA extender unit using the combined actions of the AT and the KS that catalyses the 
condensation of neighbouring extender units to form a growing polyketide chain.  
Some of the modules also encode for KR, DH and ER subunits to modify the extender 
unit that is added by modifying the oxidative state of the b-keto group as described 
above.  Once the poly-b-keto intermediate is released from the ACP by the TE, it is 
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cyclised to form 6-deoxyerythronolide B before hydroxylase, O-methyltransferase 
and glycosyltransferase enzymes form the final erythromycin A structure (Figure 
1.1).
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Figure 1.1: Erythromycin A is synthesised by a type I PKS consisting of six modules that each incorporate a methylmalonyl-CoA extender unit onto the growing polyketide 
chain.  Each extender unit is loaded onto the acyl carrier protein (ACP) by an acyltransferase (AT).  A ketosynthase (KS) domain then forms the carbon-carbon bond between 
neighbouring extender units which can be further modified by ketoreductases (KR), dehydratases (DH) and enoylreductases (ER) to change the oxidative state of the keto 
group.  Carbons in bold represent the extender unit incorporation.  Figure adapted from (Chan et al., 2009).
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In contrast, type 2 PKS gene clusters usually consist of a separately encoded ACP 
enzyme and the two subunits of the heterodimeric KS, KSa and KSb, that are used 
iteratively to generate a polyketide chain (Fischbach and Walsh, 2006).  KSa is 
responsible for the Claisen condensation between extender units while KSb controls 
the number of units incorporated, therefore it is often referred to as the chain length 
factor (Hertweck et al., 2007; Chen, Re and Burkart, 2018).  Additional 
ketoreductases, cyclases and aromatases can then act on the resulting poly-b-keto 
intermediate to generate a range of polyphenolics that can be tailored by 
oxygenases, methyltransferases, glycosyltransferases and halogenases that are also 
encoded within the BGC, much like in type 1 polyketide biosynthesis (Hertweck et al., 
2007; Rutledge and Challis, 2015).  Assembly by these pathways is considered more 
complex than Type 1 PKSs as the process relies on multiple enzymes instead of a 
single modular protein, making structural predictions difficult.  Furthermore, the 
highly unstable poly-b-keto intermediates that are generated are often 
spontaneously cyclized and therefore cannot be isolated for characterisation 
(Hertweck et al., 2007).  Type 3 PKS gene clusters use free CoA-linked thioester 
substrates without the need for an ACP (Ray and Moore, 2002). 
Type 2 PKS BGCs are employed by actinomycete bacteria to create a diverse family 
of polyphenolic compounds with a wide range of bioactivities (Figure 1.2).  Perhaps 
the most intensively studied T2PKS gene cluster is the actinorhodin BGC.  
Actinorhodin is a blue-pigmented benzoisochromanequinone antibiotic produced by 
the model actinomycete Streptomyces coelicolor (Okamoto et al., 2009; Chen, Re and 
Burkart, 2018).  The actinorhodin BGC was the first cluster of genes to be cloned and 
heterologously expressed in another organism.  It was this work that laid the 
groundwork for all natural products biochemistry being conducted today; the fact 
that a non-producing strain of Streptomyces could produce the compound without 
lethality on introduction of the 35 kb chromosomal fragment meant that all the 
genes for biosynthesis, regulation and host-resistance were all clustered together 
(Malpartida and Hopwood, 1984).  Actinorhodin is often studied today as the model 
secondary metabolite from Streptomyces because its distinct blue colour means that 
production levels can easily be quantified.  The tetracyclines also originate from 
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T2PKS pathways in multiple Streptomyces species and are one of the most important 
antibiotic classes to modern medicine.  These broad spectrum antibiotics inhibit both 
Gram-positive and Gram-negative pathogens by blocking the attachment of tRNA to 
the ribosomal acceptor (A) site, thereby preventing protein synthesis (Chopra and 
Roberts, 2001).  Another example is doxorubicin, an anthracycline made by a T2PKS 
pathway in Streptomyces peucetius, that has potent anticancer activity due to its 
ability to intercalate DNA.  Compounds of this class can also inhibit the activity of 
DNA topoisomerase enzymes, giving them antibacterial activity as well (Marinello et 
al., 2018).   
 
Figure 1.2: Example structures of natural products with antibiotic activity that originate from T2PKS 
pathways. 
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1.3.2 Non-ribosomal peptides 
 
NRPSs are large, multifunctional mega-proteins responsible for the biosynthesis of a 
significant subclass of peptide natural products.  Like polyketide synthases, NRPS 
complexes have a highly organised architecture where individual catalytic domains 
are responsible for the incorporation and modification of a single monomer unit onto 
the growing peptide chain.  The major difference here is that the monomers are 
amino acids instead of carboxyl groups (Hur, Vickery and Burkart, 2012; Singh, 
Chaudhary and Sareen, 2017).  Much like polyketide synthases, NRPSs can be 
classified into three groups.  Type A NRPS biosynthesis occurs in a linear manner 
where the number of modules present in the synthetase determines the number and 
order of the amino acids in the final peptide product (Hur, Vickery and Burkart, 2012).  
A minimal module consists of an adenylation (A) domain responsible for selecting the 
amino acid monomer, a condensation (C) domain which forms the peptide bond 
between the amino acids and a thiolation (T) domain, also known as the peptidyl 
carrier protein (PCP) which acts as a carrier and holds the growing peptide chain in 
place while it is modified by downstream enzymes (Fischbach and Walsh, 2006; Hur, 
Vickery and Burkart, 2012; Singh, Chaudhary and Sareen, 2017).  The process of 
activation and condensation of amino acids is repeated until the final module 
containing the thioesterase (TE) domain is reached, where the peptide chain will be 
released by hydrolysis (Figure 1.3) (Singh, Chaudhary and Sareen, 2017).  During type 
B biosynthesis, modules or domains of the synthetase are used iteratively to 
synthesise the final product, which will consist of multiple repeated peptide 
sequences.  Finally, type C NRPS clusters are non-linear and generate peptide 
sequences that are independent of the modules present in the synthetase (Hur, 
Vickery and Burkart, 2012).  
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Figure 1.3 NRPSs consist of multiple modules encoding an adenylation (A) domain for selecting the amino acid monomer, a condensation (C) domain that forms peptide 
bonds between amino acid monomers and a peptidyl carrier protein (PCP) domain to hold the growing peptide product.  During this modular peptide biosynthesis, each 
module adds a single amino acid to the growing peptide chain until the thioesterase (TE) domain is reached.  In this example, the cyclic lipopeptide surfactin is synthesised 
by the modular NRPS encoded by Bacillus subtilis.  Once released from the NRPS, the peptide chain is cyclised to form the final product. Figure adapted from (Martínez-Núñez 
and López, 2016).
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NRPS natural products also represent a hugely diverse class of chemical structures.  
In addition to the variety of available A domains, NRPSs can incorporate both L-and 
D-amino acids into the peptide using the action of epimerization enzymes (Fischbach 
and Walsh, 2006; Singh, Chaudhary and Sareen, 2017).  The presence of D-amino 
acids provides the stereochemical constraints for proper modification of the peptide 
chain by downstream tailoring domains.  As more amino acids are incorporated into 
polypeptide chain, cysteine, serine and threonines can be modified by cyclisation 
domains to form heterocyclic rings which can be further reduced or oxidised to 
generate additional structural diversity.  Tailoring enzymes can also incorporate 
sugars and fatty acids to the peptide chain, further altering both the structure and 
the biological activity of the resulting natural product (Hur, Vickery and Burkart, 
2012).  Some NRPS BGCs have also been shown to diverge from the typical ‘rules’ 
described above and instead of following a linear biosynthetic pathway, modules can 
be skipped or used iteratively to create further diversity between structures.  An 
example is in the biosynthesis of the siderophore coelichelin, from the tri-modular 
cch gene cluster of S. coelicolor, where the first module is used iteratively to 
incorporate two copies of the same residue into the peptide, and the second module 
is skipped in one of these iterations to form a direct linkage between the amino acid 
substrates from the first and third modules (Corre and Challis, 2009). 
Glycopeptide antibiotics like vancomycin, that are invaluable for the control of Gram-
positive infections in the clinic, are synthesised by Type A NRPS BGCs (Felnagle et al., 
2008).  This diverse group of compounds is characterised by high levels of crosslinking 
between the amino acids present in the peptide.  Glycopeptides inhibit biosynthesis 
of the bacterial cell wall by interacting with both peptidoglycan and Lipid II.  This 
distinct mechanism of action means that resistance to glycopeptides usually evolves 
more slowly than other classes of antibiotics as pathogens are unable to respond by 
upregulating transporters or mutating target enzymes (Yim et al., 2014).  
Nevertheless, strains of vancomycin-resistant Enterococci now present a major 
clinical challenge, so the discovery of new glycopeptide antibiotics is considered of 
high importance.   
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Recently, several novel NRPS natural products have been discovered that represent 
promising advances in the search for new antibiotics with activity against drug-
resistant infections (Figure 1.4).  For example, daptomycin is a natural product from 
an NRPS BGC in Streptomyces roseosporus initially discovered in the early 1980s (Hur, 
Vickery and Burkart, 2012; Singh, Chaudhary and Sareen, 2017).  The biosynthesis of 
daptomycin is interesting as it is initiated by the condensation of the N-terminal 
amino acid, tryptophan, with a long-chain b-OH fatty acid (Fischbach and Walsh, 
2006; Wittmann et al., 2008).  The presence of the fatty acid side chain means that 
when calcium ions bind to the cyclic peptide, daptomycin can insert itself into the 
bacterial cell membrane, perforating it and causing cell death.  This mechanism of 
antibacterial activity is unique and makes daptomycin a valuable treatment against 
drug-resistant infections, particularly vancomycin-resistant MRSA (Hur, Vickery and 
Burkart, 2012).  The recent discovery of teixobactin also gained much attention from 
both scientists and the public as it represented a new class of antibiotics.  Teixobactin 
was discovered using the iChip, a new tool used to screen for microorganisms that 
cannot be grown using standard microbiological approaches, a group that is thought 
to represent over 99% of all microorganisms on Earth (Nichols et al., 2010; Ling et al., 
2015; Piddock, 2015).  Teixobactin is a peptide antibiotic consisting of eleven amino 
acid residues, including seven L-amino acids and four D-amino acids, synthesised by 
two large NRPS genes in the previously unknown b-proteobacterium Eleftheria 
terrae.  Teixobactin shows potent antimicrobial activity against MRSA, vancomycin-
resistant Enterococcus (VRE), penicillin-resistant Streptococcus pneumonia, 
Clostridium difficile and M. tuberculosis and does not produce resistant mutants 
under laboratory conditions.  Teixobactin is predicted to inhibit peptidoglycan 
biosynthesis by binding lipid II, however the mode of action and the potential 
resistance mechanisms are yet to be extensively investigated (Guo et al., 2018).  
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Figure 1.4: Example structures of natural products with antibiotic activity that originate from NRPS 
pathways.  
 
1.3.3 Ribosomally synthesised natural products 
 
PKS and NRPS BGCs are relatively easy to identify in actinomycete genomes due to 
their characteristic modular organisation.  The increased availability of genome 
sequence data in recent years has also revealed the range of unexplored 
biochemistry available from Ribosomally synthesised and Post-translationally 
modified Peptides, known as RiPPs.  The first RiPPs to be identified were the 
bacteriocins, a diverse family of small peptides produced by more than 99% of 
bacteria in order to kill or inhibit the growth of other microorganisms during normal 
environmental competition (Devine, Hutchings and Holmes, 2017).  Several key 
properties of bacteriocins, such as their heat-stability and the fact that they are 
sensitive to proteases and therefore generally harmless to humans and the 
environment, mean that bacteriocins have been widely used to treat bacterial 
infections, aid cancer treatments and extend the shelf-life of food products (Yang et 
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and have been the subject of many natural product discovery efforts in recent years.  
This structural diversity originates from the variety of post-translational 
modifications that can occur on these peptides and contributes to the wide-ranging 
activity displayed by these compounds (Ortega and Van Der Donk, 2016).   
Most RiPPs are encoded as relatively simple precursor peptides usually consisting of 
an N-terminal leader region, which contains a recognition site for downstream 
enzymes, and a C-terminal core which becomes the mature compound after post-
translational modification.  The leader peptide is removed by proteases, so does not 
become part of the final product, but the physical separation of the recognition 
sequence and the core peptide means that a variety of different core peptides can 
be modified by individual enzymes in a biosynthetic pathway (Ortega and Van Der 
Donk, 2016; Hudson and Mitchell, 2018).  A wide variety of remarkable structures 
have been described that originate from these ribosomally synthesised peptides.  For 
example, the lasso-peptides are bioactive compounds with a characteristic 
‘threaded-loop’ structure where the C-terminal peptide tail is threaded through a 
macrolactam ring formed at the N-terminal.  Thiopeptides like thiostrepton from 
Streptomyces azureus, are macrocyclic peptides that all contain a central six-
membered nitrogen-containing ring and lanthipeptides such as nisin contain the 
thioether amino acids lanthionine of 3-methyllanthionine formed by the dehydration 
and subsequent thiolation of selected serine and threonine residues (Ortega and Van 
Der Donk, 2016; Hudson and Mitchell, 2018).  Perhaps the most complex of the RiPPs 
are the bottromycins, that contain a macrocyclic amidine, several non-proteinogenic 
amino acids, three b-methylated amino acids and a thiazole.  The biosynthesis of the 
bottromycins is unusual amongst RiPPs as they use a C-terminal follower peptide 
instead of the N-terminal leader peptide to encode the recognition sequence for 
post-translational processing.  These complex molecules represent a promising new 
class of antibiotics with broad ranging activity against drug resistant pathogens 
(Figure 1.5) (Crone, Leeper and Truman, 2012; Gomez-Escribano et al., 2012).  
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Figure 1.5: Example structures of ribosomally synthesised natural products with antibiotic activity.   
1.3.4 Discovering the natural product antibiotics of the future 
 
Genes encoding the biosynthetic machinery for antimicrobial secondary metabolites 
are found in many microorganisms, but the actinomycetes are best known for the 
diversity of molecules they are able to produce.  Recent advances in genome 
sequencing technologies has revealed that most actinomycetes encode many more 
natural products than previously identified, but only a fraction of these BGCs are 
expressed under standard laboratory conditions.  Even though microbiologists and 
natural products chemists have been studying the model actinomycete, 
Streptomyces coelicolor, since the 1960s, only five antibiotic gene clusters were 
characterized in any detail before the early 2000s.  When the full genome sequence 
of the strain was published in 2002, it was revealed the strain actually contained the 
genetic information for around 30 secondary metabolites (Bentley et al., 2002; 
Challis, 2014; van Keulen and Dyson, 2014; Ward and Allenby, 2018).  This discovery 
regenerated the process of natural product discovery by introducing an era of 
‘genome mining’.  This term is now used to cover a breadth of secondary metabolite 
analysis including the identification and structural elucidation of new compounds 
from a producing organism, the bioinformatic prediction of gene products and 
pathways and the study of the regulatory control of biosynthetic pathways (O 
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Bachmann, Van Lanen and Baltz, 2014).  The relative explosion of bacterial genome 
sequencing in recent years has made identifying BGCs encoding for novel natural 
products easier than ever before.  Upon completion of a new genome sequence, 
bioinformatic tools like AntiSMASH can be used to search for genes that may be 
responsible for the synthesis of these complex molecules by searching for certain 
known characteristics of these BGCs (Weber et al., 2015).  The focus now is on 
identifying novel compounds from both old and new bacterial strains with an 
emphasis on developing more sophisticated screening methods in order to prevent 
rediscovery (Manteca and Yagüe, 2018).   
1.4 The genus Streptomyces 
 
Streptomyces are filamentous, Gram-positive bacteria of the order Actinomycetales, 
whose members are commonly known as actinomycetes.  These saprophytic 
organisms are obligate aerobes and are among the most numerous bacteria found in 
the soil (Bentley et al., 2002).  As a genus, Streptomyces dominate the bacterial world 
in the large variety of secondary metabolites they produce, from signalling molecules 
to antimicrobials.  They are responsible for the production of about 80% of all known 
bioactive natural products (Demain, 2009).  Although Streptomyces species have 
been intensively screened for novel natural products since the Golden Age of 
antibiotic discovery, efforts intensified after genome sequencing data showed most 
strains can produce many more antibiotics than previously thought.  Sequencing of 
the relatively large genomes of Streptomyces bacteria has shown that each strain 
contains between 20 and 60 secondary metabolite gene clusters, even though most 
only produce a few of their encoded secondary metabolites under standard 
laboratory conditions.  This means that the majority of the chemistry available from 
these organisms is yet to be discovered (Watve et al., 2001; Kemung et al., 2018).  
The challenge now is to identify novel BGCs and encourage production of the 
encoded compounds in the laboratory.  By drawing connections between secondary 
metabolites and the gene sequences that encode them, we can gain more of an 
insight into how these compounds contribute to the basic biology of the producing 
organisms and the role these molecules play within their natural environments.  
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Together, these approaches will allow the expression of novel natural products in the 
laboratory and lead to the discovery of new antimicrobials (O Bachmann, Van Lanen 
and Baltz, 2014). 
1.4.1 Streptomyces biology 
 
Most of what we know about the complex, multicellular developmental stages of 
Streptomyces growth comes from the extensive investigation of the model 
organisms, S. coelicolor and, more recently, S. venezuelae which sporulates rapidly 
even in liquid culture.  Streptomyces species grow as multi-cellular branched 
filaments that form a mass of fungus-like mycelium.  In fact, the name Streptomyces 
means ‘twisted fungus’ due to their appearance under the light microscope 
(Hopwood, 2007).  Streptomyces hyphae originate from the germination of a single 
spore that produces vegetative mycelium comprised of branching filaments that 
grow outwards by polar tip extension in order to scavenge for nutrients (Bush et al., 
2015).  Under nutrient-rich conditions, dense mycelial growth can be achieved as 
streptomycetes can break down the insoluble remains of other organisms in the soil 
environment, including lignocellulose and chitin (Bentley et al., 2002).  From these 
vegetative mycelium, reproductive aerial hyphae emerge that are coated in a 
hydrophobic sheath which allows the hyphae to escape the aqueous environment of 
the vegetative mycelium.  When aerial hyphae are formed, chromosome replication 
and segregation occurs, followed by cell division and cell wall assembly.  This highly 
synchronised and tightly regulated process differentiates the multi-genomic hyphae 
into a long chain of uni-genomic pre-spores, separated by multiple septa that form 
along the chain.  On receipt of appropriate environmental signals, these pre-spore 
compartments will mature and be released as dormant, thick-walled spores, that will 
only germinate when conditions are suitable for the growth of new vegetative 
mycelium (Figure 1.6) (Bush et al., 2015). 
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Figure 1.6: Life cycle of Streptomyces species. Under nutrient rich conditions, single spores 
germinate and form vegetative hyphae which grow out into the soil. Upon nutrient starvation, aerial 
hyphae are then erected, which differentiate into a long chain of pre-spores, each containing a single 
chromosome.  Once the spores have matured, they are dispersed into the environment where they 
lay dormant until conditions favour germination.  Figure adapted from (Bush et al., 2015). 
Streptomyces spores are ubiquitous in soils around the world.  The soil is a 
particularly complex and variable environment, made up of highly mixed microbial 
communities that are all competing for nutrition and physical space.  As well as 
allowing streptomycetes to survive these harsh environments, the formation of 
desiccation-resistant spores allows the otherwise non-motile mycelium to disperse 
to more favourable environments under competition and other environmental 
stressors  (Bentley et al., 2002; Bush et al., 2015).  The production of a wide array of 
secondary metabolites also gives Streptomyces species a distinct advantage in these 
harsh conditions.  Secondary metabolites are non-essential for growth and are 
usually made after vegetative growth, as the organism is entering the sporulation 
stage.  Their range of biological activities contributes to the inhibition of other 
microorganisms present in the surroundings that may be competing for the same 
nutrients, as well as signalling between microbes or triggering differentiation and 
transporting metal ions.  The ability of streptomycetes to produce antimicrobial 
secondary metabolites also means these strains are often able to colonize plant roots 
and protect the host plant against pathogens.  In return, the Streptomyces bacteria 
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acquire rich nutrients from the plant, again contributing to a survival advantage 
(Challis and Hopwood, 2003). 
Streptomyces DNA has an unusually high GC content, often over 70%, and is 
structured in large, linear chromosomes.  Their genomes range in size between 7 and 
11 Mb and the chromosome contains a large number of genes enabling these 
bacteria to compete in the dynamic soil environment (Hopwood, 2006).  Most of the 
essential genetic material responsible for cell growth and development is located at 
the centre of the chromosome, with a remarkable number of genes in this region 
being highly conserved between Streptomyces species and other actinomycetes.  In 
contrast, around 1-2 Mb at either end of the chromosome consists of highly variable 
DNA sequences, often containing the BGCs for secondary metabolite production.  
High rates of lateral DNA transfer between Streptomyces and other species can take 
place at these chromosome arms, allowing for the exchange of secondary metabolite 
biosynthesis genes, resistance genes and regulatory elements and ultimately, the 
evolution of new BGCs.  Horizontally acquired genes that provide a sufficient 
selective advantage can make their way towards the more stable, central region of 
the chromosome over time to become a more permanent part of the genome 
(Chater and Chandra, 2006).   
1.4.2 Regulation of antibiotic production in Streptomyces 
 
1.4.2.1  Linking growth and development to secondary metabolism 
 
As described above, the production of secondary metabolites by Streptomycetes 
generally begins during the development of aerial hyphae and continues during 
sporulation.  The links between these processes are complex and tightly regulated by 
multiple gene families.  The bld gene family of regulators are involved in the precise 
control of multiple developmental processes, in particular the erection of aerial 
hyphae, but they have also been shown to play a role in the control of secondary 
metabolite production (Bibb, 2005).  For example, the DNA binding protein BldD 
interacts with cyclic di-GMP to repress around 170 genes involved in sporulation 
during vegetative growth including genes encoding for vital components of cell 
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division, chromosome segregation and septation formation (Bush et al., 2015).  The 
BldD-cyclic di-GMP complex also indirectly affects antibiotic biosynthesis in 
Streptomyces by interacting with other bld regulators such as BldC, a small DNA-
binding protein that controls transcription of genes within multiple secondary 
metabolite gene clusters.  BldD-cyclic di-GMP can also control the expression of 
biosynthetic genes directly by binding to promoter regions within BGCs itself (Hengst 
et al., 2010).  The onset of aerial growth can be triggered by variations in multiple 
conditions such as the availability of nutrients in the environment, changes in 
metabolism and extra-cellular signals, all of which will also affect secondary 
metabolism.  For example, AdpA is a transcriptional regulator of a large number of 
sporulation genes that also regulates secondary metabolite BGCs in response to the 
accumulation of an extracellular hormone-like molecule, g-butyrolactone (GBL) 
which is often an indicator of competing microorganisms in the surrounding 
environment (Chater, 2016).   
Although produced during secondary metabolism, the biosynthesis of antimicrobials 
depends on precursors and cofactors that are derived from the primary metabolism, 
therefore nutrient availability and secondary metabolism are tightly linked.  
Streptomyces contain a “stringent response” where, during environmental stress, 
gene transcription is modulated to divert resources away from growth and division 
and towards amino acid biosynthesis and/or fatty acid biosynthesis to promote 
survival.  This response is regulated by the nucleotide guanosine tetraphosphate 
(ppGpp), which modulates transcription by binding to RNA polymerase.  The 
concentration of ppGpp increases as nutrients are used up, inducing the transcription 
of antibiotic biosynthesis genes, therefore increasing the survival advantage of 
Streptomyces against any other microorganisms that might be in the environment 
and competing for the limited nutrients (Bibb, 2005; Rutledge and Challis, 2015).  The 
availability of carbon, nitrogen and phosphate in the environment have all been 
shown to affect both morphological differentiation and secondary metabolism in 
Streptomyces.  The mechanisms underpinning this remain unclear and are beyond 
the purpose of this thesis, however, it is important to recognise the importance of 
global regulatory systems in Streptomyces species that can modulate the primary 
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metabolism and limit the availability of biosynthetic precursors for secondary 
metabolite biosynthesis (Romero-Rodríguez et al., 2017).   
1.4.2.2 Two component systems 
 
Two-component systems (TCS) allow bacteria to change their intracellular processes 
in response to environmental stimuli by activating or repressing the transcription of 
specific genes.  A classical TCS consists of a sensor histidine kinase, often membrane 
associated to allow bacteria to respond to extracellular signals, and an associated 
cytoplasmic response regulator (Jacob-Dubuisson et al., 2018).  In these classical TCS, 
the sensor kinase comprises an extra-cytoplasmic domain that responds to specific 
environmental stimuli, flanked by two transmembrane helices.  On receipt of an 
activating signal, a conserved histidine residue in the kinase is autophosphorylated 
using ATP.  This phosphate is then transferred to a conserved aspartate in the 
receiver domain of the corresponding response regulator, which can then alter gene 
transcription using the effector domain, usually via DNA-binding.   
Streptomyces species generally encode a large number of TCSs, even considering 
their relatively large genome size, presumably to allow them to adapt to their 
competitive natural environment (Hutchings et al., 2004).  Many of the highly 
conserved TCSs found in Streptomyces genomes have been characterised in model 
organisms such as S. coelicolor, S. lividans and S. venezuelae.  During this work, 
numerous TCSs have been implicated in the control of secondary metabolite 
production.  For example, many secondary metabolites are only produced under 
phosphate-limited conditions.  Phosphate levels are sensed by the membrane-
associated PhoR sensor kinase.  Under low phosphate conditions, PhoR activates the 
DNA-binding response regulator PhoP.  Mutants lacking phoP (or phoR and phoP in 
combination) have been shown to overproduce the antibiotics actinorhodin and 
undecylprodigiosin (Martín, 2004).  Similarly, the AfsQ1/Q2 system has been shown 
to activate the biosynthesis of actinorhodin, calcium-dependent antibiotic, 
undecylprodigiosin and coelimycin through the binding of the AfsQ1 response 
regulator to multiple promoter regions within the relative BGCs.  AfsQ1 has also been 
shown to regulate production of the sigma factor SigQ, a negative regulator of 
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antibiotic production divergently transcribed from afsQ1/2 (Rodríguez et al., 2013; 
Chen et al., 2016).  Mutation of the CutRS TCS also results in overproduction of 
actinorhodin, although the mechanism of this is so far unknown (Hutchings et al., 
2004; Rodríguez et al., 2013).  The signals needed to activate the majority of TCSs 
also remain unknown; for example, MtrAB is a highly conserved TCS that regulates 
global expression of genes involved in DNA replication, cell division and antibiotic 
biosynthesis, but no external stimulus has yet been identified (Som et al., 2017).  
Usually the genes encoding the sensor kinase and the corresponding response 
regulator are adjacent in the genome, however this is not always the case, leading to 
some unpaired sensor kinases and orphan response regulators of unknown function 
in Streptomyces genomes (Hutchings et al., 2004). 
1.4.2.3 Cluster situated regulators 
 
In addition to being under the control of global regulators, most secondary 
metabolite BGCs also contain cluster situated regulators (CSRs) that regulate the 
expression of genes within the cluster.  These CSRs are often under the control of 
higher regulatory systems like the ones described above (Bibb, 2005).  Some clusters, 
like the actinorhodin cluster, only contain a single regulatory gene, whereas others 
encode multiple regulators, some of which activate and others that repress 
production of the metabolite (Aigle and Corre, 2012).  Some CSRs can also cross-
regulate the expression of genes located in other BGCs elsewhere in the genome 
(Rodríguez et al., 2013).  An example is JadR1 in S. venezuelae, the main activator of 
the jadomycin BGC, which has also been shown to repress chloramphenicol 
biosynthesis (Chater, 2016).  Many CSRs characterised in Streptomyces species 
encode for proteins belonging to the Streptomyces antibiotic regulatory protein 
(SARP) family, all consisting of a winged helix-turn-helix motif responsible for DNA 
binding, that recognise heptameric repeats within the promoter regions of the genes 
they regulate (Bibb, 2005; Aigle and Corre, 2012).  Other CSRs belong to the LuxR 
family of proteins and are referred to as large ATP-binding regulators of the LuxR 
family (LAL) regulators.  These regulators contain an N-terminal nucleotide 
triphosphate (ATP/GTP) binding motif and a LuxR-like helix-turn-helix motif at the C-
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terminus for DNA binding (Bibb, 2005; Lu et al., 2017).  The FscRI regulator is a LAL 
regulator situated in the candicidin BGC that controls expression of both the 
candicidin BGC and the antimycin BGC in S. albus.  Other common families of 
regulatory proteins found within Streptomyces BGCs include the LysR and TetR 
families (van der Heul et al., 2018).  Some clusters also contain their own cluster-
situated TCS that are involved in activating or repressing transcription of genes within 
that BGC.  An examples is the TCS cinKR that controls expression of genes within the 
cinnamycin BGC in Streptomyces cinnamoneus DSM 40646 (O’Rourke, Widdick and 
Bibb, 2017).   
Antibiotics themselves can also act as regulators of secondary metabolism.  Many 
CSRs bind to ligands such as biosynthetic products or intermediates in order to cause 
changes in the expression of the same or another BGC.  For example, JadX, another 
regulator of the jadomycin BGC can interact with both jadomycins and 
chloramphenicol and deletion of the jadX gene affects production levels of both 
compounds (Xu et al., 2010; Chater, 2016).  MarR regulators, named after the 
Multiple antibiotic resistance Regulators in E. coli, are a family of transcription factors 
found throughout bacteria; they exist as homodimers where each monomer 
contributes a winged helix-turn-helix DNA binding motif.  MarR proteins often 
repress transcription of the genes they regulate by binding to palindromic DNA 
sequences within promoter regions.  They are well known to also bind small molecule 
ligands or phenolic compounds, however, unusually for CSRs, MarR regulators bind 
DNA and ligands in the same domain.  On ligand binding, there is a conformational 
change in the transcription factor that changes the interaction with DNA and 
therefore affects target gene expression.  Where MarRs are responsible for the 
regulation of biosynthetic enzymes, the ligand is often the substrate of the enzyme 
or a closely related compound.  MarR regulators are also commonly involved in 
regulating genes that control the export of antibiotics, such as drug efflux pumps, 
and therefore the associated ligand is often the molecule required for export (Grove, 
2017).  
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1.5 Tools for genome mining and natural product discovery in Streptomyces 
 
Traditional methods of searching for new natural products primarily consists of 
growing the antibiotic-producing microorganism in pure culture in a laboratory and 
screening the culture extract for bioactivity.  This approach gives low returns and high 
rates of rediscovery (Rutledge and Challis, 2015).  Understanding the biology of 
antibiotic-producers and the ways in which they regulate the biosynthesis of their 
secondary metabolites can help to unlock the potential novel biochemistry encoded 
in cryptic BGCs (Aigle and Corre, 2012).  BGCs that are silent under laboratory 
conditions are more likely to be a source of compounds with novel chemical 
structures and could therefore be useful in the treatment of drug-resistant infections 
(Corre and Challis, 2007). 
1.5.1 Pleiotropic methods of inducing secondary metabolism 
The tight regulatory control of secondary metabolism means that many BGCs are not 
expressed under laboratory conditions due to missing signals from the surrounding 
environment.  By triggering global changes in gene regulation, the expression of 
multiple BGCs can be affected in a pleiotropic manner.  Although unpredictable, this 
can allow for the discovery of novel natural products from organisms that are less 
well-studied and where the regulation of specific BGCs is not well understood.  One 
of the simplest ways to induce global changes in bacterial gene expression is to 
change the growth conditions; perhaps by using different constituents in the growth 
media, including or omitting various trace elements, or cultivating the strain with 
extracts of soil in order to replicate the natural environment (Rutledge and Challis, 
2015; Devine, Hutchings and Holmes, 2017).  Strains of interest can also be co-
cultured with other microorganisms to encourage competition and therefore 
production of secondary metabolites, for example, cultivation of S. coelicolor with 
the predatory microbe Myxococcus xanthus significantly increases the production of 
actinorhodin (Pérez et al., 2011).  Streptomycetes that are co-cultured with mycolic 
acid-containing bacteria often begin producing secondary metabolites, for example 
the production of the red antibiotic undecylprodigiosin in S. lividans and the 
discovery of the novel antibiotic alchivemycin A, produced by Streptomyces endus in 
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response to Tsukamurella pulmonis (Onaka et al., 2011).   Co-culture of 
actinomycetes with fungal isolates is also particularly successful at inducing the 
production of novel secondary metabolites.  N-acetyl glucosamine is the monomeric 
form of chitin, a major component of fungal cell walls and insect cuticles which is 
therefore abundant in the soil.  N-acetylglucosamine has been shown to increase the 
biosynthesis of secondary metabolites via the global regulator DasR (Martín et al., 
2010). Adding N-acetylglucosamine to the growth media is an approach that has 
been used to increase the production of antimicrobials including enhancing 
actinorhodin production in S. coelicolor (Abdelmohsen et al., 2015).  Whilst screening 
a strain under numerous conditions may seem like a daunting task using traditional 
culturing techniques, modern advances such as the development of microfluidic 
devices makes antibiotic discovery using these methods more high-throughput than 
ever before (Baltz, 2018). 
Various physical and chemical methods can also be used to induce mutations in 
producing organisms that can permanently alter the secondary metabolite profile.  
Chemical mutagenesis using N-methyl-N’-nitro-N-nitrosoguanidine (MNNG), ethyl 
methanesulfonate (EMS), or nitrous acid (NA) can generate strains with high levels 
of secondary metabolite production, as well as physical mutagenesis by ultraviolet 
light or X-rays (Baltz, 2015).  The use of histone deacetylase inhibitors activates gene 
expression in fungi by unwinding the DNA from the histones and increasing 
transcription. This method has also been used in actinomycetes such as 
Pseudonocardia and Streptomyces strains from fungus-farming ants where the 
addition of sodium butyrate to the growth media induced the expression of 
antifungal gene clusters, however the activation mechanism in these bacteria is 
unknown (Moore et al., 2012; Seipke et al., 2012).  An alternative approach is to 
select for mutations in genes encoding RNA polymerase and ribosomal proteins in 
order to upregulate the transcription and translation of cryptic BGCs.  Mutations in 
the RNA polymerase beta-subunit (rpoB) and the ribosomal S12 protein (rpsL) can be 
selected for by culturing strains on either rifampicin or streptomycin, respectively 
(Ochi and Hosaka, 2013).  In a study of over 1000 actinomycetes isolated from soil, 
43% of the non-producing Streptomyces species gained the ability to produce 
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antibiotics after a selection on either rifampicin or streptomycin, and by sequentially 
introducing different mutations in the same strain, up to 180-fold higher levels of 
secondary metabolite production have been seen in some organisms (Wang, Hosaka 
and Ochi, 2008; Hosaka et al., 2009).  Mutation of global regulators can also be 
effective at increasing secondary metabolism; deletion of mtrB results in increased 
chloramphenicol production in S. venezuelae and deletion of dasR in S. coelicolor 
induces a cryptic T1PKS cluster (Aigle and Corre, 2012; Som et al., 2017).  However, 
modifying global regulatory machinery can have detrimental effects on the growth 
and development of the producing organism and may therefore not be optimal for 
industrial-scale antibiotic production.  
1.5.2 Genome editing of BGCs for discovery of novel natural products 
 
Although effective, pleiotropic methods of inducing secondary metabolism are 
unpredictable and often result in the production of a complex mixture of 
metabolites, making isolation and structural identification of novel compounds 
difficult.  Ideally, clusters of interest would be studied in isolation to build an accurate 
picture of the molecules synthesised by the specific pathway.  With the increased 
availability of genomic data, it is possible to estimate the structure of some 
secondary metabolites by looking at the modules encoded in the predicted BGCs.  
However, caution must be taken as even high-quality genomes can contain errors in 
these highly repetitive regions of sequence.  Furthermore, it is extremely difficult to 
predict any structural features of products from iterative pathways due to the nature 
of their biosynthesis, so it is usually necessary to express the genes and isolate the 
metabolite(s) produced (Rutledge and Challis, 2015).  Because the genes for 
biosynthesis, regulation and transport of antibiotics are very often located together 
in the genome, one experimental approach to determine the product of a novel BGC 
is to heterologously express the pathway in an organism that has been optimised for 
the production of secondary metabolites.  This can be beneficial if the BGC of interest 
is in an environmental isolate where not much is known about the optimal culture 
conditions, or where the producing organism is never isolated, as in the case of 
metagenomics studies (Feng, Kallifidas and Brady, 2011; Baltz, 2015).  Multiple 
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heterologous hosts have been generated in model Streptomyces strains, including S. 
coelicolor, by deleting BGCs for known antibiotics that are produced in vitro to 
remove competing sinks of carbon and nitrogen sources required for antibiotic 
biosynthesis, and introducing mutations in the ribosomal and RNA polymerase 
machinery to pleiotropically increase secondary metabolism (Gomez-Escribano and 
Bibb, 2011).  Gene clusters of interest can either be captured using TAR cloning or 
artificial chromosome libraries for heterologous expression within the optimised 
host (Nah et al., 2017).  Whilst this approach has been effective for the discovery of 
multiple novel natural products, production levels are often low and many clusters 
are not expressed at all outside of the native host (Gomez-Escribano and Bibb, 2011; 
Baltz, 2015).  Furthermore, this approach does not allow for methods of cross-cluster 
regulation to be investigated, as other native BGCs are not present in the 
heterologous host (Mclean et al., 2019).  For these reasons, it is often preferable to 
genetically modify the regulatory machinery within the producing organism in order 
to upregulate BGC expression. 
Until recently, genome editing in streptomycetes was commonly achieved through 
homologous recombination, a method that is considered both time- and labour- 
intensive in comparison with the genetic modification of other microorganisms, 
especially if an unmarked mutant is required (Tong, Weber and Lee, 2018).  Recently 
however, highly-efficient tools such as CRISPR/Cas9-mediated genome editing have 
been developed for Streptomyces species.  The CRISPR/Cas system is a form of 
acquired immunity in bacterial cells where Clustered Regularly Interspaced Short 
Palindromic Repeat (CRISPR) sequences from viruses that have previously infected 
cells are used to recognise foreign DNA during subsequent infections so that they can 
be destroyed by nucleases.  In recent years, this system has been developed for 
generating double stranded breaks in DNA to facilitate targeted genome editing in 
multiple species (Jiang et al., 2013).  The pCRISPomyces-2 system is one example of 
a CRISPR/Cas9 system that has been developed specifically for genome editing in 
Streptomyces species.  CRISPR/Cas9-mediated genome editing requires three 
components; a Cas9 nuclease enzyme, a short CRISPR RNA (crRNA) to confer target 
site specificity and a trans-activating CRISPR RNA (tracrRNA) to process crRNA and 
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recruit the Cas9 enzyme.  The pCRISPomyces-2 system uses a codon-optimised Cas9 
nuclease from Streptococcus pyogenes to generate a double-stranded break at a 
specified DNA site, known as a protospacer.  Any site can be targeted, so long as the 
required protospacer-adjacent motif (PAM) sequence is present at the 3’ end.  For 
the S. pyogenes Cas9, this PAM sequence must be NGG, where N is any nucleotide.  
As Streptomyces genomes are GC rich, this motif is usually present within a target 
DNA sequence, making this system highly suitable for use in these organisms.  The 
benefits of pCRISPomyces-2 are that the crRNA and tracrRNA have been fused into a 
single synthetic guide RNA (sgRNA) into which the protospacer can be assembled, 
and the plasmid also contains sites for integration of editing templates for repair by 
homologous recombination, allowing for highly efficient genome editing in 
Streptomyces species (Figure 1.7) (Cobb, Wang and Zhao, 2015; Alberti and Corre, 
2019). 
 
Figure 1.7: The pCRISPomyces-2 system was developed by Cobb et al. for specific gene editing in 
Streptomyces species (Cobb, Wang and Zhao, 2015).  The synthetic guide RNA (sgRNA) confers target 
specificity and recruits the Cas9 nuclease which results in a double strand break.  One of the main 
advantages of the pCRISPomyces-2 plasmid is that homology repair arms can also be incorporated 
into the plasmid so that specific gene edits can be made.  When gene deletions are required, no scar 
or resistance marker is left behind in the genome, meaning that clean mutants can be generated and 
used for a variety of downstream applications. 
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Using these new genetic tools, deletion or disruption of other competing pathways 
in a Streptomyces genome can be achieved in order to increase the flux of carbon 
through the desired BGC and activate the production of a particular natural product 
(Gomez-Escribano and Bibb, 2014).  Additionally, cluster situated regulators can be 
mutated to switch on expression of the BGC of interest, for example by deleting 
pathway repressor genes or overexpressing activator genes.  A new class of 
macrolide antibiotics, the stambomycins, were discovered in this way after the 
overexpression of a LAL regulator from within the previously cryptic pathway in 
Streptomyces ambofaciens (Laureti et al., 2011).  The ability to genetically 
manipulate microbial genomes also allows for the production of novel natural 
products via metabolic engineering (Corre and Challis, 2009).  The modular 
architecture of many natural product BGCs also means that enzymatic domains can 
be removed, exchanged or fused to generate novel analogous of existing compounds 
(Hur, Vickery and Burkart, 2012; Baltz, 2015).  This was recently exemplified by the 
accelerated evolution of the modular PKS BGC that led to the production of novel 
rapamycin analogues in Streptomyces rapamycinicus (Wlodek et al., 2017).   
The development of CRISPR for use in Streptomyces means that efficient genetic 
engineering can be achieved in both model organisms and environmental isolates 
alike, provided a good quality genome sequence is available.  Whilst it should be 
noted that some species remain genetically intractable even with CRISPR, and the 
deletion of large clusters of ³50 kb and above can still be challenging, these genetic 
techniques have opened up numerous opportunities for natural product discovery 
from previously inaccessible sources (Baltz, 2015).  For example, the anti-tubercular 
compound, scleric acid, was recently discovered from the genetically intractable 
Streptomyces sclerotialus by capturing the cluster using TAR cloning, inserting the 
cloned cluster into a heterologous expression host and de-repressing the pathway by 
inactivating the repressor sclM4 using CRISPR (Alberti et al., 2019).  These 
developments mean that we are no longer restricted to mining the cryptic BGCs of 
model streptomycetes but can also explore the abundant biochemistry available in 
novel species isolated from the environment. 
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1.6 Exploring novel environments to find new antibiotic producers 
 
Analysis of biosynthetic genes present within metagenome libraries shows that even 
ecologically similar environments with similar phylum distributions at the 16S level 
contain hugely diverse secondary metabolite potential when separated 
geographically (Reddy et al., 2012).  This means that by isolating bacteria from 
multiple environments across various geographic locations, we can significantly 
increase the chances of discovering new species with novel secondary metabolite 
profiles, reducing rates of rediscovery substantially.  Unprecedented numbers of 
antibiotic producing actinomycetes are found not only in soils around the world but 
in deserts, marine sediments and fresh water ecosystems.  Due to the perceived 
challenges for microbial growth in such harsh environments, exploration of these 
niches was largely neglected during the Golden Age of antibiotic discovery (Devine, 
Hutchings and Holmes, 2017; van der Meij et al., 2017).  New genera of 
actinomycetes such as Salinospora and Saccharomonospora have recently been 
isolated from marine environments and remain a promising source of novel natural 
products, such as the cytotoxic salinosporamides and the lipopeptide antibiotic 
taromycin (Williams et al., 2005; Reynolds et al., 2018).  Novel and distinct 
Streptomyces isolates have also been cultured from desert samples such as the 
chaxalactin- and chaxamycin-producing Streptomyces leeuwenhoekii, and 
Streptomyces asenjonii which produces antibiotics with activity against MRSA 
(Busarakam et al., 2014; Goodfellow et al., 2017).  
16S analysis shows that most environmental samples contain thousands of unique 
bacteria, however most are not culturable using standard microbiological 
techniques, meaning their biosynthetic potential remains largely unexplored.  The 
recently developed iChip allows growth components and signalling molecules from 
the natural environment into small growth chambers via diffusion for improved 
culture and isolation of bacteria from soil and aquatic sediments (Nichols et al., 
2010).  Culture-independent methods are also becoming increasingly successful, 
particularly the use of metagenomics, which allows genetical material to be cloned 
directly from all varieties of environmental samples, and BGCs of interest can be 
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heterologously expressed in laboratory-grown organisms (Milshteyn, Schneider and 
Brady, 2014).  The malacidins are antibiotics that are broadly active against Gram-
positive bacteria including MRSA.  The producing organism of the malacidins has so 
far not been identified; instead, metagenome libraries from diverse soil samples 
were screened for NRPS clusters containing conserved Asp-X-Asp-Gly motifs that are 
characteristic of calcium-binding antibiotics like daptomycin (Hover et al., 2018).  
Whilst this approach will allow for the discovery of many more novel natural 
products, it is predicted that most unculturable bacteria have small genomes of less 
than 3.5 Mb, whereas the most prolific antibiotic producers are known to have large 
genomes.  Focussing on natural product discovery from novel but culturable bacteria 
with large genomes is predicted to identify greater numbers of novel natural 
products in the near future (Baltz, 2018).   
Increasingly, antibiotic-producing actinomycetes are being recognised for their 
important interactions with higher eukaryotes and these previously neglected 
environments represent a particularly promising source of novel natural products.  
Although some Streptomyces strains are plant pathogens, many can act as beneficial 
endosymbionts.  The secondary metabolites produced by Streptomyces in plant roots 
have been shown to have plant growth promotion properties, as well as 
antimicrobial activity against prominent plant diseases and may therefore serve as 
promising biocontrol agents in the future as well as a source of novel natural 
products (Vurukonda, Giovanardi and Stefani, 2018).  Streptomyces species also 
associate with marine sponges and multiple novel strains with significant 
biosynthetic potential have been isolated from them (Khan et al., 2011; Li et al., 
2011).  Some actinomycetes, including Streptomyces species, are also known to form 
mutualistic symbioses with insects.  The antennal glands of female digger wasps are 
populated with antibiotic-producing Streptomyces that are applied to the surface of 
larvae to protect them from infection and chemical analysis of the secondary 
metabolites produced by the symbiotic Streptomyces species reveals a broad range 
of bioactivity (Poulsen et al., 2011; Nechitaylo, Westermann and Kaltenpoth, 2014).  
Some insects cultivate a fungal food source by foraging for plant material and many 
who display this behaviour are known to make use of the natural products produced 
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by streptomycetes and other actinobacteria to help them in this mutualism.  The 
southern pine beetle, Dendroctonus frontalis grows its symbiotic fungus in the 
hollowed out bark of pine trees and recruits antibiotic producing actinomycetes to 
help out-compete antagonistic fungi which threaten the survival of its fungiculture 
(Scott et al., 2008).  Termites also cultivate a fungus, known as Termitomyces, and 
termite nests are also associated with antibiotic producing Streptomyces, however 
the nature of this symbiosis is less well characterised (van der Meij et al., 2017).  One 
of the most well studied insect-fungiculture systems is that of the attine leafcutter 
ants.  Found in central and southern America, these ants cultivate the Leucoagaricus 
gongylophorus fungus as their primary food source by scavenging for and breaking 
down plant material from their surroundings.  The Leucoagaricus produces nutrient-
rich fruiting bodies, or gongylidia, that the ants can digest.  In return, the ants tend 
to the Leucoagaricus fungus and protect it from pathogens.  Escovopsis species are 
specialized pathogens of the attine ant fungus garden and infection can cause colony 
collapse within just two days (Currie et al., 1999).  To combat this, the ants have 
evolved several grooming techniques to weed out infected parts of their fungal 
cultivar, but more importantly, they have also co-evolved a secondary symbiosis with 
antibiotic producing actinomycetes that cover their cuticles.  A single strain of 
Pseudonocardia is vertically transmitted by the queen to all new worker ants and 
Streptomyces species are acquired from the ants’ environment.  These bacteria 
cluster around crypts in the cuticle that have exocrine glands below, suggesting that 
the ants can provide some sort of nutritional benefit to the actinomycetes that reside 
there (Figure 1.8) (Currie et al., 2006). 
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Figure 1.8: A) Attine leafcutter ants have antibiotic-producing actinobacteria on their cuticle that 
help protect the symbiotic food fungus, Leucoagaricus, from infection.  B) SEM imaging shows the 
presence of filamentous actinomycetes such as Pseudonocardia and Streptomyces on the ant cuticle. 
C) The actinobacteria in the ant microbiome cluster around crypts on the ants’ cuticle; it is presumed 
that glands below these crypts provide nutritional benefit to the actinomycetes that might also 
encourage the production of secondary metabolites.  Images courtesy of Dr Neil Holmes (formerly 
Hutchings Laboratory) and Sarah Worsley (Hutchings Laboratory).  Scanning electron microscopy 
conducted by Kim Findley (JIC Imaging Facility). 
The strains associated with the attine leaf-cutter ants are capable of producing 
multiple antimicrobials, many of which have potent activity against the Escovopsis 
weberi pathogen in vitro (Currie, Bot and Boomsma, 2003; Barke et al., 2010).  
Streptomyces albus S4, for example, produces the antifungals candicidin and 
antimycin in addition to encoding for several other NRPS and PKS compounds within 
its genome (Seipke et al., 2011).  This multi-drug approach could explain why the ants 
have never faced an antimicrobial resistance problem like the one humans are 
currently facing, even though they are predicted to have evolved this symbiotic 
relationship over 50 million years ago.  These insect microbiomes are evolutionarily 
primed for the production of antimicrobials and recent data suggest that strains of 
Streptomyces from these systems are often more promising as a source of novel 
natural products compared to their soil-dwelling relatives (Chevrette et al., 2019).  
Furthermore, recent work has also shown that it is not just the bacteria in this system 
that produce specialised metabolites; the Escovopsis pathogen also produces 
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compounds that inhibit the antibiotic producing bacteria and worker ants, implying 
that this complex system is the subject of a competitive evolutionary arms race which 
likely increases the rate of evolution of novel natural product BGCs in 
microorganisms present (Heine et al., 2018).   
1.7 Streptomyces formicae 
 
Some species of plant-ants have also been shown to use fungiculture, although the 
system is less evolutionarily developed than the attines.  Tetraponera ants colonise 
the African Acacia drepanolobium plant (known as swollen thorn acacia) which are 
common in sub-Saharan Africa.  These ants cultivate a fungus of the Chaetomium 
species inside the domatia of the acacia thorns and in return, provide the host plant 
with some protection against herbivores.  Until recently, this system had not been 
investigated as a source of novel antimicrobials, as the focus had mostly been on the 
attine ants.  Sequencing of DNA from the bacterial community on the surface of 
Tetraponera penzigi ants from Kenya, as well as the bacteria in the domatia of the 
host plant, shows members of various phyla are present including Proteobacteria, 
Firmicutes and Bacteroidetes, but Actinobacteria with promising antimicrobial 
activities could also be easily isolated (Seipke et al., 2013).  One such isolate, named 
Streptomyces formicae, displayed a unique range of antimicrobial activity against 
drug-resistant bacteria and fungi, including MRSA and Lomentospora prolificans 
(Figure 1.9).  Based on sequence analysis of six phylogenetic markers (16S RNA, atpD, 
rpoB, gryA, recA, and trpB), S. formicae is thought to be of unique lineage, with its 
closest relative being Streptomyces sp. NRRL S-920, a soil isolate of unknown origin 
(Qin et al., 2017). 
 
 46 
 
Figure 1.9: The new species, Streptomyces formicae, isolated from the fungus-farming plant ant, 
Tetraponera penzigi, has potent antibacterial and antifungal activity, including against drug resistant 
strains.  The bioassays imaged above were carried out by Rebecca Devine during this thesis project. 
The genome of S. formicae was sequenced using the PacBio and 454 platforms, with 
Illumina MiSeq to correct for base changes, revealing a 9.6 Mbp linear chromosome 
with 71.38% GC and 8162 protein coding sequences.  Analysis by AntiSMASH version 
4.0 predicts the presence of 34 secondary metabolites within the S. formicae 
genome, however, manual inspection reveals that many of these predicted clusters 
actually contain the biosynthetic genes for multiple distinct compounds.  We 
therefore estimate that this talented strain in fact contains at least 45 secondary 
metabolite BGCs, almost double the average for a strain of Streptomyces, and many 
look as though they may produce novel compounds (Table 1.1)  (Holmes et al., 2018).  
There are multiple PKS, NRPS and RiPP BGCs predicted within the genome sequence, 
including a bacteriocin, a glycopeptide-like antibiotic and some terpenes which all 
may be responsible for the production of antimicrobial secondary metabolites.  
Siderophores and osmolyte BGCs are also present for example those encoding for 
desferrioxamine and ectoine, which are likely to produce compounds that help 
survival during environmental stress.  The S. formicae genome also contains a 
geosmin synthase, a metabolite produced by all known Streptomyces species.  As 
with other strains of Streptomyces, these ‘essential’ and well-conserved BGCs are 
located towards the centre of the genome, whereas BGCs for antimicrobials sit on 
the chromosome arms.  From this analysis, it was not possible to identify which BGCs 
are responsible for the antibacterial and antifungal activities seen in the bioassays 
above. 
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Table 1.1: AntiSMASH (version 4.0) analysis of the S. formicae genome predicted the presence of 34 
BGCs, however, manual inspection revealed that some of these predicted gene clusters are likely to 
contains two or more BGCs that make distinct products.  We therefore predict that S. formicae 
contains at least 45 BGCs.  Where AntiSMASH predicted clusters are likely to encode more than one 
product, they are annotated a, b, c and d (Holmes et al., 2018). 
BGC BGC type Notes 
1 Other - 
2 RiPP (lantipeptide) Single A-gene 
3 Mixed NRPS-Type 1 PKS transAT type PKS module 
4a RiPP (lantipeptide) Two A-genes 
4b NRPS Two siderophore-like ORFs 
4c Type 3 PKS Phloroglucinol synthase-like 
4d Possible RiPP Two radical SAM genes 
5 NRPS Probable pentapeptide 
6a NRPS Telomycin-like BGC 
6b Terpene 2-methyl isoborneol BGC 
6c Aminoglycoside - 
6d NRPS Probable decapeptide 
7 NRPS Probable pentapeptide 
8 Mixed Type 1 PKS-NRPS - 
9 Mixed RiPP (lantipeptide)-Type 1 
PKS 
Abyssomicin-like BGC 
10 Terpene - 
11 Ectoine Ectoine BGC 
12 Mixed Type 1 PKS-NRPS-RiPP - 
13 RiPP SapB BGC 
14 Melanin - 
15 Siderophore Desferrioxamine B BGC 
16 RiPP - 
17a NRPS Griseobactin-like BGC 
17b Laspartomycin Probably tridecapeptide 
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18 Mixed NRPS-FAS/PKS - 
19 Terpene Pentalene synthase-like 
20 Terpene Albaflavenone BGC 
21 Siderophore Aerobactin like 
22 Butyrolactone - 
23 Bacteriocin - 
24 NRPS Calcium dependent antibiotic-like lipo-
hexapeptide 
25 Terpene Geosmin BGC 
26 Type 2 PKS - 
27 NRPS - Type 1 PKS - 
28 Terpene Hopene BGC 
29a RiPP (lantipeptide) Single A-gene 
29b Mixed Type 3 PKS-FAS - 
29c RiPP (lassopeptide) Single precursor gene 
30 Type 1 PKS Polyene-like, probable octadecaketide 
31 NRPS Glycopeptide antibiotic like BGC 
32 NRPS - 
33 Type 1 PKS Lasaloic acid, probable undecaketide 
34a NRPS Single module, terminal thioester reductase 
domain 
34b Clavam (beta-lactam) Clavam-like 
34c Type 1 PKS - 
 
1.8 Novel antibiotics from Streptomyces formicae 
 
Bioassay guided fractionation of culture extracts of S. formicae led to the isolation of 
both antibacterial and antifungal fractions (Figure 1.10).  Although purification of the 
antifungal compounds was possible, structural elucidation has proved challenging.  
In contrast, it was possible to isolate and purify the compounds from the antibacterial 
fraction, and the structures of these were solved using nuclear magnetic resonance 
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(NMR) by Dr Zhiwei Qin (post-doctoral researcher, Wilkinson Laboratory).  This 
revealed thirteen new antibacterial type 2 polyketide natural products from S. 
formicae (Qin et al., 2017).  These new compounds were classified into two groups; 
the first group of compounds (1-3) were named fasamycins C-E, due to their 
structural similarity to fasamycins A and B described previously (Feng, Kallifidas and 
Brady, 2011).  The remaining compounds (4-13) are significantly modified compared 
to the fasamycins and were named the formicamycins.  The formicamycins are 
pentacyclic compounds that can be halogenated at up to four positions on the carbon 
backbone.  In addition, supplementation of the S. formicae growth media with 
sodium bromide resulted in the incorporation of bromine to yield three additional 
formicamycin congeners (14-16), further increasing the novel biochemistry already 
identified from this strain (Figure 1.11). 
 
Figure 1.10: Bioassay guided fractionation using silica gel chromatography of culture extracts of S. 
formicae for the separation of the antifungal and antibacterial fractions. UV absorbance of fractions 
measured at 280 nm.  Experiment performed by Dr Zhiwei Qin at the John Innes Centre. Figure 
reproduced with permission. 
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Figure 1.11: Structures of previously reported fasamycins A and B (Feng, Kallifidas and Brady, 2011) 
along with the new fasamycin congeners C-E and the new formicamycins A-M from S. formicae (Qin 
et al., 2017).  For the purpose of labelling absorbance data in this thesis, the compounds isolated from 
S. formicae are numbered 1-16 as shown.  Compounds 1-16 were isolated at the John Innes Centre 
and their structures solved by NMR conducted by Dr Zhiwei Qin.  
With the purified compounds in hand, Dr John T Munnoch (former PhD student in 
the Hutchings Laboratory) investigated the structure activity relationship (SAR) of the 
formicamycins by examining the growth of Bacillus subtilis in liquid medium 
supplemented with micromolar concentrations of the formicamycins.  An example 
growth curve for formicamycin I (12) is shown (Figure 1.12).  These experiments 
revealed that the formicamycins were at least as potent as other known antibiotics 
like apramycin and ampicillin.   
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4.Formicamycin A R1=H, R2=Cl, R3=H, R4=H, R5=H, 
5.Formicamycin B R1=Cl, R2=Cl, R3=H, R4=H, R5=H, 
6.Formicamycin C R1=H, R2=Cl, R3=Cl, R4=H, R5=CH3,  
7.Formicamycin D R1=Cl, R2=Cl, R3=Cl, R4=H, R5=H  
8.Formicamycin E R1=Cl, R2=Cl, R3=Cl, R4=H, R5=CH3  
9.Formicamycin F R1=Cl, R2=Cl, R3=H, R4=Cl, R5=CH3  
10.Formicamycin G R1=H, R2=Cl, R3=Cl, R4=Cl, R5=CH3 
11.Formicamycin H R1=Cl, R2=H, R3=Cl, R4=Cl, R5=CH3  
 12.Formicamycin I R1=Cl, R2=Cl, R3=Cl, R4=Cl, R5=H  
13.Formicamycin J R1=Cl, R2=Cl, R3=Cl, R4=Cl, R5=CH3  
14.Formicamycin K R1=H, R2=Cl, R3=Br, R4=Cl, R5=CH3  
15.Formicamycin L R1=Cl, R2=Cl, R3=Br, R4=Cl, R5=CH3 
16.Formicamycin M R1=H, R2=Br, R3=H, R4=H, R5=CH3  
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Figure 1.12: Growth curve of Bacillus subtilis in the presence of various concentrations of 
formicamycin I (12) as well as apramycin (Apr), ampicillin (Amp) or methanol (MeOH) to control for 
the solvent used.  Assays conducted by Dr John T  Munnoch and figure reproduced with permission 
(Qin et al., 2017). 
The minimum inhibitory concentrations (MICs) for each compound against B. subtilis, 
MRSA and VRE were identified (Table 1.2). 
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Table 1.2: MIC data for the fasamycins and formicamycins from S. formicae against B. subtilis, and 
MRSA and VRE clinical isolates. Values indicating “Not tested” or with “<” or “>” indicate issues with 
compound availability and/or a decision not to test further concentrations, i.e. they represent the 
lowest/highest concentrations tested.  Assays conducted by Dr John T Munnoch and reproduced with 
permission (Qin et al., 2017). 
Compound 
Minimum Inhibitory Concentration (µM) 
B. subtilis MRSA VRE 
Fasamycin C <20 40 40 
Fasamycin D 10 10 10 
Fasamycin E 5 80 80 
Formicamycin A 5 >80 >80 
Formicamycin B 10 10 10 
Formicamycin C 5 1.25 80 
Formicamycin D 10 20 10 
Formicamycin E 10 20 10 
Formicamycin F 5 20 2.5 
Formicamycin G 5 Not tested Not tested 
Formicamycin H 10 Not tested Not tested 
Formicamycin I <2.5 <2.5 1.25 
Formicamycin J <20 0.625 1.25 
Formicamycin K <2.5 2.5 5 
Formicamycin L <2.5 1.25 2.5 
The formicamycins are all potent inhibitors of Gram-positive bacteria, including drug-
resistant clinical isolates of MRSA and VRE.  The potency of the compounds appears 
to increase as the number of chlorine atoms on the compound increases.  In addition, 
formicamycins appear to be generally more bioactive than fasamycins.  This could be 
due to the saturation of ring C and/or the ability to add more halogen atoms to the 
scaffold, as fasamycins are only halogenated at two positions on the backbone 
whereas formicamycins can be halogenated at up to four different positions.  
Addition of bromine to the scaffold appears to make the compounds marginally more 
potent than the equivalent chlorinated formicamycin. 
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To investigate whether bacteria can acquire spontaneous resistance to 
formicamycins in vitro, Dr John T Munnoch grew MRSA for 20 generations in the 
presence of half-MIC concentrations of formicamycins A, J and L along with a no 
compound control.  No spontaneous resistant mutants were isolated on agar and 
there appeared to be no change in MIC for these compounds, suggesting they exhibit 
a high natural barrier for the development of resistance, at least under the conditions 
tested here (Qin et al., 2017).  Whilst this is a beneficial property for a compound 
designed to be used in a clinical setting, it does raise challenges in determining the 
mechanism of action of the formicamycins.  Previous studies have suggested that 
fasamycins A and B act by inhibiting type 2 fatty acid biosynthesis and it is possible 
that the formicamycins act in the same way.  Overall, these preliminary results show 
that the formicamycins are attractive compounds for further investigation. 
1.9 Aims and objectives of this thesis 
The aim of this thesis was to investigate antibiotic production in Streptomyces 
formicae by applying new genomic tools to a novel environmental isolate.  During 
the work presented, the biosynthesis of the formicamycins was fully characterised 
by identifying the genes responsible for production within the host and assigning 
functions to the enzymes present in the pathway.  Regulation of formicamycin 
production and mechanisms of host resistance were also investigated.  Using this 
knowledge, we have engineered strains of S. formicae that overproduce the 
formicamycins as well as their biosynthetic precursors, intermediates and side-
products.  This has led to the discovery of several novel chemical structures with a 
range of antibiotic activities.  The mechanism of bioactivity of the formicamycins has 
also been investigated.  Furthermore, experiments have been conducted to identify 
the BGC responsible for the production of the antifungal compounds from S. 
formicae.  This work has revealed a prolific potential for the discovery of novel 
antimicrobials from this talented environmental isolate.  The development of 
protocols for the genetic manipulation of S. formicae during this project will allow 
further work to be conducted on this organism in the future to identify further novel 
natural products. 
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2 Materials and Methods 
 
2.1 Chemicals and Reagents 
 
Chemicals and reagents used are laboratory standard grade or above, purchased 
from Sigma Aldrich (UK) or Thermo Fisher Scientific (UK) unless otherwise stated. All 
media and solutions were made using deionised water (dH2O) except where stated 
otherwise. 
2.2 Bacterial strains 
 
The bacterial strains used or generated in this study are listed in the appendix of this 
thesis (Chapter 8.1). Growth media are listed in Table 2.1 with selection 
concentrations of antibiotics listed in Table 2.2. E. coli strains were routinely grown 
shaking at 220 rpm, in LB broth or on LB agar at 37°C unless stated otherwise.  Agar 
plates of Streptomyces formicae were grown at 30°C. 
 
Table 2.1: Growth media used in this thesis and their constituents 
Media Recipe (per litre) Water pH 
SFM 
20 g soy flour 
20 g mannitol 
20 g agar 
Tap  
MYM 
4 g maltose 
4 g yeast extract 
10 g malt extract 
+/- 18 g agar 
50:50 Tap:deionised 7.3 
ISP2/YEME 
4 g yeast extract 
10 g malt extract 
4 g glucose 
20 g agar 
Tap  
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LB 
10 g tryptone 
5 g yeast extract 
10 g NaCl (omitted when selecting 
with Hygromycin) 
+/- 20 g agar 
Deionised 7.5 
2YT 
16 g tryptone 
10 g yeast extract 
5 g NaCl 
Deionised 7.0 
Oat 
25 g oats (crushed in a pestle and 
mortar) 
20 g agar 
Tap  
TSB 
17 g tryptone 
3 g soya peptone 
5 g NaCl 
2.5 g dipotassium phosphate 
2.5 g glucose 
Deionised 7.3 
PGA 
4 g potato extract 
20 g glucose 
17 g agar 
Deionised 7.5 
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Table 2.2: Antibiotics used in this thesis and their selection concentrations 
Antibiotic Selection concentration (µg/ml) 
Ampicillin/Carbenicillin 100 
Apramycin 50 
Chloramphenicol 30 
Erythromycin 10 
Hygromycin 50 
Kanamycin 50 
Nalidixic Acid 25 
Thiostrepton 30 
2.3 Preparation of Streptomyces spores 
 
A single colony of Streptomyces was picked and plated to give a confluent lawn on 
SFM or MYM agar and grown at 30°C for 7-10 days until spores were visible.  A sterile 
cotton bud was then used to scrub the spores from the surface of the plate with 1.5 
ml 20% glycerol.  Harvested glycerol and spore solutions were preserved at -80°C.  
2.4 Glycerol Stocks 
 
Glycerol stocks of E. coli, B. subtilis, S. aureus, Enterococcus and C. albicans were 
produced by resuspending 1-3 ml of overnight culture in LB and glycerol (final 
concentration 20%).  Stocks were stored at -80°C. 
2.5 Microscopy 
 
A standard light microscope was used to check for sporulation in Streptomyces 
cultures.  Scanning electron microscopy was conducted by Elaine Barclay the 
bioimaging facility at the John Innes Centre.  Briefly, the sample was cryo-fixed by 
plunging into sub-cooled nitrogen and transferred into the cryo-preparation 
chamber under vacuum.  Charge was reduced by coating the samples in a fine layer 
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of platinum and the sample was transferred onto the cold-stage within the SEM 
chamber for imaging. 
2.6 DNA Extraction 
 
Phage-derived artificial chromosome (PAC) DNA (Chapter 8.2) and genomic DNA was 
extracted from E. coli and Streptomyces species respectively by pelleting 1 ml of 
overnight culture in a benchtop microcentrifuge at 13000 rpm for 5 minutes and 
resuspending in 100 µl solution I (50 mM Tris/HCl, pH 8; 10 mM EDTA).  Alkaline lysis 
was performed by adding 200 µl solution II (200 mM NaOH; 1% SDS) and mixing by 
inverting ten times.  150 µl solution III (3M potassium acetate, pH 5.5) was added 
and samples mixed by inverting five times before being centrifuged at 13 000 rpm 
for 5 minutes.  The supernatant was extracted in 400 µl phenol:chloroform:isoamyl 
alcohol by vortexing for 2 minutes and centrifuging at 13 000 rpm for 5 minutes.  The 
upper phase was transferred to a fresh microcentrifuge and 600 µl 2-propanol added.  
The samples were then incubated on ice for 10 minutes to aid precipitation of the 
DNA.  Samples were centrifuged at 13 000 rpm for 5 minutes and the DNA pellet 
washed with 200 µl 70% ethanol.  After centrifuging again at 13 000 rpm for 5 
minutes, the DNA pellet was air-dried for 5 minutes before being resuspended in 
autoclaved dH2O. 
2.7 DNA Quantification 
 
Isolated DNA was analysed using the Nanodrop 2000 UV-Vis Spectrophotometer and 
the Qubit assay using the QubitÒ fluorimeter 2.0. Both the high-sensitivity and the 
broad-range kits were used depending on the sample concentration estimated by 
Nanodrop. 
2.8 Primers 
 
All primers were designed manually in ApE (A Plasmid Editor) and ordered from 
Integrated DNA Technologies (IDT).  A table of all primers used in this work is 
available in the appendix of this thesis (Chapter 8.3). 
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2.9 Polymerase Chain Reaction (PCR)  
 
Two different DNA polymerases were used depending on the application. PCRBIO® 
Taq DNA Polymerase (from PCR Biosystems) was used for diagnostic PCR reactions, 
whereas Q5® High-Fidelity DNA polymerase was used to amplify DNA fragments for 
subsequent cloning.  PCRs were generally conducted as below using either a DNA 
engine PTC 300 (BIORAD®) or Prime (Techne) PCR machine (Table 2.3). 
Table 2.3: Conditions used for PCRs conducted during this thesis 
Cycles Temperature Time Notes 
1 95°C 2 min Initial denaturation 
30 
95°C 30 sec Denaturation 
55°C to 72°C 30 sec 
Anneal (Tm was calculated using NEB 
calculator at http://tmcalculator.neb.com) 
72°C 30 sec per kb Extension 
1 72°C 10 min Final extension 
1 4°C hold Final hold 
2.9.1 PCRBIOâ  Taq DNA Polymerase 
For diagnostic PCR, the following reaction mix was generated (Table 2.4). 
Table 2.4: Reaction constituents for PCRBIO Taq reactions conducted during this thesis 
Reagent 20 µl reaction 
Final 
concentration 
Notes 
2x PCRBIO Taq Mix 10 µl 1x  
DMSO   1 µl 5% To help primer annealing 
Forward primer 
(5μM) 
0.5 µl 125nM  
Reverse primer 
(5μM) 
0.5 µl 125nM  
Template DNA 0.5 µl variable <10 ng plasmid or gDNA 
dH2O 7.5 µl    
 59 
2.9.2 Q5® High-Fidelity DNA polymerase 
 
To amplify DNA fragments for cloning, the following reaction mix was generated 
(Table 2.5). 
Table 2.5: Reaction constituents for Q5 reactions conducted during this thesis 
Reagent 
50 µl 
reaction 
Final 
concentration 
Notes 
5X Q5  
Reaction Buffer 
 10 µl 1x  
5X Q5 High GC Enhancer  10 µl 0.5% Reduces Tm 
10 mM dNTPs    1 µl 200 µM  
Forward primer (10 μM) 0.5 µl 100 nM  
Reverse primer (10 μM) 0.5 µl 100 nM  
Template DNA 0.5 µl variable 
<10ng plasmid or 
gDNA 
Q5 High-Fidelity 
Polymerase 
0.5 µl   
dH2O 27 µl    
 
2.10 Agarose gel electrophoresis 
 
Gels were made with 1% agarose in TBE buffer (90 mM Tris HCl, 90 mM Boric Acid, 2 
mM EDTA) with 2 μg/ml ethidium bromide. DNA samples and loading buffer (5x) 
(0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene-cyanol blue, 40% (w/v) sucrose 
in water) were run alongside a 1 kb plus DNA ladder plus loading dye for size 
determination. Electrophoresis occurred at 120 V (Sub-Cell GT electrophoresis 
system, BIOLINE) for 30-60 minutes depending on size (larger fragments were run 
longer for clearer separation). DNA was visualised by UV-light using a Molecular 
Imager Gel Doc System (BIO-RAD). 
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2.11 Gene Synthesis 
 
Gene synthesis was conducted by GenScript.  When appropriate, Streptomyces genes 
were codon-optimised for expression in E. coli. 
2.12 Plasmid preparation 
 
The plasmids used or generated in this study are listed in the appendix of this thesis 
(Chapter 8.2). Plasmid DNA was prepared using QIAprep Spin Miniprep kits (QIAGEN) 
from 3-5 ml overnight cultures as per manufacturer’s instructions. Plasmids where 
eluted from the column using 30 μl autoclaved dH2O. 
2.13 Restriction digest 
 
Both Roche and NEB restriction enzymes were used to digest plasmid DNA and PCR 
fragments in 50-100 µl total volumes in accordance with manufacturer’s guidelines. 
Digests were carried out with optimal buffer, which was outlined by Roche or NEB. 
Digestion of 1 µg of DNA was typically performed at 37°C for 1 hour by adding 1 unit 
of the appropriate restriction enzyme. Then the restriction enzymes were heat 
inactivated at 65°C for 10 minutes and 2 µl shrimp alkaline phosphatase was added 
to dephosphorylate the digested plasmid DNA to prevent re-ligation. Digests were 
then analysed by gel electrophoresis; the desired bands were excised and gel 
extracted for downstream applications.  
2.14 Gel extraction 
 
Gel fragments containing DNA bands of interest were excised using a scalpel and 
extracted using a QiaQuick Gel Extraction Kit (QIAGEN), according to the 
manufacturer’s instructions. DNA was eluted in 30 μl autoclaved dH2O. 
2.15 Ligation 
 
Ligation reactions were carried out using T4 DNA Ligase according to the 
manufacturers’ instructions.  A standard ratio for reactions was 1:3 of plasmid to 
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insert.  Volumes were calculated using the (NEB) NeBio Ligation Calculator (at 
https://nebiocalculator.neb.com) to account for differences in DNA size and 
concentration.  
2.16 Golden Gate 
 
Constructs were assembled in 20 μl reactions with 100 ng purified backbone and 0.3 
μl insert in the presence of 2 μl T4 ligase buffer (NEB) and 1 μl T4 ligase (NEB) with 1 
μl BbsI (NEB) and dH2O.  This was run in a thermocycler under the following 
conditions: 
• 10 cycles of the following: 
• 10 minutes at 37°C 
• 10 minutes at 16°C 
• 5 minutes at 50°C 
• 20 minutes at 65°C 
• 4°C hold 
Assembly of small inserts such as 20 nucleotide synthetic protospacers were 
confirmed by blue/white screening using X-Gal and sequencing by Eurofins.  Larger 
inserts were confirmed using colony PCR (Chapter 2.21) or restriction digestion 
(Chapter 2.13) followed by gel electrophoresis (Chapter 2.10). 
2.17 Gibson Assembly 
 
Multiple DNA fragments were assembled into digested vector backbones using 
designed overlaps of between 18 and 24 nucleotides.  Gel extracted DNA fragments 
were incubated in a ratio of 1:3 of plasmid to insert (1:5 for inserts smaller than 300 
nucleotides) in the presence of Gibson Assembly master mix (NEB) at 50°C for 1 hour. 
2.18 Preparation and transformation of electrocompetent E. coli 
 
Single colonies of E. coli ET12567/pUZ8002 and Top10 were grown as 10 ml overnight 
cultures in LB containing appropriate antibiotics (Table 2.2) and sub-cultured to an 
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OD600 of approximately 0.4.  Cultures were pelleted by centrifugation at 4000 rpm 
for 5 minutes at 4°C and resuspended in 10 ml ice-cold 10% v/v glycerol.  Pellets were 
washed in ice-cold 10% v/v glycerol twice before being either flash frozen in liquid 
nitrogen and stored at -80°C or being used for transformation immediately.  For 
transformation, approximately 2 µg of DNA was added to 50 µl of cells and the 
mixture transferred to an ice-cold electroporation cuvette.  Electroporation was 
carried out using the BioRad Electroporator set to: 200 Ω, 25 μF and 2.5 kV.  The 
electroporated cells were diluted in LB and transferred to a micro-centrifuge tube for 
recovery at 37°C for 1 hour with 220 rpm shaking before plating on selective media 
for overnight incubation and colony selection. 
2.19 Preparation and transformation of chemically competent E. coli 
 
Single colonies of Top10 E. coli were grown as 10 ml overnight cultures in LB 
containing appropriate antibiotics, and sub-cultured to an OD600 of approximately 
0.4.  Cultures were pelleted by centrifugation at 4000 rpm for 5 minutes at 4°C and 
resuspended in 10 ml of ice-cold 100 mM CaCl2.  Pellets were washed in ice-cold 100 
mM CaCl2 twice before being either flash frozen in liquid nitrogen and stored at -80°C 
or being used for transformation immediately.  For transformation, approximately 2 
µg of DNA was added to 50 µl of cells, mixed gently and incubated on ice for around 
30 minutes.  This mixture was then heat-shocked for 30 seconds at 42°C then 
immediately cooled on ice for 2 minutes.  The transformed cells were diluted in LB 
and recovered at 37°C for 1 hour with 220 rpm shaking before plating on selective 
media for overnight incubation and colony selection. 
2.20 Tri-parental mating 
 
The three strains required for tri-parental mating (usually E. coli DH10b containing 
the PAC clone, Top10 with pR9604 and ET12567/pUZ8002) were inoculated into 
liquid LB with appropriate antibiotic selection and grown overnight at 37°C, 250 rpm.  
The following day, these were sub-cultured and grown to exponential phase 
(measured by OD600 0.4-0.6) and washed by centrifugation to remove antibiotics.  20 
µl of each strain was spotted onto the centre of a LB agar plate with no antibiotic and 
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incubated overnight at 37°C.  The spot was then re-streaked onto LB + antibiotics to 
select for the intended strain containing the desired combination of plasmids.  The 
presence of the required plasmids was tested and confirmed by colony PCR.  
2.21 Colony PCR in E. coli 
 
After overnight incubation, single colonies were picked with a sterile pipette tip and 
transferred to the base of a 0.2 ml PCR Tube.  The tip was then discarded into an 
Eppendorf containing 500 µl sterile LB media.  Biotaq PCR was conducted as 
described above (Chapter 2.9.1) and reactions analysed by gel electrophoresis.  
Positive colonies were then transferred to 10 ml LB supplemented with antibiotics 
for overnight incubation and plasmid amplification. 
2.22 Constructing gene deletions using Lambda l RED methodology (ReDirect) 
 
PAC clones were PCR targeted by ReDirect by replacing genes of interest with an 
apramycin resistance gene as described previously (Gust et al., 2003).  The published 
methodology was edited to remove the oriT from the apramycin cassette, as this 
sequence is also present in the PAC and therefore encouraged undesirable 
recombination events.  A linear PCR product (FRT – flanked resistance gene 
construct) was purified and electroporated into E. coli BW25113 pIJ1790 containing 
the desired cosmid for PCR targeting.  The expression of Lambda red genes was 
induced by addition of L-arabinose (final concentration 10 mM) to the growth 
medium to allow the introduction of linear DNA.  Edited cosmids were PCR confirmed 
before conjugation into Streptomyces via ET12567/pUZ8002. 
2.23 Constructing gene knockouts using CRISPR/Cas9 genome editing 
 
Clean deletions were made using the pCRISPomyces-2 system as described 
previously (Cobb et al., 2015) (Figure 2.1).  Approximately 20 base pair protospacers 
for use in the synthetic guide RNA (sgRNA) were designed so that the last 15 
nucleotides, including the NGG sequence, were unique in the genome to minimise 
off target effects.  The forward and reverse sequences were ordered as oligos from 
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IDT and annealed by heating to 95°C for 5 minutes followed by ramping to 4°C at 
0.1°C/second.  Annealed protospacers were then assembled into the BbsI site of the 
pCRISPomyces-2 vector using golden gate assembly (Chapter 2.16).  This vector was 
then digested with XbaI (Chapter 2.13) and a 2kb PCR-amplified homology repair 
template (1 kb from either side of the target region) was assembled into the vector 
using Gibson assembly (Chapter 2.17).  The final vector was cloned in E. coli, isolated, 
confirmed by PCR and sequencing, and transformed into the desired Streptomyces 
strain by conjugation via the non-methylating E. coli strain ET12567/pUZ8002 
(Chapter 2.25).  Once the required deletion event had taken place, loss of the 
temperature-sensitive pCRISPomyces-2 plasmid was encouraged by plating mutants 
on media lacking antibiotic selection at 37°C for multiple generations.   
 
Figure 2.1: The pCRISPomyces-2 vector (Cobb, Wang and Zhao, 2015) visualised and annotated in 
SnapGene.  The synthetic gRNA is seen, along with the BbsI site for integration of the desired 
protospacer.  The Cas9 enzyme causes the double stranded break in DNA at the target site specified 
by the protospacer.  The chromosome is then repaired according to the homologous repair template 
assembled into the XbaI site of the plasmid. 
To confirm the desired deletion event had occurred within the genomic DNA, two 
PCR products of just over 1kb each were generated using primer pairs 1F/1R and 
2F/2R from either genomic DNA prepped by the phenol:chloroform method (Chapter 
2.6) or lysed mutant colonies (Chapter 2.26) (Figure 2.2).  This approach allows PCR 
confirmation to be conducted on mutants that still contain the pCRISPomyes-2 
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plasmid (i.e. before multiple generations to cure the plasmid have been undertaken) 
as the external primers bind within the genomic DNA and not within the 2 x 1 Kb 
homologous repair template in the deletion vector.  PCR products in the wild-type 
(WT) strain will be longer than the mutants as the gene(s) of interest are still present.  
For large deletions such as whole clusters, the WT strain does not generate a band 
at all, because the region of DNA would be too long for amplification by standard 
PCR.  Using this experimental design, primers 2F and 1R can also be used together to 
generate a smaller product, however, this is only suitable on apramycin-sensitive 
strains that no longer contain the pCRISPomyces-2 plasmid, as this region would also 
be present here. 
 
 
Figure 2.2: For all CRISPR/Cas9 deletions generated in this thesis, two products of just over 1kb each 
were generated in order to confirm the desired deletion event had occurred within the genomic DNA.  
The example shown here illustrates two mutants that have had an approximately 300 bp region of the 
genome deleted.  The bands from the WT template are approximately 300 bp longer than the bands 
from the mutant strains.  Some non-specific binding is present as the ‘template’ here is lysed 
Streptomyces colonies.  The bands were excised and confirmed by sequencing. 
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2.24 Sequencing of small DNA fragments and plasmids 
 
Cloned DNA constructs were confirmed by Sanger sequencing using the Mix2Seq 
service from Eurofins Genomics. Plasmid DNA was diluted according to the 
manufactures instruction and test primers were added directly with sterile dH2O and 
a final concentration of 5% DMSO. 
2.25 Conjugation 
 
Single colonies of non-methylating E. coli ET12567/pUZ8002 containing the required 
plasmid were selected from plates and grown in 10 ml LB broth plus antibiotics at 
37°C overnight at 250 rpm. Subcultures of OD600 between 0.4 and 0.6 were washed 
twice in LB to remove antibiotics.  Between 10 and 200 µl of Streptomyces spores 
were heat shocked at 50°C for 10 minutes in 500 µl 2YT to encourage germination 
and added to the washed E. coli cells.  The cell mixture was pelleted by centrifugation 
at 13 000 rpm for 1 minute, the supernatant was removed and cells were 
resuspended in the residual liquid.  This was plated on SFM + 10 mM MgCl2 at various 
dilutions and incubated at 30°C for 16-20 hours.  For selection of desired ex-
conjugants, 0.5 mg Nalidixic acid and an appropriate concentration of the selection 
antibiotic (to give final concentrations as described in Table 2.2 was added in 1 ml 
dH2O to each plate and cultures returned to the 30°C incubator for 5 days or until 
colonies appeared. 
2.26 Colony PCR in Streptomyces species 
 
Following purification by re-streaking on antibiotic selective media, Streptomyces ex-
conjugants were confirmed by colony PCR.  Single colonies were picked and soaked 
in 100µl 50% DMSO at 50°C for 1 hour.  This was then used as template for BioTaq 
PCR (Chapter 2.1) at 10% of the final volume of the reaction (usually 2.5 µl in 25 µl). 
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2.27 Genetic complementation 
 
Complementation of individual gene deletions were achieved by fusing the gene to 
either a native S. formicae promoter in pMS82 by Gibson assembly or by ligating the 
digested gene product downstream of the ermE* promoter in pIJ10257.  The 
complementation construct was then conjugated into the relevant mutant as 
described (Chapter 2.25).   
2.28 Chemical Extraction of Secondary Metabolites from agar plates 
 
Agar plates were inoculated with S. formicae and incubated at 30°C for 9 days.  For 
small scale extractions, three circular regions of the agar were sampled using the lid 
of a falcon tube and a razor to excise the agar from the plate.  The weight of the 
samples was measured to three decimal places.  1mL of ethyl acetate was added to 
the samples and shaken for 1 hour.  For larger scale extractions for compound 
isolation, at least 40 plates of each strain were inoculated and grown as above.  The 
agar was then crushed and extracted in a minimal volume of ethyl acetate.  The ethyl 
acetate was evaporated in a Rotovap or Genevac depending on the sample volume 
and the sample resuspended in a minimal volume of HPLC grade methanol. For both 
extraction methods, the samples were then centrifuged to remove insoluble 
material, dried using the Genevac and resuspended in methanol for analysis. 
2.29 High-performance Liquid Chromatography (HPLC) and Mass Spectrometry 
(LCMS) 
 
For HPLC analysis, extracts in 100% methanol were run on the Agilent 1100 HPLC 
system using a Gemini-NX C18 00F0-4453-EO column (150 X 4.6 mm, 3 µm; 
Phenomenex).  Solvent A was water + 0.1% formic acid and solvent B was 100% 
methanol.  Compounds were separated through the column as follow: initially, 50% 
B (methanol) was run through the column to equilibrate, then, an elution of 50-100% 
B (methanol) was run through the column over 14 minutes.  The concentration of B 
(methanol) was then reduced to 50% to wash the column. 
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For HPLC LCMS analysis, samples were run on a Shimadzu Nexera XR ultra high-
performance liquid chromatographer (UHPLC) attached to a Shimadzu ion-trap time-
of-flight (IT-ToF) mass spectrometer.  For UHPLC, the Phenomenex Kinetex C18 
column was used (100 x 2.1 mm, 100 Å) with solvent A as water + 0.1% formic acid 
and solvent B as 100% methanol.  Compounds were separated through the column 
as follows; initially, 20% B (methanol) was run through the column to equilibrate, 
then, an elution of 20%-100% B (methanol) was run through the column over 12 
minutes, followed by 2 minutes of 100% B to fully elute all the compounds off the 
column.  The flow-through was then reduced back down to 20% B, which was run 
through the column for a total of 3 further minutes to fully clean the column.  The 
flow rate during these experiments was set to 0.6 mL/minute, the injection volume 
was 10 µL and positive-negative mode switching was used.  The spray chamber was 
calibrated using sodium trifluoroacetate cluster ions according to the manufacturer’s 
instructions.  The heat block was set to 300 °C, with the nebulizer gas rate at 1.5 
L/min and the drying gas on. 
All HPLC and LCMS experiments described in this thesis were run by Dr Zhiwei Qin 
and/or Hannah McDonald from Professor Barrie Wilkinson’s group at the John Innes 
Centre.  All strains were generated by Rebecca Devine and strain fermentation and 
extractions were conducted by both groups. 
2.30 Protein overexpression and purification 
 
The gene of interest was codon optimised and synthesised by GenScript and sub-
cloned into pGS-21a for expression as a His-GST fusion protein.  Protein was over-
produced in 2L E. coli BL21 grown at 37°C for 3 hours and induced overnight with 0.1 
mM IPTG at 20 °C, 200 rpm shaking.  The following day, cells were harvested by 
centrifugation at 6000 rpm for 30 minutes.  The pellets were frozen at -80°C for 
purification at a later date or processed immediately. 
Pellets were thawed on ice and resuspended in PBS + lysozyme (100 µg/ml) + EDTA-
free protease inhibitor.  Cells were passed through a French press operated at x16000 
lb/in2 twice to lyse and separated into soluble and insoluble fractions by 
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ultracentrifugation at 42 000 rpm for 1 hour 30 minutes.  A His-trap (1ml) column 
was loaded onto an AKTA FPLC (UPC-900, Frac-950, INV-907, M-925) and washed in 
20% ethanol before the soluble fraction was loaded.  The column was then washed 
with 40 mls of PBS.  After that, a 40 mM solution of imidazole was passed through 
the column for 15 minutes to reduce non-specific binding before a fast gradient up 
to 500 mM imidazole was used to elute the bound protein.  Fractions were collected 
every minute and analyzed by SDS page.  Fractions that contained relatively pure 
protein were concentrated in Amicon Ultra 50 KDa centrifugal filters (Millipore) and 
exchanged into PBS + 10% (v/v) glycerol for storage.  Protein was flash frozen in liquid 
nitrogen in aliquots for further use. 
2.31 Protein analysis by SDS-PAGE 
 
A standard resolving gel of 16.6 % (w/v) Acrylamide:Bis-Acrylamide 37.5:1 (Fisher 
BioReagents) was made as per the table below and cast using Mini-PROTEANÒ Tetra 
hand cast systems (BIO-RAD) using 0.75mM glass plates.  The resolving gel was left 
to polymerise at room temperature for a minimum of 30 minutes.  Subsequently, a 
short stacking gel of 8% (w/v) Acrylamide was cast on top of the resolving gel and a 
0.75mm comb used to set the lanes (Tables 2.6 and 2.7). 
Samples to be analysed were defrosted on ice or analysed immediately post 
collection and resuspended in 50-200 μl SDS loading buffer (950 μl Bio-Rad® laemmli 
buffer, 50 μl β-mercaptoethanol) before boiling (100°C, 10 minutes). Cell debris was 
pelleted by centrifugation (5 minutes, 13000 rpm) and 20-50 μl of sample loaded 
onto SDS-PAGE gels with 3 μl PageRule Prestained Protein Ladder® (Thermo 
Scientific) as a marker.   
Gels were electrophoresed (150V, 60 minutes) in 1 x TGS running buffer (0.025 M 
Tris-HCl, 0.192 M glycine, 1% SDS v/v) and stained with InstantBlue Protein Stain 
(Expedeon) with agitation at room temperature for 1 hour or overnight.  Gels were 
de-stained in dH2O for at least 1 hour and imaged using white light on a Molecular 
Imager Gel Doc System (BIORAD). 
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Table 2.6: Constituents of buffers used for making SDS-PAGE gels in this thesis 
 
 
 
Table 2.7: Constituents of SDS-PAGE gels used in this thesis 
Constituent 
Stock 
solution 
Volume Final concentration 
Resolving gel    
Resolving buffer 4x 2.5 ml 1x 
Acrylamide 40% (w/v) 4.15 ml 16.6% 
dH2O  3.35 ml  
Tetramethylethylenediamine (TEMED) >99%    10 µl 0.1% 
Ammonium persulfate (APS) 10% (w/v)  100 µl 1% 
Stacking gel    
Stacking buffer 4x 2.5 ml 1x 
Acrylamide 40% (w/v) 2 ml 8% 
dH2O  5.5 ml  
TEMED >99%    10 µl 0.1% 
APS  10% (w/v)  100 µl 1% 
 
2.32 Quantification of protein from whole cell lysates 
 
Protein samples of unknown concentration were compared to samples of Bovine 
serum albumin (BSA) at a known concentration using the Bradford assay (Bradford, 
1976).  All samples were diluted in Bradford Dye Reagent solution (BIO-RAD) and 
dH2O as below in 1.6 mL cuvettes (semi-micro disposable polystyrene 10 mm path 
length; Fisherbrand) and mixed by inverting (Tables 2.8 and 2.9).  Absorbance was 
measured at A595 and a standard curve produced by plotting the absorbances of BSA 
4x Resolving Buffer 4x Stacking Buffer 
1.5 M Tris-HCl, pH 8.8 0.5 M Tris-HCl, pH 6.8 
0.4% SDS 0.4% SDS 
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standards against their known protein concentration (mg/ml).  Using this, the protein 
concentrations of unknown samples was calculated based on their absorbances.   
Table 2.8: Constituents of standards used for protein quantification in this thesis 
 
 
 
 
 
 
 
 
Table 2.9: Constituents of unknown samples generated for protein quantification in this thesis 
 
 
 
 
2.33  Western blot 
 
Protein samples were subjected to SDS-PAGE as above (Chapter 2.31) before being 
transferred to a nitrocellulose Biodyne A membrane (Pall Corporation) in a Trans-Blot 
SD Semi-Dry Transfer Cell (BIORAD).  Three layers of blotting paper, equal size to the 
gel, were soaked in 1 x transfer buffer (25 mM Tris, 192 mM Glycine, 0.1 % SDS + 20% 
methanol) and placed on the transfer cell anode plate.  Nitrocellulose membrane was 
soaked in 100% methanol (1 minute), followed by washing in transfer buffer (5 
minutes) and placed on top of the blotting paper.  The SDS polyacrylamide gel of 
proteins to be transferred was placed on top of the membrane, followed by three 
more layers of soaked blotting paper before transfer took place (10 V, 1 hour). A 
BSA (µl) Bradford Reagent (μL) dH2O 
0 200 800 
1 200 799 
3 200 797 
5 200 795 
8 200 792 
10 200 790 
15 200 785 
Sample (µl) Bradford Reagent (μL) dH2O 
1 200 800 
3 200 797 
5 200 795 
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blocking solution of 5% (w/v) fat-free skimmed milk powder in 1 x TBST (50 mM Tris 
Cl pH 7.5, 150 mM NaCl, 1% Tween) was poured over the membrane and incubated 
at room temperature overnight with gentle agitation.  Anti-Flag antibody conjugated 
to horseradish peroxidase (HRP) was diluted 1: 20,000 in 1 x TBST and used to check 
strains containing 3xFlag tagged proteins.  The membrane was incubated in 20ml of 
the respective antibody suspension at room temperature for 1 hour and washed 3 
times for 10 minutes in TBST.  Membranes were developed for 1 minute in a 50:50 
mix of solutions A and B (Table 2.10) and fluorescence was detected using the ECL 
setting for imaging using a SYNGENE G:Box.  
Table 2.10: Constituents of developing solutions used in this thesis 
 
 
 
 
2.34 Analysis of compounds by UV-Vis 
 
Samples were analysed by UV-Vis using the Nanodrop 2000 UV-Vis 
spectrophotometer to generate wavelength scans between 200 and 800 nm. 
2.35 RNA Extraction 
 
For all RNA work, RNase-free water was prepared by DEPC treating (0.1% v/v) at 37°C 
O/N and autoclaving twice before use.  All other equipment required for the 
processing of RNA was double autoclaved before use. 
Samples were harvested using a sterile spatula from plates with cellophanes and 
flash frozen in liquid nitrogen for storage at -80°C before extraction.  Pellets were 
thawed and crushed in liquid nitrogen using a sterile pestle and mortar on dry ice.  
Samples were resuspended in 1 mL RLT Buffer (Qiagen) supplemented with b-
mercaptoethanol (10 µl in every 1 ml buffer) and vortexed for 1 minute.  Samples 
were then applied to a QIA-shredder column (Qiagen) and centrifuged for 2 minutes.  
Developing Solution A Developing Solution B 
10 ml 100 mM Tris pH 8.5 10 ml 100 mM Tris pH 8.5 
100 µl luminal 6 µl 30% hydrogen peroxide 
45 µl coumaric acid  
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Flow through was collected (leaving the pellet behind) and mixed with 700 µl acidic 
phenol-chloroform for 1 minute.  Samples were then incubated at room temperature 
for 3 minutes before centrifuging at 13000 rpm for 20 minutes.  The upper phase was 
collected and mixed with 0.5 volumes of 96% ethanol.  This was then applied to a 
RNeasy Mini spin column (Qiagen) and purified following the manufacturers protocol 
including on column DNase treatment.  Following elution, the Turbo-DNase kit was 
then used according to the manufacturers protocol and a further Qiagen RNeasey 
mini clean-up was conducted.  Samples were then aliquoted for quantification or 
other downstream processes and flash frozen in liquid nitrogen for storage at -80°C. 
2.36 RNA Quantification 
 
For quantification, RNA was analysed by Nanodrop and formaldehyde gel 
electrophoresis.  To prepare the formaldehyde gel, 1.2 g agarose was mixed with 10 
ml 10x FA buffer (200mM 3-[N-morpholino]propanesulfonic acid (MOPS), 50 mM 
sodium acetate, 10 mM EDTA, pH to 7.0 with NaOH) and RNase free water to 100 ml, 
heated and cooled to 65°C in a water bath.  1.8 ml 37% formaldehyde and 1ul 10 
mg/ml ethidium bromide was added and the gel poured into a pre-treated, RNase-
free gel support.  1 volume of RNA loading buffer (16 µl bromophenol blue, 80 µl 500 
mM EDTA pH 8.0, 720 µl 375 formaldehyde, 2 ml 100% glycerol, 3.084 ml formamide, 
4 ml 10 x FA gel buffer, RNase free water to 10 ml) was added to 4 volumes of RNA.  
Samples were incubated at 65°C for 3-5 minutes, chilled on ice and loaded onto the 
gel.  The gel was run at 70V in 1 x FA gel running buffer (100 ml 10X FA gel buffer, 20 
ml 37% formaldehyde, 880 ml RNase-free water) for approximately 1 hour. 
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2.37 RT-PCR 
 
RT-PCR reactions were conducted using the Qiagen OneStep RT-PCR Kit.  Reactions 
were set up in 50 µl volumes (Table 2.11).  To each reaction, 1 µl RNA was added. 
Table 2.11: Constituents of RT-PCR reactions used in this thesis 
Reagent 50 µl reaction Final concentration 
RNase-free water variable  
5x Qiagen OneStep RT-PCR Buffer   10.0 µl 1x 
dNTP mix (containing 10 mM of each dNTP) 2.0 µl 400 µM of each dNTP 
Forward primer variable 0.6 µM 
Reverse primer variable 0.6 µM 
Qiagen OneStep RT-PCR Enzyme Mix 2.0 µl  
Thermocyclers were programmed as follows including an initial heating step at 95°C 
for 15 minutes to activate HotStarTaq DNA Polymerase (Table 2.12). 
Table 2.12: Reaction conditions for RT-PCR reactions conducted in this thesis 
Cycles Temperature Time Notes 
1 50°C 30 min Reverse transcription 
2 95°C 15 min Initial PCR activation step 
30 
95°C 30 sec Denaturation 
55°C to 72°C 30 sec 
Anneal (Tm was calculated using NEB 
calculator 
(http://tmcalculator.neb.com/#!/)) 
72°C 30 sec per kb Extension 
1 72°C 10 min Final extension 
1 4°C hold Final hold 
 
PCR products were analysed by gel electrophoresis with no-RT controls to confirm 
no contamination of gDNA (Chapter 2.10). 
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2.38 Cappable RNA Sequencing 
 
RNA was sent to Vertis Biotechnologie AG for sequencing and analysed by capillary 
electrophoresis.  The RNA was then enriched by capping the 5’ triphosphorylated 
RNA with 3’-desthiobiotin-TEG-guanosin 5’ triphosphate (DTBGTP) (NEB) using the 
vaccinia capping enzyme (VCE) (NEB) for reversible binding of biotinylated RNA 
species to streptavidin.  Enriched RNAs were poly(A)-tailed using poly(A) polymerase.  
5’Illumina TruSeq sequencing adapters (carry 50% of each tag; ATTACTCG and 
TCCGGAGA) were then ligated to the 5’ mono-phosphate groups of processed 
transcripts.   The samples were then treated with CapClip Acid Pyrophosphatase 
(Cellscript) to convert 5’ triphosphate (5’PPP) structures into 5’ monophosphate 
ends.  To the newly formed 5’P groups, the 5’ Illumina TruSeq sequencing adapters 
(carry 50% of each tag; CGCTCATT and GAGATTCC) were ligated.  First-strand cDNA 
synthesis was performed using an oligo(dT)- adapter primer and the M-MLV reverse 
transcriptase.  The resulting cDNAs were PCR-amplified to about 10-20 ng/µl using a 
high-fidelity DNA polymerase. 
For Illumina sequencing, 100-300 bp long 5’ fragments were isolated from the full-
length cDNAs.  The cDNA was fragmented and the 5’-cDNA fragments were bound to 
streptavidin magnetic beads.  The bound cDNAs were blunted and the 3’ Illumina 
sequencing adapter ligated to the 3’ ends before PCR amplification.  The cDNA 
libraries were pooled in approximately equimolar amounts and confirmed to be 
around 200-500 bp.  The cDNA pool was sequenced on an Illumina NextSeq 500 
system using a 75 bp read length.  
FASTQ sequencing files were sorted, quality checked, trimmed to remove rRNA 
reads, mapped and annotated by Vertis Biotechnologie AG. 
2.39 Chromatin Immuno-precipitation (ChIP) Sequencing 
 
For ChIP-seq experiments, spores were inoculated onto cellophane disks on SFM 
plates and grown for 2-4 days at 30°C.  The discs were removed and the mycelium 
submerged in 10 ml of a 1% (v/v) formaldehyde solution for 20 minutes at room 
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temperature to cross-link proteins to DNA.  The discs were then incubated in 10 ml 
of 0.5 M glycine for 5 minutes before the mycelium was harvested, washed twice 
with 25 ml ice-cold PBS (pH 7.4) and flash frozen at -80°C until needed.  At the same 
time, a small sample was taken for western blot analysis to confirm expression of the 
tagged protein of interest. 
For all downstream steps, EDTA-free protease inhibitor tablets were added to 
working solutions (2 tablets per 10 ml buffer).  To lyse the cells, pellets were 
resuspended in 2 ml lysis buffer (10 mM Tris-HCl pH 8.0, 50 mM NaCl, 10 mg/ml 
lysozyme) and incubated at 37°C for 30 minutes.  To fragment the DNA, 1 ml IP buffer 
(100 mM Tris-HCl pH 8.0, 500 mM NaCl, 1% v/v Triton-X) was added and samples 
mixed by pipetting up and down.  Samples were sonicated 20 times at 50 Hz, for 10 
seconds per cycle, and incubated on ice for >2 minutes between pulses.  
25 µl of crude lysate was mixed with 75 μl TE buffer (10 mM Tris-HCl pH 8.0, 1 mM 
EDTA) and extracted with 200 μl phenol:chloroform.  Of this extract, 25 μl was 
harvested and 2μl RNaseA (1mg/ml) was added.  This was incubated at 37°C for 30 
minutes and run on a 1% agarose gel to confirm the DNA fragments were within the 
desired size range for sequencing. 
Once fragmentation was confirmed, the remaining crude lysate was cleared by 
centrifugation at 4000 rpm for 15 minutes at 4°C.  For binding, 500μl Anti-FLAG M2 
magnetic beads were prepared by washing in 2.5 ml 0.5 IP buffer.  40μl of the 
prepared beads were incubated with the cleared lysate for each sample on a vertical 
rotor overnight at 4°C.  The beads were washed with 0.5 IP x 4 for 10 minutes each 
at 4°C.   
To elute the bound DNA, 100 μl elution buffer (50mM Tris-HCl pH 8.0, 10 mM EDTA, 
1% SDS) was added and samples incubated at 65°C overnight.  Another 50 μl elution 
buffer was added and the samples incubated for a further 5 minutes at 65°C.  The 
150 μl total eluate was purified by adding 2 μl proteinase K and incubating at 55°C 
for 1.5 hours.  DNA was extracted in 150 μl phenol-chloroform and purified on a 
QIAquick column (Qiagen).  DNA was eluted in 50 μl EB buffer (10 mM Tris-HCl pH 
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8.5); 45 μl was frozen for sequencing and 5 μl retained for quantification by nanodrop 
and Qubit (Chapter 2.7).  The DNA was then sent to GenewizÒ for sequencing using 
the Illumina HiSeq platform.   
2.40 Analysis of ChIP-Sequencing data 
 
Raw sequencing data were received as FASTQ files from GenewizÒ and processed by 
Dr Govind Chandra at the JIC.  Raw reads were aligned to the reference genome and 
extracted coordinates were listed in .bed files.  These .bed files were visualised in 
Integrated Genome Browser (IGB) to show peaks of enrichment present across the 
whole genome.  A cut off of around 2000 reads was enough to remove background 
noise and visualise only the significant peaks that indicate binding sites for each 
protein.   
2.41 Solid culture colony bioassay 
 
To assess the antibiotic production by a strain in solid culture, an agar plate (usually 
MYM, SFM for growth of C. albicans, see table 2.1) was inoculated in the centre with 
2 μl Streptomyces spores and incubated at 30°C for 5-10 days.  To overlay the 
bioassays with E. coli, MRSA, Bacillus subtilis or Candida albicans, the indicator strains 
were grown overnight in 10 ml LB at 30°C, and sub-cultured for 3-4 hours the 
following day to ensure the cells were in exponential growth phase.  The subculture 
was diluted 1 in 10 into soft LB (0.5% agar) at 50°C which was used to overlay the 
plate.  The hydrophobic nature of the Streptomyces colony means the overlay will 
not go over the top of the colony, but rest around the outer edge. 
For Lomentospora prolificans, the fungus was re-streaked from a PGA stock plate 
onto the plate with the growing Streptomyces colony.  E. coli, MRSA and B. subtilis 
assays were incubated at 30°C overnight before being visually examined.  C. albicans 
plates were incubated at room temperature for 2-3 days until visible 
growth/inhibition was evident.  Bioassays inoculated with L. prolificans were 
incubated at 30°C for 1 week or until sufficient growth/inhibition was evident. 
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3 Identifying the formicamycin biosynthetic gene cluster and the 
mode of action of the formicamycins 
 
Understanding the biosynthesis of a natural product depends on the characterisation 
of the biosynthetic gene cluster (BGC).  The aim of this work is to identify the genes 
responsible for the biosynthesis of the formicamycins in Streptomyces formicae.  
Finding the genes responsible for the assembly of a particular microbial metabolite 
is extremely important; in order to obtain high yields of a compound of interest it is 
often necessary to generate mutations in the BGC in the native producer or even 
heterologously express the genes in a microorganism that is more genetically 
tractable (Ward and Allenby, 2018).  Furthermore, increasing our understanding of 
secondary metabolite production in nature can inform future drug discovery and 
synthesis efforts by medicinal chemists.  Identifying a BGC in the native host usually 
requires that the organism is genetically tractable.  When working with 
environmental isolates of Streptomyces, this can be especially challenging as the 
biomass available for laboratory investigation is often limited due to difficulties in 
culturing the organism and many of the traditional genetic tools are not directly 
applicable.  The availability of a high-quality genome sequence for S. formicae meant 
that bioinformatic analysis could be applied in combination with a newly developed 
CRISPR/Cas9 tool for genetic manipulation of this environmental isolate in order to 
identify the genes responsible for the biosynthesis of the formicamycins. 
When working with novel natural products, it is also important to identify their 
mechanism of action, as this can provide an insight into the potential toxicity of the 
agent and therefore its suitability for development into a clinically useful drug.   As 
described in Chapter 1.8, the formicamycins display clear antimicrobial activity 
against Gram-positive pathogens, however, no mechanism of action has previously 
been defined, so this is also investigated during this chapter.   
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3.1 Identifying the formicamycin biosynthetic gene cluster 
 
Using the previously described AntiSMASH analysis of the S. formicae genome, the 
predicted BGCs were examined to identify potential genes that may be involved in 
the biosynthesis of the formicamycins. The halogenation of the compounds enabled 
any clusters without halogenase enzymes to be eliminated.  This left three BCGs (8, 
26 and 27), only one of which was predicted to be a T2PKS gene cluster (BGC 26) 
(Table 1.1).  Based on the aromatic structure of the compounds, it was predicted that 
this cluster must be responsible for the production of the formicamycins.  Putative 
gene products were assigned using the National Centre for Biotechnology 
Information (NCBI) Basic local alignment search tool (Blast) (Altschup et al., 1990) 
(Figure 3.1).  The predicted T2PKS cluster contains genes encoding for the ACC 
carboxylase enzymes necessary for making the extender units for polyketide 
biosynthesis, as well as the essential acyl-carrier protein and ketosynthase enzymes 
for building the polyketide backbone.  In addition, there are 5 putative cyclase 
enzymes encoded in the BGC, which may correspond with the pentacyclic structure 
of the formicamycins, as well as several methyltransferases, including two O-
methyltransferases, which could be responsible for the O-methylation at R5 and R6 
(Figure 1.5).  There is also a putative halogenase enzyme encoded within this cluster.  
The formicamycins can be chlorinated at up to four positions on the carbon chain, 
which would require at least one halogenase enzyme.  Finally, there are also several 
regulatory genes and transporters that are common within BGCs encoding 
antimicrobial secondary metabolites. 
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# Gene AA Annotation # Gene AA Annotation 
1 orf4 306 NAD-dependent 
epimerase/dehydratase 
23 forS 106 Monooxygenase/cyclase 
2 orf3 336 MarR family 
transcriptional regulator 
24 forT 342 O-Methyltransferase 
3 orf2 199 Hypothetical protein 25 forU 119 Monooxygenase/cyclase 
4 orf1 170 Transposase 26 forV 430 Halogenase 
5 forQ 422 Decarboxylase 27 forW 341 O-Methyltransferase 
6 forP 217 b-lactamase 
(metallohydrolase) 
28 forX 571 Monooxygenase 
7 forO 259 Exodeoxyribonuclease III 29 forY 315 Oxidoreductase 
8 forN 590 Acylhydrolase 30 forZ 172 MarR family 
transcriptional regulator 
9 forM 261 Methyltransferase 31 forAA 513 Multidrug resistance 
protein 
10 forL 113 PKS cyclase 32 forBB 220 LuxR family response 
regulator 
11 forK 478 Na+/H+ exchanger 33 forCC 417 Sensor histidine kinase 
12 forJ 149 MarR family 
transcriptional regulator 
34 orf6 321 ABC transporter 
13 forI 455 ACC biotin carboxylase 35 orf7 284 ABC transporter 
permease 
14 forH 607 ACC carboxyl transferase 36 orf8 529 Glutamate synthase 
15 forG 363 Sensor histidine kinase 37 orf9 166 Hypothetical protein 
16 forF 219 LuxR family response 
regulator 
38 orf10 203 Hypothetical protein 
17 forE 171 ACC biotin carboxy carrier 
protein 
39 orf11 164 Hypothetical protein 
18 forD 153 PKS cyclase/dehydratase 40 orf12 247 Glutamate ABC 
transporter 
19 forC 96 PKS ACP 41 orf13 310 ABC transporter 
substrate binding protein 
20 forB 415 KSb 42 orf14 214 ABC transporter 
permease 
21 forA 420 KSa 43 orf15 289 ABC transporter 
permease 
22 forR 131 Cupin 
(cyclase/monooxygenase) 
    
Figure 3.1: Predicted T2PKS BGC by AntiSMASH 4.0 and annotation of putative gene products assigned 
using NCBI Blast.  AA = number of amino acids; ACC = acetyl-CoA carboxylase; PKS = polyketide 
synthase (Qin et al., 2017). 
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Heterologous expression of the predicted formicamycin BGC in multiple 
Streptomyces superhosts including S. coelicolor M1152, M1146, M1154 and S. 
venezuelae M1714, M1702 and M1711 did not result in the production of any 
compounds (data not shown).  Therefore, to confirm this predicted T2PKS gene 
cluster is responsible for formicamycin biosynthesis, experiments were designed to 
delete the entire predicted BGC in the producing organism.  As with many 
environmental isolates, little was known about the ideal growth conditions for S. 
formicae and no attempts had previously been made to genetically manipulate the 
strain.  A cosmid library was not available, so traditional methods of gene editing 
were not applicable, therefore CRISPR/Cas9 was chosen as the most appropriate 
method to optimise for use in S. formicae.   
Generating the required plasmid for deletion of the predicted formicamycin BGC was 
relatively simple, as good quality genomic DNA could be isolated from S. formicae 
grown in liquid medium and used for cloning into the pCRISPomyces-2 backbone.  
However, in order to move the finished plasmid into S. formicae, it was necessary to 
obtain dense spore stocks for use in conjugation reactions with E. coli, therefore 
media screens were carried out to identify the optimal growth conditions for 
sporulation of S. formicae under laboratory conditions.  Eight media recipes were 
initially tested and the resulting biomass was examined under a light microscope.  
Methods of stressing the bacteria into sporulation by nutrient starvation were 
unsuccessful as no growth was evident on water agar after 1 month’s incubation at 
30°C and there was limited growth on minimal media under the same conditions.  
Growth on SFM, SMASH agar and ISP4 was good after 10 days, however, limited signs 
of sporulation were visible under the light microscope (data not shown) (Table 2.1).  
Good growth and sporulation were evident on MYM, ISP2/YEME and oat agar after 
10 days at 30°C, so these samples were further analysed using scanning electron 
microscopy (SEM) conducted by Elaine Barclay at the John Innes Centre to determine 
which medium would be optimal for generating spore stocks of S. formicae (Figures 
3.2-3.4). 
While all three samples did contain sporulating S. formicae, samples grown on MYM 
showed the most even and healthy spores.  The spore chains cultured on ISP2/YEME 
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have a thin and ropey appearance.  There is also a variety of different spore sizes 
present, which may be indicative of uneven chromosomal segregation.  Similarly, the 
samples grown on oat agar appear thin and under-developed.  Although growth 
seems to be denser on oat agar than on ISP2/YEME, some of the hyphae have still 
not differentiated into spores at day 10.  Furthermore, there is evidence of uneven 
septum distribution when sporulation does occur.  In contrast, the MYM samples 
show dense growth with smoother chains of spores that are all even in size, 
suggesting regular chromosomal segregation. 
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Figure 3.2: Streptomyces formica was grown on ISP2 YEME agar for 10 days at 30°C, flash frozen in liquid nitrogen and visualised by cryo-SEM at the John Innes 
Centre by Elaine Barclay.  Samples were visually inspected for signs of sporulation at a variety of magnifications.  Samples are pictured here at A: 5000x magnification 
and B: 10 000x magnification. Sporulation is evident although septum distribution appears uneven in places. 
A B 
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Figure 3.3: Streptomyces formica was grown on MYM agar for 10 days at 30°C, flash frozen in liquid nitrogen and visualised by cryo-SEM at the John Innes Centre 
by Elaine Barclay.  Samples were visually inspected for signs of sporulation at a variety of magnifications.  Samples are pictured here at A: 5000x magnification and 
B: 10 000x magnification.  Healthy sporulation is evident and growth is dense. 
A B 
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Figure 3.4: Streptomyces formica was grown on oat agar for 10 days at 30°C, flash frozen in liquid nitrogen and visualised by cryo-SEM at the John Innes Centre by 
Elaine Barclay.  Samples were visually inspected for signs of sporulation at a variety of magnifications.  Samples are pictured here at A: 6000x magnification and B: 
10 000x magnification.   Sporulation is evident although septum distribution appears uneven in places. 
A B 
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Spores were thus prepared from 10-day old cultures of S. formicae grown on MYM 
agar.  A 20 nucleotide protospacer was designed to be specific to a region within the 
predicted formicamycin BGC.  This oligonucleotide was assembled into the BbsI site 
of the pCRISPomyces-2 vector by golden gate assembly (Chapter 2.16) to confer 
target site specificity.  Then, 1kb flanking arms were PCR amplified from either side 
of the putative formicamycin BGC and assembled together into the XbaI site using 
Gibson assembly (Chapter 2.17) to generate a vector that would encourage the 
complete, clean deletion of the 46 kb region predicted by AntiSMASH using the 
method described in Figure 1.7.  Although a dense spore stock was used, only five 
colonies were obtained from conjugation reactions between wild-type S. formicae 
and E. coli ET12567 pUZ8002 containing the deletion vector.  Nevertheless, three of 
the five were confirmed to contain the desired deletion and were cured of the 
plasmid resulting in three biological replicates of the unmarked, whole cluster 
deletion mutant (S. formicae Dfor). These mutants were confirmed by PCR and 
sequencing of the resulting PCR product as described in Chapter 2.23.  To determine 
whether the deletion of the T2PKS cluster had any effect on formicamycin 
production, the three mutants were grown in parallel with the wild-type control 
under previously established formicamycin producing conditions (incubation at 30°C 
for 9 days on SFM agar).  LCMS analysis of mutant extracts (conducted by Dr Zhiwei 
Qin, JIC) confirmed that no fasamycins or formicamycins were produced by the S. 
formicae Dfor strains (Figure 3.5) (Qin et al., 2017).   
To ensure that loss of fasamycin and formicamycin biosynthesis was due to deletion 
of the T2PKS gene cluster and not off target effects, genetic complementation of the 
mutant was required.  BioS&T Co. (Montreal, Canada) generated a P1-derived 
artificial chromosome (PAC) library of the S. formicae genome made in pESAC13 and 
they screened the library using three primer pairs, one each for the beginning, middle 
and end of the predicted formicamycin BGC, to identify a single clone carrying the 
entire predicted BGC.  This clone, named pESAC13-215-G, was used to re-introduce 
the whole BGC in trans to generate S. formicae ∆for: ΦC31 for 215-G.  LCMS analysis 
of this complemented strain confirmed fasamycin and formicamycin biosynthesis 
had been restored in the mutant, although titres were lower in the complemented 
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strain than in the wild-type.  This is probably because the cluster is expressed in trans 
and not in its native locus, resulting in changes in the levels of transcription.  
Nevertheless, these results indicate that the predicted BGC does indeed encode for 
the biosynthesis of the fasamycins and formicamycins in S. formicae (Figure 3.5) (Qin 
et al., 2017). 
 
Figure 3.5: HPLC traces (UV 250 nm) showing extracts of: (A) S. formicae wild-type; (B) S. formicae 
Dfor; (C) S. formicae Dfor: ΦC31 for 215-G with any peaks from blank media removed.  Deletion of the 
T2PKS BGC abolished fasamycin and formicamycin production.  Re-introducing the cluster in trans 
restored production of all compounds, although at lower titres than in the wild-type (Qin et al., 2017).  
Three biological replicates of each strain were generated for analysis.  The presence of all compounds 
labelled was confirmed by LCMS analysis.  HPLC(UV) and LCMS analysis was conducted by Dr Zhiwei 
Qin at the John Innes Centre. 
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3.2 Defining the edges of the formicamycin BGC 
 
Having identified the BGC responsible for the biosynthesis of the fasamycins and 
formicamycins, we next wanted to identify the roles of the gene products encoded 
by this BGC.  Often, BGCs predicted by AntiSMASH are larger than the minimal cluster 
of genes required for compound biosynthesis.  In accordance with this, the predicted 
gene annotations in the formicamycin cluster suggest that several of the genes at the 
cluster edges may not be required for fasamycin or formicamycin biosynthesis 
(Figure 3.1). 
As such, the ReDirect method was used to sequentially PCR target the edges of the 
gene cluster on the pESAC13-215-G DNA in E. coli (Gust et al., 2004).  The ReDirect 
method allows genes of interest to be deleted and replaced by a resistance cassette.  
In this case, the protocol was modified slightly so that the genes were replaced with 
just an apramycin resistance gene.  The entire resistance cassette described in the 
original protocol was not used since there is already on oriT in the PAC and having 
one in the cassette as well would result in undesired recombination events.  The 
altered PACs with truncated versions of the formicamycin BGC were then conjugated 
into S. formicae Dfor.  Levels of formicamycin production were compared between 
all strains to determine the effect of removing either edge of the BGC on the 
progression of the biosynthetic pathway. 
Initially genes 1-4 and 36-43 were deleted and replaced with the apramycin 
resistance gene.  When these altered cosmids were introduced into S. formicae Dfor, 
all the fasamycins and formicamycins were produced at approximately wild-type 
levels, suggesting the deleted genes are not required for their biosynthesis (data not 
shown, HPLC(UV) LCMS conducted by Dr Zhiwei Qin, JIC).  The experiment was then 
repeated to remove genes 1-7 and 34-43.  Similarly, production of all fasamycins and 
formicamycins was evident in these strains (Figure 3.6).  
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Figure 3.6: HPLC traces (UV 250 nm) showing extracts of: (A) S. formicae wild-type; (B) S. formicae Dfor; (C) S. formicae Dfor: jC31 for 1-7 aac(3) IV; (D) S. formicae 
Dfor: jC31 for 32-43 aac(3) IV.  The edges of the formicamycin BGC were PCR targeted and replaced with an apramycin resistance gene to determine the minimal 
cluster required for biosynthesis.  Expression of the edited, truncated BCGs in the S. formicae Dfor mutant resulted in production of all compounds, therefore genes 
1-7 and 34-43 are not required for fasamycin and/or formicamycin biosynthesis.  Three biological replicates of each strain were generated for analysis.  HPLC(UV) 
LCMS analysis conducted by Dr Zhiwei Qin at the John Innes Centre. 
0
100
200
300
400
500
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
0
100
200
300
400
500
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
B
0
100
200
300
400
500
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
C
0
100
200
300
400
500
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
D
1
4 3
13
12
6-11
2 5
1 43
13
12
6-11
25
1
43 1312
6-11
25
A
 90 
This shows that genes 1-7 and 34-43 are not required for the biosynthesis of the 
formicamycins.  Further experiments (described later) also indicate that ForBB and 
ForCC (genes 32 and 33) are not required for fasamycin or formicamycin biosynthesis 
(Chapter 4.2).  Therefore, the minimal BGC was defined as the core 24 genes 
identified by AntiSMASH, from forN (gene 8) to forAA (gene 31) (Figure 3.7). 
 
# Gene AA Annotation # Gene AA Annotation 
8 forN 590 Acylhydrolase 20 forB 415 KSb 
9 forM 261 Methyltransferase 21 forA 420 KSa 
10 forL 113 PKS cyclase 22 forR 131 Cupin 
(cyclase/monooxygenase) 
11 forK 478 Na+/H+ exchanger 23 forS 106 Monooxygenase/cyclase 
12 forJ 149 MarR family 
transcriptional 
regulator 
24 forT 342 O-Methyltransferase 
13 forI 455 ACC biotin carboxylase 25 forU 119 Monooxygenase/cyclase 
14 forH 607 ACC carboxyl 
transferase 
26 forV 430 Halogenase 
15 forG 363 Sensor histidine kinase 27 forW 341 O-Methyltransferase 
16 forF 219 LuxR family response 
regulator 
28 forX 571 Monooxygenase 
17 forE 171 ACC biotin carboxy 
carrier protein 
29 forY 315 Oxidoreductase 
18 forD 153 PKS 
cyclase/dehydratase 
30 forZ 172 MarR family transcriptional 
regulator 
19 forC 96 PKS ACP 31 forAA 513 Multidrug resistance 
protein 
Figure 3.7: The defined, minimal formicamycin (for) BGC and predicted gene products. 
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3.3 Identifying the enzyme responsible for halogenation of the formicamycins 
 
There are nearly 5000 reported halogenated natural products, many of which are 
antibiotics.  In fact, around 20% of all reported active pharmaceutical agents are 
halogenated compounds.  As stated previously, the formicamycins can be 
chlorinated at up to four positions on the carbon chain and supplementation of the 
S. formicae growth media with sodium bromide results in the production of 
additional brominated congeners (Qin et al., 2017).  Increased halogenation of the 
formicamycin backbone increases antimicrobial activity against Gram-positive 
bacteria.  The beneficial effects of a carbon-halogen bond include increased stability 
against biodegradation and oxidation, as well as increased membrane permeability, 
both of which will contribute to increased bioactivity in most molecules (Cantillo and 
Kappe, 2017; Latham et al., 2017).  It is unsurprising therefore that incorporation of 
one or more halogen atoms into organic molecules is one of the most important and 
often required transformations in organic synthesis.  Currently, synthetic 
halogenation events present a challenge industrially as they often require expensive 
reagents that are highly corrosive and result in the generation of toxic waste products 
(Pongkittiphan, Theodorakis and Chavasiri, 2009; Schnepel and Sewald, 2017).  As 
such, there has been a lot of interest in biological halogenation in recent years.  
Halogenase enzymes usually display high regioselectivity (van Pée et al., 2016).  It is 
surprising therefore that the formicamycin BGC only contains a single predicted 
halogenase, given that there are four different sites for potential halogenation.  One 
possibility is that other halogenase enzymes encoded elsewhere in the genome are 
involved in halogenation of the formicamycins at R1-4. To investigate this, 
CRISPR/Cas9 was used to delete forV, which encodes the predicted halogenase 
within the for BGC, to generate the mutant strain S. formicae DforV.  The extracts of 
three forV deletion mutants were analysed by HPLC(UV) LCMS by Dr Zhiwei Qin.  
Deletion of forV abolished the production of any halogenated fasamycins or 
formicamycins.  Only fasamycin C, the non-halogenated fasamycin, along with a 
predicted structural isomer of the same compound with the same molecular 
formulae and UV spectrum, were present.  The isomer has not been isolated and 
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therefore its structure remains unknown.  The production level of fasamycin C (1) in 
S. formicae DforV was also much higher than is observed in the wild-type strain.  Re-
introduction of forV in trans under the predicted native promoter reinstated the 
production of all compounds at approximately wild-type levels (Figure 3.8).  This 
suggests ForV acts non-specifically at all 4 different positions on the 
fasamycin/formicamycin backbone.  Furthermore, the data indicate that ForV 
performs a gatekeeper role in controlling progression of the biosynthetic pathway 
as, when forV is deleted, only the non-chlorinated fasamycin accumulates, with no 
evidence of any non-halogenated formicamycins present in the extract of the 
mutant, implying halogenation must occur before formicamycin biosynthesis can be 
initiated (Qin et al., 2017).   
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Figure 3.8: HPLC traces (UV 250 nm) showing extracts of: (A) S. formicae wild-type; (B) S. formicae 
DforV; (C) S. formicae DforV: jBT1 forV pforU.  Deletion of forV results in the production of non-
halogenated fasamycin C (1) only, the structure of which is shown in the insert.  Re-introducing forV 
in trans restores production of all compounds (Qin et al., 2017).  Scales are increased to demonstrate 
the accumulation of fasamycin C (1) in S. formicae DforV.  The presence or absence of all fasamycins 
and formicamycins was confirmed by LCMS and is indicated by UV traces with smaller scales in the 
inserts where necessary. Three biological replicates of each strain were generated for analysis.  
HPLC(UV) LCMS analysis conducted by Dr Zhiwei Qin at the John Innes Centre. 
ForV is predicted by BlastP to be a FAD-dependent halogenase, a member of the 
flavin-dependent monooxygenase family, to which the extensively studied 
tryptophan halogenases also belong.  Halogenation by these enzymes is usually 
carried out in the presence of O2, Cl- and FADH2, which is formed by the reduction of 
the FAD cofactor by a reductase enzyme (Dorrestein et al., 2005).  Using this reduced 
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flavin, these enzymes can then go on to activate molecular oxygen to generate C4a-
hydroperoxy flavin, which allows diverse downstream reactions such as 
hydroxylation and Baeyer-Villager oxidation to occur in many NRPS and PKS 
pathways.  Although chlorination by these halogenases is more common, they are 
also able to brominate their substrate if appropriate concentrations of bromine are 
present in the surrounding environment (Latham et al., 2017).  Due to the fact that 
flavin-dependent halogenases display high regioselectivity and often halogenate at 
chemically unfavourable positions, much investigation into the structures and 
mechanisms of these enzymes has been conducted in recent years (Schnepel and 
Sewald, 2017).   
All flavin-dependent halogenases contain a characteristic GxGxxG motif for flavin 
binding.  In addition to this, all known FAD-dependent halogenase enzymes display 
high structural similarity.  There are usually two distinct sites for substrate binding 
and cofactor binding, often separated by around 10 Å in distance.  The flavin cofactor 
is usually located near the surface, to allow for rapid reduction of FAD even in the 
absence of the substrate, whereas the substrate binding site is buried deep within 
the protein (Schnepel and Sewald, 2017).  To connect these sites, there is a tunnel of 
non-polar residues leading to the active site, often containing the WxWxIP motif 
(Latham et al., 2017).  At the end of this tunnel, there is a highly conserved lysine 
residue in the active site which interacts with the chlorinating agent either via 
hydrogen bonding or by forming a chloramine intermediate, to enable halogenation 
of the substrate (Andorfer and Lewis, 2018).  Several studies have shown that 
mutating this residue in other flavin-dependent halogenases (K79 in RebH and PrnA, 
K74 in Rdc2 and RadH) completely abolishes halogenation activity in the enzyme 
(Dong et al. 2005; Yeh et al. 2006; Menon et al. 2017; Andorfer & Lewis 2018).  
Modelling in Swiss-model reveals that ForV shows the greatest homology to CndH 
(34.99% identity), an FAD-dependent halogenase involved in the biosynthesis of the 
antimicrobial secondary metabolite chondrochloren by the myxobacterium, 
Chondromyces crocatus Cm c5 (Jansen et al., 2003; Buedenbender et al., 2009; 
Rachid et al., 2009; Waterhouse et al., 2018).  Similarly, analysis of ForV in I-TASSER 
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showed that the structural templates with the highest significant similarity to ForV 
were likely to be those of CndH and PltA, a flavin-dependent halogenase from the 
pyoluteorin biosynthetic gene cluster in Pseudomonas fluorescens Pf-5 (Roy, 
Kucukural and Zhang, 2010; Pang, Garneau-Tsodikova and Tsodikov, 2015).  
Pyoluteorin is an antifungal produced by a PKS-NRPS hybrid BGC halogenated by PltA 
at two sites on the scaffold (Figure 3.9).  PltA was one of the first flavin dependent 
halogenases to be functionally characterised (Pang, Garneau-Tsodikova and 
Tsodikov, 2015).  Alignment of ForV with CndH and PltA using T-Coffee multiple 
sequence alignment tools (Notredame, Higgins and Heringa, 2000) shows that all 
three protein sequences contain the characteristic lysine residue at position 76 (Lys-
76), highlighted in green, and the WxWxIP fingerprints, highlighted in yellow, as well 
as the GxGxxG motif common to all flavin binding monooxygenases, highlighted in 
cyan (Figure 3.10).  ForV and CndH display the highest sequence similarity to one 
another, although PltA also aligns well at the active site and the cofactor binding site.  
Interestingly, all three peptide sequences show unique C-terminal regions that do 
not align well to each other.  This region may therefore serve an alternative function 
and be highly evolved and specific for each antibiotic biosynthesis pathway. 
 
Figure 3.9: Structures of the halogenated natural products, chondrochloren and pyoluteorin.  The 
halogenase enzymes responsible for the addition of the chlorine atoms on the rings of these molecules 
show similarity to ForV from the for BGC, therefore they may act via similar mechanisms. 
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CLUSTAL W (1.83) multiple sequence alignment 
CndH            MSTR-PEVFDLIVIGGGPGGSTLASFVAMRGHRVLLLEREAFPRHQIGES 
ForV            MSDQ-QRHYDVVVVGGGPAGASTAALLATEGRSVLVLEREKFPRYHIGES 
PltA            GPHMSDHDYDVVIIGGGPAGSTMASYLAKAGVKCAVFEKELFEREHVGES 
                 .    . :*::::****.*:: *: :*  *    ::*:* * * ::*** 
CndH            LLPATVHGICAMLGLTDEMKRAGFPIKRGGTFRWGKEPEPWTFGFTRH-- 
ForV            LIPGVW-PTLDRLGLRERLENMGLVRKYGGTLVWGRDLPQWTFSFA---- 
PltA            LVPATT-PVLLEIGVMEKIEKANFPKKFGAAWTSADSGPEDKMGFQGLDH 
                *:*..       :*: :.::. .:  * *.:   . .    .:.*    
   
CndH            --------------PDDPYGFAYQVERARFDDMLLRNSERKGVDVRERHE 
ForV            --------------DGGPYPYAYQVRRADFDALLLTRARELGAHVVEDAT 
PltA            DFRSAEILFNERKQEGVDRDFTFHVDRGKFDRILLEHAGSLGAKVFQGVE 
                               .    ::::* *. ** :** .:   *..* :    
CndH            VIDVLFEGERAVGVRYRNTEGVELMAHARFIVDASGNRTRVSQAVGERVY 
ForV            VKEPLFDGERMTGVRYQPRGGDPVEAHADLVVDASGQQRWLGRHFDLIRW 
PltA            IADVEFLSPGNVIVNAK-LGKRSVEIKAKMVVDASGRNVLLGRRLGLREK 
                : :  * .   . *. :      :  :* ::*****..  :.: ..     
CndH            SRFFQNVALYGYFENGKRLPAPRQGN----ILSAA--FQDGWFWYIPLSD 
ForV            HEDLRNIAVWAYFQGCRRYEGQESGN----VLIEY--RPGGWLWFIPLGD 
PltA            DPVFNQFAIHSWFDNFDRKSATQSPDKVDYIFIHFLPMTNTWVWQIPITE 
                   :.:.*: .:*:.  *  . .. :    ::       . *.* **: : 
CndH            TLTSVGAVVSREAAEAIKDGHEAALLRYIDRCPIIKEYLAPATRVTTGDY 
ForV            GTTSIGYVTPTATLAESGLTAEKLWAEQTAESREVARMMEPATRVS---- 
PltA            TITSVGVVTQKQNYTNSDLTYEEFFWEAVKTRENLHDALKASEQVR---- 
                  **:* *.            *    .       :   : .: :*      
CndH            GEIRIRKDYSYCNTSFWKNGMALVGDAACFVDPVFSSGVHLATYSALLVA 
ForV            -GFRTIKDWSYNLERFHGPGWLAVGDAACFVDPLLSTGVTLALRGGATAA 
PltA            -PFKKEADYSYGMKEVCGDSFVLIGDAARFVDPIFSSGVSVALNSARIAS 
                  ::   *:**    .   .   :**** ****::*:** :*  ..  .: 
CndH            RAINTCLAGEMSEQRCFEEFERRYRREYGNFYQFLVAFYDMNQDTDSYFW 
ForV            SAAGMMLDTPATAHETGRRYEESYRRFLTGILDFVRAFYDQRKNRGEYYE 
PltA            GDIIEAVKNNDFSKSSFTHYEGMIRNGIKNWYEFITLYYRLNILFTAFVQ 
                      :      :    .:*   *.   .  :*:  :*  .     :   
CndH            SARKIINTEER--ANEAFVRLIAGRSNLDEPVFQSVAKDFFTEREGFGAW 
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ForV            DAKKILDRGEGLPADVDFVTLVSGLSD---------GGDFFESP------ 
PltA            DPRYRLDILQLLQGDVY------------------------S-------- 
                ..:  ::  :   .:                                    
CndH            FGGLVTSMAKGDGGGLMVGEGATDATESTGFAPENFMQGFTREITELQHL 
ForV            -----------PEGGLELLEKLRSRVSAPPMTV----------------- 
PltA            ------------GKRLEVLDKMREIIAAVESDPEHLWHKYLGDMQVPTAK 
                               * : :   .   :                       
CndH            AMFGEDRGPETPLWSGGLVPSRDGLAWAVESGEDAAG 
ForV            -----------------------------ERGR---- 
PltA            PAFEND------------------------------- 
Figure 3.10: Alignment of ForV with CndH and PltA, two known FAD-dependent halogenases.  The key 
motifs present in all FAD-dependent halogenases are present; the GxGxxG motif at the site of FAD 
binding (cyan), the conserved lysine residue within the active site (Lys-76) (green) and the WxWxIP 
motif within the tunnel that leads to the active site (yellow).  CndH and ForV have the highest 
sequence similarity.  All three peptide sequences have highly variable C-terminal regions. 
Previous studies have solved the crystal structures of CndH and PltA to 2.1 Å and 2.75 
Å respectively (PDB 3e1t and 5dbj).  Both models show the site of FAD binding as well 
as the site of the chlorine anion, although the C-terminal region is missing from the 
crystal structure of CndH as it is thought to have denatured during the crystallisation 
process (Buedenbender et al., 2009).  The predicted model of ForV generated in I-
TASSER was therefore aligned in PyMol with the published models of both CndH and 
PltA.  This showed that the structure of the FAD binding site and the substrate binding 
site were highly conserved between the proteins meaning that the ligand binding 
sites in ForV are likely to be the same.  This implies that these enzymes likely function 
via similar mechanisms.  By overlaying the models of CndH and ForV, the site of FAD 
binding and the hydrophobic tunnel leading to the active centre become clear, 
however, surprisingly, the active site seems to be open and exposed to the surface 
in both enzyme models (Figure 3.11).  It should also be noted that the C-terminal 
regions of these proteins did not align, as the similarity between the regions is too 
low, so this region does not appear in the model below.   
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Figure 3.11: Alignment of the predicted model of ForV generated in I-TASSER (green) with the crystal 
structure of CndH (3e1t) (cyan) showing the binding sites of the FAD cofactor (dark blue) and the 
chlorine anion (yellow), generated in PyMol.  The WxWxIP fingerprint is highlighted in orange, the FAD 
binding site GxGxxG motif is shown in magenta and the conserved lysine residue is shown in red 
(labelled).  The structures align well in these key regions of the enzyme, suggesting that the 
mechanisms are likely to be similar. The C-terminal regions of these peptides do not align as the 
sequence similarity is too low and therefore this region does not appear in the model.  In the absence 
of the C-terminal region, the active site is exposed to the surface of the protein. 
Experiments were designed to generate in vitro activity data for ForV and produce 
crystals for accurate structural characterisation.  To do this, forV was synthesised and 
codon optimised for expression in E. coli by GenScriptâ.  This codon optimised gene 
sequence was sub-cloned into pGS-21a and expressed as a His-GST-ForV fusion 
protein in E. coli BL21 using 0.1 mM IPTG induction at 18°C for 16 hours.  Even with 
the glutathione S-transferase (GST) tag, solubility of ForV was poor and as such, yields 
of pure protein were limited, however, MS-MS (conducted by Gerhard Saalbach at 
the proteomics facility at the JIC) confirmed that the small amount of protein 
obtained did align back to the sequence of ForV. 
On incubation of purified ForV with substrate (either fasamycin C or formicamycin 
B), FAD reductase, FAD cofactor, NADH and a chlorine donor in phosphate buffered 
saline (PBS) at 30 °C for 1 hour, no halogenation activity was seen (data not shown).  
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Experiments were extensively optimised, including removing the GST tag from ForV 
in case this interfered with the enzyme activity, increasing the concentration of FAD 
in the reaction mixture, increasing the incubation time from 1 hour to overnight, and 
replacing the commercially available FAD reductase with a cloned and purified 
reductase enzyme that had previously been shown to activate a tryptophan 
halogenase (personal communication, Professor Changjiang Dong, 2016).  In 
addition, a variety of different buffers for the reaction were tried including HEPES as 
well as changing the solvents for the substrates to remove any constituents that 
might inhibit the activity of ForV.  However, no chlorination of substrates by ForV 
was witnessed in any of the experiments conducted in this project.  Due to the low 
yields of ForV obtained and the absence of any observable in vitro activity, crystal 
screens were not conducted.   
During the expression and purification of CndH, similar problems with poor solubility 
and low protein yield were encountered.  Although the authors were successful in 
generating crystals after 3 weeks, no in vitro activity data was collected and this was 
predicted to be because either the reducing agent or the carrier protein was 
unknown (Buedenbender et al. 2009).  During this investigation into CndH, the 
authors proposed that phenolic flavin-dependent halogenases could be broadly 
classified into two groups; type A halogenases that accept free substrates such as 
amino acids and type B enzymes that only accept substrates that are bound to a 
carrier protein (Buedenbender et al. 2009).  PltA has previously been shown to 
specifically recognise the pyrrolyl substrate on the carrier protein scaffold, with no 
activity being present with the free substrate (Dorrestein et al., 2005).  Subsequently, 
when the crystal structure of PltA was solved in 2015, it showed the presence of a C-
terminal region blocking the binding cleft that was not present on many previously 
studied flavin-dependent halogenases.  The authors proposed that this region of the 
protein is responsible for binding to the carrier protein, inducing a conformational 
change allowing access to the substrate binding site for halogenation to occur (Pang, 
Garneau-Tsodikova and Tsodikov, 2015).  They also noted that this C-terminal region 
is highly divergent between PltA and other halogenases, including CndH, in both 
sequence similarity and structural model (Figure 3.12).  The absence of the C-
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terminal domain might therefore explain why the active centre of CndH remains 
open in the crystal structure shown above.  It may be that the highly variable C-
terminal regions present on these flavin-dependent halogenases block the active site 
until they interact with the appropriate carrier protein, where a conformational 
change allows access for the required substrate.  If this is the case, it is also likely that 
the C-terminal domain is unstable in the absence of the carrier-bound substrate and 
that is why previous studies have not enabled the crystallisation of this region, 
however a structure of the complex between the enzyme and the carrier-bound 
substrate would be necessary to confirm this hypothesis (Buedenbender et al. 2009). 
 
Figure 3.12: Models of the Type B halogenases PltA (crystal structure solved experimentally) and CndH 
(partial crystal structure and partial model) showing the highly variable C-terminal region in blue, 
compared with the Type A tryptophan halogenase RebH from the rebeccamycin biosynthetic gene 
cluster (crystal structure solved experimentally).  It is predicted that the C-terminal covers the active 
site of Type B halogenases until the appropriate carrier is recognised, allowing the substrate into the 
active site.  Figure adapted from (Pang, Garneau-Tsodikova and Tsodikov, 2015). 
Using the model of ForV generated in I-TASSER, which predicts secondary structures 
based on the properties of the amino acids in the peptide chain, rather than aligning 
proteins to the most similar match as Swiss-model does, the C-terminal region of 
PltA
RebH
(Tryptophan halogenase)
CndH
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ForV appears quite flexible and disordered, implying it may interact with other 
proteins (Figure 3.13).  This model is highly speculative, as the C-terminal region does 
not align to either CndH or PltA, or any other proteins in the database, so no 
conclusions can be drawn from this model.  However, it is possible that this region is 
specific to a carrier protein from within the formicamycin biosynthetic pathway and 
is responsible for recognition of the bound substrate for halogenation.  Type B 
halogenases are probably more common in NRPS and PKS systems and these 
secondary metabolites are often synthesised by multi-enzyme complexes.  
Substrates are anchored to a carrier protein and passed from one module to another 
to ensure the pathway runs to completion with minimal side reactions occurring 
(Schnepel and Sewald, 2017).  We therefore predict that ForV only recognises 
substrates that are bound to a carrier and this is why no activity was seen in vitro 
when purified fasamycins or formicamycins were used as the substrate.   
 
Figure 3.13: Predicted model of ForV generated in I-TASSER and visualised in PyMol.  The WxWxIP 
fingerprint is highlighted in orange, the FAD binding site GxGxxG motif is shown in magenta and the 
conserved lysine residue is shown in red.  The unique C-terminal region of ForV is shown in dark blue.  
The structure of this region is predicted at this moment but it appears highly flexible and may 
therefore be able to interact with other proteins from the formicamycin biosynthesis pathway. 
 102 
Further in vitro work on ForV will be challenging until the carrier or enzyme complex 
can be identified or until a substrate-bound crystal structure of the enzyme can be 
solved.  However, these type B halogenases are not thought to be effective catalysts 
for industrial halogenation at present due to the limitations discussed in this chapter 
(Schnepel and Sewald, 2017).  For use in synthetic halogenation events, type A flavin 
dependent halogenases such as RadH, an enzyme involved in the biosynthesis of 
radicicol in Chaetomium chiversi which has recently been shown to halogenate a 
range of aromatic substrates in vitro, may be more appropriate due to their ability to 
accept free substrates (Menon et al., 2017).   
3.4 Predicted formicamycin biosynthetic pathway 
 
Having identified the genes responsible for biosynthesis and halogenation of the 
fasamycins and formicamycins, we can tentatively put forward a predicted 
biosynthetic pathway for these compounds, based on previous knowledge of 
bacterial type 2 polyketide biosynthesis.  Generally, this starts with a single acetyl-
CoA starter unit loaded onto the acyl carrier protein (ACP).  This is then transferred 
to the heterodimeric ketosynthase (KS) enzyme that is responsible for condensing 
multiple malonyl-CoA extender units to form a polyketide chain of a pre-determined 
length (Zhang, Pan and Tang, 2017).  In the biosynthesis of the formicamycins, we 
predict that ForH, ForI and ForE generate the malonyl-CoA extender units by 
carboxylating acetyl-CoA and transferring them to the ACP.  ForABC forms the 
minimal PKS, where ForA (KSa) and ForB (KSb) form the heterodimeric KS and ForC is 
the ACP.  Feeding experiments with labelled acetate previously conducted by Dr 
Zhiwei Qin suggest that the condensation of multiple malonyl-CoA starter units by 
the PKS machinery forms a tridecaketide intermediate (17) which can then be 
cyclised, dehydrated, decarboxylated and methylated with the predicted enzymes as 
shown, to form fasamycin C (Figure 3.14) (Qin et al., 2017).  The functions of the 
latter enzymes are speculative at this point and are investigated experimentally later 
in this thesis.   
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Accumulation of fasamycin C in S. formicae DforV suggests that chlorination of the 
backbone by the ForV halogenase is the next step in the pathway and is required 
before formicamycin biosynthesis can be completed.  This, together with the low 
levels of fasamycins in the extracts of wild-type S. formicae compared to the levels 
of formicamycins, suggests that fasamycins are biosynthetic precursors to the 
formicamycins (Qin et al., 2017).  The detailed mechanism underlying the conversion 
of a fasamycin into a formicamycin is investigated later in this thesis, although it is 
predicted at this stage to involve ForX and ForY, the monooxygenase and the 
oxidoreductase, respectively.  ForN, the acylhydrolase, is likely to remove the 
cyclised intermediate from the ACP, at which point a decarboxylation reaction would 
also be required to remove the carboxyl group.  This may be enzymatically catalysed 
by ForQ, the decarboxylase, in the wild-type strain, however, as seen in Chapter 3.2, 
deletion of ForQ does not affect formicamycin biosynthesis, therefore this reaction 
may also occur spontaneously.  It is not yet clear at which point the intermediate is 
released from the ACP and whether that is the carrier that facilitates halogenation 
by ForV.  This will also be discussed further later in this thesis.
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Figure 3.14: Proposed biosynthetic pathway for the fasamycins and formicamycins.  Bold bonds in compound number 17 indicate the positions of the [1.2- 13C2] 
sodium acetate units incorporated into the polyketide backbone during feeding experiments conducted by Zhewei Qin (Qin et al., 2017).  
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3.5 Mode of action of the formicamycins 
 
Having established that the formicamycins exhibit potent antibacterial activity, 
attention turned to identifying the mechanism of action of these compounds.  As 
described above, the formicamycins are predicted to be derived from their 
biosynthetic precursors; the fasamycins.  Fasamycins A and B were previously 
isolated through the heterologous expression of environmental DNA (eDNA) cosmid 
libraries that were constructed using DNA isolated from soil samples collected in 
Arizona (Feng, Kallifidas and Brady, 2011).  Initial bioactivity studies showed that 
these compounds, like the fasamycins and formicamycins from S. formicae, are 
antibiotics with specific activity against Gram-positive bacteria including MRSA and 
VRE.  A later study by the same researchers suggests fasamycins A and B target type 
II fatty acid biosynthesis, specifically by inhibiting FabF, with docking studies 
indicating the tricyclic chloro-gem-dimethyl-anthracenone substructure is the key 
pharmacophore, much like in other FabF inhibitors (Feng et al., 2012).  When 
comparing this region of the fasamycin molecule to the formicamycins, there are 
significant differences in the three dimensional structure, therefore it is possible that 
the formicamycins may have a distinct mode of action, or at least different affinities 
for their target (Figure 3.15) (Qin et al., 2017).  
 
Figure 3.15: Comparison of the lowest energy conformers of fasamycin E and formicamycin B.  The 
fasamycins appear to be much flatter than the formicamycins.  The latter compounds have a bend in 
the tetracyclic backbone that makes them occupy a different 3-dimentional space (Qin et al., 2017).  
Image generated by Dr Zhiwei Qin based on NOESY NMR data and reproduced with permission. 
(S)-Fasamycin E 
(10R, 19R)-Formicamycin B
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To investigate this further, multiple reporter strains were obtained from Professor 
Jeff Errington (Newcastle University).  The panel of six B. subtilis reporter strains were 
generated by fusing a lacZ gene to various promoters to indicate responses to specific 
antimicrobial stresses.  The reporter strains provided were sensitive to either 
inhibition of fatty acid biosynthesis (fabHA), cell wall damage (ypuA), DNA gyrase 
inhibition (PL39), DNA damage (ɸ105), RNA polymerase inhibition (helD) or cell 
envelope stress (lial)  (Kepplinger et al., 2018).  Assays were conducted using 
fasamycin E and formicamycin J, due to the availability of these compounds in high 
titres from biosynthetic mutants created during this project (described later) and the 
fact that these were identified from previous bioassays to be among the most potent 
compounds from each class.  Each assay was conducted at least three times under 
the same conditions, with at least two technical replicates being conducted in parallel 
on each attempt.  The results reported here are a representative summary of all the 
assays conducted during this project (Figure 3.16).   
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Figure 3.16: Paper discs with 40 µg fasamycin E or formicamycin J (or methanol control) were placed 
on soft LB (0.5% agar) inoculated with 1:10 B. subtilis at OD600 0.4.  B. subtilis ɸ105 (lacZ fusion to a 
late promoter in a ɸ105 prophage) is the DNA damage reporter, B. subtilis PL39 gyrA::pMUTIN4 ermC 
gyrA’-lacZ PspacgyrA+ is the DNA Gyrase inhibition reporter, B. subtilis helD::pMUTIN4 helD-lacZ ermC 
is the RNA polymerase inhibition reporter, B. subtilis fabHA::pMUTIN4 ermC gyrA’-lacZ Pspac-gyrA+ is 
the fatty acid synthesis inhibition reporter, B. subtilis liaI::pMUTIN4 liaI-lacZ ermC is the cell envelope 
reporter, B. subtilis ypuA::pMUTIN4 ermC ypuA’-lacZ is the cell wall damage reporter. Negative control 
antibiotics are those that will be active against the B. subtilis strains but will not trigger a reporter 
reaction as they act via a different mechanism of action.  In contrast, positive control antibiotics are 
those that will trigger a reporter reaction as they act via the desired mechanism of action.  Chl= 
chloramphenicol (125 µg/disc); Spect = spectinomycin (1 mg/disc); Dox = doxorubicin (10 µg/disc); 
Nov = novobiocin (10 µg/disc); Rif = rifampicin (10 µg/disc); Tri = triclosan (150 µg/disc); Bac = 
bacitracin (500 µg/disc); Cef = cefotaxime (125 µg/disc).  Formicamycin J produced a positive reporter 
result when tested against the DNA damage reporter.  Fasamycin E did not elicit a positive reporter 
response in any of the strains tested. 
As expected, the methanol negative control produced no reporter activity or 
bioactivity in any of the experiments conducted.  The negative control antibiotics 
display bioactivity with an absence of reporter activity and the positive control 
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antibiotics show positive bioactivity and reporter activity.  For both fasamycin E and 
formicamycin J there is some level of bioactivity against each reporter strain.  This is 
expected, as the compounds exhibit potent activity against Gram-positive bacteria, 
including B. subtilis.  In every assay conducted with these compounds, the only 
positive reporter activity for formicamycin J was against the f105 reporter indicative 
of DNA damage.  There were no positive results for fasamycin E against any of the 
reporter strains tested.  However, this does not necessarily mean that the fasamycins 
do not inhibit fatty acid biosynthesis as stated by Brady and colleagues in previous 
research.  The reporter strain for fatty acid biosynthesis used here is based on the 
inhibition of FabH.  Biochemical studies conducted by Feng et al. indicate that 
fasamycins A and B specifically bind to FabF and rule out any interaction with FabH.  
It is likely that fasamycins C-E behave in the same way and therefore no positive 
reaction would be expected with the reporter strain used here.  Furthermore, it may 
be that higher concentrations of compounds are needed to get positive results for 
this type of reporter assay. 
From this, we began investigating the possibility that formicamycins cause DNA 
damage.  The positive control for this assay, doxorubicin, is a natural product of 
Streptomyces peucetius var. casieus.  It is an anthracycline polyketide most widely 
used as an anticancer agent, however, it also displays antibiotic activity due to its 
ability to intercalate DNA (Westman et al., 2012).  The anthracyclines are a group of 
Streptomyces natural products produced by T2PKS clusters that are characterised by 
a planar anthraquinone chromophore that can intercalate between adjacent base 
pairs of DNA (Rayner and Cutts, 2014).  Some examples of known anthracyclines are 
shown below (Figure 3.17). 
 
 
 109 
 
Figure 3.17: The structures of the fasamycins and formicamycins were compared to known 
anthracycline antibiotics, some of which are shown.  There are some similarities in the planar rings 
present between fasamycins and the anthracycline antibiotics which may be indicative of a similar 
mode of action. 
The fasamycins have similar planar ring structures compared to these other known 
DNA binding compounds and therefore may be able to interact with DNA.  In 
contrast, the bend between the two central rings of the formicamycins send the 
structure off-plane, and therefore likely inhibits DNA binding.  To confirm this, DNA 
was titrated onto a fixed concentration of Fasamycin E and Formicamycin J, and 
absorbance of the compound was measured between 300 and 500 nm using the 
Nanodrop UV Spectrophotometer.  Although there should be no absorption of DNA 
in this region, DNA + solvent controls were run in parallel and used to calculate the 
absorbances of compound only (Figure 3.18).  The data confirm that addition of DNA 
to fasamycin E causes a change in the absorbance of the compound in a 
concentration dependent manner.  This is likely reflecting some interaction between 
the DNA and the compound as a similar shift in absorbance is seen when doxorubicin, 
a known DNA intercalator, is titrated onto ctDNA (Agudelo et al., 2014).  However, 
addition of DNA to formicamycin J caused no change in absorbance at any of the DNA 
concentrations tested, implying there is no interaction between them, at least at the 
tested concentrations.   
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Figure 3.18: Increasing concentrations of calf-thymus DNA (ctDNA) was added to a fixed concentration 
(3 µg) of either formicamycin J (A) or fasamycin E (B), in PBS buffer in a total volume of 20 µl.  
Absorbance of the compound was measured between 300 and 500 nm.  Appropriate controls were 
run to account for any effect of increasing DNA concentration, the buffer and the solvent the ligand 
was in (DMSO).   No significant change in absorbance of formicamycin J is seen on addition of 
increasing concentrations of DNA.  However, increasing the concentration of DNA does appear to 
change the absorbance of fasamycin C in a concentration dependent manner. 
This DNA binding activity of the fasamycins does not explain the observations made 
in the reporter assay experiment, where formicamycins appeared to cause DNA 
damage but fasamycins did not.  Anthracycline antibiotics are also known to target 
bacterial Type II DNA topoisomerase enzymes, DNA gyrase and topoisomerase IV.  
These enzymes function together to dictate the topological organisation of DNA 
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(Mitscher, 2005).  DNA Gyrase catalyses the super-coiling of double-stranded DNA 
while Topoisomerase IV relaxes supercoils in order to remove knots and tangles in 
the bacterial chromosome (Reece and Maxwell, 1991).  As part of this function, these 
enzymes generate transient double-stranded breaks in order to allow double helices 
to pass each other.  As a result, they are major targets for several other classes of 
antibiotics, including the quinolones (Levine, Hiasa and Marians, 1998).  Quinolone 
antibiotics bind non-covalently at the enzyme-DNA interface of the cleavage complex 
and physically block the re-ligation of DNA after cleavage.  As a result these so called 
‘topoisomerase poisons’ essentially convert gyrase and topoisomerase IV into 
cellular toxins that cause double strand breaks in DNA, triggering programmed cell 
death (Aldred, Kerns and Osheroff, 2014). 
To investigate whether fasamycins and/or formicamycins are able to inhibit type II 
DNA Topoisomerase enzymes, extracts were provided to Inspiralis on the Norwich 
Research Park who provide high throughput topoisomerase inhibitor screening 
assays.  The fasamycins and formicamycins were tested for both inhibition of 
topoisomerase IV relaxation and inhibition of gyrase supercoiling and compared to 
the quinolone antibiotic, ciprofloxacin, a known inhibitor of both processes.  Enzymes 
from both Gram-positive (S. aureus) and Gram-negative (E. coli) organisms were also 
used, to determine whether the compounds have higher affinity for one over the 
other.  Supercoiled plasmid substrate was incubated with Topoisomerase IV and DNA 
Gyrase was incubated with relaxed plasmid, either with or without the drug present, 
and the resulting DNA visualised using agarose gel electrophoresis.  Supercoiled DNA 
runs further through a gel in a given time compared to relaxed DNA.  Inhibition levels 
(% supercoiled or relaxed DNA) were measured by determining the relative 
fluorescence of the band using gel scanning software and used to calculate IC50 values 
for the most active compound from each group (personal communication with 
Inspiralis, 2018) (Figure 3.19). 
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Figure 3.19: IC50 values were calculated for the most potent compounds in each group by Inspiralis.  These values were plotted in Excel and compared with the 
known topoisomerase inhibitor, ciprofloxacin.  The potency of the fasamycins and formicamycins compares well to ciprofloxacin against all enzymes tested.
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IC50 is the concentration of an inhibitor required to reduce the activity of a target by 
50% and is often used as a measure of potency of a compound.  From these data, it 
appears that fasamycins and formicamycins inhibit DNA topoisomerase enzymes 
with a potency that is comparable to the known topoisomerase inhibitor, 
ciprofloxacin, under all conditions tested.  The inhibition of the Gram-positive DNA 
Gyrase by the fasamycins and formicamycins is significantly stronger than the 
ciprofloxacin control.  Inhibition of Gram-positive Topoisomerase IV is the same as 
the ciprofloxacin control.  Interestingly, the fasamycins and formicamycins also 
appear to have relatively potent activity against Gram-negative enzymes, particularly 
Topoisomerase IV, when only Gram-positive activity has been seen in vivo.   
Based on these data, we hypothesise that fasamycins and formicamycins are able to 
inhibit bacterial type II DNA topoisomerase enzymes.  This could explain the DNA 
damage detected in the reporter strains, as this mechanism of action might result in 
double stranded breaks in the bacterial chromosome or dysregulated topological 
organisation of the bacterial chromosome.  Although there was no reporter activity 
in the PL39 reporter strain, designed to detect inhibition of DNA Gyrase, it is possible 
that the reporter strain generated was not sensitive to inhibition by fasamycins 
and/or formicamycins if these compounds act via a novel mechanism.  The bacterial 
DNA Gyrase enzyme is made up of two distinct functional subunits, known as GyrA 
and GyrB.  GyrA is the subunit responsible for the interactions with DNA whereas 
GyrB contains the ATPase active site (Collin, Karkare and Maxwell, 2011).  The in vitro 
data from Inspiralis clearly shows these compounds are able to inhibit the activity of 
topoisomerase enzymes, however, we currently have no information about the 
mechanism by which this occurs and where on the enzyme these compounds bind.  
Novobiocin, the recommended positive control used in the Bacillus reporter assays, 
is known to target GyrB, but quinolones and anthracyclines are known to bind GyrA, 
which contains the active site that attaches to cleaved DNA (Aldred, Kerns and 
Osheroff, 2014).  In future, it will be important to obtain ligand-bound crystal 
structures of these topoisomerase enzymes in the presence of fasamycins and 
formicamycins to investigate this interaction further. 
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All microorganisms that encode for and produce antimicrobial secondary 
metabolites must also encode a resistance mechanism in order to evade self-toxicity.  
These can either modify the target, and this can help identify the mechanism of 
action, or increase the efflux of the compounds from the cell via transport systems 
(D. A. Hopwood, 2007; Mak, Xu and Nodwell, 2014).  Manual investigation of the 
formicamycin BGC and the surrounding genes does not indicate any obvious gene 
candidates for self-resistance to the formicamycins by S. formicae.  We predict that 
the two transporters encoded in the for BGC provide some level of host-resistance 
via an export mechanism and this is investigated further later in this thesis (Chapter 
4.4).  However, compounds will still accumulate intracellularly, therefore the host 
must have some mechanism of resistance encoded within its genome to overcome 
self-toxicity.  Analysis using Antibiotic Resistance Target Seeker (ARTS) does identify 
known resistance mutations in the genes encoding for both the DNA gyrase A subunit 
(KY5_4068) and the DNA gyrase/topoisomerase B subunit (KY5_4067).  Furthermore, 
a search of the annotated S. formicae genome on StrepDB reveals two additional 
genes, KY5_5972c and KY5_5956, which are also predicted to encode for a DNA 
topoisomerase IV subunit A and a type IIA DNA topoisomerase subunit B with 42.44% 
identity (91% coverage) and 44% identify (96% coverage) to KY5_4068 and KY5_4067 
respectively.  This implies that, as well as having known resistance mutations in the 
topoisomerase machinery, there may have been gene duplication events over the 
course of evolution that might enable S. formicae to be resistant to 
fasamycins/formicamycins during biosynthesis and before export.   
As discussed above, previous work has shown that fasamycins also inhibit fatty acid 
biosynthesis.  It is possible that fasamycins and formicamycins are able to target both 
fatty acid synthases and DNA topoisomerases but with different affinities.  If these 
compounds are able to target both fatty acid synthases and DNA topoisomerases, 
this would make these compounds unique in respect to other antibiotics, in that they 
can inhibit two distinct molecular targets.  This dual-target mechanism of action 
might explain the lack of resistant mutants generated in vitro during earlier work 
(Chapter 1.8), but further investigation is needed to confirm this theory.  Developing 
a comprehensive structure-activity relationship using in vitro gyrase/topoisomerase 
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inhibition assays, DNA cleavage assays and in vitro fatty acid synthase inhibition 
assays will be the priority going forward.  If crystals of the inhibitor-target complex 
could be obtained, we could confirm the interaction with topoisomerase enzymes 
and therefore gain information about the potential toxicity of the compounds if they 
were ever to be considered for clinical use.  Furthermore, the generation of resistant 
mutants to provide information on the mechanisms of resistance to these 
compounds and therefore the likely mechanism of action will be key.  Although 
previous work in the Hutchings laboratory did not successfully obtain resistant 
mutants to these compounds, the experiment was only conducted using MRSA.  
Using a different susceptible strain, such as Enterococcus faecalis as in the previous 
study on fasamycin mechanism of action, may be more successful (Feng et al., 2012).  
This will be the subject of future investigation in the Wilkinson laboratory.   
Finally, while the compounds did not show any activity against Gram-negative 
bacteria in vivo, the results presented here show that there is some affinity towards 
enzymes from Gram-negative bacteria in vitro.  Gram-negative bacterial pathogens 
are infamously challenging to treat with antibiotics due to the layer of 
lipopolysaccharide (LPS) in the outer membrane that forms an impermeable barrier 
to prevent compounds entering the cell.  When this cell envelope is disrupted, large-
scaffold antibiotics are taken up more efficiently (Muheim et al., 2017).  In 
accordance with this, previous work has shown that fasamycins A and B are active 
against membrane permeabilised E. coli, suggesting that the absence of activity in 
Gram-negative bacteria may be due to the inability of the compounds to access their 
target, rather than a decreased affinity (Feng et al., 2012).  As such, a strain of E. coli 
with an in-frame deletion of imp, a gene encoding for a protein involved in the 
assembly of LPS in the outer membrane (E. coli NR698), was obtained from the John 
Innes Centre and assayed against fasamycin C and formicamycin J, the most potent 
fasamycin and formicamycin against Gram-positive pathogens isolated from S. 
formicae.  In contrast to all previously conducted assays of these compounds against 
Gram-negative organisms, there were significant zones of inhibition for both 
compounds when tested against E. coli NR698 (Figure 3.20). 
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Figure 3.20: 20 uL of approximately 300 ng/µl fasamycin C and formicamycin J were dried on 
Whatman paper discs (approximately 5 mM of each compound per disc).  Discs were placed on 0.5% 
agar LB plates inoculated with E. coli NR698 and incubated at 30°C overnight.  The zones of inhibition 
against this membrane-permeabilised strain imply that the fasamycins and formicamycins do act on 
the intracellular target of Gram-negative cells, however, they cannot cross the normal LPS-rich Gram-
negative cell membrane. 
This further suggests that these compounds are in fact broadly bioactive against both 
Gram-positive and Gram-negative pathogens but cannot cross the Gram-negative 
outer membrane. In future, analogues of the formicamycins that are more 
membrane permeable could be chemically synthesised.  Alternatively, the 
formicamycins could be co-administered with small molecules that increase the 
permeability of Gram-negative cell membranes.  For example, the small molecule 
MAC13243 is an inhibitor of LolA, a chaperone that traffics lipoproteins from the 
inner membrane to the outer membrane.  It has antimicrobial activity against Gram-
negative pathogens but degrades in aqueous solution and therefore was concluded 
to not be a clinically relevant lead compound.  However, sub-inhibitory 
concentrations of MAC13243 have been shown to increase the uptake and resultant 
bioactivity of large-scaffold antibiotics such as novobiocin and erythromycin 
(Muheim et al., 2017).  If this or another similar small molecule could be found to 
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increase the uptake of formicamycins by Gram-negative cells, their clinical potential 
could be significant. 
3.6 Discussion 
 
In this chapter, the genes responsible for fasamycin and formicamycin production 
were successfully identified using CRISPR/Cas9-mediated genome editing of the new 
species Streptomyces formicae.  Since 2015, CRISPR/Cas9 genome editing has been 
applied to several streptomycetes and other rare actinomycetes, enabling the 
manipulation of environmental isolates with greater efficiency than ever before (Tao 
et al., 2018).  The CRISPR system does not rely on the availability of cosmid libraries, 
only a good quality genome sequence, something which is becoming more accessible 
as sequencing becomes cheaper and easier to do.  That said, not all strains are 
genetically tractable using CRISPR and often, the use of these tools in new organisms 
requires extensive optimisation.  The development of the protocols used in this 
chapter will allow further genetic work to be carried out in S. formicae, including 
additional work on the formicamycin BGC, such as identification and generation of 
pathway intermediates and novel bioactive analogues.   
So far, we have used the pCRISPomyces-2 system to show that two related but 
distinct compound families, the fasamycins and the formicamycins, originate from a 
single BGC in S. formicae, by generating strains with the whole BGC deleted.  The 
deletion of the formicamycin BGC (approximately 46 Kbp) represents the largest 
published single deletion conducted using the pCRISPomyces-2 system recorded to 
date (Tong, Weber and Lee, 2018).  Furthermore, we were able to complement this 
large deletion using DNA from an artificial chromosome library, all in the native host.  
In addition, the work in this chapter identified the core genes required for the 
biosynthesis of these compounds and began to identify the mechanisms of some of 
the novel enzymes encoded by this genetic machinery.  Later in this thesis, further 
work will investigate how these enzymes work together to synthesise these 
compounds and experiments will be conducted to determine the biosynthetic link 
between the fasamycin precursors and the more potent formicamycins.  The fact that 
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these novel compounds originate from a previously uncharacterised environmental 
isolate may mean that we uncover novel mechanisms of biosynthesis that can be 
used to inform future drug discovery efforts.   
Antimicrobial resistance is a major threat to modern healthcare and the discovery of 
new antimicrobials will be vital in combating this threat.  Anything we can learn about 
the biosynthesis of natural products is valuable, however, priority should be given to 
compounds that display novel mechanisms of action as these represent more 
promising candidates for clinical development as they may be effective against drug-
resistant infections.  The work in this chapter has begun to assess the suitability of 
the fasamycins and formicamycins as clinically relevant antibiotics.  We have shown 
that these novel compounds display potent antibacterial activity against Gram-
positive pathogens including multi-drug resistant isolates like MRSA and VRE and 
have also shown that they have the potential to inhibit Gram-negative pathogens 
too.  Although the fasamycins and formicamycins have distinct three-dimensional 
structures, the evidence so far suggests that they may act via the same mechanism, 
specifically by targeting DNA topoisomerases and possibly also fatty acid synthases.  
If we can prove that these compounds can indeed inhibit two distinct intracellular 
targets using the experiments described above, the formicamycins would be unique 
amongst antibiotics and potentially very attractive for further clinical development.   
Overall, this work shows that by searching underexplored environments and using 
new genomic techniques, novel anti-infectives can be identified that may bypass 
current antimicrobial resistance mechanisms.  In future, the development of these 
antibiotics into clinically relevant medicines may rely on mass production on an 
industrial scale.  So far, S. formicae only produces the fasamycins and formicamycins 
during growth on agar plates, making extraction protocols lengthy and complex.  If 
we could identify a mutation that makes S. formicae produce these compounds 
during liquid culture, perhaps by changing the way the host regulates the 
biosynthesis of these compounds, there would be great potential for using S. 
formicae for the production of these clinically relevant antibiotics in the future. 
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4 Regulation of formicamycin production in Streptomyces formicae 
and mechanisms of host resistance 
 
The formicamycins are polyketide antibiotics produced by S. formicae that represent 
promising new compounds for clinical development.  Antibiotics are produced by 
microorganisms as part of their secondary metabolism and are not essential for 
growth.  The production of these highly decorated molecules can be metabolically 
expensive, therefore expression of BGCs is very tightly regulated and controlled by 
the native host to ensure that transcription is only activated when the production of 
the secondary metabolite will provide a significant survival advantage (Chater, 2016; 
van der Meij et al., 2017).  As such, microbial genomes contain a large number of 
transcriptional activators and repressors that together form a complex regulatory 
network that controls the expression of biosynthetic genes (Busby, 2019).  For most 
secondary metabolites, one or more regulatory proteins are encoded in the BGC and 
these are responsible for controlling the expression of all the genes within the 
cluster.  These are known as cluster situated regulators (CSRs).  Work presented in 
the previous chapter identified the genes required for formicamycin biosynthesis and 
defined the borders of the BGC.  Several putative CSRs are encoded within the for 
BGC, including two MarR-family regulators and two two-component systems (TCSs).  
The aim of this chapter is to investigate the role of these CSRs and determine how 
production of the formicamycins is controlled in the native host.   
In addition, work in the previous chapter began to elucidate the mechanism of action 
of the fasamycins and formicamycins.  Previous attempts to raise mutants of MRSA 
with resistance to these potent antimicrobials was unsuccessful, therefore 
identifying the mechanism of action remains a challenge.  As discussed in the 
previous chapter, all antibiotic producing microorganisms will encode a host-
resistance mechanism to evade self-toxicity upon compound biosynthesis.  Within 
the formicamycin BGC in S. formicae, there are two putative transporter genes.  
These are predicted to export fasamycins and formicamycins across the cell 
membrane and provide some host-resistance by preventing toxic intracellular 
accumulation.  The roles of these gene products will be investigated during this 
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chapter.  By identifying the host regulation and resistance mechanisms, it may be 
possible to generate mutant strains of S. formicae with increased formicamycin 
biosynthesis capabilities, which could be useful for the industrial production of these 
clinically relevant molecules.   
4.1  Determining the transcriptional organization of the formicamycin BGC  
 
The regulation of antibiotic production begins with the initiation of transcription 
within the BGC (Romero et al., 2014).  Transcription is the process by which the DNA 
encoding for a gene is transcribed into messenger RNA (mRNA) by RNA polymerase 
(RNAP).  This mRNA will be translated into the functional protein by the ribosome.  
The first step of bacterial transcription initiation is promoter recognition by RNAP.  
Identifying the promoter of a putative gene or operon can thus inform how the 
transcription is controlled by the binding of transcription factors.  For example, 
binding of a transcriptional activator or the release of a transcriptional repressor, can 
increase RNAP binding to a promoter sequence within the DNA.  This results in the 
DNA strands around the transcription start site unwinding and the template strand 
entering the catalytic site of the RNAP for transcription of the gene and generation 
of the mRNA (Busby, 2019).  mRNA usually consists of a 5’ untranslated region 
(5’UTR) upstream of the translation start site which is important for regulation of 
translation of the transcript via binding of the ribosome at the Shine-Dalgarno 
sequence.  This promoter region is usually present within intergenic regions of DNA 
directly upstream of the start codon of the gene.  
Identifying transcription start sites within secondary metabolite BGCs can be 
complex, because often they contain genes whose coding regions overlap with the 
gene either upstream or downstream, leading to the generation of multi-gene 
transcripts or polycistronic mRNAs.  Genes with overlapping DNA sequences are 
thought to have evolved due to translational coupling (Dangel et al., 2009).  For 
example, the biosynthesis of secondary metabolites often requires multi-enzyme 
complexes like the alpha and beta subunits of the KS enzyme required for polyketide 
biosynthesis.  Thus, it is evolutionarily advantageous to encode for both enzyme units 
on the same transcript, as the functionality of one enzyme directly relies on the 
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presence of the other.  As such, these genes are usually also co-located in operons 
within BGCs.  In the formicamycin BGC, many of the genes encoding for the major 
biosynthetic machinery are co-located and overlapping.  The overlapping genes forH 
and forI are predicted to encode the enzymes that synthesise the malonyl-CoA 
starter unit and the forA, forB and forC genes encode the core PKS.  The formicamycin 
BGC contains various length intergenic regions between the coding regions of DNA, 
from short regions of just a few base pairs up to large regions of several hundred 
base pairs (Figure 4.1).  In general, longer intergenic regions are indicative of 
promoters that drive the transcription of one or multiple downstream genes, for 
example the 247 bp region upstream of forM, which is predicted to contain a 
promoter driving the transcription of the forMLKJ transcript.  Adding to the 
complexity is the occurrence of genes in different orientations within a single BGC.  
Divergent promoters that control the transcription of adjacent genes in opposite 
directions are common and there are predicted to be several within the 
formicamycin BGC, for example the region between forH and forG and between forT 
and forU.   
 
Figure 4.1: The formicamycin BGC with overlapping coding sequences of DNA labelled (above) and 
intergenic regions (below).  In general, longer intergenic regions are indicative of promoter regions.  
Overlapping DNA sequences are probably transcribed on a single mRNA transcript.  Several of the 
intergenic regions within the formicamycin BGC could contain divergent promoters that control the 
transcription of multiple adjacent genes in opposite directions. 
RNA sequencing allows the highly dynamic bacterial transcriptome, or the complete 
set of expressed mRNAs within an organism, to be characterised under different 
conditions.  This can be useful to learn more about which genes are expressed under 
certain conditions, but it does not map the transcript start sites (TSSs).  More 
recently, methods of using RNA-sequencing to identify TSSs across bacterial genomes 
have been developed and these enable the promoter regions of genes to be 
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identified by pin-pointing the start of the 5’UTR.  Cappable RNA sequencing is similar 
to differential RNA sequencing (dRNA-Seq) but instead of depleting 5’ degraded RNA 
molecules, the 5’end of full length, primary transcripts are specifically targeted and 
enriched for sequencing by enzymatically modifying the 5’ triphosphorylated end 
with a selectable tag. In this way, the primary transcripts present in a cell can be 
compared with the monophosphorylated mRNA molecules in order to identify the 
TSSs.  This allows the promoters in multi-gene operons to be identified, as well as 
indicating which genes are co-transcribed on polycistronic mRNAs (Ettwiller et al., 
2016).  In order to determine the transcripts expressed from the formicamycin BGC, 
RNA was extracted from 2-, 3- and 4-day old cultures of wild-type S. formicae grown 
under formicamycin producing conditions and quantified using formaldehyde gel 
electrophoresis and Qubit analysis.  RNA capping and sequencing was conducted by 
Vertis Biotechnologies AG.  The cappable RNA sequencing technique was used to 
enrich the 5’ ends of all the expressed full-length mRNA transcripts and identify all 
the TSSs (EMBL-EBI Array Express accession number E-MTAB-7975).  The data were 
listed in a table of all the TSSs using the Vertis Biotechnologies AG bioinformatics 
platform to a single nucleotide resolution with enrichment scores for each.  
Significant peaks were called as those with enrichment scores of 10 or more 
compared to the untreated samples and these were annotated as TSSs.  This revealed 
11 significant TSSs within the formicamycin BGC and shows that the 26 genes within 
the cluster are expressed on 10 transcripts as described below (Table 4.1).  
Table 4.1: Cappable RNA sequencing was used to locate the transcription start sites across the S. 
formicae genome.  In this table, a summary of transcription start site locations within the 
formicamycin BGC are described.  Transcription start sites are listed in relation to the position of the 
start codon of the predicted genes.   
Transcript Gene  Function Chromosome position TSS 
relative to 
ATG of first 
gene 
Start  End TSS DNA 
strand 
1 forN  7756911 7755139 7757095 - -184 
2 forM Methyl 
transferase 
7757158 7757943 7757123 
 
+ -35 
 
forL Cyclase 7757978 7758319 
 123 
 
forK Resistance 
transporter 
7758327 7759763 
3 forJ Transcriptional 
regulator 
7759841 7760290 7759783 + -58 
4 forH ACC biotin 
carboxylase 
7763484 7761661 7763527 - -43 
forI ACC carboxyl 
transferase 
7761679 7760312 
5 forG Sensor kinase  7763994 7765085 7763765 + -229 
forF Response 
regulator 
7765093 7765752 
6 forE ACC biotin 
carboxy carrier 
protein 
7766271 7765756 7771343 
 
- -53 
forD Cyclase 7766729 7766268 
forC PKS ACP 7767022 7766732 
forB KSβ 7768266 7767019 
forA KSα 7769525 7768263 
forR Cyclase 7769917 7769522 
forS Cyclase 7770265 7769945 
forT O-
Methyltransferase 
7771290 7770262 
7 
 
forU Cyclase 7771411 7771770 7771370 
7772595 
  
+ -41 
Middle of 
forV 
forV Halogenase 7771763 7773055 
forW O-
Methyltransferase 
7773052 7774077 
forX Monooxygenase 7774087 7775802 
forY Oxidoreductase 7775981 7776928 
8 forZ Transcription 
regulator 
7777403 7776885 7777403 - +1 
(leaderless) 
9 forAA Resistance 
transporter 
7777492 7779033 7777443 + -49 
10 forBB Response 
regulator 
7779705 7779043 7780997 - +1 
(leaderless) 
forCC Sensor kinase 7780997 7779702 
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As predicted, most of the intergenic regions within the BGC contain TSSs and 
therefore must act as promoters for the genes either up- or downstream (Figure 4.2).   
 
Figure 4.2: Visual representation of the TSSs identified within the formicamycin BGC in relation to the 
nearest start codon.  The 26 gene formicamycin BGC is expressed on 10 transcripts as shown.  The 
majority of the biosynthetic machinery is co-transcribed on two multi-gene transcripts, transcripts 6 
and 7, which are under the control of a single, divergent promoter. 
The acylhydrolase gene forN and the MFS family transporter gene forAA are 
expressed on their own as single transcripts.  The expression of the acylhydrolase 
gene is driven by a divergent promoter that also contains the TSS for forM, forL and 
forK, encoding the putative methyltransferase, cyclase and sodium/hydrogen 
exchanger respectively.  Somewhat surprisingly, the forJ gene, encoding a putative 
MarR-family regulator, is also under the control of its own promoter, even though 
the intergenic region upstream of the coding sequence is relatively small, at only 77 
base pairs long.  Most promoter sequences contain binding sites for transcriptional 
activators and repressors in addition to the RNAP, and therefore it is unlikely that 
this 77 base pairs alone represents the whole promoter region as this length of DNA 
is probably not long enough.  We predict that the promoter region of forJ continues 
back into the coding region of the upstream forK.  The genes encoding for the 
production of the starter units required for polyketide biosynthesis, forH and forI, are 
co-transcribed on a single transcript, likely resulting in translationally coupled 
proteins.  Similarly, the TCS operons, forGF and forBBCC are expressed on single 
transcripts.  This is common for TCSs, as the sensor kinase cannot function to control 
gene expression in the absence of the response regulator.   
The majority of the formicamycin core biosynthetic machinery is expressed on two 
long transcripts, transcripts 6 and 7, which are under the control of the divergent 
promoters pforU and pforT.  This suggests that co-transcription and translation is 
most efficient for these genes and may indicate that at least some of the biosynthetic 
forK forG FM JL forI forH forAAZE D C forB forA R S forT U forV W forX forY
Biosynthesis Transport / Resistance Regulation
forN
-184 -35 -58 -43 -229 -53 -41 +1 -49
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machinery from the formicamycin biosynthetic pathway functions as a multi-enzyme 
complex.  Interestingly, although there is a 198 base pair intergenic region between 
forX and forY, there was no TSS present within this region in any of the sequenced 
samples.  Thus, forY must be transcribed with forUVWX and the intergenic region 
between forX and forY must have an alternative role.  It may still be some sort of 
regulatory element, but instead of acting as a promoter it could be an enhancer of 
downstream transcription or somehow affect translation, perhaps by changing the 
secondary structure of the mRNA.  There is also a TSS within the coding region of 
forV.  Internal promoters like this have been identified previously in Streptomyces 
genomes and are predicted to be important for maintaining the transcription levels 
in long operons where the distance of the terminal genes from the transcription start 
site can negatively affect the levels of transcription of downstream genes (Dangel et 
al., 2009).  In the formicamycin BGC, we predict that the internal promoter within 
forV has evolved to maintain transcription levels of forY at the end of the 
polycistronic mRNA transcript forUVWXY.  Furthermore, transcription of the second 
putative MarR regulator gene in the formicamycin BGC, forZ, and the second TSS, 
forBBCC, are leaderless, with the TSS occurring on the start codon.  This is a 
phenomenon in bacterial transcriptomics where an mRNA transcript does not 
contain the usual 5’UTR and Shine-Dalgarno sequence and therefore the start codon 
itself serves as the signal for initiation of translation.  Although considered to be 
relatively uncommon in bacteria such as E. coli, leaderless transcripts have been 
found to be quite common in actinomycete genomes which have had their global 
TSSs mapped, accounting for approximately 20% of all the genes present in 
sequenced actinobacterial genomes deposited in the database (Zheng et al., 2011; 
Romero et al., 2014).   
 
 
 
 
 126 
4.2 Characterising cluster situated regulators of formicamycin biosynthesis 
 
Having identified the transcriptional organization of the formicamycin gene cluster 
and the locations of the promoters for the genes and operons within the BGC, it was 
important to identify the functions of the putative CSRs.  CSRs can respond either 
directly to extracellular signals or indirectly via signals from global regulatory 
systems.  They can either activate or repress transcription of secondary metabolite 
biosynthesis genes within the same gene cluster and/or, cross-regulate other BGCs 
in the genome.  Often, CSRs encode for small DNA binding proteins that control 
transcription by binding to promoters or other regulatory regions within a BGC.  The 
formicamycin BGC is predicted to encode two MarR-family regulators, ForJ and ForZ 
as well as two TCSs, ForGF and ForBBCC.  It is likely that at least some of these 
putative gene products work together to activate or repress expression of the 
formicamycin biosynthesis genes.  
ForBB is predicted to be a DNA-binding response regulator of the LuxR family and 
ForCC is predicted to be a sensor histidine kinase.  Together, these genes likely form 
a TCS.  Due to the location of these genes at the outer perimeter of the formicamycin 
BGC, deletion mutants of the whole TCS were generated using CRISPR/Cas9.  S. 
formicae DforBBCC was grown under formicamycin producing conditions and the 
extracts were quantitatively analysed by HPLC(UV) MS by Dr Zhiwei Qin.  Deletion of 
forBBCC had no effect on formicamycin or fasamycin production and was therefore 
judged to be outside the border of the minimal BGC (data not shown) (see Figure 
3.7).  The deletion mutant had no clear phenotype under the conditions tested, so 
function of the ForBBCC TCS is currently unknown but it is not predicted to be 
involved in the regulation of fasamycin/formicamycin biosynthesis. 
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4.2.1 The MarR-family regulator, ForJ 
 
Bioinformatic analysis of ForJ shows that it is a putative DNA-binding transcriptional 
regulator of the MarR-family that contains a helix-turn-helix domain typical of these 
Multiple antibiotic resistance Regulators.  MarR proteins often repress transcription 
by binding to palindromic sequences within the promoter regions of secondary 
metabolite BGCs. In order to determine the role of ForJ in regulating formicamycin 
biosynthesis, an in-frame unmarked deletion was generated in forJ using 
pCRISPomyces-2.  The S. formicae DforJ strain was genetically complemented, but 
this experiment was conducted while waiting for the cappable RNA sequencing data, 
so the complementation construct had forJ under the control of pforM instead of its 
own native promoter as we assumed forMLKJ formed an operon.  Three biological 
replicates of S. formicae DforJ and the complemented strain were grown under 
formicamycin producing conditions and extracts were analysed by HPLC/LMCS by Dr 
Zhiwei Qin to compare the levels of formicamycins in the samples to the wild-type 
(Figure 4.3).  Deletion of forJ resulted in a large increase in the levels of all 
formicamycin congeners present in the extracts compared to the wild-type strain.  
Production levels decreased to wild-type levels on re-introduction of the forJ in trans.   
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Figure 4.3: HPLC traces (UV 280 nm) showing extracts of: (A) S. formicae wild-type; (B) S. formicae 
DforJ; (C) S. formicae DforJ: jBT1 forJ pforM.  Deletion of forJ results in increased accumulation of all 
fasamycins and formicamycins compared to the wild-type levels.  Complementation of forJ in trans 
reduces formicamycin production to a similar level to the wild-type.  Scales are decreased to 
demonstrate the accumulation of compounds in S. formicae DforJ in a manner that is comparable 
across samples.  The presence of formicamycin congeners was confirmed by LCMS and is indicated by 
UV traces with smaller scales in the inserts.  Three biological replicates of each strain were generated 
for analysis. HPLC(UV) LCMS analysis conducted by Dr Zhiwei Qin at the John Innes Centre. 
These data suggest ForJ is a repressor of the formicamycin BGC.  When grown under 
formicamycin producing conditions next to a wild-type control, S. formicae DforJ also 
has a clear phenotype indicative of formicamycin over-production.  The mycelia are 
very yellow compared to the wild-type and fasamycins are yellow when purified.  
Furthermore, S. formicae DforJ does not sporulate even after extended incubation 
on MYM agar at 30°C.  In addition, the mutant only makes approximately 60% of the 
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biomass of the wild-type.  This could be because over-production of these antibiotics 
is overwhelming the host-resistance mechanisms and resulting in self-toxicity that 
negatively affects the growth and development of the mutant.  This phenotype is 
only partially rescued in the complementation mutant S. formicae DforJ:ΦBT1 forJ 
pforM (Figure 4.4).  This is likely due to the fact that pforM is not the native promoter 
of forJ and it may have been more effective to use 200-300 base pairs upstream of 
the forJ gene to capture the TSS and the full promoter region.  Alternatively, the 
change of location when the gene was introduced in trans may have affected the 
relative levels of expression.  Nevertheless, the fact that reintroducing forJ under the 
control of pforM reduces the levels of formicamycin production compared to the 
DforJ mutant implies that over-production is a result of the forJ deletion and further 
suggests that forJ represses the transcription of some or all of the genes within the 
formicamycin BGC.  
 
Figure 4.4: Deletion of forJ in S. formicae results in an extreme phenotype, with bright yellow 
mycelium forming.  After 10 days incubation on MYM, the wild-type can be seen to be sporulating 
(white, fluffy appearance on a plate) whereas S. formicae DforJ does not sporulate.  Similarly, the 
biomass of S. formicae DforJ is significantly lower than the wild-type (two-tailed T-test, p = 0.03).  The 
complementation mutant shows a phenotype in-between that of the mutant and the wild-type.  This 
is probably because pforM was used instead of the native promoter. 
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Previous attempts to heterologously express the formicamycin BGC were 
unsuccessful (data not shown).  However, we predicted that we could use this 
knowledge of formicamycin BGC repression by ForJ to switch on the for BGC in a 
heterologous host.  As such, the modified ReDirect protocol described in Chapter 3.2 
was used by Dr Neil Holmes (previous post-doctoral researcher in the Hutchings 
laboratory) to modify the PAC 215-G containing the entire formicamycin BGC and 
replace the coding region forJ with an apramycin resistance gene.  This construct was 
then introduced into S. coelicolor M1146 which is optimised for the expression of 
secondary metabolite BGCs through the deletion of the BGCs encoding for 
actinorhodin, prodiginines, coelimycin and the calcium-dependent antibiotic 
(Gomez-Escribano and Bibb, 2014).  The ex-conjugant colonies had a yellow 
appearance suggestive of fasamycin/formicamycin production that was not present 
in the no-PAC control or the strain containing the un-modified 215-G (Figure 4.5).  To 
confirm these strains were producing fasamycins/formicamycins, cultures were 
grown on SFM agar and extracted for HPLC(UV) LCMS analysis, conducted by Hannah 
McDonald (JIC).  This showed that only S. coelicolor M1146 containing the modified 
PAC with forJ deleted produced fasamycins and formicamycins, whereas the no-PAC 
control and the strain containing the unmodified PAC showed no evidence of any 
formicamycin congeners in the extracts.  This demonstrates that deletion of forJ 
results in de-repression of the gene cluster in a heterologous host, further providing 
evidence for the role of ForJ as a major repressor of the formicamycin BGC. 
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Figure 4.5: HPLC(UV) traces (250 nm) showing extracts of: (A) S. coelicolor M1146 no-PAC control 
(containing pSET152 in the same integrative site); (B) S. coelicolor M1146 215-G; (C) S. coelicolor 
M1146 215-G forJ:apr.  Heterologous expression of the 215-G PAC containing the whole formicamycin 
BGC in S. coelicolor M1146 did not results in the production of any fasamycins or formicamycins. 
However, when the PAC is de-repressed by deleting forJ, transcription of the BGC is activated resulting 
in biosynthesis of the compounds in the heterologous host.  This is evidenced by the yellow 
colouration of the media in the host containing the de-repressed PAC.  HPLC(UV) LCMS conducted by 
Hannah McDonald, JIC. 
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4.2.2 The two-component system, ForGF  
ForG is predicted to be a signal transduction histidine kinase and ForF is a DNA-
binding response regulator with a conserved receiver domain.  These genes are 
typical of a classical bacterial TCS.  To determine the role of forGF in the regulation 
of formicamycin biosynthesis, the entire operon was deleted using CRISPR/Cas9 to 
generate the S. formicae DforGF strain.  This mutant, along with a wild-type control 
and a complemented strain expressing forGF in trans under the control of its native 
promoter were grown under formicamycin producing conditions and the culture 
extracts analysed by HPLC(UV) LCMS by Dr Zhiwei Qin.  Deletion of the TCS operon 
forGF completely abolished fasamycin and formicamycin biosynthesis, with no 
congeners present in the culture extracts.  The complementation mutant S. formicae 
DforGF: ΦBT1 forGF pforG produces fasamycins and formicamycins although the 
levels of production are higher than the wild-type suggesting expression is higher 
when the genes are placed in trans (Figure 4.6).   
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Figure 4.6: HPLC traces (UV 280 nm) showing extracts of: (A) S. formicae wild-type; (B) S. formicae 
DforGF; (C) S. formicae DforGF: jBT1 forGF pforG.  Deletion of forGF abolished fasamycin and 
formicamycin biosynthesis.  Complementation of forGF in trans restores production of all congeners 
to approximately wild-type levels.  Three biological replicates of each strain were generated for 
analysis.  HPLC(UV) LCMS analysis conducted by Dr Zhiwei Qin at the John Innes Centre. 
These data strongly suggest that the TCS ForGF is required to activate the 
biosynthesis of the formicamycins.  TCSs often control the expression of their target 
genes in response to extracellular signals.  We hypothesise that ForG is a membrane 
associated sensor kinase that controls the activity of ForF in response to an 
extracellular signal.  On receipt of the signal, ForF is phosphorylated and activated, 
causing DNA binding and the initiation of transcription of some or all of the 
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biosynthetic genes within the formicamycin pathway.  At this time, the DNA target 
of ForF is unknown and therefore there is no way to know which genes within the 
formicamycin BGC are under the control of this two-component system.  The 
activation signal of ForG is also unknown.  Although many TCSs have been identified 
and characterised across Streptomyces genomes, very few have known activation 
signals and most are implicated in global regulation rather than cluster-specific 
regulation.  Experimentally characterising the activation signal is challenging because 
these TCSs function as part of a diverse and highly complicated regulatory system 
that links the multi-cellular developmental stages of Streptomyces growth with both 
the primary and secondary metabolism (Hutchings et al., 2004). 
 
4.2.3 The MarR-family regulator, ForZ 
 
ForZ is predicted to be another DNA-binding transcriptional regulator of the MarR-
family.  Domain analysis predicts the presence of a helix-turn-helix motif for DNA 
binding.  BlastP analysis shows that ForZ is quite different to ForJ, the other MarR 
regulator encoded in the formicamycin BGC, with relatively low identity between the 
two sequences (44% coverage and 30.77% identity).  Therefore, it is likely that they 
play distinct roles in the regulation of formicamycin biosynthesis.  To determine the 
function of ForZ, gene deletion of forZ was conducted using CRISPR/Cas9 followed by 
complementation, in trans, with forZ under the control of its native promoter.  S. 
formicae ∆forZ and S. formicae ∆forZ: ΦBT1 forZ pforZ were grown in parallel with a 
wild-type control under formicamycin producing conditions and extracts were 
analysed by HPLC(UV) LCMS by Dr Zhiwei Qin.  All fasamycin and formicamycin 
congeners were present in the extracts of the forZ deletion mutant, however, they 
were at lower levels than in the wild-type extracts (Figure 4.7).  This suggests that 
ForZ may be able to activate the transcription of some genes within the 
fasamycin/formicamycin biosynthesis pathway, however, it is not absolutely 
required for compound production.   
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Figure 4.7: HPLC traces (UV 280 nm) showing extracts of: (A) S. formicae wild-type; (B) S. formicae 
DforZ; (C) S. formicae DforZ: jBT1 forZ pforZ.  Deletion of forZ reduced the levels of fasamycin and 
formicamycin biosynthesis by around 50% compared to the wild-type.  Complementation of forZ in 
trans restores production of all congeners to approximately wild-type levels.  Three biological 
replicates of each strain were generated for analysis. HPLC(UV) LCMS analysis conducted by Dr Zhiwei 
Qin at the John Innes Centre. 
Overall, this work shows that ForJ and ForZ, the MarR regulators, and the TCS ForGF, 
are all involved in the regulation of formicamycin biosynthesis.  ForGF appears to be 
the main activator of transcription of the formicamycin BGC, whereas ForJ is the 
repressor.  ForZ also appears to have a role in the activation of expression of genes 
within the formicamycin BGC. 
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4.3  Identifying targets of ForJ, ForF and ForZ within the formicamycin BGC 
 
4.3.1 ChIP Sequencing 
 
The previous section shows that forJ, forGF and forZ encode regulators of 
formicamycin biosynthesis in S. formicae.  In order to learn more about the functions 
of the encoded CSRs, it was important to determine their binding sites to predict 
which transcripts were under the control of which regulators.  Some regulators 
specifically control the transcription of a single gene within a BGC whereas others 
may bind to multiple DNA sites across the cluster to generally regulate the expression 
of secondary metabolite biosynthesis genes.  Furthermore, some CSRs are known to 
bind to multiple BGCs across the genome.  Chromatin Immunoprecipitation 
combined with sequencing (ChIP-Seq) is a widely employed technique used to 
identify the target sites of DNA-binding proteins (Bush et al., 2016; Som et al., 2017).  
Proteins of interest are crosslinked to DNA using formaldehyde, the DNA is then 
sheared into small fragments and the DNA-protein complex of interest is 
immunoprecipitated using a specific antibody against the regulator.  The DNA that is 
‘pulled down’ in this reaction can be sequenced and mapped back to the genome to 
identify the genetic targets of the specified DNA-binding protein.  In order to identify 
the binding sites of ForJ, ForF and ForZ, mutant strains of S. formicae expressing 
3xFlag-tagged versions of each protein were generated.  As not much was known 
about each protein, a 15 amino-acid long linker was included between the coding 
sequence and the tag to increase the flexibility of the tag and reduce negative effects 
on the overall protein functionality.  The linker-FLAG region was added to the C-
terminus of each regulator and used to express 3x-Flag-tagged ForJ, ForF or ForZ in 
trans in each of the corresponding deletion mutants generated in the previous 
section.  These tagged complementation strains were shown by LCMS analysis to 
have restored formicamycin biosynthesis, suggesting that the tags did not adversely 
affect the activities of the regulators (data not shown).   
These strains were therefore used to perform ChIP against duplicate cultures of each 
strain after 2, 3 and 4 days under formicamycin producing conditions with wild-type 
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S. formicae as the negative control.  These time points were chosen because the 
yellow colour indicative of fasamycin and formicamycin production appears around 
day 3 and it is expected that the regulatory and biosynthetic genes are expressed in 
advance of compound detection in order for synthesis to occur (Seipke, Patrick and 
Hutchings, 2014).  Day 2 was the earliest time point that sufficient biomass could be 
harvested for ChIP-Seq.  RT-PCR was used to confirm that all the regulatory genes 
were expressed at these time points (data not shown).  After sampling for ChIP, small 
amounts of mycelium were also lysed and analysed by western-blot using an anti-
FLAG antibody to confirm the presence of the flag-tagged proteins in the cell lysate 
(data not shown).  The isolated DNA was quantified using Nanodrop UV-Vis and Qubit 
analysis before being sent to Genewiz (New Jersey) for sequencing using the Illumina 
HiSeq platform (EMBL-EBI Array Express accession number E-MTAB-8006).  FASTQ 
files were processed and analysed by Dr Govind Chandra (JIC) to generate bedgraph 
files that could be visualized in Integrated Genome Browser.  
As expected, some level of noise was present in all samples, with an average 
coverage depth of approximately 1500 background reads mapping across the 
reference genome.  By comparing the reads present in the wild-type samples with 
those present in the ForJ, ForF and ForZ samples, the minimum limit of coverage was 
set at 2000 reads in order to view significantly enriched peaks.  Significance was 
confirmed by analysis conducted by Dr Govind Chandra where every 25 nucleotides, 
the area of enrichment over 4000 nucleotides was divided by the reads of the central 
50 nucleotides.  These resulting enrichment values were then analysed according to 
a negative binomial distribution and only enrichment values with statistical 
significance of p < 0.05 were included.  This ensures that peaks shown are significant 
compared to the surrounding background reads as well as compared to the wild-
type.  In general, only a few significant peaks were present in the day 2 samples, 
probably due to S. formicae still being in an early growth stage and therefore the 
activity of secondary metabolite BGCs is likely to be low at this time point.  However, 
by day 4, there were multiple significant peaks present compared to the wild-type 
background, mostly present within the formicamycin BGC.  All peaks that were 
present in the day 2 sample were still present in the day 4 sample, showing that even 
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these small peaks were significant and the limit of background reads set was 
appropriate for this dataset. 
 
3xFlag-ForJ binds at multiple locations across the formicamycin BGC.  Significant 
peaks were called upstream of the following transcripts; forMLK, forHI, forTSRABCDE 
and forUVWXY (Figure 4.8).  These data, combined with the HPLC(UV) LCMS 
presented above, suggests that ForJ might repress the expression of most of the 
major transcripts within the formicamycin BGC by binding to these promoters and 
preventing recognition of the promoter sequence by the RNAP.  By binding to 
pforT/U, ForJ is likely preventing transcription of the forTSRABCDE transcript, and 
these genes encode the core biosynthetic machinery required for formicamycin 
biosynthesis (see later chapters).  Therefore, the repression of this transcript is 
important for the repression of formicamycin biosynthesis.  Interestingly, ForJ also 
appears to bind within the coding sequences of itself and forE, which encodes the 
ACC biotin carboxylase.  In addition to preventing the RNAP initiating transcription 
by binding to promoters, some DNA binding proteins prevent transcription via a 
roadblock mechanism where they bind within the coding region of a gene (Roy et al., 
2016).  Thus, we predict that ForJ is auto-repressing transcription of forJ and forE 
through a roadblock mechanism.  In addition, ForJ binds upstream of two genes 
elsewhere in the genome; KY5_3182, which encodes a putative MoxR-type ATPase 
and KY5_5812, which encodes a hypothetical protein.  The significance of these 
binding sites is currently unknown.   
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Figure 4.8: ChIP-seq results from S. formicae ∆forJ:ΦBT1 forJ 3x Flag strain at day 4.  ForJ binds at five 
different positions within the formicamycin BGC, suggesting it is a major regulator of formicamycin 
biosynthesis.  Elsewhere in the genome there were only two peaks present, suggesting ForJ may 
specifically be a regulator of formicamycin biosynthesis. Peaks represent enrichment relative to the 
wild-type background. 
It should be noted that generally the enrichment values for the peaks in the 3xFlag-
ForJ dataset were lower than for the other regulators tested.  This is predicted to be 
because the ForJ deletion mutant grows more slowly compared to the wild-type and 
complementation with the Flag-tagged copy of ForJ was conducted using pforM, 
before we knew forJ had its own promoter, meaning the biomass obtained for this 
strain was lower compared to the other mutants and the wild-type control.  This was 
reflected in the fact that the total amount of DNA obtained from the 3xFLAG-ForJ 
samples was also lower.  This could have led to less coverage in the sequencing 
overall, bringing down the relative enrichment values compared to the wild-type.  
The peaks are still statistically significant and reflective of real protein-DNA 
interactions.  
 
Analysis of the 3xFlag-ForF dataset revealed there was only a single binding site 
within the formicamycin BGC which was between the divergent forHI and forGF 
transcripts (Figure 4.9).  As the LCMS data above suggests that ForGF is the activator 
of formicamycin biosynthesis, it is possible that initial binding of the response 
regulator to this promotor region allows autoregulation and transcription of forHI, 
forming the initial malonyl-CoA starter unit, which presumably initiates biosynthesis 
of the formicamycins.   
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Figure 4.9: ChIP-seq results from S. formicae ∆forGF:ΦBT1 forGF 3x Flag at day 4.  ForF appears to 
only bind to a single divergent promoter within the formicamycin BGC.  Peaks represent enrichment 
relative to the wild-type background. 
ForF also appears to bind upstream of KY5_0375.  BlastP analysis suggests this gene 
may encode for an NLPc/P60 family protein.  This protein family consists of cell-wall 
peptidases that are widespread across multiple bacterial lineages.  Those that have 
been characterised in Bacillus subtilis have been shown to hydrolyse the D-glutamyl-
meso-diaminopimelate linkage present in cell wall peptides (Anantharaman and 
Aravind, 2003).  Perhaps more interestingly to this project, this gene sits within 
another predicted BGC from the AntiSMASH analysis of the S. formicae genome, 
predicted to encode for a RiPP due to the presence of two radical SAM enzyme 
encoding genes (Holmes et al., 2018).  This suggests ForGF may be responsible for 
regulating the production of more than one antimicrobial in S. formicae, a hypothesis 
which is investigated later in this thesis (Chapter 7.2).  
 
Analysis of the 3xFlag-ForZ dataset revealed the presence of just one peak in the 
whole genome of S. formicae.  ForZ binds to the divergent promoter region between 
forZ and forAA (Figure 4.10).   
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Figure 4.10: ChIP-seq results from S. formicae ∆forZ:ΦBT1 forZ 3x Flag at day 4.  ForZ binds to a single 
divergent promoter within the formicamycin BGC.  Peaks represent enrichment relative to the wild-
type background. 
MarR regulators are generally involved in regulating the activity of genes involved in 
stress responses and the degradation or export of toxic molecules such as phenolic 
compounds and antibiotics from the cell.  The conventional mode of regulation via a 
MarR protein occurs via binding to an intergenic region between two divergent 
genes, one encoding for the MarR regulator itself and the other encoding for the 
gene under its regulation (Perera and Grove, 2010).  ForZ is therefore predicted to 
autoregulate and regulate the expression of the putative multidrug resistance 
transporter gene forAA, which may be responsible for export of formicamycins.  If 
this is the case, it is currently unclear why deletion of ForZ in the previous section 
resulted in a decrease in formicamycin production.  It is possible that there is some 
sort of feedback loop that limits the levels of expression of the biosynthetic genes 
until transcription of the export mechanism is activated to prevent compounds 
accumulating to toxic levels. 
4.3.2 Motif analysis of DNA binding sites identified by ChIP-seq 
The DNA-binding sites of each CSR identified using ChIP-seq are only to 
approximately 100-300 base pair resolution  (Figure 4.11).  Normally, transcriptional 
regulators specifically recognize short inverted repeat sequences within their target 
DNA, usually between 16 and 20 bp long, that are either palindromic or inverted 
repeats.  It is possible to use bioinformatic approaches to search for motif sequences 
within the identified target promoters for example by using motif-based sequence 
analysis tools such as MEME (Bailey et al., 2015).  As only a single binding site was 
identified for ForZ, MEME could not be used to search for motifs with any statistical 
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significance.  Similarly, ForF only had two binding sites in the ChIP experiment, so any 
binding sites identified by MEME would likely not be significant.  Furthermore, 
response regulators are hugely diverse and proteins within the family are able to bind 
a variety of different motif sequences, making it hard to define search criteria in this 
type of analysis.  However, there were five binding sites for ForJ within the 
formicamycin BGC and MarR-family regulators are known to frequently bind inverse 
repeat sequences, therefore MEME analysis is more likely to identify significant 
motifs within the target promoters. 
 
Figure 4.11: TSS (indicated by arrows) were identified using cappable RNA sequencing.  Approximate 
binding sites for each cluster situated regulator were determined by ChIP-sequencing and are 
represented by the circles.  These binding sites are only defined to approximately 100-300 bp 
resolution. 
The DNA regions identified as ForJ binding sites were entered into the MEME tool to 
look for motifs that were present in all sequences and to preferentially search for 
palindromic motifs.  The results gave three predicted motifs, the most significant of 
which is shown (Figure 4.12). The locations of all the identified motifs were examined 
in comparison with the TSSs identified from the cappable RNA sequencing 
experiment.  It might be expected that the ForJ repressor would bind on or very near 
to the TSS to prevent binding of the RNA polymerase.  The motif shown in Figure 4.12 
appears exactly across the TSS of pforM and pforT as well as being within just 21 base 
pairs of pforU.  The motif also appears almost exactly half way through the intergenic 
region between forH and forG, sitting between the two TSSs of this divergent 
promoter.  The motif is also present at the 3’ end of the coding region of both forJ 
and at the edge of the peak identified in the coding region of forE, right at the end of 
the overlapping coding region with forD (Table 4.2).  We therefore propose that 
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these 14 base pair imperfect inverted repeat sequences are the DNA binding sites of 
ForJ.  The locations of the other two predicted motifs identified by MEME were not 
as striking in terms of proximity to the transcription start sites, therefore, due to their 
lower significance scores, it was concluded that these did not represent likely binding 
sites for ForJ.  Many CSRs found in actinomycete genomes been shown to recognise 
heptameric repeat sequences within promoter regions and the motif presented here 
is a non-perfect inverted heptameric repeat sequence, further implying that it may 
represent the DNA binding site of ForJ.   
 
Figure 4.12:  MEME analysis identified a 14 base pair inverted repeat sequence that is almost 
palindromic within the binding sites identified in the ChIP-seq data (E value 2.4e+000).  The motif, 
identified by a light blue dot, is located at or near the transcription start site within each of the target 
promoters of ForJ and within all the binding sites identified in the ChIP experiment.  This motif likely 
represents the DNA binding site of ForJ.  
 
 
 
 
 
 
 
 
 
 
forK forG FM JL forI forH forAAZE D C forB forA R S forT U forV W forX forYforN
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Table 4.2:  Nucleotide positions of the promoter regions or coding regions within the for BGC that 
were identified as targets of ForJ during ChIP-Sequencing along with the positions of the nearest TSS 
and the possible ForJ binding site identified by MEME. In all the identified promoter region targets of 
ForJ, the motif identified by MEME sits across or very close to the TSS identified by capable RNA 
sequencing.  
 Promoter or coding 
region position 
Nearest 
TSS 
Site of ForJ binding 
site  
Start End Start End 
pforM 7756912 7757157 7757123 7757115 7757130 
forJ 7759841 7760290 7759783 7760248 7760262 
pforHI/pforGF 7763485 7763994 7763527 
7763765 
7763714 7763728 
forE 7765756 7766271 7771343 7766385 7766399 
pforT/U 7771291 7771410 7771343 
7771370 
7771335 7771349 
 
4.3.3 Mechanistic insights into regulation of the formicamycin BGC 
 
This work has begun to characterise the mechanisms of regulation of formicamycin 
biosynthesis by the MarR-family regulators ForJ and ForZ, and the TCS, ForGF.  We 
predict that ForJ represses biosynthesis of the formicamycins by binding to multiple 
regions across the for BGC, through the recognition of a short 14 bp palindromic 
repeat sequence.  In this way, as well as autoregulating, ForJ is likely able to block 
the transcription of much of the core biosynthetic machinery within the 
formicamycin BGC by a combination of preventing the recognition of promoter 
regions by the RNAP or preventing transcription through roadblock.  The TCS ForGF 
likely controls the transcription of forHI, the genes encoding for production of the 
starter unit for polyketide biosynthesis, i.e. the first stage of formicamycin 
biosynthesis, as well as autoregulating.  On receipt of an appropriate signal, the 
histidine kinase ForG presumably activates its response regulator ForF, which can 
then bind to the divergent promoter pforG/H allowing expression of the forHI 
transcript and autoregulation of forGF.   
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The majority of classical response regulators belong to the OmpR/PhoB subfamily 
and consist of a typical conserved a/b domain referred to as the receiver domain and 
a C-terminal effector domain that is responsible for DNA binding.  The response 
regulator ForF aligns most closely with the vancomycin-resistance associated 
response regulator VraR from Staphylococcus aureus, with 30.14% identity and 95% 
coverage. VraR regulates the cells response to antibiotic-related cell wall stress in 
conjunction with its partner sensor histidine kinase.  Experimental characterization 
of VraR has shown that upon phosphorylation and dimerization, the response 
regulator binds DNA in a sequence specific manner to control transcription of the 
genes in its regulon (Liu et al., 2009).  Modelling of ForF in Swiss-model shows the 
receiver domain likely consists of the highly conserved five-stranded parallel b sheets 
surrounded by five amphipathic helices found in most OmpR/PhoB a/b domains.  
Characterisation of other OmpR/PhoB family response regulators shows that the 
receiver domain contains conserved aspartate residues for phosphorylation by the 
sensor kinase.  Phosphorylation of the receiver domain causes small conformational 
changes in the structure of the response regulator causing enhanced DNA binding 
affinity in the C-terminal effector domain (Gao, Mack and Stock, 2007).  This is also 
highly likely to be the method of transcriptional activation by ForF.  The C-terminal 
domain of ForF consists of a typical winged helix-turn-helix structure for optimal DNA 
binding and transcriptional control (Figure 4.13). 
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Figure 4.13:  Modelling of the response regulator ForF shows that it forms a homodimer for DNA 
binding and activation of transcription of the formicamycin BGC.  Like many classical response 
regulators, it consists of a conserved N-terminal a/b receiver domain that can be phosphorylated and 
a C-terminal effector domain that likely binds to DNA. 
Modelling suggests that like most MarR regulators, ForJ and ForZ are also winged 
helix-turn-helix DNA binding proteins that form triangular homodimers (Figure 4.14).  
ForJ and ForZ share low sequence homology, suggesting that they each act via 
different mechanisms.  ForJ is predicted to be most similar to the MarR 
transcriptional regulator YusO (26.81% identity, 90% coverage) which functions as a 
homodimer to repress expression of itself and the divergent multidrug resistance 
protein YusP in Bacillus subtilis (Kim et al., 2009).  ForZ aligns most closely to the 
transcriptional regulator RdhR-CbdbA1625 (16.08% identity, 83% coverage) that 
represses transcription of reductive dehalogenase homologues in the obligate 
organohalide-respiring Dehalococcoides mccartyi in response to dichlorophenol 
ligands (Wagner et al., 2013).  It has been shown for other MarR regulators that the 
recognition helix within the DNA binding pocket binds to the major groove of DNA 
while the wing region is essential for stabilising the binding by interacting with the 
adjacent minor grove.  This mechanism reduces distortions caused to the DNA 
molecule (Perera and Grove, 2010).   
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Figure 4.14:  Modelling of ForJ (red) and ForZ (orange) in Swiss model and PyMol shows that both 
proteins likely function as homodimers that form a triangular shape with a DNA-binding pocket 
between each monomer unit.   
MarR-family regulators have ligand-binding capabilities in addition to DNA-binding 
and, unlike other cluster situated regulators, they bind their ligand and the DNA in 
the same domain.  Ligand binding changes the confirmation or flexibility of the MarR 
transcription factor and alters its DNA-binding activity, resulting in a change in target 
gene expression levels (Grove, 2017).  MarR regulators are often encoded in 
pathways that synthesise aromatic compounds and the ligands for the regulators are 
often substrates of the biosynthetic enzymes under the control of the MarR regulator 
(Perera and Grove, 2010).  It is possible that when ForF activates transcription of 
forHI, the malonyl-CoA starter unit binds to ForJ, causing it to de-repress 
transcription of the other biosynthetic genes in the for BGC, resulting in the 
production of formicamycins.  This hypothesised mechanism means that 
transcription of the for BGC remains repressed by ForJ until there are enough starter 
units available for formicamycin biosynthesis. 
In addition, many MarR regulators are known to be involved in the regulation of 
expression of host resistance mechanisms in response to accumulating antibiotics 
within the cell.  For example, OtrR is a MarR-family regulator encoded in the 
oxytetracycline biosynthetic pathway in Streptomyces rimosus that has been shown 
to repress the expression of the divergent gene otrB, which encodes for a membrane 
associated MFS family transporter.  The activity of OtrR is sensitive to the presence 
of oxytetracycline and other biosynthetic intermediates from the pathway which 
induce the expression of otrB (Pickens and Tang, 2010; Mak, Xu and Nodwell, 2014).  
ForJ ForZ
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The ForAA protein is thought to be responsible for exporting formicamycins out of 
the cell and therefore contributing to the host-resistance.  Generally, the expression 
of host resistance mechanisms is tightly controlled to ensure that it occurs either 
prior to compound biosynthesis or at the same time.  Without this tight control, 
antimicrobial natural products would accumulate inside the cell causing self-toxicity.  
The expression of these host resistance mechanisms is often induced by the 
antibiotic products themselves or by biosynthetic intermediates produced by the 
pathway.  In this way, the host can respond to increasing compound titres and 
prevent overwhelming its own capacity for resistance (Mak, Xu and Nodwell, 2014).    
Given this information, we predict that accumulating formicamycins or other 
biosynthetic intermediates from the pathway bind to ForZ, causing it to de-repress 
the expression of forZ and the divergent forAA transporter gene to ensure that the 
compounds are removed from the cell before they can cause toxicity to the host.   
However, the data presented earlier in this chapter indicate that the role of ForZ goes 
beyond simply the control of forZ/forAA expression, as deletion of forZ reduced the 
production of formicamycins by around 50% (Chapter 4.2.3).  This suggests that ForZ 
can also activate formicamycin biosynthesis or somehow increase levels of 
compound production.  Recently, the cluster-situated MarR regulator SAV4189 from 
the avermectin BGC in S. avermitilis was shown to repress the transcription of itself 
and the adjacent transporter gene as well as also indirectly activating transcription 
of other avermectin biosynthesis genes by changing the expression levels of aveR, 
the cluster-situated activator.  In a SAV4189 deletion mutant, levels of the aveR 
activator were lower and avermectin yields were reduced by approximately five fold 
(Guo et al., 2018).  The amino acid sequence of ForZ aligns to SAV4189 with 30.91% 
identity and 55% coverage.  It could be that as well as autoregulating and controlling 
the transcription of forAA, the putative resistance transporter, ForZ is able to interact 
with another CSR from the formicamycin BGC to further increase the transcription of 
other biosynthetic genes within the for BGC, increasing the titres of formicamycins 
produced.  This mechanism ensures that high-titres of formicamycins are only 
produced once expression of the host-resistance mechanism is switched on, to avoid 
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self-toxicity.  It also explains why, in a forZ deletion mutant, where expression of 
forAA remains repressed, formicamycin production levels are lower (Figure 4.15).   
 
Figure 4.15: Regulation of the formicamycin BGC is controlled by the combined actions of the MarR 
regulators, ForJ and ForZ, as well as the TCS, ForGF.  Transcription of forHI is predicted to be activated 
by the TCS, ForGF.  The forHI transcript encodes the genes responsible for the biosynthesis of the 
malonyl-CoA starter unit.  Transcription of the entire for BGC is thought to be repressed by ForJ until 
something, possibly the accumulation of malonyl-CoA, causes it to fall off the DNA and allow 
transcription of the biosynthetic genes.  Once transcription of formicamycin biosynthesis genes is 
activated through this de-repression by ForJ, formicamycins accumulate.  The binding of 
formicamycins or pathway intermediates to ForZ is predicted to de-repress pforZ/AA, inducing 
transcription of the host-resistance transport gene, forAA.  ForZ may also be able to indirectly further 
increase transcription of the for BGC perhaps through interactions with another CSR.  In this figure, 
solid arrows represent interactions that have been experimentally confirmed in this chapter and 
dashed lines represent predictions made based on the data available at this time. 
4.4 Understanding the mechanisms of host resistance to formicamycins in S. 
formicae 
 
Most secondary metabolite BGCs that encode for antibiotics also encode for at least 
one resistance mechanism to enable the host to produce the compounds without 
causing toxicity to itself.  These host resistance mechanisms can be extremely 
diverse, ranging from target modification, antibiotic inactivation or transport via 
efflux pumps (Mak, Xu and Nodwell, 2014).  Analysis of the formicamycin BGC 
presented previously (Chapter 3.5) did not identify any candidates for host-
resistance within the cluster or near the cluster edge.  However, there are two 
putative transport genes encoded within the formicamycin BGC.  ForK is predicted to 
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be a cation/H+ antiporter and ForAA is a putative major facilitator superfamily (MFS) 
drug resistance transporter.  Data described above suggest that ForAA may be 
involved in the export of formicamycins out of the cell under the control of ForZ.  So 
far, the role of ForK is unknown.  In order to determine the roles of the transporter 
genes in the formicamycin BGC, CRISPR/Cas9-mediated deletions of each gene were 
made in S. formicae.  The initial hypothesis was that one of the transporters would 
be essential and that deletion would be lethal as a result of self-toxicity via 
formicamycin accumulation.  Deletion mutants were therefore generated in both the 
wild-type S. formicae, which produces formicamycin congeners when grown under 
standard laboratory conditions and S. formicae DforGF, which has been shown 
previously to not produce any fasamycin or formicamycin congeners.  We predicted 
that deletion of the host-resistance mechanism would be possible in S. formicae 
DforGF but not in the wild-type.  Conversely to our predictions, confirmed replicates 
of S. formicae DforK and S. formicae DforAA were generated in both the wild-type 
and DforGF background.  When grown under formicamycin producing conditions 
alongside a wild-type control, both the S. formicae DforK and S. formicae DforAA 
mutants appear to grow more weakly than the wild-type strain, although the 
phenotype is not extreme.  This suggests that neither transporter on its own is 
essential for export of the fasamycins/formicamycins and perhaps that the two 
transporters work synergistically.  To test this hypothesis, the pCRISPomyces-2 
system was used to generate a mutant strain lacking both transporters, S. formicae 
DforAA DforK.  This strain had quite a severe phenotype, much like S. formicae DforJ 
strain described previously; the mycelia were extremely yellow and the strain did not 
sporulate even after extended incubation under conditions that normally cause 
sporulation in wild-type S. formicae (Figure 4.16). 
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Figure 4.16:  Each putative transport gene encoded in the formicamycin BGC (forK and forAA) was 
deleted using CRISPR/Cas9 both individually and in combination in the wild-type background.  When 
grown under formicamycin producing conditions, the single deletion mutants (S. formicae DforK and 
S. formicae DforAA) do not show a severe phenotype compared to the wild-type strain, however, the 
double mutant (S. formicae DforK DforAA) grows poorly and does not sporulate, suggesting toxic 
compounds are accumulating within the cell. 
Although the strain appears sick, deletion of both transporter genes is not lethal in 
S. formicae.  The most likely explanation for this is that similar transporters encoded 
elsewhere in the genome can partially compensate for their loss and prevent 
lethality.  Indeed, BlastP analysis of the S. formicae genome identifies multiple gene 
products with significant homology to both forK and forAA that might have the 
potential to function via a similar mechanism and transport these molecules out of 
the cell. There are 158 putative MFS family drug-resistance transporters encoded in 
the S. formicae genome, 64 of which show significant similarity to ForAA and 4 other 
cation/H+ antiporters that show homology to ForK (homology in this case is 
measured as >25% identity and/or >80% coverage to the query sequence).  It is highly 
likely that one or more of these homologous transporters encoded elsewhere in the 
genome can export low levels of formicamycins out of the cell.  In addition, S. 
formicae likely possesses its own host-resistance mechanism, for example additional 
copies of DNA gyrase as discussed in chapter 3.5, and can therefore tolerate low 
levels of compound accumulation.  However, the obvious phenotype of the double 
transporter mutant, S. formicae DforK DforAA, suggests that the strain is struggling 
to cope with the accumulation of these compounds.  This suggests that the other 
transporters are much less efficient at removing formicamycins from the cell and 
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shows that the presence of forAA and forK together is very important for host 
resistance.  In the future, in order to determine which compounds from the for BGC 
are exported by each of the transporters, the transporter deletion strains will be 
grown on solid agar with cellophane discs so that the biomass can be removed from 
the growth media after fermentation to isolate the intracellular compounds from the 
ones that have been exported.  These samples can then be quantitatively analysed 
by HPLC(UV)/LCMS to understand which compounds are exported via each 
transporter and at what levels.  We also have complementation strains for the single 
deletion mutants, S. formicae DforK: ΦC31 forK pforM and S. formicae DforAA: ΦC31 
forAA pforAA with each gene placed in trans under the control of its native promoter.  
Phenotypically, these strains appear and grow like the wild-type strain (data not 
shown).  The complementation strains will also be analysed by HPLC(UV)LCMS 
alongside the mutants as described above.   
 
MFS transporters like ForAA are widespread in nature, ranging in functions from 
resistance-conferring efflux pumps in bacteria to glucose transporters in large 
mammals.  Most MFS transporters consist of 12 or 14 trans-membrane helices and 
contain two domains that together form a channel across the cell membrane.  They 
are usually specifically evolved for the transport of structurally related substrates.  
Some drug-efflux systems rely on energy from the hydrolysis of ATP to move large 
molecules across the membrane, however, many, including some of the MFS 
transporters, are driven by the proton motive force (PMF) generated by the 
electrochemical gradient across the membrane (Paulsen, Brown and Skurray, 1996).  
These ‘secondary-active’ multidrug transporters function as antiporters that couple 
efflux of their substrate(s) to the influx of protons or sodium ions down the 
electrochemical gradient.  The PMF provides the energy for the transporter to switch 
between inward and outward oriented states via a series of consecutive 
conformational changes between the two halves of the protein (Du et al., 2015).  
ForK is predicted to be a putative cation/H+ antiporter that is responsible for moving 
protons across the cell membrane.  We therefore hypothesise that ForK functions to 
increase the electrochemical gradient across the cell membrane due to increased ion 
exchange, providing more energy for efflux via ForAA and more efficient transport.  
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If this hypothesis is true, S. formicae DforK is able to survive because ForAA will 
export formicamycins, albeit to a lower efficiency than in the wild-type strain.  In the 
S. formicae DforAA strain, we might expect levels of overall transcription of the for 
BGC to be lower through the indirect actions of ForZ with another CSR when the 
major host-resistance gene is removed or inactivated, meaning that compounds do 
not accumulate intracellularly to toxic levels.  To test this in the future, in addition to 
HPLC(UV) and LCMS analysis, transcriptomic analysis such as qRT-PCR or RNA 
Sequencing of the regulator and transporter mutants could be conducted to compare 
the expression levels of the transcripts within the for BGC in the different 
backgrounds.   
 
So far, this work shows that both transporters work synergistically to export 
fasamycins and formicamycins out of the cell.  As well as providing more information 
about the risk of resistance to these compounds arising in pathogenic bacteria if they 
are ever used clinically, this knowledge of host resistance to formicamycins in S. 
formicae can be used to generate mutant strains with increased biosynthetic 
capabilities.  Earlier in this chapter, we showed that deletion of forJ in S. formicae 
resulted in higher titres of fasamycins/formicamycins, however, it also resulted in 
severe phenotypic effects and the mutant grew poorly compared to the wild-type S. 
formicae (Figure 4.4).  We hypothesised that over-production of fasamycins and 
formicamycins in S. formicae DforJ overwhelms the natural resistance mechanisms 
and transporters, resulting in a toxic accumulation of the compounds.  We predicted 
we could generate strains that would both over-produce fasamycins/formicamycins 
and grow rapidly to a high biomass by increasing the expression of the host-
resistance mechanism in S. formicae DforJ.  Initially, strains of S. formicae DforJ 
overexpressing either ForK or ForAA in trans under the control of the constitutive 
promoter permE* were generated as they were predicted to give the highest level of 
host resistance via compound efflux.  However, ForAA and ForK are membrane 
proteins and their overexpression caused the resulting strains to grow extremely 
poorly, even compared to S. formicae DforJ, probably due to disruptions to the cell 
membrane (data not shown).  Therefore, the constructs generated previously for 
 154 
complementation of the deletion mutants with each transporter expressed under 
the control of its native promoter were conjugated into S. formicae DforJ to generate 
strains with an extra copy of either forK or forAA.  The resulting strains showed 
greatly increased growth and sporulation compared to S. formicae DforJ.  The extra 
copy of forAA seemed to increase both sporulation and biomass to a greater degree 
than the additional copy of forK, resulting in the strain S. formicae ∆forJ: ΦBT1 forAA 
pforAA that seems to grow and develop the same as the wild-type (Figure 4.17).  This 
further suggests that ForAA might be the major transporter of formicamycin 
congeners, whereas ForK plays a role in increasing the efficiency of transport by 
ForAA. 
 
Figure 4.17:  Previous work showed that S. formicae DforJ overproduces fasamycin and formicamycins 
but the strain is sick, presumably due to accumulation of toxic compounds inside the cell, resulting in 
significantly less biomass in the mutant compared to the wild-type (two-tailed T-test, p = 0.03).  To 
overcome this, extra copies of the transporters fork and forAA were expressed in trans in the forJ 
mutant to increase the capacity of the host-resistance mechanism.  The extra copy of forK resulted in 
a moderate increase in biomass and sporulation, however, the addition of an extra copy of forAA fully 
complemented the growth and development to that of the wild-type strain. 
These strains will also be fully and quantitatively analysed by HPLC/LCMS in the 
future to characterise their levels of antibiotic production and export, however, it is 
assumed that they represent strains that overproduce fasamycins and formicamycins 
without the detrimental effect of self-toxicity on the host.  These strains of S. 
formicae may be useful in future for the isolation of high titres of compounds for use 
in in vitro studies.  It would also be interesting to determine whether these strains 
are capable of overproducing compounds during liquid culture as the majority of 
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industrial antibiotic production is performed in flasks and bioreactors (Manteca and 
Yagüe, 2018).  For these clinically relevant antibiotics to be produced at an industrial 
scale, it will be important to continue improving strains of S. formicae for this purpose 
in the future.   
4.5  Discussion 
During this chapter, we have begun to understand the transcriptional organisation 
and regulatory control of the formicamycin BGC.  Cappable RNA sequencing allowed 
us to characterise the transcriptional organisation of the BGC and enabled the 
identification of the promoters and transcripts required for expression of the 
formicamycin biosynthesis genes.  This showed that many of the genes within the 
formicamycin BGC are translationally coupled, suggesting their functions are tightly 
linked.  The roles of the biosynthetic enzymes encoded on these transcripts is fully 
investigated in the following chapters.  The identification of the promoters within the 
formicamycin BGC is also used in genetic experiments characterising the roles of the 
biosynthetic genes within the cluster as it allows complementation constructs to be 
generated using the native promoter.  We have also identified the CSRs that bind the 
gene promoters required for formicamycin biosynthesis and predicted which 
transcripts are likely to be under their control using ChIP-sequencing.  This work 
begins to provide a detailed understanding of the complex systems that regulate 
biosynthesis of the formicamycins and host-resistance to this important new group 
of antibiotics.   
Formicamycin biosynthesis appears to be activated by the ForGF TCS.  ChIP-seq of a 
strain producing a 3xFlag-tagged ForF shows that it binds upstream of the forHI 
transcript, which encodes the proteins responsible for the first step of formicamycin 
biosynthesis, the generation of the malonyl-CoA starter unit.  The majority of 
characterised TCSs are from the genomes of model actinomycetes such as S. 
coelicolor and S. venezuelae, due to the availability of genome data and protocols for 
genetic manipulation in these organisms (Rodríguez et al., 2013).  Of the TCSs studied 
in these organisms, many have been suggested to play a role in the higher-level 
regulation of both antibiotic biosynthesis and morphological differentiation, with 
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fewer cluster-situated TCSs having been characterised so far.  Loss of ForGF does not 
appear to result in a phenotype in S. formicae, at least under the conditions tested 
during this work, therefore it is unlikely that ForGF plays a role in morphological 
differentiation in addition to its function as an activator of formicamycin 
biosynthesis.  Some CSRs are also able to alter the expression of BGCs elsewhere in 
the genome through cross-cluster regulation.  For example, JadR1 is an OmpR-type 
regulator that sits within the jadomycin BGC in S. venezuelae.  JadR1 has been shown 
to activate the expression of genes within the jadomycin BGC as well as repress genes 
involved in chloramphenicol biosynthesis (Chater, 2016).  ForF is the only CSR 
encoded in the formicamycin BGC that appears to interact with DNA in another BGC, 
as it binds to a promoter in cluster 4 (Table 1.1).  This could imply that ForGF, like 
many other TCSs that have been characterised in Streptomyces genomes, can 
regulate the expression of genes from multiple BGCs across the genome of S. 
formicae.  As cluster 4 is predicted to be silent under formicamycin producing 
conditions, it is currently unclear what effect deletion of ForGF has on the expression 
of this BGC.  The potential cross-cluster regulation by the ForGF TCS is investigated 
later in this thesis.   
TCSs are known to respond to extracellular signals but the specific signals that most 
TCSs respond to remain unknown (Hutchings et al., 2004).  Similarly, we do not know 
what signal(s) the ForGF TCS responds to.  We do know that formicamycins are 
produced by S. formicae on both MYM and SFM, both of which are relatively rich and 
complex media, and production is evident relatively early in the growth of the 
organism, usually by day 5 and the CSRs are all expressed by day 2.  This suggests 
that nutrient depletion is not the signal activating the transcription of the 
formicamycin biosynthetic genes, as is the case for some other BGCs.  In the future, 
characterising the signals that activate cluster-situated activators of antibiotic 
biosynthesis like ForGF will be useful as the knowledge could be used to activate 
those BGCs which remain silent under normal laboratory conditions (Rutledge and 
Challis, 2015).   
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The work in this chapter also shows that expression of all the major transcripts in the 
for BGC are likely repressed by binding of the MarR regulator ForJ to their promoter 
regions.  This is consistent with the fact that a DforJ mutant has significantly 
increased levels of formicamycin production compared to the wild-type.  The vast 
majority of MarR-type regulators reported in bacterial and archaeal genomes are 
repressors of transcription  (Wilkinson and Grove, 2006).  The ligand binding 
capabilities of these MarR proteins implies that the accumulation of a ligand, perhaps 
the early biosynthetic starter unit generated by ForHI, causes ForJ to release from 
the DNA, de-repressing the expression of the formicamycin transcripts.  The other 
MarR regulator encoded in the formicamycin BGC, ForZ, appears to be involved in 
the regulation of the host-resistance mechanism by controlling the expression of a 
major transporter, ForAA, in response to accumulating levels of formicamycins or 
other biosynthetic intermediates.  CSRs of this type such as MarR and TetR regulators 
that can alter the levels of transcription in response to signals from one or more 
molecules within the cell are referred to as one component systems (Cuthbertson 
and Nodwell, 2013).  In the future, it will be important to experimentally characterize 
the DNA binding sites identified in this chapter and the ligand binding capabilities of 
both the MarR regulators encoded in the formicamycin BGC.  This could be done 
using an electrophoretic mobility shift assay (EMSA) where the purified protein is 
incubated with fluorescently tagged DNA probes and then run on a polyacrylamide 
gel.  Protein-DNA complexes run more slowly through a gel compared to free protein 
and therefore protein-DNA interactions are represented by an upward ‘shift’.  In 
order to characterise ligand binding, formicamycin precursors and intermediates 
could be included in the EMSA reactions to determine whether the presence of these 
compounds abolishes the DNA-protein interaction.  Furthermore, with the purified 
proteins in hand, crystal structures for both MarR regulators could also be generated.  
If possible, crystals of the regulator bound to both the ligand and/or DNA could be 
generated, however, this may be challenging as the optimal conditions for protein 
purification are often not optimal for stable DNA.  This will be the subject of further 
investigations in the Hutchings laboratory. 
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Whilst the results from the cappable RNA sequencing experiment were highly 
informative and allowed the locations of all the TSSs to be identified, this type of 
transcriptomic analysis provides no information about the strength of the promoters 
or the levels of transcription of each gene/transcript in relation to others in the 
genome.  In the future, transcription levels could be quantified using traditional RNA 
sequencing methods or qRT-PCR in both the wild-type and the regulator mutant 
backgrounds (S. formicae DforJ, S. formicae DforGF and S. formicae DforZ) to 
determine how the levels of transcription change in the absence of each CSR.  For 
example, we might expect levels of the major transcripts from the for BGC to be 
higher in S. formicae DforJ, as this strain produces higher titres of formicamycin 
congeners and does not have the major repressor, however, this may not be the case 
for every transcript within the BGC.  It would also be interesting to identify whether 
ForZ has any indirect roles in controlling levels of expression of any for BGC 
transcripts or other CSRs in addition to the de-repression of pforZ/AA.   
Promoter activity can be measured by fusing the promoter to a reporter gene and 
then measuring the activity of the reporter gene product.  In this way, the strengths 
of each promoter in the BGC can be compared in different genetic backgrounds.  A 
stronger promoter will result in higher levels of reporter activity and vice versa.  A 
reporter assay using the b-glucuronidase (gusA) gene has been developed for the 
characterisation of promoter strength and transcription levels in Streptomyces 
(Myronovskyi et al., 2011).  When incubated with b-glucuronide substrates such as 
4-nitrophenyl b-D-glucopyranoside (PNPG), b-glucuronidase produces coloured 
breakdown products by hydrolysis, specifically 4-nitrophenol (PNP) which has a peak 
absorbance at 415 nm, the presence of which can be measured 
spectrophotometrically.  The protocol for conducting these GUS reporter assays in S. 
formicae grown on solid culture was recently optimised by Katie Noble (former 
undergraduate student in the Hutchings Laboratory).  Each of the promoters 
identified in the formicamycin BGC have been fused to gusA and conjugated into 
both the wild-type and S. formicae DforJ strains.  Initial results show that the activities 
of pforM, pforG and pforU are significantly higher in S. formicae DforJ compared to 
the wild-type strain, whereas the activities of pforH, pforT, pforZ and pforAA do not 
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change.  This suggests that ForJ represses transcription of forMLK, forGF and 
forUVWX but does not affect expression of forHI (which is likely activated by ForF), 
forTSRABCDE, forZ or forAA.  Quantitative RT-PCR analysis is required to confirm 
these data but it leaves the question of what controls production of the core PKS 
through expression of forTSRABCDE.  Currently, the gusA fusion to pforJ has not been 
tested as the strain was not available at the time of this undergraduate project, 
however, a full library of S. formicae GUS strains has since been constructed and will 
be the subject of future investigation to thoroughly compare the activities of each 
promoter in either the wild-type or formicamycin overproducing background, as well 
as in S. formicae DforZ and S. formicae DforGF mutants.  This will help to confirm our 
hypotheses about the regulation of formicamycin biosynthesis, as it will highlight 
which CSRs control the activity of which promoters through the DNA binding 
activities identified in the ChIP-Sequencing experiment.   
The knowledge of formicamycin regulation and host-resistance gained during this 
chapter has also been used to generate mutant strains of S. formicae with enhanced 
formicamycin production.  In the future, it may be possible to generate even more 
enhanced production strains.  For example, the stambomycin BGC in S. amboficiens 
is poorly expressed under normal laboratory conditions, however, activation of the 
cluster-situated LAL regulator, samR0484, by constitutive overexpression induced 
the expression of biosynthetic genes leading to the discovery of these novel 
macrolide antibiotics (Laureti et al., 2011).  Using the same approach, we could use 
CRISPR to knock-in a constitutive promoter such as permE* in front of the genes 
encoding for ForGF in the S. formicae ∆forJ: ΦBT1 forAA pforAA mutant background.  
This strain should have enhanced formicamycin biosynthesis as a result of deletion 
of the repressor ForJ and the overexpression of the activator ForGF, as well as 
enhanced host-resistance through the extra copy of ForAA.  Furthermore, if ForGF 
does indeed regulate other genes outside of the formicamycin BGC, it is possible that 
constitutive activation of ForGF may affect the transcription of other secondary 
metabolite genes in S. formicae.  In addition, an extra copy of ForK could also be 
added to the overproducing strain at a different integrative site to further help with 
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the host-resistance mechanism.  A strain like this could be extremely valuable for the 
industrial production of these antibiotics.   
Overall, the work in this chapter demonstrates that S. formicae has evolved a tightly 
regulated system for controlling the expression of formicamycin biosynthesis genes 
and the coordination of the host-resistance mechanism by compound efflux.  This 
ensures that biosynthesis of these antibiotics is not deleterious to the host, but 
rather provides an evolutionary advantage in its natural environment.  The results 
from these experiments show how the transcription of the biosynthetic genes 
encoded in the formicamycin BGC is initiated.  The following chapters will investigate 
the functions of each of these genes in more detail and begin to describe how the 
biosynthetic pathway progresses to produce the complex mixture of fasamycins and 
formicamycins seen in culture extracts of S. formicae. 
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5 The biosynthetic and evolutionary link between fasamycins and 
formicamycins 
 
Previous work in this thesis has shown that the formicamycin BGC in S. formicae also 
produces pentacyclic polyketides called fasamycins.  Despite the common 
biosynthetic origin, the carbon backbone and 3-dimensional structure of the 
fasamycins and formicamycins is significantly different.  Previously, other fasamycins 
have been isolated from environmental DNA (eDNA) heterologously expressed in an 
S. albus host, but there were no co-produced formicamycins reported (Feng, 
Kallifidas and Brady, 2011).  Experiments presented earlier in this thesis indicate that 
the fasamycins are the biosynthetic precursors of the formicamycins, as they are 
present in lower titres in the extracts of S. formicae, display lower bioactivity and 
accumulate in the DforV mutant.  Although we know that ForV has a gatekeeper 
function, little else is known about the biosynthetic steps that link the fasamycins 
and formicamycins or how S. formicae came to evolve a single BGC that was capable 
of synthesising both molecules; it may be that they originate from two distinct BGCs 
or that the fasamycin BGC requires the addition of further biosynthetic genes to 
convert these precursors into formicamycins.  The aim of this chapter is to identify 
the evolutionary development of the fasamycin and formicamycin BGC in S. formicae 
by searching for related BGCs in other organisms and identifying the biosynthetic 
steps that link these related but distinct compound families.  By identifying additional 
strains that contain the genes for fasamycin and/or formicamycin biosynthesis, we 
may be able to find a strain that can produce these compounds to higher titres.  By 
understanding the biosynthetic steps that are involved in the conversion of a 
fasamycin to a formicamycin, the BGC could be rewired so that only the more potent 
formicamycins are produced, instead of a mixture of formicamycins and fasamycins.  
Furthermore, knowledge of the biosynthesis of these antibacterial compounds can 
be used to inform future drug discovery efforts, especially if novel mechanisms are 
discovered. 
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5.1 Searching for BGCs related to the formicamycin BGC  
 
The soil is a highly competitive environment and the transfer of genetic material 
between microorganisms is common.  Although the producing organism was never 
identified, eDNA encoding a fasamycin BGC was isolated from soil samples collected 
in Arizona (Feng, Kallifidas and Brady, 2011; Feng et al., 2012).  The core carbon 
backbone of the compounds produced by this cloned BGC is the same as the 
fasamycins purified from S. formicae, with the only differences being the chlorination 
sites and the additional O-methylation at the base of ring A on the molecules isolated 
from S. formicae (Figure 5.1). 
                         
Figure 5.1: Fasamycins A and B were isolated through the heterologous expression of cloned eDNA 
from soil samples collected in Arizona (Feng, Kallifidas and Brady, 2011).  The related compounds, 
fasamycins C, D and E, are produced by the formicamycin BGC in S. formicae (Qin et al., 2017). 
Although S. formicae was isolated from the Tetraponera system, we have no 
evidence that it is primarily an ant-associated strain, as the symbiosis between plant-
ants and actinomycetes has not been studied to the same extent as the attine ant 
system.  It may be that S. formicae is a soil-dwelling actinomycete that happened to 
be in proximity of the Tetraponera nest at the time of sampling, or that it is a strain 
the ants acquired during normal foraging behaviour.  It is possible that S. formicae 
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might somehow be related to the soil-dwelling organism whose DNA was isolated 
and cloned in Arizona, or they may have exchanged the genes for fasamycin 
biosynthesis when they encountered each other over the course of evolution.  BlastP 
was used to compare the proteins encoded in the BGC isolated in Arizona, expressed 
on cosAZ154 (GenBank accession number HQ828985), to the gene products of the 
formicamycin BGC in S. formicae.  The analysis showed that although there has been 
significant rearrangement of the coding regions between these BGCs, many of the 
same putative gene products are present (Table 5.1). 
Table 5.1: BlastP analysis results comparing putative gene products from cosAZ154 to proteins from 
the formicamycin BGC.  Annotations of the gene products from cosAZ154 are displayed as reported 
in (Feng, Kallifidas and Brady, 2011) with protein IDs for each putative gene product and % similarities 
to proteins encoded within the formicamycin BGC in S. formicae. 
Putative gene product 
cosAZ154 Protein ID 
Similarity to gene products from S. 
formicae BGC 
% coverage % amino acid 
identity 
Annotation 
Pyridoxamine 5’-
phosphate oxidase-related 
FMN-binding protein 
AEM44246.1 30 30 ForM 
Luciferase family protein AEM44247.1 58 33 ForY 
Acyltransferase AEM44248.1 - - - 
Hypothetical protein AEM44249.1 - - - 
Glycoside hydrolase family 
48 protein 
AEM44250.1 - - - 
Beta-galactosidase AEM44251.1 - - - 
Hypothetical protein AEM44252.1 - - - 
Serine/threonine kinase AEM44253.1 - - - 
Histidine kinase AEM44254.1 57 27 ForG 
Two-component 
transcriptional regulator 
(LuxR family) 
AEM44255.1 98 36 ForF 
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MMPL-domain containing 
protein 
AEM44256.1 - - - 
SARP family 
transcriptional regulator 
AEM44257.1 - - - 
TetR family transcriptional 
regulator 
AEM44258.1 - - - 
FAD dependent 
monooxygenase 
AEM44259.1 99 51 ForX 
Antibiotic biosynthesis 
monooxygenase 
AEM44260.1 94 72 ForU 
whiE protein I AEM44261.1 87 53 ForS 
O-methyltransferase AEM44262.1 99 65 ForT 
Halogenase AEM44263.1 99 60 ForV 
Cyclase AEM44264.1 97 59 ForL 
Cyclase AEM44265.1 98 54 ForD 
Acyl carrier protein AEM44266.1 96 28 ForC 
Keto synthase beta 
subunit 
AEM44267.1 97 53 ForB 
Keto synthase alpha 
subunit 
AEM44268.1 96 61 ForA 
Cyclase AEM44269.1 89 50 ForR 
EmrB/QacA family drug 
resistance transporter 
AEM44270.1 93 50 ForAA 
O-methyltransferase AEM44271.1 88 39 ForW 
Cytochrome P450 AEM44272.1 - - - 
Lankamycin synthase, 
modules 5 and 6 
AEM44273.1 - - - 
Sodium/hydrogen 
exchanger 
AEM44274.1 90 34 ForK 
Putative polyketide 
cyclase 
AEM44275.1 96 44 ForD 
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Carboxylase AEM44276.1 97 57 ForI 
Acetyl-CoA carboxylase 
biotin carboxyl carrier 
protein 
AEM44277.1 92 40 ForE 
Acetyl-CoA carboxylase 
alpha subunit-like protein 
AEM44278.1 98 61 ForH 
 
Many of the gene products within the cloned fasamycin BGC on cosAZ154 show 
homology to proteins from the formicamycin BGC in S. formicae, especially the core 
biosynthetic proteins such as the KS a and b subunits (ForA and ForB), which show 
high percentage coverage and identity.  This makes sense as the core carbon 
skeletons of the molecules are so similar that they likely require very similar enzymes 
for biosynthesis.  There are homologs of ForH, ForE and ForI that are likely 
responsible for making the starter units for chain extension and a carrier protein for 
loading onto the KS.  Homologs to all five putative cyclase enzymes (ForD, ForL, ForR, 
ForS and ForU) are also present within the eDNA-derived cluster and these are 
predicted to aromatise the polyketide intermediate to form the pentacyclic 
fasamycin backbone.  Interestingly, two separate gene products on cosAZ154 show 
homology to ForD.  It may be that one of the copies of forD has become redundant 
over the course of evolution, explaining its absence in the S. formicae cluster.  
Similarities between cosAZ154 and the formicamycin BGC continue with respect to 
the transporters present in the system, with homologs to both ForAA and ForK 
present.  This further supports the hypothesis made in the previous chapter that 
these transporters work synergistically to provide host resistance via compound 
efflux.  
It is also worth noting that only one halogenase is encoded in cosAZ154 but fasamycin 
B is halogenated at two positions on the carbon chain when heterologously 
expressed in S. albus.  The halogenase shows high homology to ForV, which we have 
shown can act at four positions on the fasamycin and formicamycin backbone 
(Chapter 3.3).  It is therefore likely that the enzyme encoded on cosAZ154 is also able 
to act non-specifically on multiple positions on the molecule.  In fact, when the 
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halogenase from cosAZ154 is modelled in I-TASSER and overlaid onto the predicted 
model of ForV in PyMol, the proteins align almost exactly, especially at the previously 
determined active site and the site of FAD binding (Figure 5.2).  Furthermore, the 
highly variable C-terminal region of ForV that could not be aligned to other known 
flavin-dependent halogenases in the database, does partially align to the predicted 
model of the halogenase from cosAZ154, implying that these enzymes may bind to 
the same carrier and function by the same mechanism.  In the future, it would be 
interesting to genetically complement S. formicae DforV with the halogenase gene 
from cosAZ154 to see whether the new complementation strain is able to synthesise 
the full catalogue of halogenated formicamycin congeners.  If so, it may be that these 
proteins do indeed act via the same mechanism and both halogenases can chlorinate 
at multiple positions on the fasamycin and formicamycin backbones. 
 
Figure 5.2: A predicted model of the halogenase from cosAZ154 was generated in I-TASSER and 
overlaid with the I-TASSER model of ForV in PyMol (generated in chapter 3.3).  ForV is represented in 
green with a dark blue C-terminal tail and the halogenase from cosAZ154 is represented in cyan.  The 
WxWxIP fingerprint is highlighted in orange, the FAD binding site GxGxxG motif is shown in magenta 
and the conserved lysine residue is in red.  The models overlay well, showing high similarity between 
both peptides, including at the highly variable C-terminal region that could not be aligned to other 
flavin-dependent halogenases in the database (Chapter 3.3). 
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By comparing the gene homologs present in these two clusters, it is clear to see how 
cosAZ154 encodes the production of fasamycins A and B, given what we know about 
fasamycin biosynthesis in S. formicae.  Although there is significant rearrangement 
of genes between the cluster on cosAZ154 and the for BGC in S. formicae, the 
percentage coverage and identities described here are generally much higher than 
the figures reported during the original study when the authors searched for protein 
homologs in the database at that time.  This implies that there is a close evolutionary 
relationship between the BGC in S. formicae and the eDNA cloned into cosAZ154.  
The main difference between the two BGCs appears to be in the regulatory 
mechanisms that control production in the native host, which was never identified 
for the fasamycin cluster isolated in Arizona.  Although there is a two-component 
system encoded on cosAZ154, the homology to ForGF is low, 27% identity between 
the response regulators and 36% identity between the sensor kinases.  This is 
surprising, especially for the sensor kinase, considering these enzymes are known to 
all contain certain conserved domains in order to function.  In addition, no MarR 
regulators are encoded on cosAZ154 but we have shown the importance of both ForJ 
and ForZ in the regulation of formicamycin production in S. formicae (Chapter 4).  
Instead, putative SARP and TetR regulatory proteins are present.  This implies the 
regulation of production varies significantly between the host organisms, perhaps 
suggesting that the organisms themselves may not be especially closely related but 
they may have exchanged DNA encoding for the biosynthetic machinery when they 
encountered each other in the environment, something that is intriguing given the 
geographic separation of the strains when isolated. 
On initial inspection of the biosynthetic gene products present encoded by the 
cosAZ154 BGC, there are no homologs missing that might account for the lack of 
formicamycin production when this cluster is heterologously expressed.  However, it 
is possible that some of the genes are miss-annotated, as Blast analysis conducted in 
this way creates a bias towards aligning sequences even when only small areas of 
similarity are present.  For example, the ForM and ForY homologs annotated in table 
5.1 are somewhat removed from the other biosynthesis genes, implying that they 
might actually lie outside of the border of the cluster.  Furthermore, the percentage 
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similarities and identities to the proteins from the formicamycin biosynthetic 
pathway are relatively low for these gene products.  The similarity highlighted during 
this analysis may just be in regions of cofactor binding, for example the flavin binding 
site of the oxidoreductase and the S-adenosyl methionine (SAM) binding site that is 
usually present in methyltransferase enzymes.  Indeed, structural analysis implies 
that conversion of a fasamycin to a formicamycin requires reduction of ring C, which 
could plausibly involve an oxidoreductase enzyme like ForY, so the lack of a true ForY 
homolog on cosAZ154 may account for the lack of formicamycin production by this 
BGC.  Similarly, the lack of a significant ForM homolog may account for the lack of O-
methylation at the base of ring A on the fasamycins produced by cosAZ154 compared 
to those produced by S. formicae.  The functions of ForY and ForM in the biosynthesis 
of the fasamycins and formicamycins from S. formicae are investigated later in this 
chapter.   
Having identified similar genes to those in the formicamycin BGC on cosAZ154, we 
investigated the possibility that similar genes may also be found in multiple related 
microorganisms whose sequences are in the database.  AutoMLST analysis 
conducted by Dr Neil Holmes shows that the closest relatives of S. formicae are S. 
luteocolor and Streptomyces sp NRRL_S-920 with an estimated average nucleotide 
identity (ANI) of 90.1% and 89.4% respectively (Alanjary, Steinke and Ziemert, 2019).  
The genomes for both S. luteocolor (accession no. NZ_BDGW00000000) and 
Streptomyces sp NRRL_S-290 (accession no. NZ_JODF00000000) were therefore 
obtained from NCBI and analysed using AntiSMASH.  There was no evidence of any 
T2PKS clusters in either genome or any biosynthetic genes that looked similar to 
genes from the formicamycin BGC.  This indicates that the formicamycin BGC is not 
present in these close relatives of S. formicae.  However, the nucleotide sequence of 
the for BGC from S. formicae displays high similarity to a region of a contig from the 
genome of Streptomyces kanamyceticus NRRL B-2535 (GenBank ID LIQU00000000.1, 
contig LIQU01000034).  The draft genome sequence of S. kanamyceticus currently 
available on NCBI is in 727 contigs  (Labeda et al., 2017).  There is no annotation 
available for the sequence of contig LIQ01000034, however BlastN analysis 
comparing the genes present in the formicamycin BGC with the S. kanamyceticus 
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sequence revealed extremely high percentage identities, even at the nucleotide level 
(Table 5.2).  
Table 5.2: Nucleotide Blasts comparing the S. kanamyceticus contig LIQU01000034 sequence with the 
formicamycin BGC shows high percentage identity between the genes present. 
Gene 
Similarity to S. kanamyceticus contig 
% coverage % nucleotide identity 
forN 100 94 
forM 99 95 
forL 100 98 
forK 99 94 
forJ 100 96 
forI 100 95 
forH 99 94 
forG 99 96 
forF 99 96 
forE 100 90 
forD 100 96 
forC 100 94 
forB 100 96 
forA 100 96 
forR 100 95 
forS 100 93 
forT 100 96 
forU 87 98 
forV 100 95 
forW 100 90 
 
 170 
This suggests that most of the genes from the formicamycin BGC in S. formicae are 
also present in S. kanamyceticus NRRL B-2535.  In addition, the putative genes in S. 
kanamyceticus are in the same order and orientation as in the formicamycin BGC, 
with a nucleotide Blast of the entire formicamycin BGC showing 99% coverage and 
94% identity to the S. kanamyceticus DNA sequence.  These striking similarities 
suggest there is a significant evolutionary relationship between the S. kanamyceticus 
DNA and the formicamycin BGC in S. formicae, even more so than the cosAZ154 BGC, 
which has been shown experimentally to encode fasamycins.  The only difference 
between the cluster in S. formicae and the region of DNA in S. kanamyceticus is the 
lack of four genes from the 3’ end of the formicamycin BGC; forX, forY, forZ and forAA.  
Apart from these four genes, the synteny between the formicamycin BGC and the S. 
kanamyceticus genome is significant and continues approximately 5 kb upstream and 
at least 40 kb downstream of the formicamycin BGC, which is as far as contig 
LIQU01000034 extends (Figure 5.3).   
 
Figure 5.3: Representation of the putative cluster identified in S. kanamyceticus contig LIQU01000034 
and the fasamycin BGC on cosAZ154 compared to the formicamycin BGC in S. formicae.  Significant 
rearrangement of genes has occurred between cosAZ154 and the formicamycin BGC in S. formicae.  
The cluster in S. kanamyceticus looks much more similar to the BGC in S. formicae, however, four 
genes are missing; forX, forY, forZ and forAA.  Continued synteny is represented by the solid black lines 
and missing regions are represented by the dashed line. 
The gene product ForX is a putative flavin-dependent monooxygenase and ForY is a 
putative flavin-dependent oxidoreductase, the same oxidoreductase that is missing 
from cosAZ154.  The genes forZ and forAA encode the MarR family transcriptional 
regulator and the MFS family transporter respectively (Chapter 4).  It was predicted 
that production of the formicamycins requires the reduction of the fasamycin ring C 
and the introduction of a hydroxyl at C10, which could plausibly require a reductive 
S. formicae
S. kanamyceticus
G F X U S T V L D C B A R AA W K D I E H cosAZ154
N M KL J I H G F E D C B A R S T U V W
N M KL J I H G F E D C B A R S T U V W X Y Z AA
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enzyme like ForY and a monooxygenase like ForX.  Given the significant homology 
between the formicamycin BGC and the putative cluster on contig LIQU01000034 of 
the S. kanamyceticus genome, as well as the lack of forX and forY in the sequence of 
the latter, we hypothesized that S. kanamyceticus NRRL B-2535 may encode for a 
fasamycin BGC and may also be a close relative of S. formicae, even though it does 
not appear in the autoMLST results.  S. kanamyceticus was therefore obtained from 
Professor Barrie Wilkinson at the John Innes Centre for further investigation.  The 
strain is known as the producer of kanamycin, an antibiotic first isolated in 1957 
which inhibits protein synthesis by binding to the 30S ribosomal subunit (Umezawa 
et al., 1957; Misumi and Tanaka, 1980).  PCR and sequencing analysis showed that S. 
kanamyceticus and S. formicae share 94% nucleotide similarity at the 16S level.  S. 
kanamyceticus has not been the subject of extensive genetic work, although the BGC 
responsible for kanamycin production has been characterised. During these 
experiments, conjugation efficiency has commonly been reported as a limiting factor 
(Yanai and Murakami, 2004; Zhang et al., 2018).   
The optimal growth conditions for S. kanamyceticus proved to be very different to S. 
formicae, with significant sporulation only observed on oat agar after incubation at 
28°C for 3-4 weeks.  Growth under these conditions resulted in the production of 
yellow mycelium with white spores, similar to the phenotype of S. formicae when 
grown under formicamycin producing conditions.  The fasamycins are yellow and 
fasamycin production is known to colour the mycelium of S. formicae, as 
overexpression of the pathway by deletion of forJ resulted in a yellow phenotype 
(Figure 4.4).  As such, plates of S. kanamyceticus on both SFM and oat agar were 
extracted and analysed by HPLC(UV) LCMS (conducted by Dr Zhiwei Qin and Hannah 
McDonald, JIC) to determine whether any fasamycins were present in the culture 
extract.  Under all conditions tested, no fasamycins or formicamycins were evident 
in the culture extracts of S. kanamyceticus, implying that the BGC may be silent under 
normal laboratory conditions and the yellow colour seen in cultures represents the 
production of another compound (data not shown). 
As such, we attempted to use our knowledge of the regulation of formicamycin 
biosynthesis in S. formicae gained in the previous chapter to induce the expression 
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of this cluster in S. kanamyceticus.  We hypothesised that by deleting the homolog 
to the major repressor, forJ, we could de-repress the pathway in S. kanamyceticus 
and induce expression of the BGC as we had done previously in the heterologous 
host, S. coelicolor M1146 (Chapter 4.2.1).  Initially, a pCRISPomyces-2 vector was 
created to generate an unmarked forJ deletion in S. kanamyceticus, however, 
repeated conjugations with this plasmid did not result in any colonies.  There are 
currently no reports of the CRISPR/Cas9 system being used in S. kanamyceticus for 
genetic manipulation.  The poor quality, draft genome sequence of S. kanamyceticus 
makes designing unique and specific synthetic guide RNAs a challenge.  As such, it 
could be that the lack of ex-conjugants during this experiment was due to the guide 
RNA non-specifically targeting areas of the genome and causing fatal double 
stranded breaks by the Cas9.  In this case, improving the quality of the genome 
sequence should be a priority for improving the use of CRISPR/Cas9 in this strain.  
Alternatively, it has been suggested that the expression levels of the Cas9 nuclease 
used in many CRISPR systems is too strong for some organisms, also resulting in lethal 
double stranded DNA breaks occurring non-specifically across the genome (Tong, 
Weber and Lee, 2018; Alberti and Corre, 2019).  It may therefore be that the 
pCRISPomyces-2 system is not suitable for use in S. kanamyceticus.  In fact, when an 
empty pCRISPomyces-2 plasmid was conjugated into S. kanamyceticus there were no 
exconjugants isolated, even when significant numbers of spores and donor E. coli 
cells were used.  Therefore, a CRISPR system that uses a weaker promoter, or even 
an inducible promoter like the pCRISPR-Cas9 system, may be more suitable for the 
genetic editing of S. kanamyceticus (Mo et al., 2019). 
Due to the lack of mutants obtained using the pCRISPomyces-2 system, the 
experiment for de-repression of the putative fasamycin BGC in S. kanamyceticus was 
re-designed and a suicide vector with an apramycin resistance gene was created that 
would disrupt forJ via homologous recombination.  Multiple attempts to conjugate 
this new plasmid into S. kanamyceticus were trialled but all were unsuccessful.  To 
confirm that induction of the putative fasamycin BGC in S. kanamyceticus was not 
fatal in the absence of ForX, ForY, ForZ and/or ForAA, ReDirect was used as previously 
described to genetically modify the 215-G PAC clone containing the whole 
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formicamycin BGC from S. formicae.  The entire BGC was deleted and replaced with 
an apramycin resistance gene with the exception of the last four genes; forX, forY, 
forZ and forAA.  This altered cosmid containing just forX, forY, forZ and forAA was 
then conjugated into S. kanamyceticus with the view of subsequently deleting forJ in 
any resulting ex-conjugants, however, none were isolated.  Conjugation protocols 
were extensively optimised during this work, including increasing spore density, 
changing pre-germination times and temperatures, increasing the concentration of 
MgCl2 or CaCl2 in the conjugation plates and trialling methods of liquid mycelial 
conjugation described by other groups (Zhang et al., 2018).  However, none of these 
methods resulted in any ex-conjugants of S. kanamyceticus.  This suggests that 
conjugation of large plasmids into S. kanamyceticus is highly inefficient and new 
protocols need to be developed to enable genetic manipulation in this organism.   
The genetic manipulation of S. kanamyceticus is limited by the poor-quality genome 
sequence and the lack of available selection markers due to the organism’s natural 
resistance to both kanamycin and hygromycin.  This work shows that some non-
model streptomycetes still remain genetically intractable or extremely challenging to 
manipulate even with the development of CRISPR and other molecular techniques.  
In future, we plan to capture the putative fasamycin BGC from S. kanamyceticus for 
heterologous expression in S. coelicolor M1146.  This could be done via TAR cloning 
or through the generation of a cosmid library.  As shown previously, de-repression of 
the 215-G PAC through the deletion of forJ does induce expression of the 
formicamycin BGC in S. coelicolor M1146 and therefore a similar approach could be 
taken with the fasamycin BGC from S. kanamyceticus in a host that is more 
genetically tractable.  Conducting these future experiments would allow us to 
experimentally prove our hypothesis that the putative fasamycin BGC in S. 
kanamyceticus does encode biosynthesis of fasamycins and may be a close 
evolutionary relative of the formicamycin BGC in S. formicae.  It does not appear that 
these strains share any other BGCs or other extensive regions of similarity between 
their chromosomes, however, a high-quality genome sequence of S. kanamyceticus 
is needed to confirm this.  
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Even without experimental characterisation of the putative fasamycin BGC in S. 
kanamyceticus, the extensive continued synteny either side of the four missing genes 
suggests an evolutionary relationship between these BGCs.  We hypothesise that the 
fasamycin BGC evolved first, with the genes encoding ForX, ForY, ForZ and ForAA 
being acquired later by S. formicae.  Blast analysis of the 4 gene region together does 
not result in any significant matches and there is no evidence of this region of DNA 
being on a transposable element.  However, BlastP analysis shows that the closest 
homologs to ForY, ForZ and ForAA are all from strains of the Actinomadura genus, 
implying that the genes encoding these three may have been acquired together in a 
single insertion event, with forX being acquired on its own from a different source at 
another point in time (Table 5.3).  It is conceivable that the addition of genes that 
enable a fasamycin producer to synthesise the more potent formicamycins would 
represent an advantageous adaptation and one that would likely become permanent 
over the course of evolution.  
Table 5.3: Amino acid Blast results of ForX, ForY, ForZ and ForAA.  ForY, ForZ and ForAA all originate 
from Actinomadura species.  In fact, it is not just the top hit that is from this species, but the top 6, 7 
and 10 results for ForY, ForZ and ForAA respectively. 
Gene 
product 
First hit in the database % amino 
acid identity 
% 
coverage 
Accession 
number 
ForX Hypothetical protein 
from  
Streptomyces 
caatingaensis 
50 94 WP_049717083.1 
 
ForY LLM class flavin-
dependent 
oxidoreductase from 
Actinomadura meyerae 
60 87 WP_089326038.1 
 
ForZ MarR transcriptional 
regulator from 
Actinomadura pelletieri 
42 84 WP_121435158.1 
 
ForAA DHA2 family efflux MFS 
transporter permease 
subunit Actinomadura 
sp. NEAU-Ht49 
57 96 WP_122199503.1 
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BlastP searches and Multigene Blast of the core peptides from the formicamycin BGC 
has not revealed any other related BGCs within the database.  Therefore, if our 
assumptions about the functions of the biosynthetic genes are correct, the 
formicamycin BGC in S. formicae represents the only currently characterized 
pathway that produces formicamycins and one of only 3 sequenced BGCs that appear 
to contain genes for fasamycin biosynthesis.   
5.2 The mechanism of conversion of a fasamycin to a formicamycin 
 
As discussed in the previous section, it appears that the fasamycins are the 
evolutionary and biosynthetic precursors of the formicamycins.  It is predicted that 
the formicamycin BGC evolved from a fasamycin BGC as a results of multiple 
horizontal gene transfer events, specifically the acquisition of four genes, forX, forY, 
forZ and forAA.  The functions of ForZ and ForAA were investigated in the previous 
chapter; they are involved in regulating host-resistance to the formicamycins.  ForX 
and ForY are predicted to be the biosynthetic enzymes responsible for converting a 
fasamycin into a formicamycin in S. formicae.  To confirm this hypothesis and assign 
functions to these gene products, in frame CRISPR/Cas9 deletion mutants were 
generated.  Three biological replicates of the DforX and DforY mutants were made 
and incubated under formicamycin producing conditions and LCMS analysis was 
conducted by Dr Zhiwei Qin at the JIC.  Both S. formicae DforX and S. formicae DforY 
lost the ability to produce any formicamycins (Figure 5.4).  S. formicae DforX only 
produces fasamycins C-E (1-3) and accumulates fasamycin E (3), the di-chlorinated 
fasamycin, to approximately 25 times the level of the wild-type strain.  This suggests 
that ForX plays an important role in the conversion of a fasamycin to a formicamycin 
as without it, biosynthesis of the formicamycins does not occur and the most 
bioactive fasamycin precursor accumulates.  In-trans complementation of forX under 
the control of the native promoter restored biosynthesis of the formicamycins.  In 
the S. formicae DforY culture extracts, there were no recognisable fasamycins or 
formicamycins present.  Instead six new peaks (a-f) were present that had not been 
seen in previous experiments.  Complementation of DforY under the control of the 
native promoter restored biosynthesis of the formicamycins to approximately wild-
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type levels, however, some of the new peaks from the DforY mutant still remained 
in the culture extract after complementation, suggesting expression levels of forY 
may have been lower in the complemented strain than in the wild-type. 
 
Figure 5.4: HPLC traces (UV 285 nm) of extracts from: (A) S. formicae wild-type; (B) S. formicae DforX; 
(C) S. formicae DforX:forX jC31; (D) S. formicae DforY; (E) S. formicae DforY:forY jC31.  Deletion of 
forX results in the production of the fasamycins only with the di-chlorinated fasamycin E (3) 
accumulating (see insert for structure).  Deletion of forY abolishes the production of fasamycins and 
formicamycins, with six new peaks (a-f) present instead.  Wild-type production returns on 
complementation of each gene under the native promoter.  HPLC(UV)/LCMS analysis conducted by 
Dr Zhiwei Qin at the John Innes Centre. 
Dr Zhiwei Qin at the John Innes Centre scaled up the fermentations of S. formicae 
DforY in order to isolate each of the new compounds present.  Small amounts 
(between 5 and 16 mg) of five of the compounds (a, c, d, e and f) were isolated and 
their structures solved by MS and NMR (Table 5.4 and Figure 5.5).  Production levels 
of b were too low to allow sufficient yields for isolation and structural elucidation.  
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Table 5.4: Large scale cultures of S. formicae DforY were grown up for compound isolation and 
purification by Dr Zhiwei Qin.  Yields of compound b were too low for compound isolation.  LCMS 
analysis of each compound by Dr Zhiwei Qin allowed molecular mass and molecular formula of each 
compound to be identified.  
 Molecular mass Molecular formula Yield from 4L agar 
a 522 C28H23O8Cl 13 mg 
b 536 C29H25O8Cl - 
c 556 C28H22O8Cl2 10 mg 
d 570 C29H24O8Cl2 5 mg 
e 590 C28H21O8Cl3 13 mg 
f 604 C29H23O8Cl3 6.3 mg 
               
Figure 5.5: The structures of five of the compounds from the extract of S. formicae DforY were isolated 
and their structure solved by NMR and MS by Dr Zhiwei Qin, JIC.  Production levels of b were too low 
to allow sufficient yields for isolation and structural elucidation.  All five of the isolated compounds 
contain a lactone at ring C, indicative of an intermediate between a fasamycin and a formicamycin.   
All five of the isolated compounds have neither a fasamycin nor a formicamycin core 
carbon skeleton and instead are ring C lactone intermediates with various levels of 
additional post-PKS tailoring such as halogenation and O-methylation.  Although 
yields of compound b were too low to allow for isolation and structural elucidation, 
we estimate from the molecular mass that it is the same as compound a with the 
addition of methyl group at R4.  The identification of these lactone intermediates 
allows us to predict how ForX and ForY function together to convert a fasamycin into 
a formicamycin.  Monooxygenase enzymes like ForX are responsible for introducing 
OH
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a R1=H, R2=Cl, R3=H, R4=H, R4=H 
c R1=Cl, R2=Cl, R3=H, R4=H, R4=H 
d R1=Cl, R2=Cl, R3=H, R4=H, R4=CH3 
e R1=Cl, R2=Cl, R3=H, R4=Cl, R4=H 
f R1=Cl, R2=Cl, R3=H, R4=Cl, R4=CH3 
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one atom of molecular oxygen into organic substrates, generating water as a bi-
product.  Baeyer-Villiger monooxygenases (BVMOs) are often present in catabolic 
pathways and are known to convert cyclic ketones into lactones.  We therefore 
hypothesise that ForX is a BVMO that converts the halogenated fasamycin precursor 
into the 7-membered ring C lactone intermediate.  The lactone intermediate 
generated by ForX can then be reduced by ForY, the flavin-dependent 
oxidoreductase, forming the formicamycin scaffold.   
There are three classes of BVMOs; type 1 enzymes are encoded by a single gene 
product and are characterised by a tightly bound FAD cofactor and the presence of 
the FXGXXXHXXXWP fingerprint sequence.  For type 1 BVMOs, the NADPH/NADP+ 
cofactor is bound during catalysis.  In contrast, type 2 BVMOs are encoded by two 
separate gene products; the reductase that generates the reduced FMN using 
NAD(P)H and the distinct oxygenase.  The third type of BVMO was classified more 
recently and is known as the type ‘O’ or atypical class.  These enzymes are encoded 
by a single gene product, have FAD tightly bound to the surface are NAD(P)H-
dependent, but do not contain the FXGXXXHXXXWP fingerprint sequence and are 
therefore neither type 1 or type 2 BVMOs (Leisch, Morley and Lau, 2011).  BlastP 
analysis of ForX shows a conserved FAD binding domain but no fingerprint sequence, 
implying it is probably the latter type of BVMO.   
We hypothesise that this two-step ring-expansion, ring-contraction mechanism is 
responsible for the conversion of a flat fasamycin to the twisted L-shaped structure 
of the formicamycins.  To the best of our knowledge, this proposed mechanism is 
unique in polyketide biosynthesis.  Efforts in the Wilkinson laboratory to express and 
purify both ForX and ForY for biochemical analysis have so far been unsuccessful, 
however, feeding experiments conducted by Dr Zhiwei Qin confirm that when S. 
formicae DforX is incubated with a lactone intermediate from S. formicae DforY, 
production of formicamycins B, E, F and J is reinstated, showing that the generation 
of the lactone intermediates by ForX is a vital step in the conversion of a fasamycin 
to a formicamycin.  The accumulation of fasamycin E in S. formicae DforX, is 
consistent with the earlier observation that S. formicae DforV accumulates fasamycin 
C, the non-halogenated fasamycin and confirms that the fasamycins are the 
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biosynthetic precursors to the formicamycins.  These results also suggest that the 
halogenase, ForV, acts first and performs a gatekeeper function within this pathway, 
controlling the conversion of fasamycins to formicamycins.  A key feature of many 
flavin-dependent halogenases like ForV is their ability to activate molecular oxygen 
using reduced flavin to generate flavin hydroperoxide, which allows for diverse 
downstream reactions including hydroxylation and Baeyer-Villiger oxidation (Latham 
et al., 2017).  The identification of halogenated lactone intermediates confirms that 
the monooxygenase ForX accepts substrates that have already been halogenated by 
ForV.  We therefore predict that the activity of ForX is dependent on the generation 
of hydroperoxy-flavin by the halogenase ForV.  The formicamycin backbone 
generated after the two-step ring-expansion, ring-contraction reaction catalysed by 
ForX and ForY can also be further halogenated by ForV, showing that these three 
flavin-dependent enzymes work closely together to convert the fasamycin 
precursors into the more potent formicamycins (Figure 5.6).   
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Figure 5.6 (see following page for figure legend) 
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Figure 5.6 (previous): Formicamycins are converted to fasamycins by the activity of three flavin 
dependent enzymes; ForV, ForX and ForY in a novel two-step ring-expansion, ring-contraction 
mechanism.  The activity of the halogenase, ForV generates hydroperoxy flavin.  The Baeyer-Villiger 
monooxygenase, ForX, then uses this flavin to generate the 7-membered ring C lactone intermediate.  
The oxidoreductase, ForY, then reduces the lactone intermediate to form the formicamycin scaffold. 
This formicamycin scaffold can then be further halogenated by ForV and methylated by a so far 
unidentified O-methyltransferase.  Adapted from Qin et al (in prep) with permission. 
In order to determine whether the expansion of ring C affects bioactivity, bioassays 
against B. subtilis were set up using the isolated lactone intermediates (Figure 5.7).   
 
Figure 5.7: The bioactivity of the lactone ring intermediates against B. subtilis was examined by disc 
diffusion bioassay.  Solutions of each compounds were made to 1 mM in a 20 ul volume.  The whole 
volume was dried onto Whatman paper discs and placed on soft LB agar inoculated with B. subtilis. 
After overnight incubation at 30°C, zones of inhibition were observed.  DMSO solvent controls were 
included as well as fasamycin E (FasE) and formicamycin J (FormJ) for comparison.  The assays showed 
that the lactone intermediates contain bioactivity that is comparable to the formicamycins, implying 
that the expansion of ring C has no effect of the mechanism of action of these compounds. 
The bioassays show that expansion of ring C to a 7-membered ring does not seem to 
significantly affect bioactivity as the lactone intermediates display comparable 
inhibitory activity against B. subtilis to the fasamycins and formicamycins.  In 
addition, increased chlorination of the lactone backbone seems to increase the 
bioactivity in the same way as the fasamycins and formicamycins, with the di- and 
tri-chlorinated compounds giving the largest zones of inhibition.  This shows that 
expansion of ring C does not change the active pharmacophore of the molecules in a 
way that causes decreased bioactivity, suggesting this area of the molecule is not 
essential for target interactions.  This work also expands the family of bioactive 
compounds to originate from S. formicae and the formicamycin BGC.  Furthermore, 
the knowledge of this two-step ring-expansion, ring-contraction mechanism in a 
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polyketide pathway may allow for further bioactive analogues of both formicamycins 
and other cyclic polyketides to be produced in the future. 
5.3 Methylation of the fasamycins and formicamycins 
 
Previous work in this thesis has identified the minimal genes required for the 
biosynthesis of the fasamycins and formicamycins and has begun to characterise the 
functions of the tailoring enzymes that modify the cyclised polyketide to generate 
the mixture of bioactive metabolites seen in extracts of S. formicae.  As well as 
studying the conversion of a fasamycin to a formicamycin, we have shown that a 
single halogenase, ForV, is responsible for the halogenation of the molecules, 
generating congeners with increased bioactivity compared to the non-halogenated 
precursors.  All fasamycin and formicamycin congeners also display various methyl 
groups that affect the structure and possibly also the bioactivity of the molecules 
(Figure 5.8).  For example, all fasamycins, formicamycins and ring C lactone 
intermediates contain a di-methylation on ring D.  All fasamycins and formicamycins 
from S. formicae show methylation at the base of ring A, although fasamycins A and 
B from cosAZ154 do not (Figure 5.1).  Some of the formicamycin congeners and some 
of the lactone intermediates, but none of the fasamycins, are also O-methylated at a 
second site on ring A (R5).  Finally, all the formicamycin congeners are O-methylated 
on ring B, but the fasamycins and lactone intermediates are not, implying this 
reaction may be an essential part of the conversion of a fasamycin to a formicamycin 
that occurs after Baeyer-Villiger oxidation by ForX.  In addition, the lactone 
intermediates described in the previous section do not contain this methylation on 
ring B, therefore this reaction must occur after the action of ForX and may therefore 
be involved in the conversion of a fasamycin to a formicamycin.   
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Figure 5.8: Structures of the fasamycin (1-3) and formicamycin (4-16) congeners from S. formicae.  All 
congeners from the formicamycin BGC in S. formicae are di-methylated on ring D and O-methylated 
at the base of ring A.  All formicamycins are O-methylated on ring B but fasamycins are not.  Some 
formicamycins can also be O-methylated at R5. 
Most methyltransferase enzymes transfer a methyl group from the cofactor SAM to 
a carbon, oxygen or nitrogen group on the relevant substrate(s) (Hertweck et al., 
2007).  BlastP analysis of both ForW and ForT shows that they contain conserved 
domains of the O-methyltransferase family of enzymes and ForM contains a known 
methyltransferase domain.  To confirm the roles of each individual 
methyltransferase enzyme within the formicamycin BGC, their encoding genes were 
deleted using CRISPR/Cas9.  Three biological replicates of each mutant were made 
and cultured under formicamycin producing conditions, before analysis by LCMS was 
conducted by Dr Zhiwei Qin at the JIC.  Deletion of forM resulted in the production 
of no fasamycin or formicamycin congeners, with no evidence of any new 
intermediates or shunt metabolites present in the culture extract.  Complementation 
in trans under the native promoter restored production of the fasamycin and 
formicamycin congeners, although production levels were considerably lower than 
OH
OH
O
HO
OH
O
O
R1
R6
R2 R3
R4
R5
OH
OH
O
O
O
O
O
R1
R3
R4
R2
OH
R5
H
A
B C D E
A
B C D E
Fasamycin A R1=H, R2=H, R3=Cl, R4=H, R5=H, R6=H 
Fasamycin B R1=H, R2=H, R3=Cl, R4=Cl, R5=H, R6=H 
1.Fasamycin C R1=H, R2=H, R3=H, R4=H, R5=H, R6=CH3 
2.Fasamycin D R1=H, R2=Cl, R3=H, R4=H, R5=H, R6=CH3 
3.Fasamycin E R1=Cl, R2=Cl, R3=H, R4=H, R5=H, R6=CH3 
 
4.Formicamycin A R1=H, R2=Cl, R3=H, R4=H, R5=H, 
5.Formicamycin B R1=Cl, R2=Cl, R3=H, R4=H, R5=H, 
6.Formicamycin C R1=H, R2=Cl, R3=Cl, R4=H, R5=CH3,  
7.Formicamycin D R1=Cl, R2=Cl, R3=Cl, R4=H, R5=H  
8.Formicamycin E R1=Cl, R2=Cl, R3=Cl, R4=H, R5=CH3  
9.Formicamycin F R1=Cl, R2=Cl, R3=H, R4=Cl, R5=CH3  
10.Formicamycin G R1=H, R2=Cl, R3=Cl, R4=Cl, R5=CH3 
11.Formicamycin H R1=Cl, R2=H, R3=Cl, R4=Cl, R5=CH3  
12.Formicamycin I R1=Cl, R2=Cl, R3=Cl, R4=Cl, R5=H  
13.Formicamycin J R1=Cl, R2=Cl, R3=Cl, R4=Cl, R5=CH3  
14.Formicamycin K R1=H, R2=Cl, R3=Br, R4=Cl, R5=CH3  
15.Formicamycin L R1=Cl, R2=Cl, R3=Br, R4=Cl, R5=CH3 
16.Formicamycin M R1=H, R2=Br, R3=H, R4=H, R5=CH3  
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the wild-type, perhaps due to changes in transcription levels caused by changing the 
location of the gene within the genome (Figure 5.9).  The fact that the DforM mutant 
produces no fasamycin or formicamycin congeners or any biosynthetic intermediates 
suggests that the reaction catalysed by ForM may be an essential step in this 
biosynthetic pathway. 
 
Figure 5.9: HPLC traces (UV 285 nm) of extracts from: (A) S. formicae wild-type; (B) S. formicae DforM; 
(C) S. formicae DforM: jBT1 forM pforM.  Deletion of forM abolishes the production of fasamycins 
and formicamycins but production returns on complementation under the native promoter.  
HPLC(UV) LCMS analysis conducted by Dr Zhiwei Qin at the John Innes Centre. 
Deletion of forT also abolished the production of fasamycins, formicamycins or any 
biosynthetic intermediates.  Genetic complementation in trans under the native 
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promoter was unsuccessful, however complementation in trans under the 
constitutive promoter permE* resulted in restored formicamycin biosynthesis but at 
lower levels than the wild-type (Figure 5.10).  This is likely due to differences in 
transcription levels by placing the gene at a different location in the genome.  These 
results suggest that methylation by ForT is also an essential step during the 
biosynthesis of the fasamycins and formicamycins. 
 
Figure 5.10: HPLC traces (UV 285 nm) of extracts from: (A) S. formicae wild-type; (B) S. formicae DforT; 
(C) S. formicae DforT: jBT1 forT permE*.  Deletion of forT abolishes the production of fasamycins and 
formicamycins but production returns on complementation under the native promoter.  HPLC(UV) 
LCMS analysis conducted by Dr Zhiwei Qin at the John Innes Centre. 
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Deletion of forW abolished the production of the formicamycin congeners and 
resulted in just the fasamycins C-E (1-3) being produced, with fasamycin E (3) 
accumulating in the culture extracts (Figure 5.11).  Complementation in trans under 
the native promoter restored production of all the formicamycin congeners.  This 
suggests that ForW is essential for the conversion of fasamycins to formicamycins 
and indicates that ForX and ForY do not function in the absence of ForW. 
 
Figure 5.11: HPLC traces (UV 285 nm) of extracts from: (A) S. formicae wild-type; (B) S. formicae 
DforW; (C) S. formicae DforW: jBT1 forW pforU.  Deletion of forW abolishes the production of 
formicamycins and results in an accumulation of fasamycins in the culture extracts.  This implies that 
forW is essential for the conversion of a fasamycin to a formicamycin. Production of the formicamycins 
returns on complementation under the native promoter.  HPLC(UV) LCMS analysis conducted by Dr 
Zhiwei Qin at the John Innes Centre. 
0
100
200
300
400
0 5 10 15 20A
bs
or
ba
nc
e 
(m
AU
) x
10
00
Retention time (mins)
0
100
200
300
400
0 5 10 15 20A
bs
or
ba
nc
e 
(m
AU
) x
10
00
Retention time (mins)
0
100
200
300
400
0 5 10 15 20A
bs
or
ba
nc
e 
(m
AU
) x
10
00
Retention time (mins)
2
41
3
5
6-11
12
13
A
2
1
3
B
2 41
3
5
6-12
13
C
 187 
Using these data, we can begin to make predictions about the methylation of the 
fasamycins and how this affects their conversion to a formicamycin.  We hypothesise 
that the first methylation reaction to occur during formicamycin biosynthesis is di-
methylation at C18 by the actions of either ForM or ForT, as all congeners from the 
formicamycin BGC contain this moiety and deletion of these enzymes results in a 
complete block on the pathway progression, implying it is an essential part of the 
early biosynthesis.  A similar reaction is seen during the biosynthesis of benastatin, 
where the methyltransferase BenF catalyses the rare geminal bis-methylation to add 
a dimethyl group onto the polyketide chain (Xu, Schenk and Hertweck, 2007).  BlastP 
analysis reveals that ForM shows low sequence identity to BenF, whereas ForT has 
95% coverage and 49% similarity to BenF.  Instead, ForM is more similar to RoqN 
(18.07% identity and 94% coverage) which has been shown to catalyse an O-
methylation reaction during the biosynthesis of the alkaloid antimicrobial, meleagrin 
(Newmister et al., 2018).  Based on this information, we predict that ForT might be 
responsible for the addition of the di-methyl group to ring D of the formicamycin 
backbone.  Further supporting this hypothesis, the di-methyl group is present on 
fasamycins A and B from cosAZ154; this BGC contains a homolog to ForT but is 
missing a significant match to ForM, implying ForM is not the enzyme responsible for 
this reaction.  Instead we predict that ForM catalyses the addition of the O-methyl 
group at C3 at the base of ring A.  This reaction is also predicted to be essential for 
progression of the formicamycin biosynthetic pathway in S. formicae as deletion of 
the gene encoding ForM resulted in no congeners being produced and all products 
from the pathway contain this moiety.  However, the fasamycins isolated from S. 
albus carrying cosAZ154 do not have this methyl group and a homolog of ForM is 
missing from this BGC.  It is possible that over the course of evolution, addition of the 
forM gene contributed to some sort of survival advantage and therefore became an 
essential component of the formicamycin BGC.  During these experiments, we were 
not able to identify or isolate any congeners or biosynthetic intermediates that 
lacked either the dimethyl group of the O-methyl group at C3, implying that these 
molecules must not exist as enzyme-free intermediates (Qin et al., 2017).  We 
therefore predict that ForM and ForT accept substrates that are still bound to the 
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ACP and act before the intermediate is released, decarboxylated and cyclised, 
forming fasamycin C. 
Following cyclisation and removal of the ACP, the next stage of formicamycin 
biosynthesis is predicted to be halogenation by ForV.  The action of the halogenase 
generates the activated oxygen in the flavin cofactor for use by the Baeyer-Villiger 
monooxygenase, ForX, to expand ring C and form the seven membered lactone 
structure.  These lactone intermediates contain the di-methyl group on ring D and 
the O-methylation at the base of ring A, however they do not contain the O-
methylation on ring B that all of the formicamycin congeners do (Figure 5.12).  This 
is therefore predicted to be an important stage of the conversion from a fasamycin 
to a formicamycin in addition to the two-step ring-expansion, ring-contraction 
mechanism described previously. It appears that the O-methylation of ring B is 
catalysed by ForW, as deletion of this enzyme blocked the pathway at fasamycin 
production and prevented the conversion of fasamycins to formicamycins.  ForW is 
most similar to the O-methyltransferase LaPhzM which methylates the aromatic 
iodinin to form myxin, a phenazine antibiotic produced by Lysobacter antibioticus 
OH13.  Interestingly, the methylated myxin has been shown to have a higher 
bioactivity than the iodinin precursor (Jiang et al., 2018).  Based on the data we have 
available, we predict that ForW acts after ForX, generating a highly reactive 
intermediate that is the substrate for reduction by ForY that enables the fasamycin 
precursor to be converted into the more bioactive formicamycin.  Currently, we have 
been unable to isolate this intermediate for analysis, however, if it is highly reactive 
it is unlikely to be apparent in culture extracts.  The formicamycin scaffold generated 
by the combined actions of ForX, ForW and ForY can then be halogenated at 
additional points on the carbon chain to produce congeners with further increased 
bioactivity.  Some formicamycins can also be additionally O-methylated at R5.  The 
data here do not reveal which methyltransferase is responsible for catalysing this 
reaction, however, some O-methyltransferases, including LaPhzM, have been shown 
to O-methylate at multiple positions on their aromatic substrates (Jiang et al., 2018).  
Therefore, we predict that ForW also carries out this role, as it is the only 
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methyltransferase encoded in the formicamycin BGC that is thought to accept free, 
non-ACP bound substrates.   
 
Figure 5.12: Compared to the fasamycins, the formicamycins display two additional points for 
methylation, highlighted here in red.  Based on the data available, we predict that ForM and ForT are 
responsible for methylation at the sites common between fasamycins and formicamycins, with ForT 
catalysing the formation of the di-methyl group, and that these enzymes act early in the biosynthesis 
of the pentacyclic fasamycin scaffold.  In contrast, ForW seems to be involved in the methylation of 
those sites specific to the formicamycins as deletion of forW has no effect on fasamycin biosynthesis. 
5.4 Discussion 
 
Previous work in this thesis indicated that fasamycins are the biosynthetic precursors 
of the formicamycins and that the formicamycins are more potent antibiotics.  The 
aim of this chapter was to identify the biosynthetic and evolutionary link between 
these two distinct chemical scaffolds.  We identified two other BGCs in the database 
that encode for fasamycins; cosAZ154 which has been shown to encode biosynthesis 
of fasamycin molecules similar to those produced by the for BGC and a putative BGC 
in S. kanamyceticus that remains to be experimentally characterised.  No other BGCs 
in the database appear to encode for formicamycins, making the BGC in S. formicae 
unique.  Streptomyces bacteria encounter many stresses in their natural 
environments and being non-motile, they have to deal with these stresses, often by 
the production of secondary metabolites.  Most Streptomyces genomes contain a 
core region that encodes all the essential proteins such as those involved in DNA 
replication, transcription and translation, while the ‘arms’ of the chromosome often 
contain the BGCs encoding for non-essential secondary metabolites.  At these 
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chromosome arms, significant exchange of genetic material between strains can 
occur via horizontal gene transfer, making the acquisition of advantageous genetic 
material common (Challis and Hopwood, 2003).  We predict that the formicamycin 
BGC in S. formicae evolved from a fasamycin BGC via multiple insertion events as a 
result of the high rates of horizontal gene transfer and gene rearrangement that 
occur at the chromosome arms in these organisms.  These genes were likely acquired 
from other soil-dwelling actinomycetes over the course of evolution and became 
permanent as they provided a significant competitive advantage by increasing the 
potency of the natural products encoded by the BGC. 
The novel ring-expansion, ring-contraction mechanism of formicamycin biosynthesis 
described here appears to involve the activities of four enzymes, ForV, ForX, ForW 
and ForY, as all are essential for the conversion of fasamycins to formicamycins.  
Flavin dependent oxygenase enzymes like ForX and ForY are common in biosynthetic 
pathways and Baeyer-Villiger reactions are particularly prevalent in the biosynthesis 
of type 2 polyketides (Hertweck et al., 2007).  One of the most well studied Baeyer-
Villiger oxygenase reactions is the conversion of the inactive precursor 
premithramycin B to the bioactive metabolite mithramycin by the atypical BVMO, 
MtmOIV in S. argillaceus.  MtmOIV has been shown by crystallisation to 
noncovalently bind the FAD cofactor near the opening of the large substrate binding 
cavity designed for accepting large polyketide backbones (Beam et al., 2009; Tolmie, 
Smit and Opperman, 2019).  Although we have so far been unable to obtain pure 
ForX, it is likely that the structure and mechanism would be very similar to MtmOIV 
as it also falls into the same group of atypical BVMOs.  Interestingly, cappable RNA 
sequencing results from chapter 4 show that ForV, ForX, ForW and ForY are all 
expressed on the same transcript in S. formicae under the control of the promoter, 
pforU.  Transcriptional coupling is often indicative of cooperative functionality in the 
encoded proteins and we predict that these enzymes all function together in the 
conversion of fasamycins to formicamycins, perhaps acting almost instantaneously, 
one after the other.  Although many natural product biosynthesis pathways are 
generally viewed as linear routes from precursor to product, cooperative interactions 
between biosynthetic enzymes are actually quite common in the assembly of 
 191 
macromolecules due to the dynamic nature of the cellular metabolism.  Even outside 
of interactions between domains of multimeric proteins such as the ketosynthase, 
monomeric proteins can cooperate using ligands to aid these interactions (Porter and 
Miller, 2012).  In the case of formicamycin biosynthesis, three of these four enzymes, 
ForV, ForX and ForY likely bind to flavin, so it is possible that this may be responsible 
for the functional coupling between these enzymes.  ForV, ForX, ForW and ForY are 
predicted to function on cyclised substrates that have been released from the ACP.  
The enzymes involved in the cyclisation of the polyketide backbone during 
formicamycin biosynthesis are explored in the following chapter. 
This work also led to the isolation of five new bioactive secondary metabolites from 
the formicamycin BGC and demonstrated that by genetically engineering a T2PKS 
gene cluster we can obtain novel, bioactive natural products.  This method of 
genetically manipulating antibiotic producing organisms to produce ‘unnatural 
natural products’ has been around for some time and has been applied to multiple 
PKSs,  such as the erythromycin biosynthesis pathway, to generate novel analogues 
of known compounds (Bérdy, 2005).  The insight gained into the biosynthesis of these 
polyketide antibiotics will inform future drug discovery efforts, both in the natural 
product field and in synthetic chemistry.  Furthermore, as a result of the experiments 
conducted in this chapter, we now have a dedicated fasamycin producing strain, S. 
formicae DforX, which will be useful for further biosynthetic studies and the isolation 
of high titres of fasamycin congeners for in vitro experiments, including bioassays 
and feeding studies.  The nature of the biosynthetic pathway means that it is not 
possible to create a dedicated formicamycin producer that does not first make 
fasamycins, as they are the biosynthetic precursors, however, it may be possible to 
create enhanced production strains by combining the biosynthetic knowledge gained 
in this chapter with our knowledge of formicamycin regulation.  This idea will also be 
explored further in the following chapter. 
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6 Genetic engineering of the formicamycin BGC to obtain novel, pre-
defined products, by-products and biosynthetic intermediates  
 
Traditionally, biosynthetic pathways are viewed as linear routes through pre-defined, 
enzymatically controlled biosynthetic steps that reach completion on production of 
a single defined end product.  In reality, the biosynthesis of secondary metabolites in 
microorganisms is inherently more complicated.  Variations in culture conditions of 
the microorganism, as well as the levels of starter units and cofactors available in the 
environment, will affect the activities of the biosynthetic enzymes and therefore the 
rates at which these reactions occur, resulting in different levels of pathway 
intermediates and biproducts accumulating at any one time (Sanchez and Demain, 
2008).  In addition, some of the proteins encoded by secondary metabolite BGCs are 
reliant on the presence or activity of other proteins from the biosynthetic pathway, 
like the well characterised KSa and KSb subunits, so if one is inhibited in some way, 
the other will also not function (Chen, Re and Burkart, 2018).  Because of this 
complexity, spontaneous side reactions can occur, generating additional bi-products 
and shunt metabolites that differ from the main product of the pathway.  Like many 
biosynthetic pathways, formicamycin biosynthesis in Streptomyces formicae is 
further complicated by the fact that it does not have a defined ‘end product’ and 
instead produces a complex mixture of both fasamycins and formicamycins.  We 
have so far identified 16 fasamycin and formicamycin congeners that all originate 
from the formicamycin biosynthetic pathway, in addition to the six bioactive Baeyer-
Villiger intermediates that accumulate on deletion of the oxidoreductase, ForY 
(Chapter 5).  The aim of this chapter is to look for further congeners from the 
formicamycin biosynthetic pathway that may have been missed during the initial 
analysis of culture extracts due to the fact that production levels of biproducts and 
shunt metabolites are generally lower than the main pathway products.  By 
identifying additional biosynthetic intermediates and shunt metabolites we aim to 
further characterize the biosynthetic pathway and define the exact steps needed for 
production of both fasamycins and formicamycins.  This analysis may also enable us 
to identify further bioactive compounds from this diverse secondary metabolite 
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pathway.  Until this point, the functions of the cyclase enzymes encoded by the 
formicamycin BGC have been predicted, but they will be fully investigated in this 
chapter.  Furthermore, by combining our knowledge of formicamycin biosynthesis 
gained throughout this thesis with our knowledge of the gene cluster regulation, we 
aimed to produce multiple strains of S. formicae with more efficient and directed 
biosynthesis of specific formicamycin pathway products, intermediates and shunt 
metabolites.  If successful, these strains could be used to overproduce specific 
bioactive compounds from the formicamycin BGC at a level that might be 
appropriate for industrial production of these clinically relevant metabolites.  
6.1 Identifying further congeners from the formicamycin biosynthetic pathway  
 
Analysis of ethyl acetate extracts of wild-type S. formicae cultures by LCMS results in 
an extremely complex dataset, with approximately 3000 unique ions present, 
including those representing the fasamycins and formicamycins.  This, in 
combination with the aromatic, polycyclic nature of the formicamycins limits the 
effectiveness of tools such as the Global Natural Product Social Molecular 
Networking (GNPS) web-platform for the identification of novel congeners from the 
formicamycin biosynthetic pathway (Wang et al., 2016).  Dr Zhiwei Qin (JIC) therefore 
developed a de-replication method using mutants generated previously in this thesis 
to identify new halogenated ions in mass spectrometry (MS) data that originate from 
the formicamycin BGC.  Profiling Solutions software (Shimadzu Corporation) was 
used to filter down the dataset by starting with the 3000 ions from the wild-type 
extracts, then removing mass spec data from blank media that was not inoculated 
with S. formicae, in order to remove ions present in the growth medium.  Next, as 
most fasamycin and formicamycin congeners are chlorinated and only two other 
BGCs in the S. formicae genome contain putative halogenase encoding genes, it was 
hypothesised that any chlorine containing ions present in the dataset would likely 
derive from the formicamycin biosynthetic pathway.  As such, the ions present in 
extracts of S. formicae DforV (the halogenase deletion mutant) were then removed 
from the dataset to leave only ions of molecules that are halogenated by ForV.  To 
further filter the results, the ions from extracts of S. formicae Dfor (with the entire 
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formicamycin BGC deleted) were removed, leaving only halogenated compounds 
that originate from the formicamycin BGC.  This filtered dataset was significantly less 
complex than the original unfiltered results, with around 200 unique ions present 
(Qin et al., 2019).   
6.1.1 6-chlorogenistein 
 
Manual curation of the filtered dataset by Dr Zhiwei Qin showed that most of the 
remaining ions corresponded to the previously identified fasamycin and 
formicamycin congeners.  Analysis of the ions in the dataset also revealed the 
presence a compound with the molecular mass of 304.0139 and a predicted chemical 
formula of C15H9ClO5.  Purification and subsequent NMR analysis of this molecule by 
Dr Zhiwei Qin showed it was a chlorinated derivative of the isoflavone, Genistein, 
specifically 6-chlorogenistein (Figure 6.1).   
 
Figure 6.1: 6-chlorogenistein was isolated from culture extracts of wild-type S. formicae and the 
structure solved by NMR.   
As discussed previously, halogenated natural products often display potent 
bioactivity.  Previous studies have focussed on identifying chlorinated natural 
products by PCR screening microbes for conserved sequences present in genes 
encoding for FAD-dependent halogenases.  This approach was used to identify the 
chlorinated Genistein molecules 3’,8-dichlorogenistein and 8-chlorogenistein from 
Actinoplanes sp. HBDN08.  These molecules were shown to display antioxidant and 
antitumor activities, however there was no evidence of antibacterial activity (Xiang 
et al., 2010).  The bioactivities of these other chlorinated genistein metabolites were 
reported at 25 µg/ml, therefore bioassays of the isolated 6-chlorogenistein from S. 
formicae were set up against B. subtilis at equivalent concentrations.  As with other 
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studies, no antibacterial activity was seen from the 6-chlorogenistein isolated from 
the S. formicae extracts, even when the concentration was increased by 10 and 100 
fold (data not shown).  We therefore conclude that, like other chlorinated genistein 
metabolites, 6-chlorogenistein does not have any significant bioactivity against 
Gram-positive bacteria.  
Based on structural analysis, we also assume that 6-chlorogenistein is not related to 
the formicamycins and does not directly originate from the formicamycin BGC.  
Genistein has been found in significant levels in soy beans and the above experiment 
conducted by Dr Zhiwei Qin was conducted on SFM agar (soy flour, mannitol agar) 
(Table 2.1) (Fukutake et al., 1996).  Therefore, it is assumed that ForV may have some 
promiscuous activity on this metabolite from the growth media, allowing 
chlorination to produce 6-chlorogenistein during fermentation.  This further supports 
the hypothesis put forward in Chapter 3.3 that the halogenase ForV can non-
specifically halogenate multiple aromatic substrates.  This broad substrate 
recognition is likely facilitated by the actions of a carrier protein that may also be 
encoded in the formicamycin BGC that brings a broad range of substrates to the 
halogenase. In this way, ForV recognises the carrier rather than the substrate, 
allowing it to act promiscuously on multiple substrates such as the isoflavone 
genistein and multiple positions on the fasamycin/formicamycin backbone.  This 
hypothesis is explored further later in this chapter. 
6.1.2 Formicapyridines; novel bi-products from the formicamycin biosynthesis 
pathway 
 
Further analysis of the filtered mass spectra data by Dr Zhiwei Qin also resulted in 
the identification of three chlorinated metabolites (21-23) with a close structural 
relationship to the fasamycins and formicamycins but varying in the number of 
methyl groups present and surprisingly, the presence of a single nitrogen atom.  By 
searching for equivalent ions lacking chlorination in the un-filtered dataset, three 
additional congeners similar to these new molecules were identified (18-20), bringing 
the total number of new compounds up to six.  In addition, by repeating the 
fermentation of wild-type S. formicae cultures supplemented with 2mM sodium 
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bromide, which we have previously shown to induce biosynthesis of brominated 
formicamycin congeners, three additional bromine containing metabolites (24-26) 
were isolated with MS characteristics similar to those of the six new metabolites.  The 
predicted molecular formulae from the mass spectrometry analysis suggested that 
these compounds represented novel structures.  We therefore hypothesised that 
these nine new nitrogen-containing compounds represent a family of novel 
biosynthetic congeners from the formicamycin biosynthetic pathway that were likely 
missed during our initial analysis due to low production levels (Qin et al., 2019). 
As such, large scale cultures of wild-type S. formicae (14L made into approximately 
450 agar plates) were grown, extracted with ethyl acetate and small amounts of the 
compounds were isolated for structural elucidation by Dr Zhewei Qin.  Full analysis 
by NMR revealed the nine compounds were polyketide alkaloids with high structural 
similarity to the formicamycins, with the exception of the presence of a pyridine at 
ring B (Figure 6.2).  We therefore named these new compounds the 
formicapyridines.  
 
Figure 6.2: De-replication of the mass spectra resulted in the identification of the formicapyridines; 
pyridine containing compounds with high structural similarity to the formicamycins with various levels 
of methylation that can be chlorinated or brominated on supplementation of the growth media. 
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R1
R2
R3
18 Formicapyridine A R1=H, R2=H, R3=H 
19 Formicapyridine B R1=CH3, R2=H, R3=H,  
20 Formicapyridine C R1=CH3, R2=CH3, R3=H,  
21 Formicapyridine D R1=H, R2=H, R3=Cl,  
22 Formicapyridine E R1=CH3, R2=H, R3=Cl,  
23 Formicapyridine F R1=CH3, R2= CH3, R3=Cl,  
24 Formicapyridine G R1=H, R2= H, R3=Br,  
25 Formicapyridine H R1=CH3, R2= H, R3=Br,  
26 Formicapyridine I R1=CH3, R2= CH3, R3=Br 
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Quantitative analysis of LCMS data from extracts of wild-type S. formicae using 
absorbances at 390 nm show that the six formicapyridines are present (no 
brominated congeners as the media was not supplemented with sodium bromide), 
but at approximately 100-fold lower levels than the fasamycins and formicamycins, 
which is why they were missed during the initial investigations.  Further interrogation 
of LCMS data shows that the S. formicae Dfor cluster deletion mutant does not 
produce the formicapyridines, whereas production of all six metabolites returns in 
the Dfor mutant in trans complemented with the PAC (215-G).  Similarly, S. formicae 
DforV accumulates the non-chlorinated formicapyridines A-C (18-20) and does not 
produce formicapyridines D-F (21-23), the chlorinated formicapyridines.  Production 
of all formicapyridine congeners is restored by in trans complementation with forV 
under the control of pforU (see Chapter 3.3) (Figure 6.3).  This confirms that the 
formicapyridines are products of the formicamycin biosynthetic pathway (Qin et al., 
2019).   
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Figure 6.3: Reconstituted HPLC (UV 390 nm) showing (A) formicapyridine standards alongside culture 
extracts of (B) wild-type S. formicae; (C) S. formicae Dfor; (D) S. formicae DforV; (E) S. formicae Dfor: 
jC31 for 215-G; (F) S. formicae DforV: jBT1 pforU forV.  Deletion of the formicamycin BGC abolished 
formicapyridine production and complementation with the PAC 215-G restores production at 
approximately wild-type levels.  Deletion of the halogenase forV results in production and 
accumulation of only the non-chlorinated formicapyridines, with all six congeners returning on in trans 
complementation.  Retention times are displayed between 4 and 10 minutes even though the method 
was run for 20 minutes as per previous experiments.  This is because the antifungal compounds 
produced by S. formicae also absorb at UV 390nm and at much higher intensity than the 
formicapyridines, making visual identification challenging when viewing the whole dataset.  Masses 
of all peaks have been confirmed by mass spectrometry to identify the compound. HPLC(UV) LCMS 
conducted by Dr Zhiwei Qin and the John Innes Centre. 
To identify whether the formicapyridines display bioactivity against B. subtilis, disc 
diffusion assays were set up using 5 µg/ml of each compound, as this is the average 
concentration used for illustrating fasamycin and formicamycin bioactivity.  No 
bioactivity was seen at this concentration, or at ten-fold higher concentration (50 
µg/ml).  Small zones of inhibition were seen at 100-fold (500 µg/ml) concentration, 
implying the MIC for these compounds is approximately 100-fold higher than that of 
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the fasamycin and formicamycins.  To confirm this was not as a result of reduced 
diffusion from the paper disc due to altered polarity of the formicapyridines, assays 
were set up to test the growth of B. subtilis in liquid culture in the presence of 
compounds 18-23.  Small 1 ml cultures containing 50 µg/ml formicapyridine (or a 
hygromycin positive control) were inoculated in 12-well plates with B. subtilis in 
exponential phase and grown for 7 hours at 37°C, shaking at 220 rpm.  After this 
incubation, the cultures were harvested and plated in serial dilutions in triplicate for 
colony count using the Miles and Misra protocol (Miles, Misra and Irwin, 1938).  This 
showed that there was no significant difference in colony forming units (CFU) per ml 
(CFU/ml) between the cultures containing formicapyridines and the methanol 
solvent control, implying that the formicapyridines do not have significant bioactivity 
against Gram-positive pathogens (Figure 6.4).   
 
Figure 6.4: (A) The formicapyridines (18-23) were tested at 5, 50 and 500 µg/ml using disc diffusion 
assays against Bacillus subtilis.  20 µl of each solution is applied to each disc.  No significant zone of 
inhibition was seen at 5 or 50 µg/ml, and only small zones were seen at 500 µg/ml.  Hygromycin 
positive control is at 50 µg/ml.  (B) In liquid culture,  50 µg/ml of each compound was added to 1 ml 
liquid culture of exponential phase  B. subtilis in LB broth and grown at 37°C for 7 hours.  Cells were 
harvested, serially diluted and plated for colony count to calculate the number of colony forming units 
present in the sample following Miles and Misra protocol (Miles, Misra and Irwin, 1938). There is no 
significant difference between the formicapyridine-containing cultures and the methanol (MtOH) 
solvent control, showing these compounds do not have significant antibacterial activity against Gram-
positive pathogens.  The only culture to have significantly lower growth than the negative control is 
the positive control with 50 µg/ml Hygromycin present (two tailed t-test, p = 0.005). 
Furthermore, samples of formicapyridine A were sent to Inspiralis to test for both 
inhibition of topoisomerase IV relaxation and inhibition of gyrase supercoiling 
alongside the fasamycins and formicamycins.  Assays were run using enzymes from 
both Gram-positive and Gram-negative bacteria as described previously (Chapter 
3.5).  In all assays, the IC50s values for the formicapyridine were higher than those 
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for fasamycin and formicamycin, confirming that these compounds have less potent 
bioactivity against the enzymes tested (Table 6.1).  While it is possible that the 
pyridine ring changes the mechanism of action of these compounds, with the above 
bioassay data, we predict that alteration of ring B in this manner is enough to reduce 
the potency of these compounds, perhaps by changing the binding potential of these 
compounds to their target.   
Table 6.1: Samples of formicapyridine A were tested by Isomerase therapeutics (NRP) for inhibitory 
activity against bacterial topoisomerase IV and DNA gyrase.  In all assays conducted, the IC50 values 
for the formicapyridines were significantly higher than the tested fasamycin and formicamycin, 
implying that the potency of these compounds is reduced. 
 Average IC50 (µM) 
E. coli gyrase 
supercoiling 
S. aureus 
gyrase 
supercoiling 
E. coli 
topoisomerase 
IV relaxation 
S. aureus 
topoisomerase 
IV relaxation 
Ciprofloxacin 0.27 52.85 1.21 2.87 
Fasamycin E 16.86 1.93 2.41 6.23 
Formicamycin J 29.21 2.36 6.64 6.28 
Formicapyridine A >100 36.98 10.78 25-50 
 
At this point, little is known about how the for BGC synthesises the formicapyridines.  
Aromatic nitrogen containing metabolites originating from T2PKS biosynthesis 
pathways are rare, with only a few examples having been reported to date (Figure 
6.5).  Jadomycins are polyketide natural products originating from Streptomyces 
venezuelae with nitrogen and oxygen containing heterocycles.  These secondary 
metabolites display potent activity against both Gram-positive and Gram-negative 
bacteria as well as cytotoxicity against cancer cell lines.  The mechanism of nitrogen 
incorporation into the jadomycin backbone remains unclear, but it is predicted to 
occur via the spontaneous, non-enzymatic incorporation of amino acids such as 
isoleucine during biosynthesis (Sharif and O’Doherty, 2012).  The pyxidicyclines are 
anthracycline-related quinone like molecules with a nitrogen-containing tetracene 
structure originating from a T2PKS pathway from the myxobacterium Pyxidicoccus 
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fallax An d48.  The pyxidicyclines have been shown to be moderate inhibitors of 
bacterial topoisomerase IV, with no significant activity against bacterial DNA gyrase, 
however, they were also shown to be potent inhibitors of human topoisomerase I 
and therefore have potential as novel anticancer agents.  In the future, it would be 
interesting to screen the formicapyridines against mammalian topoisomerase 
enzymes and cancer cell lines to determine if they have any inhibitory activity.  In 
contrast to the biosynthesis of the jadomycins, the mechanism of nitrogen 
incorporation in pyxidicyclines is thought to be via the attachment of a serine to the 
polyketide chain by a dedicated AMP-dependent synthetase/ligase and 
aromatase/cyclase di-domain protein, PcyJ, which then closes this ring with the help 
of two other cyclase enzymes, PcyK and PcyL (Panter et al., 2018).  At this point, it is 
unclear whether incorporation of the nitrogen and subsequent formation of the 
pyridine ring of the formicapyridines is spontaneous or enzymatically controlled, 
however no equivalent enzyme to PycJ is found within the formicamycin BGC, 
suggesting that biosynthesis of the formicapyridines in S. formicae may occur via a 
novel mechanism (Qin et al., 2019). 
 
Figure 6.5: Structures of other natural products from T2PKS pathways that contain aromatic nitrogens.  
During the biosynthesis of both the jadomycins and the pyxidicyclines, amino acids are attached to 
the polyketide chain before cyclisation to allow nitrogen incorporation into the ring structures, either 
enzymatically or spontaneously.  It is currently unclear how nitrogen is incorporated into the 
formicapyridine scaffold, although no enzyme candidates can be identified either within the BGC or 
near the cluster boundaries implying it may occur spontaneously during cyclisation. 
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6.2 The functions of the five putative cyclases in the biosynthesis of fasamycins, 
formicamycins and formicapyridines 
 
The low titres of formicapyridines present in the wild-type extracts led us to 
hypothesise that these compounds are shunt metabolites produced spontaneously 
during the cyclisation of the poly-b-keto intermediate, specifically when cyclisation 
of ring B becomes derailed.  To further investigate the biosynthesis of the 
formicapyridines, the roles of the cyclase enzymes encoded by the formicamycin BGC 
were considered.  Sometimes, cyclisation of poly-b-keto intermediates in T2PKS 
biosynthesis is spontaneous, however, more often the process is controlled by 
dedicated cyclase enzymes or chaperone proteins that help direct the reaction to 
generate the desired final product.  We hypothesised that generation of the 
pentacyclic formicamycin backbone from the poly-b-ketone tridecaketide (17) 
described previously requires the combined activities of five putative cyclases and 
antibiotic biosynthesis monooxygenases encoded in the formicamycin BGC; ForD, 
ForL, ForR, ForS and ForU (Table 6.2).  These gene products are some of the few that 
remain uncharacterised in the formicamycin BGC at this point and therefore their 
function is currently unclear. 
During fasamycin and formicamycin biosynthesis, we assume that ring A is closed 
first, followed by the sequential cyclisation and aromatisation of rings E, D, C and B.  
However, if this series of cyclisation steps is derailed before completion, specifically 
before complete cyclisation of ring B, a highly reactive b-ketoacid species would be 
generated, that might be prone to spontaneous decarboxylation and transamination. 
The for BGC does not encode for a transaminase/aminotransferase and a search of 
the S. formicae genome does not reveal any transaminase or aminotransferase gene 
candidates that might be involved in this reaction therefore we predict that the 
incorporation of nitrogen into the formicapyridine backbone may be spontaneous 
and/or as a result of the actions of endogenous enzymes from the cellular milieu.  
Once transaminated, the species could then theoretically undergo cyclisation, 
dehydration and oxidation to generate a formicapyridine (Figure 6.6). 
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Table 6.2: Bioinformatic analysis of each of the putative cyclases and antibiotic biosynthesis 
monooxygenases was conducted using BlastP.  This analysis shows that these five genes show 
similarity to other polyketide cyclases and antibiotic biosynthesis monooxygenases in the database 
and therefore they are predicted to be involved in aromatisation of the poly-b-ketone intermediate 
during formicamycin biosynthesis.  This table also appears in (Qin et al., 2019). 
Name Protein ID Top BlastP hit Annotation % 
coverage 
% 
amino 
acid 
identity 
ForD WP_098245758.1 WP_003962252.1 
 
Polyketide cyclase 
(TcmN), 
Streptomyces 
clavuligerus ATCC 
27064 
95 73 
ForL WP_055544278.1 WP_076971949.1 
 
TcmI family type 2 
polyketide cyclase, 
Streptomyces 
sparsogenes 
97 52 
ForR WP_098245762.1 AUI41024.1 Polyketide WhiE II 
Streptomyces sp. 
(abxR), cupin domain 
96 75 
ForS WP_098245763 SDF47214.1 Antibiotic 
biosynthesis 
monooxygenase, 
Lechevalieria fradiae 
96 48 
ForU WP_098245765.1 PZS28546.1 Antibiotic 
biosynthesis 
monooxygenase, 
Pseudonocardiales 
bacteria 
84 46 
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Figure 6.6: We hypothesise that cyclisation of the poly-b-ketone tridecaketide to form a fasamycin backbone requires the activity of some/all of the five putative 
cyclases and antibiotic biosynthesis monooxygenase enzymes encoded in the formicamycin BGC; ForD, ForL, ForR, ForS and ForU.  If this sequential cyclisation is 
disrupted, generating a highly reactive b-ketoacid species, spontaneous decarboxylation and transamination may form the formicapyridine backbone as shown.  
Adapted from (Qin et al., 2019).
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We aimed to characterise the roles of the putative cyclase and antibiotic biosynthesis 
monooxygenase enzymes encoded in the formicamycin BGC and specifically to 
identify which of the five cyclase enzymes were responsible for closing ring B in order 
to experimentally characterise formicapyridine biosynthesis.  In addition, by 
identifying a single gene product that controls production of the formicapyridines, 
specifically cyclisation of ring B, it may be possible to engineer a mutant strain of S. 
formicae with enhanced levels of formicapyridine production and possibly even 
abolish fasamycin and formicamycin biosynthesis to generate a specific 
formicapyridine producer.  To determine the roles of these enzymes in fasamycin, 
formicamycin and formicapyridine biosynthesis, CRISPR-Cas9 was used to generate 
in frame, unmarked deletion mutations in each gene and examine the effect of these 
mutations on fasamycin, formicamycin and formicapyridine biosynthesis.  
Bioinformatic analysis of ForD shows homology to multiple polyketide 
cyclase/dehydratase enzymes including the N-terminal aromatase/cyclase domain of 
the multifunctional tetracenomycin protein TcmN.  The crystal structure of TcmN 
reveals an interior binding pocket for binding nascent polyketide intermediates and 
shows it plays a central role in the cyclisation and aromatisation of tetracenomycin, 
particularly catalysing the sequential cyclisation and aromatisation of rings 1 and 2 
via multiple dehydration reactions (Ames et al., 2008).  We therefore hypothesise 
that ForD might catalyse the cyclisation of rings E and D on the formicamycin 
backbone.  To experimentally characterise the role of ForD in the biosynthesis of 
fasamycins, formicamycins and formicapyridines, three biological replicates of S. 
formicae DforD were cultivated under formicamycin producing conditions.  Culture 
extracts were analysed by HPLC(UV) and LCMS by Dr Zhiwei Qin at the JIC.  Deletion 
of forD completely abolished biosynthesis of fasamycins, formicamycins and 
formicapyridines with no new shunt metabolites or biosynthetic intermediates 
evident in the culture extract.  Genetic complementation of forD in trans under the 
control of the native promoter (pforT) reinstated production of all congeners from 
the pathway (Figure 6.7).  This suggests that ForD plays a central role in the 
biosynthesis of all metabolites originating from the formicamycin biosynthetic 
pathway.   
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Figure 6.7: Reconstituted HPLC-UV at 280 nm to capture fasamycins and formicamycins (1-13) and 
390 nm to capture formicapyridines (18-23) in culture extracts of (A and B) wild-type S. formicae at 
280nm and 390 nm respectively; (C and D) S. formicae DforD at 280nm and 390 nm respectively; (E 
and F) S. formicae DforD: jBT1 forD pforT at 280nm and 390 nm respectively. n=3 replicates of each 
mutant and complementation strain.  Deletion of the putative cyclase forD abolished fasamycin, 
formicamycin and formicapyridine biosynthesis.  Production is reinstated on in trans 
complementation under the native promoter.  Figures are scaled comparatively within the same 
wavelengths.  Peak intensity cannot be compared between different wavelengths.  HPLC (UV) LCMS 
conducted by Dr Zhiwei Qin, JIC. 
ForL belongs to the polyketide synthase cyclase family of enzymes and shows closest 
homology to the polyketide cyclase TcmI from the tetracenomycin biosynthetic 
pathway.  TcmI has been shown to catalyse the closure of the final ring of 
tetracenomycin F2 to produce tetracenomycin F1 (Thompson et al., 2004).  This 
reaction is remarkably similar to the predicted reaction needed to cyclise ring B, 
therefore we predict that ForL may be the enzyme responsible for catalysing 
cyclisation of ring B.  If this were true, we might expect that a deletion mutant of forL 
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may only produce formicapyridines, due to derailed formicamycin biosynthesis as a 
result of no cyclisation of ring B.  However, HPLC(UV) and LCMS analysis of culture 
extracts of S. formicae DforL by Dr Zhiwei Qin showed no fasamycins, formicamycins 
or formicapyridines are produced and no other biosynthetic intermediates or shunt 
metabolites are evident.  Genetic complementation of forL in trans under the control 
of the native promoter (pforM) reinstated production of all congeners from the 
pathway, implying that ForL also plays an essential role in the cyclisation of the poly-
b-ketone tridecaketide (Figure 6.8). 
 
Figure 6.8: Reconstituted HPLC-UV at 280 nm to capture fasamycins and formicamycins (1-13) and 
390 nm to capture formicapyridines (18-23) in culture extracts of (A and B) wild-type S. formicae at 
280nm and 390 nm respectively; (C and D) S. formicae DforL at 280nm and 390 nm respectively; (E 
and F) S. formicae DforL: jBT1 forL pforM at 280nm and 390 nm respectively. n=3 replicates of each 
mutant and complementation strain.  S. formicae DforL does not produce any fasamycin, 
formicamycin or formicapyridine congeners.  Production is reinstated on in trans complementation 
under the native promoter.  HPLC (UV) LCMS conducted by Dr Zhiwei Qin. 
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ForR is a member of the cupin-like superfamily with close homology to the polyketide 
cyclase RemF involved in the cyclisation of the pentacyclic polyketide core of 
resistomycin in Streptomyces resistomycificus (Silvennoinen, Sandalova and 
Schneider, 2009).  When grown under formicamycin producing conditions, HPLC(UV) 
and LCMS analysis of culture extracts of S. formicae DforR show no fasamycins, 
formicamycins, formicapyridines or related ions showing it also likely plays an 
important role in the cyclisation of the formicamycin core.  Genetic complementation 
of forR in trans under the control of the native promoter (pforT) was unsuccessful, 
resulting in HPLC (UV) profiles that looked the same as traces for S. formicae DforR.  
The complementation was therefore repeated using a construct with forR placed 
under the control of the constitutive and high-level ermE* promoter.  When the new 
complementation mutant was grown under formicamycin producing conditions and 
analysed by HPLC (UV) LCMS, all formicamycin congeners returned, but at lower 
levels than is seen in the wild type culture extracts (Figure 6.9).  It is unclear why 
complementation of forR under the control of pforT was unsuccessful in this case, as 
the pforT promoter has been used to complement other deletion mutations in genes 
under its control during this work.  When complementing genes in trans on 
integrative vectors such as pMS82, the new location of the gene can be important in 
determining the levels of transcription, so it may be that in this case, transcription 
levels of forR were too low under pforT but the stronger promoter permE* generated 
enough transcript for complementation.  Nevertheless, this shows that all three 
putative cyclases encoded within the formicamycin biosynthesis pathway (ForD, ForL 
and ForR) are essential for the biosynthesis of any metabolites from the 
formicamycin pathway.  It may be that these enzymes all function as a multi enzyme 
complex and that removal of one cyclase de-stabilises the complex, resulting in no 
activity by the other two enzymes.  This is explored further later in this chapter. 
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Figure 6.9: Reconstituted HPLC-UV at 280 nm to capture fasamycins and formicamycins (1-13) and 
390 nm to capture formicapyridines (18-23) in culture extracts of (A and B) wild-type S. formicae at 
280nm and 390 nm respectively; (C and D) S. formicae DforR at 280nm and 390 nm respectively; (E 
and F) S. formicae DforR: jBT1 forRA permE* at 280nm and 390 nm respectively. n=3 replicates of 
each mutant and complementation strain.  Deletion of forR abolishes formicamycin, fasamycin and 
formicapyridine production.  Complementation under the constitutive promoter permE* reinstated 
production of all congeners, but at lower levels than the wild-type strain.  HPLC (UV) LCMS conducted 
by Dr Zhiwei Qin. 
ForS is an antibiotic biosynthesis monooxygenase (ABM) protein.  Members of this 
protein superfamily are involved in the biosynthesis of several antibiotics by 
Streptomyces species and often function as multimers, either with each other or with 
proteins from other superfamilies (Sciara et al., 2003).  Replicates of S. formicae DforS 
were grown under formicamycin producing conditions and culture extracts were 
analysed by HPLC(UV) and LCMS by Dr Zhiwei Qin.  Interestingly, the levels of 
formicamycin production in S. formicae DforS were reduced to about a third of the 
levels produced by the wild-type strain.  In contrast, levels of formicapyridines in the 
culture extracts increased by approximately 25 times in the mutant.  
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Complementation of forS in trans under the control of pforT was unsuccessful, 
however, in trans complementation of forS under the control of permE* resulted in 
partial complementation, with production levels of formicamycin congeners still 
being less than in the wild-type strain, but formicapyridine production being reduced 
to wild-type levels once again (Figure 6.10).   
The increase in formicapyridine titres in S. formicae DforS suggests that ForS plays an 
important role during the closure of ring B.  However, formicamycins are still present 
in the extracts, albeit at lower levels than in the wild-type extracts, demonstrating 
that cyclisation of ring B can still occur without ForS and that the enzyme is not solely 
responsible for catalysing the reaction.  Instead, it may be that ForS functions as a 
chaperone that supports the other cyclase enzymes during the aromatisation of the 
polyketide backbone and that without it, the cyclisation of the polyketide is less 
efficient and more shunt metabolites are produced.  Interestingly, the levels of 
fasamycins present is approximately equal in both the wild-type and the DforS 
extract samples.  This could suggest that ForS is somehow involved in the conversion 
of a fasamycin to a formicamycin, as fasamycin biosynthesis is unaffected but 
formicamycin biosynthesis is significantly reduced (Figure 6.11). 
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Figure 6.10: Reconstituted HPLC-UV at 280 nm to capture fasamycins and formicamycins (1-13) and 
390 nm to capture formicapyridines (18-23) in culture extracts of (A and B) wild-type S. formicae at 
280nm and 390 nm respectively; (C and D) S. formicae DforS at 280nm and 390 nm respectively; (E 
and F) S. formicae DforS: jBT1 forS permE* at 280nm and 390 nm respectively. n=3 replicates of each 
mutant and complementation strain.  Deletion of forS reduces fasamycin and formicamycin titres to 
approximately one-third of the wild-type levels.  In contrast, formicapyridines are produced at 25-
times higher titres in S. formicae DforS.  Complementation under the constitutive promoter permE* 
returned production of all congeners to approximately wild-type levels.  HPLC (UV) LCMS conducted 
by Dr Zhiwei Qin. 
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Figure 6.11: Titres of compounds present in the fermentation extracts were measured by quantitative 
integration of HPLC(UV) and mass ion data using calibrations based on standards to calculate the 
relative amounts of each compound in the extracts of the wild-type (WT) and the S. formicae DforS 
(DforS) mutant.  The forS deletion mutant produces less formicamycins than the wild-type but more 
formicapyridines.  Error bars represent standard error of the mean.  Data generated by Dr Zhiwei Qin 
for (Qin et al., 2019).  Figure adapted and reproduced with permission. 
During further analysis of S. formicae DforS, a new minor congener was identified 
that is not present in any wild-type fermentations.  Growth of S. formicae DforS was 
therefore scaled up and 3.4 mg of the new compound was isolated for structural 
elucidation by NMR by Dr Zhiwei Qin. This new metabolite is a new fasamycin 
congener that is not halogenated but contains a carboxyl group on ring B (Figure 
6.12).  The new fasamycin congener, named fasamycin F (27), appears to be a 
cyclised polyketide intermediate that has been hydrolysed from the ACP but has not 
undergone subsequent decarboxylation to form the fasamycin scaffold.  This further 
suggests that ForS is involved in the final step of cyclisation of the fasamycin 
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backbone and although not essential, supports the role of other enzymes involved in 
modifying ring B (Qin et al., 2019).  
 
Figure 6.12: Structure of the new fasamycin congener, fasamycin F, isolated from S. formicae DforS.  
Fasamycin F is the only compound isolated from the for BGC that contains the carboxylic acid group 
on ring B. 
ForU is also a member of the ABM protein superfamily and shows the greatest 
homology to the monooxygenase ActVA-orf6 from the actinorhodin biosynthetic 
pathway in S. coelicolor, a protein that itself has homology to TcmI, the closest 
relative of ForL (Sciara et al., 2003; Thompson et al., 2004).  Extracts of S. formicae 
DforU were cultivated under formicamycin producing conditions and analysed by 
HPLC(UV) and LCMS by Dr Zhiwei Qin, JIC.  Once again, no fasamycin, formicamycin, 
formicapyridine or related ions were present in the resulting dataset.  This implies 
that ForU also plays an important role in the cyclisation of the core carbon backbone 
during formicamycin biosynthesis.  Genetic complementation of forU in trans under 
the control of the native promoter resulted in only the production of low levels of 
the non-halogenated fasamycin, formicamycin and formicapyridine congeners (data 
not shown).  When designing pCRISPomyces-2 constructs, care is taken not to delete 
regions of neighbouring genes where the coding regions overlap.  For example, there 
is a nine base pair overlap between forU and forV, therefore this region was not 
included in the deletion of forU.  Interestingly, in trans complementation of S. 
formicae DforU with a construct containing a fusion of the coding regions for both 
forU and forV to permE* does restore production of all fasamycins, formicamycins 
and formicapyridines, including the chlorinated congeners (Figure 6.13).  This could 
imply that deletion of forU results in a polar effect of the transcription of downstream 
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forV, perhaps due to the presence of a ribosome binding site (RBS) for forV within 
the coding region of forU.  Alternatively, it could be that as well as performing a role 
in the cyclisation of the poly-b-ketone tridecaketide, ForU has a role in allowing 
activity of ForV, perhaps by acting as the carrier for substrates to the active site.  In 
this case, the activity of ForV would be sensitive to the levels of ForU present in the 
cell.  When S. formicae DforV was complemented in trans with forV under the control 
of pforU, expression levels of forU were unaffected, as it remained in its native locus, 
therefore any transcribed forV from the complementation construct would be 
functional due to the presence of ForU.  However, when S. formicae DforU was 
complemented with forU under the native promoter, some ForU is produced, as a 
fully cyclised fasamycin 1 is seen in the culture extract, but perhaps expression levels 
were lower, as seen in the complementation of other genetic mutants in this project.  
In this case, transcription of forV would be unaffected, but the resulting protein may 
not be functional, or may only function at low levels.   
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Figure 6.13: Reconstituted HPLC-UV at 280 nm to capture fasamycins and formicamycins (1-13) and 
390 nm to capture formicapyridines (18-23) in culture extracts of (A and B) wild-type S. formicae at 
280nm and 390 nm respectively; (C and D) S. formicae DforU at 280nm and 390 nm respectively; (E 
and F) S. formicae DforU: jBT1 forU-V permE* at 280nm and 390 nm respectively. n=3 replicates of 
each mutant and complementation strain.  Deletion of forU abolishes fasamycin, formicamycin and 
formicapyridine production.  Complementation under the native promoter was unsuccessful, but 
complementation with a construct containing forU and downstream forV under the control of permE* 
restored fasamycin formicamycin and formicapyridine production.  HPLC (UV) LCMS conducted by Dr 
Zhiwei Qin. 
These results show that ForD, L, R and U are required for the production of all the 
pathway derived metabolites and therefore likely play major roles in the cyclisation 
of the pentacyclic formicamycin backbone.  In addition, removal of any one gene 
individually abolishes fasamycin, formicamycin and formicapyridine production.  This 
implies that these cyclase enzymes work together in a large, multi-enzyme complex 
to cyclise the poly-b-keto intermediate, rather than as independent proteins.  In 
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contrast, ForS is not essential for the biosynthesis of any congeners from the 
formicamycin biosynthetic pathway, therefore, ForS does not have an essential role 
in cyclisation of the carbon backbone.  However, ForS does appear to play an 
important role in the overall productivity of the formicamycin biosynthesis pathway.  
Deletion of forS resulted in less formicamycin biosynthesis and increased levels of 
shunt metabolites like the formicapyridines.  It also affected the decarboxylation of 
ring B after cleavage of the ACP, as shown by the isolation of the new fasamycin 
congener, fasamycin F.  Therefore, it may be that ForS stabilises the multi-enzyme 
cyclase complex for optimal formicamycin production and/or ForS may act as a 
chaperone to modulate the biosynthetic pathway and direct nascent intermediates 
for complete cyclisation.  In this way, ForS ensures that most of the poly-b-keto 
intermediate is fully cyclised and becomes a fasamycin and, ultimately, a 
formicamycin, with only low levels of formicapyridines and other shunt metabolites 
being produced as side products.  Furthermore, ForS may be involved in chaperoning 
the cyclised intermediate to other enzymes further downstream in the pathway for 
conversion into formicamycins.  This may explain why S. formicae DforS makes wild-
type levels of fasamycins but significantly less formicamycins. 
Similarly, it is possible that ForU has a role in the activity of the halogenase ForV, 
perhaps by acting as a carrier or by tethering ForV to the cyclase complex in order to 
guide the cyclised intermediate to the halogenase for chlorination.  Evolutionary 
analysis of fasamycin and formicamycin BGCs suggests that ForU and ForV are always 
encoded on the same transcript, even on cosAZ154 which shows significant 
rearrangement of other genes compared to the formicamycin BGC in S. formicae, 
indicating they may be functionally linked (Chapter 5.1).  If ForU does stabilise the 
interaction between the cyclase enzymes and the halogenase, removal of ForU 
would not only affect halogenation but would prevent the activity of the cyclases 
ForD, ForL and ForR, explaining the loss of any fasamycins and formicamycins in the 
extract of the deletion mutant.  In future, it would be interesting to co-express and 
purify ForU and ForV together to determine whether in vitro halogenation activity is 
dependent on the presence of ForU.   
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Overall, this experiment highlights the importance of ABM domain containing 
proteins, especially ForS, for the productivity of the formicamycin biosynthesis 
pathway.  Genes encoding for ABM domains are encoded in many PKS pathways and 
they have a variety of biological functions.  Based on these data, we suggest one of 
their functions may be to fine-tune PKS pathways by stabilising multi-enzyme 
complexes or guiding intermediates through various stages of biosynthesis to 
generate the desired pathway products with high efficiency.  Similar pathways to the 
formicamycin BGC that also encode for ABM family proteins include the xantholipin 
biosynthesis pathway in Streptomyces flavogriseus and the pradimicin biosynthetic 
pathway in Actinomadura hibisca P157-2 (Figure 6.14).  Xantholipin is a hexacyclic 
aromatic polyketide with antibacterial activity against Gram-positive pathogens in 
addition to significant anticancer activity.  The BGC encodes for three putative 
cyclases and four ABM family proteins.  The predicted biosynthesis pathway only 
requires a single monooxygenase although one of the ABM family monooxygenases 
is predicted to assist the Baeyer-Villiger monooxygenase during the oxidation to 
produce the xanthone ring (Zhang et al., 2012).  Currently there is no predicted role 
for the other ABM family proteins encoded in this pathway and it is possible that they 
are chaperones that support the activities of the encoded cyclases.  Similarly, the 
pradimicins are pentacyclic aromatic polyketides with some structural similarities to 
the formicamycins.  The BGC encoding for pradimicins contains three putative 
cyclases and two putative ABM domain proteins, PdmH and PdmI.  Heterologous 
expression of these genes has shown that in addition to all three cyclases, the ABM 
domain monooxygenase PdmH must also be expressed for complete pradimicin 
biosynthesis, as it is required for the formation of the quinone moiety.  Experimental 
characterisation has shown that the three cyclases function as a multi-enzyme 
complex and the authors of the study propose that the complex is able to span the 
entire length of the uncyclized polyketide to ‘lock the backbone in place’ and prevent 
undesired spontaneous cyclisation reactions.  Furthermore, co-expression of PdmH 
with the core biosynthetic machinery changes the predominant product of the 
pradimicin biosynthetic pathway and decreases the levels of production of the major 
congeners to less than 10% of the normal levels (Zhan, Watanabe and Tang, 2008).  
This suggests that the cyclase enzymes from the pradimicin biosynthetic pathway 
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also require the activity of the ABM family protein PdmH to chaperone or fine-tune 
the biosynthesis in the same way as ForS in the biosynthesis of the formicamycins.  
 
Figure 6.14: Structures of the polyketides xantholipin and pradimycin which also have ABM domain 
containing proteins encoded within their BGCs.  Is it possible that some of the ABM domain proteins 
involved in the biosynthesis of these molecules act as chaperones to guide the cyclisation of the 
multiple rings as ForS does during the biosynthesis of the formicamycins.  Structures downloaded from 
PubChem and adapted in ChemDraw for figure. 
Furthermore, many PKS pathways encode for PKS cyclases with an ABM domain 
fused to the end of the protein, such as the polyketide synthase CurD from 
Streptomyces ambofaciens (WP_053126740.1) which contains an ABM domain at its 
N-terminus.  If ABM domains do indeed act as chaperones that support cyclisation 
reactions during polyketide biosynthesis, it is possible that these genes may 
represent examples of highly evolved systems where these chaperones have become 
an essential part of the core essential biosynthetic machinery and are now 
transcribed as a single gene product with the cyclase, further highlighting their 
important functions in these complex secondary metabolite biosynthesis pathways.  
Phylogenetic analysis of the top 100 BlastP hits against ForS shows that the ABM 
domain containing proteins cluster broadly into two main groups; those associated 
with cyclases and those with predicted monooxygenase activity.  Within the 
monooxygenase cluster, there are two further sub-groups, within which ForS and its 
Xantholipin
Pradimycin A
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closest homologs cluster (Chapter 8.4).  It is possible that these two groups of 
monooxygenases represent one group of chaperones and another group of those are 
monooxygenases with enzymatic activity.  However, too few ABM proteins have so 
far been characterised to make any firm conclusions regarding this hypothesis at this 
time. 
Using the information gained in this chapter, we predict that the cyclases ForD, ForL 
and ForR are essential for forming the pentacyclic fasamycin scaffold, with ForL being 
the most likely candidate for closure of ring B.  The ABM proteins ForS and ForU 
function as chaperones that support the cyclisation process.  ForD, ForL, ForR and 
ForU likely form a multi-enzyme complex where the presence of all enzymes is 
necessary for any one of them to function.  This complex may engulf the entire 
formicamycin polyketide during cyclisation to form the pentacyclic scaffold.  ForS is 
important for the final step in the cyclisation of the fasamycin scaffold and reduces 
the formation of the less bioactive formicapyridine shunt metabolites.  ForU also 
appears to play a role as a chaperone protein and its function may be linked to the 
functionality of the halogenase, ForV.  More information is needed to further confirm 
the roles of these ABM family proteins, such as coexpression of the proteins for in 
vitro biochemistry studies, however, this work provides much information about the 
biosynthesis of the fasamycins, formicamycins and formicapyridines in S. formicae as 
well as indicating potential roles of ABM family proteins in other T2PKS pathways 
(Qin et al., 2019).   
6.3 Engineering highly efficient strains of S. formicae that overproduce specific 
pathway products 
 
Using the knowledge of fasamycin, formicamycin and formicapyridine biosynthesis 
gained above in combination with previous biosynthetic and regulatory data 
presented earlier in this thesis, we hypothesised that it would be possible to generate 
mutant strains of S. formicae with enhanced biosynthetic efficiency that could 
specifically produce pre-defined pathway products.  For example, we know from 
previous work that removing the major repressor of the pathway, ForJ, results in 
increased expression of the biosynthetic machinery and therefore increased titres of 
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formicamycins in the culture extracts.  Furthermore, experiments conducted by Dr 
Zhiwei Qin at the JIC show that S. formicae DforJ also produces two new 
formicamycin congeners, represented by the additional peaks on the HPLC trace (28 
and 29) (Figure 6.15).   
 
Figure 6.15: Reconstituted HPLC-UV at 280 nm in culture extracts of S. formicae DforJ.  Previously in 
this thesis, deletion of the pathway repressor, forJ, has have been shown to cause accumulation of 
high levels of formicamycin congeners in the culture extract of the mutant compared to the wild-type 
strain.  However, in addition to the known formicamycin congeners (1-12) two new peaks were visible 
of the HPLC trace (28,29).  HPLC (UV) LCMS conducted by Dr Zhiwei Qin. 
When cultures of S. formicae DforJ were scaled up, small amounts (approximately 2 
and 7 mg) of the two compounds were isolated and their structure solved by NMR 
by Dr Zhiwei Qin.  This showed that the peaks represent new formicamycin 
congeners with additional chlorination sites on the carbon backbone (Figure 6.16). 
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Figure 6.16: S. formicae DforJ was cultured at large scale (4L MYM agar) and compounds extracted for 
structural elucidation by NMR by Dr Zhiwei Qin.  This showed that the new peaks represented two 
new formicamycin congeners, formicamycin N (28) and formicamycin O (29) that have five chlorine 
atoms on the carbon scaffold.  
These new formicamycin congeners are chlorinated at five positions on the carbon 
backbone, where previously isolated congeners have a maximum of four chlorine 
moieties present on the molecule.  We have shown that ForV can halogenate 
multiple positions on the formicamycin backbone as well as several other aromatic 
substrates.  The overexpression of the formicamycin pathway caused by deletion of 
forJ likely results in the accumulation of formicamycins to high titres as well as 
increased levels of biosynthetic enzymes, including the halogenase ForV, in the 
cellular environment.  As such, the halogenase is likely to chlorinate at these 
additional positions that are perhaps less energetically favourable and therefore do 
not occur when substrate and/or enzyme concentrations are lower in the wild-type 
strain.  Currently we do not know whether these additional chlorine moieties 
increase the bioactivity of formicamycins N and O compared to the previously 
isolated molecules, however this will be investigated in the future. 
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Based on the above observation, we hypothesised that by combining the deletion of 
the pathway repressor with multiple biosynthetic mutations presented earlier in this 
thesis, we could generate strains of S. formicae that would over-produce either 
fasamycins, formicapyridines or the lactone intermediates, depending on which 
biosynthetic genes were deleted.  In addition, the overexpression of the pathway in 
combination with these biosynthetic mutations may also encourage the production 
of additional novel congeners by increasing the occurrence of energetically less 
favourable reactions.  As such, S. formicae DforJ was subjected to further genetic 
manipulation using the pCRISPomyces-2 system to generate S. formicae DforJ DforV, 
a strain lacking the major pathway repressor and the halogenase.  Extracts of three 
biological replicates of this mutant were analysed by HPLC(UV)/LCMS by Dr Zhiwei 
Qin and Hannah McDonald.   As expected, S. formicae DforJ DforV, overproduced 
specifically the non-halogenated fasamycin C (1) to approximately 3 times the level 
of the S. formicae DforV single mutant (Figure 6.17).  No new congeners were 
isolated from this experiment, further confirming our hypothesis that ForV acts on 
the fasamycin backbone early in the biosynthesis and performs a gatekeeper 
function to allow progression of the pathway. 
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Figure 6.17: Reconstituted HPLC-UV at 280 nm in culture extracts of (A) wild-type S. formicae; (B) S. 
formicae DforV; (C) S. formicae DforJ DforV.  As shown previously, deletion of forV results in only the 
production of the non-halogenated fasamycin C (compound 1).  When combined with the deletion of 
the pathway repressor,  forJ, deletion of forV results in accumulation of compound 1 to approximately 
286% of the wild-type strain.  HPLC (UV) LCMS conducted by Dr Zhiwei Qin and 
quantification/integration conducted by Hannah McDonald. 
Next, the S. formicae DforJ strain was used to generate S. formicae DforJ DforX, a 
strain lacking the major repressor and the Baeyer-Villiger monooxygenase.  The 
single deletion mutant, S. formicae DforX generated only fasamycins, therefore we 
expected this strain to be a specific fasamycin over-producer.  The extracts of three 
biological replicates of this mutant were quantitatively analysed by HPLC(UV)/LCMS 
by Dr Zhiwei Qin and Hannah McDonald.  The resulting strain produced titres of 
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fasamycins that were approximately 6 times higher than that of the wild-type.  This 
staggering increase in fasamycin accumulation also highlighted the presence of 
other, new peaks which had not been seen in previous experiments (Figure 6.18).     
 
Figure 6.18: Reconstituted HPLC-UV at 280 nm in culture extracts of (A) wild-type S. formicae; (B) S. 
formicae DforX; (C) S. formicae DforJ DforX.  As shown previously, deletion of forX results in only the 
production of fasamycins C-E (compounds 1-3).  When combined with the deletion of the pathway 
repressor,  forJ, deletion of forX results in accumulation of fasamycins to approximately 596% of the 
wild-type strain.  There also appears to be other peaks present in the extracts of S. formicaeDforJ 
DforX that do not appear in the single mutant.  HPLC (UV) LCMS conducted by Dr Zhiwei Qin and 
quantification/integration conducted by Hannah McDonald. 
 
0
200
400
600
800
1000
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
0
200
400
600
800
1000
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
0
200
400
600
800
1000
0 5 10 15 20
Ab
so
rb
an
ce
 (m
AU
) x
10
00
Retention time (mins)
1 43
13
12
6-112 5
1 2
3
3
2
A
B
C
1
36
37
30
31
32
33
34
35
 225 
As a result, S. formicae DforJ DforX fermentations were scaled up and the extracts 
were further analysed by HPLC and LCMS to identity the masses and predicted 
molecular formulae for each compound represented by these new peaks (Table 6.3).  
The masses imply that these new peaks represent a range of novel fasamycin 
congeners in addition to fasamycins C-E (1-3) that have been described previously in 
this thesis.  Six of the eight new fasamycin congeners (30-35) were produced in high 
enough levels that they could be isolated from these large-scale cultures and their 
structures elucidated by NMR by Dr Zhiwei Qin (Figure 6.19).  The remaining two 
compounds (36 and 37) are also predicted to be fasamycins, however, this is 
unconfirmed at this point as the yield of these compounds was too low to enable 
structural elucidation. 
Table 6.3: Cultures of S. formicae DforJ DforX were scaled up and the mass of each new peak was 
calculated using mass spectrometry.  The predicted molecular formulae suggest that S. formicae DforJ 
DforX produces the known fasamycins C-E (1-3) along with 8 novel fasamycin congeners.  LCMS 
conducted by Dr Zhiwei Qin. 
Compound number Compound name Molecular mass Molecular formula 
1 Fasamycin C 473 C28H24O7 
2 Fasamycin D 507 C28H23O7Cl 
3 Fasamycin E 540 C28H22O7Cl2 
30 Fasamycin G 574 C28H21O7Cl3 
31 Fasamycin H 574 C28H21O7Cl3 
32 Fasamycin I 574 C28H21O7Cl3 
33 Fasamycin J 588 C29H23O7Cl2 
34 Fasamycin K 608 C28H20O7Cl4 
35 Fasamycin L 608 C28H20O7Cl4 
36 Unknown 538 C28H20O7Cl2 
37 Unknown 572 C28H19O7Cl3 
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Figure 6.19: Nine fasamycin congeners were produced in high enough titres from S. formicae DforJ 
DforX, that they could be isolated for structural elucidation by NMR by Dr Zhiwei Qin.  Three of the 
congeners were the previously known fasamycins C-E.  The other 6 compounds produced by S. 
formicae DforJ DforX were novel fasamycin congeners G-L which have not been described previously.  
The new fasamycin congeners display halogenation at additional positions along the 
fasamycin backbone that has not been seen in previously isolated fasamycins.  As 
discussed previously, ForV can halogenate the fasamycin and formicamycin 
backbone at multiple positions on the carbon chain.  The overexpression of the 
formicamycin BGC caused by deletion of forJ will lead to both accumulation of 
fasamycins and increased levels of ForV.  As ForX is also removed in this strain, these 
extra fasamycin precursors cannot progress through the pathway for conversion into 
a formicamycin.  As such, the fasamycin precursors that accumulate are more likely 
to encounter high levels of the halogenase which will start to chlorinate at additional 
positions on the carbon backbone.  In addition, fasamycins H and K represent the 
only compounds isolated from the formicamycin BGC that do not contain a methyl 
group at the base of ring A.  Work in the previous chapter predicted that ForM was 
the enzyme responsible for this reaction and concluded that methylation at this 
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position occurred early in the biosynthesis as no congeners had been isolated 
without this moiety and deletion of forM abolished the production of all previously 
known fasamycin and formicamycin congeners.  The discovery of these new 
compounds that lack this moiety is not necessarily converse to this theory; we 
propose that whilst clearly not essential, methylation by ForM occurs early in the 
biosynthesis of the formicamycins.  The overexpression of the formicamycin BGC in  
S. formicae DforJ DforX will mean that fasamycin precursors accumulate much more 
rapidly in this strain than in the wild-type and it is possible that ForM, even though 
likely overexpressed itself, is overwhelmed by all the additional substrates, meaning 
that some intermediates are shunted further down the pathway, missing this step of 
the biosynthesis.  These two congeners also display chlorination on ring A, an 
addition that has not been seen on any previously described fasamycins or 
formicamycins.  It may be that normally the methyl group would prevent chlorination 
at this position and in its absence, ForV is able to add a chlorine to this position.  All 
of the new fasamycin congeners contain the di-methylation on ring D like all other 
metabolites isolated from this pathway, confirming our previous hypothesis that this 
is essential for fasamycin and formicamycin biosynthesis.  Furthermore, none of 
these new fasamycins are methylated on ring B, which agrees with our previous 
hypothesis that methylation here is part of the conversion of a fasamycin to a 
formicamycin.  Due to the deletion of forX, this cannot occur in this double mutant 
as the pathway is stopped at fasamycin biosynthesis.   
Using the same method of combining mutations, we also demonstrate that a mutant 
of S. formicae that overproduces the lactone intermediates can be generated by 
deleting the oxidoreductase gene in combination with DforJ to form the strain S. 
formicae DforJ DforY.  HPLC(UV)/LCMS analysis of this mutant by Dr Zhiwei Qin shows 
that no fasamycins, formicamycins or formicapyridines are produced, only the 
lactone intermediates, which accumulated to significantly higher titres than in the S. 
formicae DforY strain (Figure 6.20).   
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Figure 6.20: Reconstituted HPLC-UV at 280 nm in culture extracts of (A) wild-type S. formicae; (B) S. 
formicae DforY; (C) S. formicae DforJ DforY.  As shown previously, deletion of forY results in only the 
production of the lactone intermediates (a-f).  When combined with the deletion of the pathway 
repressor,  forJ, deletion of forY results in accumulation of the lactone intermediates.  HPLC (UV) LCMS 
conducted by Dr Zhiwei Qin. 
Finally, we aimed to generate a strain of S. formicae that could overproduce the 
formicapyridines.  When studying the roles of the cyclase enzymes above, deletion 
of forS resulted in up-regulation of the formicapyridines and a significant reduction 
in the production of the fasamycin and formicamycin congeners (Chapter 6.2).  The 
double mutant S. formicae DforJ DforS was generated and extracts analysed by 
HPLC(UV)/LCMS by Dr Zhiwei Qin (Figure 6.21).  The results show that the strain S. 
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formicae DforJ DforS overproduces formicapyridines at much higher levels than the 
single DforS mutant.   
 
Figure 6.21: Reconstituted HPLC-UV at 390 nm in culture extracts of (A) wild-type S. formicae; (B) S. 
formicae DforS; (C) S. formicae DforJ DforS.  As shown previously, deletion of forS results in increased 
production of formicapyridines 18-23.  When combined with the deletion of the pathway repressor 
gene,  forJ, deletion of forY results in further accumulation of the formicapyridines.  HPLC (UV) LCMS 
conducted by Dr Zhiwei Qin. 
This library of strains that can specifically over-produce various biosynthetic 
congeners, intermediates and shunt metabolites from the formicamycin pathway 
can be used in the future to isolate high titres of individual compounds for further in 
vitro work.  This work has also led to further novel fasamycin and formicamycin 
congeners being isolated from S. formicae and the for BGC.  Furthermore, preliminary 
analysis suggests that S. formicae DforJ DforX produces the new fasamycin congeners 
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during liquid culture in TSB medium (Table 2.1) (personal communication with Dr 
Zhiwei Qin, March 2019).  It is currently unknown whether all the double mutants 
generated here can produce compounds during liquid culture but this will be the 
subject of further investigation in the Wilkinson laboratory.  If these strains do all 
produce during liquid fermentation, they could be very attractive for the industrial 
production of these clinically relevant natural products. 
6.4 The proposed fasamycin, formicamycin and formicapyridine biosynthesis 
pathway in S. formicae 
 
Using the data described above in combination with the biosynthetic data collected 
throughout this thesis, we are now able to propose a complete and detailed 
biosynthetic pathway for the fasamycins, formicamycins and formicapyridines.  
Condensation of acetyl-CoA by the ACC carboxylase enzymes, ForH and ForI, results 
in the formation of the malonyl-CoA extender units required for polyketide chain 
formation.  Feeding data described previously (chapter 3.4) shows that these 
multiple malonyl-CoA starter units are condensed, presumably by the combined 
actions of the minimal PKS, ForA, ForB and ForC as well as ForE, to form a 
tridecaketide intermediate (17).  We predict that this intermediate then enters the 
multi-enzyme complex formed by ForD, ForL, ForR and ForU for sequential cyclisation 
to form a pentacyclic structure, with the aid of the chaperone ForS to increase 
pathway efficiency.  Based on bioinformatic analysis above we predict that ring A is 
closed first, followed by rings E and D, which are cyclised by ForD.  Cyclisation of ring 
C likely occurs next, followed by formation of ring B, a reaction which is probably 
catalysed by ForL.  It is thought that the methyltransferase ForT acts next, possibly 
as part of the multi-enzyme complex or closely linked, to catalyse the addition of the 
di-methyl group on ring C, as all isolated metabolites from the formicamycin BGC 
contain this moiety.  The cyclised, di-methylated pentacyclic intermediate produced 
by the cyclase/methyltransferase complex is then cleaved from the ACP by the 
actions of ForN followed by decarboxylation (either spontaneous or catalysed by 
ForQ) with the aid of ForS, to form fasamycin C.  During the process of cyclisation and 
decarboxylation, some intermediates can undergo spontaneous side-reactions to 
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generate shunt metabolites like the formicapyridines.  The formicapyridines can be 
halogenated by ForV and O-methylated at various positions on the carbon chain.  The 
pathway products are next likely O-methylated by ForM after cyclisation and 
liberation from the ACP, as both fasamycins and formicamycins are usually O-
methylated at the base of ring A and deletion of this enzyme abolishes the production 
of any congeners, implying it works closely with the core multi-enzyme complex to 
produce the non-halogenated fasamycin C.   
The fasamycin C formed by the above reactions can then be brought to ForV for 
halogenation, perhaps by the chaperone ForU.  The activity of ForV activates 
molecular oxygen to generate hydroperoxy flavin that is used by the Baeyer-Villiger 
monooxygenase, ForX, to convert the fasamycin precursors into the lactone 
intermediates (Chapter 5.2).  We predict that the lactone intermediates are then O-
methylated on ring B by ForW, generating the highly reactive intermediate for 
reduction by ForY and conversion of the lactone intermediates into the formicamycin 
backbone.  Formicamycins A and B can then be further halogenated by ForV to form 
the full family of formicamycin congeners seen in extracts of wild-type S. formicae 
(Figure 6.22).   
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Figure 6.22 (see following page for figure legend) 
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Figure 6.22 (previous): Schematic of the full fasamycin, formicamycin and formicapyridine 
biosynthetic pathway in S. formicae.  The malonyl-CoA starter units synthesised by ForH and ForI are 
used to by ForA, ForB, ForC and ForE to assemble the polyketide chain.  This is cyclised by ForD, ForR, 
ForL, ForS and ForU and di-methylated by ForT to form the core carbon scaffold.  This is then released 
from the ACP and decarboxylated either spontaneously or by ForQ to form fasamycin F.  During this 
process, ForM can methylate ring A.  Shunt metabolites like the formicapyridines can also be formed 
during this stage of the biosynthesis due to a leaky pathway.  Both the fasamycins and the 
formicapyridines generated at this stage of the biosynthesis can be halogenated by ForV at multiple 
positions on the carbon chain (R1-R4).  The formicapyridines can also be O-methylated by one of the 
methyltransferase enzymes encoded in the pathway at R5, either ForM or ForW.  During the 
halogenation of the fasamycins and formicapyridines, activated molecular oxygen is generated in the 
form of the flavin hydroperoxide that is used by the Baeyer-Villiger ForX to form the lactone 
intermediates.  These are then predicted to be O-methylated by ForW to generate a reactive 
intermediate for reduction by ForY, forming the formicamycin backbone.  This formicamycin backbone 
can then be further halogenated by ForV to generate the full family of congeners. 
Further work is currently being conducted in the Wilkinson laboratory to build the 
formicamycin pathway in a heterologous host a single enzyme unit at a time.  As well 
as providing a platform to reconstruct the formicamycin pathway to generate further 
novel analogues, this work will provide more information about how these enzymes 
function together in the native pathway and provide more evidence to support the 
proposed biosynthetic pathway outlined above.   
6.5 Discussion 
 
This chapter aimed to further elucidate the formicamycin biosynthetic pathway and 
has resulted in a much greater understanding of the functions of many of the 
enzymes encoded by the formicamycin BGC.  Furthermore, using targeted 
metabolomics, we have identified a new family of pyridine containing polyketide 
natural products from the formicamycin BGC, showing that this single T2PKS pathway 
can synthesise three distinct but related families of compounds; the fasamycins, the 
formicamycins and the formicapyridines.  The results presented here show that the 
production of this complex mixture of secondary metabolites occurs via a multi-step 
pathway that consists of several routes for the production of bi-products and shunt 
metabolites like the formicapyridines.  Many of the enzymes involved in 
formicamycin biosynthesis appear to interact, with the activity of one affecting the 
function of another.  For example, the cyclase enzymes, ForD, ForL, ForR and ForU 
appear to function as a multi-enzyme complex, as deletion of one abolishes the 
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biosynthesis of any products or intermediates.  Accessory enzymes like the 
halogenase, ForV and the methyltransferase, ForT also appear to interact with 
enzymes from this complex or other chaperones that function closely with this multi-
enzyme structure.  The importance of multi-enzyme interactions is well recognised 
in modular systems such as T1PKS pathways and is generally accepted as being 
fundamental for the proper progression of these biosynthetic pathways (Tran et al., 
2010; Robbins et al., 2016; Dodge, Maloney and Smith, 2018; Kosol et al., 2018).  In 
iterative systems like the T2PKSs, interactions between domains of the ketosynthase 
enzymes are well characterised, but protein-protein interactions between the 
tailoring enzymes are less well recognised.  Type 2 polyketide biosynthesis is related 
to Type 2 fatty acid biosynthesis, where the ACP performs the central role for 
recognition by the multiple biosynthetic enzymes (Chen, Re and Burkart, 2018).  
While the ACP has been shown to play an important role in substrate recognition in 
other T2PKS pathways during the early stages of biosynthesis, mainly by the KS, we 
believe that some of the enzymes involved in methylation and cyclisation of the 
formicamycin backbone recognise substrates that have already been liberated from 
the ACP.  This suggests that other proteins encoded within the formicamycin 
biosynthetic pathway are likely responsible for the coordination of the actions of 
these multiple enzyme units instead.   
Many complex pathways like the formicamycin biosynthesis pathway encode for 
dedicated chaperone proteins that help direct nascent intermediates into defined 
reaction channels in order to synthesise more of the desired final product and less of 
the shunt metabolites (Hertweck et al., 2007).  Through our investigations into the 
functions of the putative cyclase enzymes encoded by the formicamycin pathway, 
we have highlighted the importance of chaperones in the formicamycin biosynthetic 
pathway, particularly ForS, the putative ABM, that appears to act as a chaperone 
during the cyclisation of the polyketide backbone and the formation of the 
pentacyclic fasamycin scaffold.  Mutational analysis showed that ForS is not essential 
for the biosynthesis of the fasamycins and formicamycins, but removal of this 
enzyme reduces the efficiency of the pathway, resulting in less of the desired final 
products and the generation of higher levels of shunt metabolites.  There is also 
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evidence in this thesis that the function of the halogenase ForV, may be dependent 
on an additional chaperone or carrier that so far remains unidentified. 
Whilst the formicapyridines do not display significant antibacterial activity, their 
discovery provides significant knowledge about the formicamycin biosynthetic 
pathway.  Furthermore, they represent novel structures and nitrogen containing 
compounds from T2PKS pathways are relatively rare.  Those examples that do exist 
in the literature have been shown to have cytotoxic activity and therefore the 
potential anticancer activity of the formicapyridines will be investigated in the future.  
The biosynthetic studies presented in this chapter also led to the discovery of 10 new 
fasamycin congeners and 2 new formicamycin congeners that have not previously 
been isolated from either the formicamycin BGC or any other fasamycin pathways in 
the database.  Due to time limitations, we are yet to identify whether these new 
congeners display any bioactivity, however, it is assumed that these metabolites will 
display similar bioactivities to the previously isolated fasamycin and formicamycin 
congeners due to their significant structural similarity.  It will be interesting to 
determine whether the additional halogenation and methylation on these new 
congeners increases the potency of the compounds.  These future bioactivity studies 
will be made easier due to the development of a library of S. formicae mutants that 
produce high titres of specific pathway products and intermediates.  These strains 
can be used to isolate large quantities of compound for use in in vitro studies.  
Furthermore, there is potential for these strains to be used in industry for the 
production of these clinically relevant compounds, particularly if we are able to show 
that they consistently produce during liquid culture. 
This work highlights the importance of multi-enzyme interactions in the biosynthesis 
of complex, polycyclic natural products.  Over the course of evolution, intricate 
systems have developed within the formicamycin biosynthetic pathway that tightly 
control the cyclisation of the extended polyketide backbone and the subsequent 
tailoring steps that occur.  By suppressing undesirable, spontaneous cyclisation 
reactions that might generate shunt metabolites and other minor congeners, nature 
can ensure that the desired secondary metabolites are generated with the highest 
efficiency by the host microorganism.  This work also shows that by genetically 
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manipulating biosynthetic pathways, not only can we learn about how these 
secondary metabolites are synthesised in vitro, but we can generate increased 
chemical diversity from these pathways and encourage the biosynthesis of 
‘unnatural’ natural products that are either not made by the wild-type strain, or are 
made at levels that are too low for isolation and structural elucidation.    
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7 Conclusions and further work 
 
7.1 Characterising the biosynthesis of the novel antibiotics, the formicamycins, 
in Streptomyces formicae 
 
The aim of this work was to begin characterising antibiotic production in 
Streptomyces formicae, a novel strain isolated from a fungus-farming plant ant nest.  
The genome sequence of S. formicae revealed that it is a talented strain, with at least 
45 secondary metabolite BGCs, many of which appear novel and display low 
homology to other BGCs in the database.  Prior to the start of this project, previous 
work from the Hutchings and Wilkinson laboratories had shown that S. formicae 
produces metabolites with antibacterial and antifungal activity under normal 
laboratory conditions, including the novel pentacyclic polyketides, the 
formicamycins.  However, little was known about the biosynthesis of these molecules 
and no attempts to genetically modify the organism had been made.  During the 
course of this project, a CRISPR-Cas9 platform for the efficient genetic engineering of 
S. formicae was developed and optimized, allowing numerous mutants to be 
generated for biochemical studies.  Using these protocols, we demonstrate that a 
single T2PKS BGC in S. formicae is responsible for the biosynthesis of three groups of 
natural products; the fasamycins, the formicamycins and the formicapyridines.  We 
have characterised the functions of most of the biosynthetic enzymes encoded by 
this BGC, a process which has revealed additional novel intermediates and shunt 
metabolites, as well as shedding light on the biosynthesis of both the formicamycins 
and other related aromatic type 2 polyketides.  
Biosynthetic pathways are often perceived as direct and linear routes that result in a 
single defined end-product, but most secondary metabolite pathways are actually 
significantly more complex.  Like the formicamycin pathway, some BGCs encode for 
the production of multiple related structures, for example the T1PKS BGC in S. 
venezuelae that is responsible for the biosynthesis of the 12-membered ring 
macrolides methymycin and neomethymicins as well as the 14-membered ring 
macrolides narbomycin and pikromycin.  In this case, the ability to produce multiple 
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structures is due to the ability of the pathway to terminate the polyketide chain at 
two different points of assembly, resulting in two macrolactones of different sizes 
(Xue et al., 1998).  In the formicamycin BGC, the production of a mixture of these 
three distinct compounds seems to be the result of a complex multi-step biosynthetic 
pathway that is prone to the build-up of precursors, intermediates and 
spontaneously generated side-products.  Fasamycins A and B were previously 
isolated from environmental DNA, however fasamycins C-E, as well as the 
formicamycins and the formicapyridines from S. formicae, represent novel structures 
(Feng, Kallifidas and Brady, 2011; Qin et al., 2017).  Our evidence suggests that the 
fasamycins are the biosynthetic precursors of the more bioactive formicamycins.  
Through a collaborative project with Dr Zhiwei Qin in Prof Barrie Wilkinson’s group 
at the JIC, we identified the biosynthetic link between these distinct but related 
compound families.  Our results describe a novel ring-expansion, ring-contraction 
mechanism via a Baeyer-Villiger monooxygenase and an oxidoreductase that 
converts the fasamycin precursor to the formicamycin.  This work also led to the 
isolation and characterisation of five bioactive lactone intermediates that also 
originate from the formicamycin BGC.  As part of the same project, we were able to 
propose a mechanism for the evolution of the formicamycin BGC from a fasamycin 
BGC, by the horizontal gene transfer of four genes encoding the monooxygenase, the 
oxidoreductase, a MarR regulator and an MFS family transporter.  In addition to the 
eDNA isolated from the metagenomics study in Arizona that has been shown to 
produce fasamycins A and B, we propose that another actinomycete, S. 
kanamyceticus, also contains a fasamycin BGC, but this is yet to be experimentally 
confirmed.  A search of the database implies that S. formicae is the only genome 
sequenced strain that has the potential to make both fasamycins and formicamycins.   
We have also characterised the role of the putative cyclase enzymes encoded within 
the BGC, as well as the methyltransferases involved in formicamycin biosynthesis.  
We have demonstrated that the majority of the core biosynthetic machinery 
functions as a multi-enzyme complex, where the presence of all the enzyme 
components is necessary to generate any products or intermediates.  In addition, we 
have highlighted the importance of chaperone proteins, particularly ABMs that direct 
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the biosynthetic pathway and guide nascent intermediates for the most efficient 
production of the main pathway products.  Antibiotic production by microorganisms 
comes at an expense and therefore secondary metabolite pathways evolve to 
become highly efficient in order to produce only those metabolites with the highest 
bioactivities that will provide the greatest competitive advantage.  In the case of the 
formicamycin BGC, this is predicted to be through the development of dedicated 
chaperone proteins that guide nascent intermediates from one enzyme to the next, 
reducing the spontaneous generation of less bioactive side-products like the 
formicapyridines.  Multi-enzyme interactions are well established in linear systems 
like the T1PKSs, however, understanding of more complex iterative pathways like the 
formicamycin BGC often fall behind.  Our work shows that the communication 
between these multiple enzymes goes beyond the recognition of the ACP and often 
involves dedicated proteins or protein subunits that coordinate these protein-
protein interactions.  Furthermore, we have shown that the single halogenase 
encoded within the BGC is able to chlorinate and brominate at multiple positions on 
the formicamycin backbone, as well as other aromatic substrates.  The halogenase 
also plays a gatekeeper role in controlling the progression of the biosynthetic 
pathway from fasamycin biosynthesis to formicamycin production.  This is also 
predicted to be depended on interactions with other biosynthetic enzymes encoded 
in the cluster, providing more evidence that progression of formicamycin 
biosynthesis pathway relies on protein-protein interactions, this time coordinated by 
a common flavin ligand.   
The fasamycins and formicamycins display potent antibacterial activity against Gram-
positive pathogens including drug-resistant clinical isolates as well as membrane 
permeabilised Gram-negative strains.  The work in this thesis shows that the 
fasamycins and formicamycins are able to inhibit the activity of bacterial 
topoisomerase enzymes in vitro.  In contrast, the formicapyridines do not display 
significant bioactivity, showing that ring B is an important part of the core 
pharmacophore involved in inhibition of topoisomerases.  Previous work suggests 
that the tricyclic chloro-gem-dimethyl-anthracenone sub-structure is responsible for 
the inhibition of fatty acid biosynthesis by the antibacterial agents, fasamycins A/B 
 240 
and BABX (Feng et al., 2012). This evidence, in addition to the lack of resistance 
developed in MRSA during previous work, led us to hypothesise that the fasamycins 
and formicamycins from S. formicae may be able to inhibit two distinct intracellular 
targets; DNA topoisomerases and fatty acid synthases.  For this reason, we propose 
that these compounds represent a promising new group of antimicrobials for clinical 
development.  By inhibiting two distinct molecular targets, the development of 
resistance in the clinic would be reduced and the compounds could be used to treat 
infections that are already resistant to currently available antibiotics.  
The genetic tools developed during this thesis were also applied to the cluster 
situated regulators within the formicamycin BGC.  Thus, we have begun to 
understand the complex regulatory cascade responsible for controlling both the 
biosynthesis of formicamycins and the host resistance mechanisms in S. formicae.  A 
single MarR regulator, ForJ, is predicted to repress the majority of the biosynthetic 
genes in the formicamycin BGC.  Activation of formicamycin biosynthesis is 
controlled by the TCS ForGF, which is predicted to induce production of the malonyl-
CoA starter units required for polyketide biosynthesis, however, the activation signal 
for the ForG sensor kinase is currently unknown.  Our evidence also suggests that the 
other MarR regulator encoded within the BGC, ForZ, controls the expression of the 
host-resistance mechanism in response to accumulating levels of products from the 
pathway.  By applying next generation sequencing technologies, we have also 
characterised the transcriptional organisation of the for BGC as well as mapping the 
transcriptional start sites across the genome for those genes that are expressed 
under formicamycin producing conditions.  As well as the for BGC, the genes 
encoding the production of the antifungal compounds that are made by S. formicae 
were also likely expressed during this experiment, as these are usually also visible 
when culture extracts are analysed by HPLC(UV), therefore we may be able to use 
this data for further characterisation of another BGC in the future.   
Overall, the work in this thesis has begun to provide a detailed understanding of the 
biosynthesis of novel antibiotics from S. formicae, with a focus on the biosynthesis of 
metabolites encoded by the for BGC.  Through the extensive genetic manipulation of 
the pathway, we have been able to put forward a detailed proposed biosynthetic 
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pathway with the functions of most of the gene products described.  This 
comprehensive knowledge of formicamycin biosynthesis can inform future drug 
discovery efforts by both natural products chemists and synthetic chemists.  Using 
the combined knowledge of formicamycin biosynthesis and regulation, we generated 
a library of S. formicae strains that produce high titres of specific pathway products 
that can be used in the future for multiple applications.  Furthermore, the genetic 
manipulation of the for BGC enabled the discovery of further novel natural products 
that were not present in the extracts of the wild-type strain, such as biosynthetic 
intermediates and the novel fasamycin and formicamycin congeners generated 
when high levels of precursors accumulate and get shunted through alternative 
biosynthetic routes. This project highlights the huge potential of genetic engineering 
of novel environmental isolates in the discovery of novel, clinically relevant natural 
products. 
Whilst this work represents significant progress towards characterising antibiotic 
production in S. formicae, a great deal of novel biochemistry still remains to be 
discovered from this strain.  The compounds studied during this work originate from 
just one of the 45 BGCs within the genome, many of which look novel.  Analysis of 
culture extracts of S. formicae grown under standard laboratory conditions shows 
the presence of multiple peaks, some of which correspond to compounds from the 
for BGC and some of which have been shown by bioassay guided fractionation to 
represent the antifungal compound(s) (Figure 1.2).  These antifungal compounds 
have potent activity against the multi-drug resistant Lomentospora prolificans.  L. 
prolificans is an emerging human pathogen and there are currently no clinically 
approved treatments for systemic infections with this agent.  Therefore, we predict 
that any compounds with activity against this fungus are likely to have novel 
structures and novel mechanisms of action.  Mass spectrometry analysis indicates 
that the antifungal activity may be due to a mixture of polyenes, however, attempts 
to isolate and purify the antifungal compounds to solve their three-dimensional 
structure have so far been unsuccessful.  The compounds co-elute and even after 
fractionation, the properties of the compounds change after relatively short periods 
of time.  This could be due to degradation or it could be conformational if the 
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compounds are able to switch between different states.  The priority now is to 
identify the BGC encoding for these compounds.  Polyene antifungal compounds like 
nystatin and candicidin often originate from T1PKS BGCs (Seipke et al., 2012).  Due 
to the modular architecture of T1PKS BGCs, once the cluster is identified, it may be 
possible to predict the structure from the sequence and modules present.  
Furthermore, we could then use the protocols developed during this thesis to 
genetically modify the cluster to subtly change the structure of the compound(s) 
produced and therefore make them easier to isolate and purify.   
7.2 The potential for the discovery of more novel natural products from 
Streptomyces formicae 
 
In addition to the antifungal compounds, there is significant potential for the 
discovery of many more natural products from S. formicae.  Many of the other BGCs 
in the S. formicae genome look promising as a potential source of novel antimicrobial 
compounds, as several have less than 10% homology to known BGCs in the database, 
according to AntiSMASH.  The hope is that because most of the BGCs encoded within 
the genome look novel, any new compounds isolated from the strain will have novel 
structures and may therefore be valuable in the treatment of drug-resistant 
infections.  The low homology to other BGCs in the database means it can be 
challenging to predict the structures of the products synthesised by the proteins 
encoded, however, there are some BGCs that look like interesting candidates for 
further investigation.  For example, two putative peptide synthetase modules within 
cluster 5 show homology to the daptomycin peptide synthetases. Daptomycin is a 
potent antimicrobial that acts via the physical perforation of the cell membrane.  As 
such, it is more challenging for pathogens to develop resistance to daptomycin, 
making it a valuable treatment against drug-resistant infections (Hur, Vickery and 
Burkart, 2012).  According to AntiSMASH, the putative proteins encoded by S. 
formicae show approximately 50% coverage and identity to the synthetases in 
daptomycin biosynthesis, implying the core peptide products may be similar.  No 
structural predictions about the product can be made at this time, however, the 
accessory enzymes encoded in the S. formicae BGC are different to those in the 
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daptomycin BGC, implying that the overall structure of the compounds encoded 
could be significantly different, potentially representing a novel agent of this class 
(Figure 7.1).  In addition, NRPS genes within cluster 31 show high homology to the 
core NRPS genes from the BGCs encoding for feglymycin, teicoplanin and balhimycin 
biosynthesis, therefore we predict that this BGC encodes a glycopeptide antibiotic 
(Figure 7.2).  Glycopeptides are rare and are also valuable in the fight against drug-
resistant infections because as well as often being active against Gram-negative 
pathogens, resistance often develops slowly to these compounds due to their ability 
to inhibit cell wall biosynthesis by binding to cell wall precursors rather than 
transpeptidase enzymes (Yim et al., 2014).  Characterising the molecules produced 
by these biosynthetic pathways is important in order to discover more novel 
antimicrobials from this talented strain. 
  
Figure 7.1: AntiSMASH analysis shows that 15% of the genes in BGC 5 in S. formicae show similarity to 
genes from within the daptomycin BGC.  Much of the similarity lies within the core NRPS genes, shown 
in purple, implying that the core peptide structures may be similar. 
 
Figure 7.2: AntiSMASH analysis shows that core NRPS genes encoded in BGC 31 in S. formicae show 
significant similarity to the NRPS genes in other glycopeptide BGCs.  Much of the similarity lies within 
the core NRPS genes, shown in pale green, implying that products may be structurally similar. 
During the course of this PhD project, some initial work has been conducted to begin 
to identify other novel compounds encoded in the putative BGCs in the S. formicae 
genome.  It was assumed that under standard laboratory conditions, all the BGCs 
except the formicamycin BGC and the antifungal BGC are silent or not expressed.  
Therefore, several pleiotropic and genotypic methods of switching on BGCs were 
trialled.  Media screens in both solid and liquid culture did not yield any significant 
BGC 5, S. formicae
Daptomycin BGC
15% of genes show similarity)
BGC 31, S. formicae
Feglymycin BGC
78% of genes show similarity)
Balhymycin BGC
45% of genes show similarity)
Teicoplanin BGC
33% of genes show similarity)
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changes to the secondary metabolite profile.  Including glass beads in the liquid 
medium before inoculation of S. formicae sporadically induces formicamycin 
production, however, this effect is variable and unreliable, so for the isolation of large 
amounts of formicamycin congeners, the use of mutants generated in this thesis 
remains the more attractive method.  RNA polymerase and ribosomal engineering 
using the antibiotics rifampicin and streptomycin have been shown in other 
actinomycetes to cause significant upregulation of expression of secondary 
metabolite genes, therefore we applied the same approach to S. formicae (Wang, 
Hosaka and Ochi, 2008; Hosaka et al., 2009).  For S. formicae, much higher 
concentrations of antibiotics than those used in the original studies had to be used 
because the strain appeared to possess some natural resistance to both antibiotics.  
Furthermore, the majority of the resistant isolates that were obtained did not 
contain mutations in the desired genes or DNA regions and showed no differences in 
secondary metabolite profiles.  We predict that due to the prolific biosynthetic 
potential of S. formicae, it will encode within its genome many host-resistance 
mechanisms and may therefore be able to evade toxicity to many antibiotic 
compounds, particularly those like rifampicin and streptomycin that also originate 
from Streptomyces species.  We therefore predict that these methods are unlikely to 
be a good way of encouraging antibiotic production in S. formicae.  Similarly, efforts 
were made to pleiotropically alter the expression of secondary metabolite BGCs by 
mutating the highly conserved TCS MtrAB, which has been shown previously by 
Nicolle Som (Hutchings laboratory) to increase antibiotic production in S. venezuelae 
(Som et al., 2017).  Whilst this method did lead to new peaks appearing in the culture 
extracts of S. formicae during analysis by HPLC/LCMS, different traces were evident 
on every LCMS run and with every biological replicate of each mutant strain (data 
not shown).  This implies that the disruption global regulators in talented strains like 
S. formicae has a dynamic effect on the secondary metabolism.  Due to the fact that 
the wild-type S. formicae already produces such a complex mixture of secondary 
metabolites under normal laboratory conditions, it can be difficult to identify new 
compounds in the extracts generated during pleiotropic studies like the ones 
described here.  These methods often result in changes to the expression of multiple 
BGCs across the genome, resulting in even more complex mixtures of products in the 
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culture extracts.  Therefore, we predict that targeted genetic approaches will be a 
more effective method for identifying novel secondary metabolites from this 
talented strain.  
Interestingly, deletion of the for BGC conducted in chapter 3.1, while abolishing the 
biosynthesis of all formicamycin congeners, did not abolish the antibacterial activity.  
HPLC(UV) results presented in this thesis clearly show that no fasamycin or 
formicamycin congeners are present in the extracts of S. formicae Dfor, however, 
when tested against Gram-positive strains like B. subtilis and MRSA, the zone of 
inhibition is actually consistently larger than the wild-type strain (Figure 7.3).   
 
Figure 7.3: Bioassays against Gram-positive strains B. subtilis and MRSA show that S. formicae Dfor 
generates much larger zones of inhibition than the wild-type strain, almost completely clearing a small 
9mm plate.  S. formicae Dfor does not produce any formicamycin congeners, therefore the 
metabolites must originate from another BGC within the genome. 
This implies that deletion of the formicamycin BGC induces the expression of another 
BGC elsewhere in the genome.  We predicted that this could be due to loss of cross-
cluster regulation through the deletion of the regulatory genes in the formicamycin 
BGC.  During the ChIP-sequencing experiment conducted in chapter 4, the MarR 
regulator ForJ and the response regulator ForF appeared to bind to the promoters of 
genes outside of the formicamycin BGC (chapter 4.3.1).  There are multiple examples 
 246 
where cluster-situated regulators from one BGC are involved in the regulation of 
another cluster elsewhere in the genome.  For example, JadR1 in Streptomyces 
venezuelae, the main activator of the jadomycin BGC, has also been shown to repress 
chloramphenicol biosynthesis (Xu et al., 2010; Chater, 2016).  We therefore 
hypothesised that either ForJ or ForF were responsible for the regulation of another 
BGC elsewhere in the genome that encodes for the production of an antimicrobial.  
If correct, removal of the formicamycin BGC in S. formicae Dfor would therefore 
remove this regulatory control and possibly induce expression of the alternative 
antimicrobial.  To test this theory, constructs containing each of the regulators, either 
ForJ or the TCS ForGF, were introduced into S. formicae Dfor in order to complement 
the loss of the regulatory elements without re-introducing formicamycin 
biosynthesis in the strain.  However, none of the complemented strains lost their 
bioactivity, with the resulting zones of inhibition against B. subtilis remaining the 
same as the S. formicae Dfor control (Figure 7.4).   
 
Figure 7.4: Bioassays against Gram-positive strain B. subtilis show that the increased bioactivity of S. 
formicae Dfor compared to the wild-type strain is not rescued on complementation with either forJ or 
forGF.  This implies that expression of the new BGC is not controlled by cross regulation from either 
of these cluster situated regulators from within the formicamycin BGC.   
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This suggests that neither ForJ or ForF are responsible for the cross-regulation of the 
BGC that is switched on in S. formicae Dfor.  It is possible that this increase in 
bioactivity is to do with the other TCS, ForBBCC, that is encoded at the edge of the 
for BGC, as this would have been included in the original whole-cluster deletion, 
before the cluster edges had been characterised.  It could also be that the loss of the 
formicamycin BGC induces expression of alternative BGC(s) elsewhere in the genome 
due to the increased availability of precursors and biosynthetic resources.  The 
biosynthesis of the formicamycins will be metabolically expensive for S. formicae and 
therefore the deletion of the BGC results in much less carbon and other resources 
being used by the cell.  These resources are then able to flux through alternative 
pathways, giving rise to the production of different secondary metabolites (Gomez-
Escribano and Bibb, 2011).  This will be investigated further in the future.  As yet, we 
have been unable to identify any peaks by either HPLC or LCMS that correspond to 
this antibacterial activity, however, the potent activity of this new antimicrobial 
against MRSA makes it a priority for further investigation.  
In addition to searching for the new antibacterial compound, further work has been 
done to try and identify the BGC responsible for the production of the antifungal.  
Without a structure of the compound(s), we are unable to identify which of the 45 
putative BGCs encoded within the genome are responsible for their production, 
however, we predict that the compounds originate from a T1PKS BGC.  There are 
multiple clusters in the S. formicae genome that show some characteristics of T1PKS 
genes, however, only clusters 30 and 33 contain significant repeated T1PKS modular 
genes that look like they may be capable of producing a polyene antifungal.  
According to AntiSMASH analysis, cluster number 33 shows 54% similarity to the 
lasalocid BGC.  Cluster number 30 shows 46% similarity to the filipin BGC, 27% 
similarity to nystatin and 28% similarity to candicidin, implying it might be more likely 
to synthesise a polyene antifungal (Figure 7.5).  We know that the antifungals are 
produced under the same laboratory conditions as the formicamycins and therefore 
the BGC responsible should be expressed in the cappable RNA sequencing 
experiment conducted in chapter 4.  Unfortunately, TSSs were mapped in both 
clusters 30 and 33, implying that some genes from both of these clusters were being 
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transcribed at the time of sampling, therefore we remain unsure which cluster is 
responsible for the biosynthesis of the antifungal compound(s).  Furthermore, 
structural predictions of the products from each of the T1PKS encoded by clusters 30 
and 33 can be made due to the modularity of the genes and the high percentage 
conservature to other sequenced PKSs in the database.  This analysis shows that of 
the two products, cluster 30 is more likely to encode the production of a polyene, as 
the poly-b-keto product contains long chains of carbon-carbon double bonds that are 
characteristic of this class of compounds (Figure 7.6).  In the future we intend to carry 
out full transcriptomic analysis of both the wild-type strain and S. formicae Dfor using 
RNA sequencing to identify which clusters are expressed in which strain to narrow 
down the producing BGC for both the antifungals and the new antibacterial 
compounds.   
 
Figure 7.5: AntiSMASH analysis shows that cluster 30, the T1PKS gene cluster encoded within the S. 
formicae genome, shows high percentage homology to other clusters that are known to produce 
polyene antifungals, particularly in the core PKS genes shown in red. This is therefore thought to be 
the gene cluster responsible for the production of the antifungal compounds purified from extracts of 
S. formicae during earlier work (Chapter 1.8). 
 
 
BGC 30, 
S. formicae
Filipin BGC
46% of genes show similarity)
Nystatin BGC
26% of genes show similarity)
Candicidin BGC
28% of genes show similarity)
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Figure 7.6: Structural predictions of the products encoded by the T1PKSs in gene clusters 30 and 33 in 
S. formicae.  From this analysis, it appears that cluster 30 is more likely to synthesise a polyene 
antifungal, as the poly-b-keto intermediate contains multiple carbon-carbon double bonds which are 
a common feature of compounds of this class.   
7.3 Preliminary results of a genome mining project using CRISPR/Cas9 in S. 
formicae 
 
An alternative method to identify which genes are responsible for the biosynthesis 
of a secondary metabolite of interest is to genetically disrupt BGCs and examine the 
effect on compound production in the mutant strain.  The linear genomes of 
Streptomyces have been shown to contain the essential genetic machinery in the 
centre, with BGCs encoding for secondary metabolites usually found on the 
chromosome arms, therefore deletion of large regions of these non-essential genes 
does not usually result in developmental defects.  For example, large deletions of PKS 
and NRPS clusters across the genome have been conducted in Streptomyces 
coelicolor using PCR targeting with no detrimental effects on sporulation of growth 
reported (Zhou et al., 2012).  Until the development of CRISPR, this approach would 
not have been possible in non-model actinomycetes like S. formicae as cosmid 
libraries were not available.  In recent years however, CRISPR has been used in 
several non-model Streptomyces species to identify the BGCs responsible for the 
production of specific metabolites.  Streptomyces sp. SD85 was isolated from marine 
sediment in Singapore and shown to produce the polyene macrolactam, 
sceliphrolactam.  The BGC responsible for the biosynthesis of sceliphrolactam was 
identified using the pCRISPR-Cas9 system to make a small 883 bp deletion within the 
predicted cluster that inactivated one of the core PKS modules and therefore 
OH OH OH OH OH OH OH O
T1PKS - Cluster 30
OH OH OH OH O O
T1PKS - Cluster 33
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abolished sceliphrolactam production (Low et al., 2018).  The deletion of the 
formicamycin BGC in S. formicae was the first examples of CRISPR being used to 
delete a whole BGC of 46 Kb in a non-model actinomycete and represents the largest 
published CRISPR deletion (46kbp) made in a Streptomyces species to date.  
Following on from this work, we hypothesised that we could use the CRISPR protocols 
optimised for use in S. formicae during this thesis to identify which BGCs are 
responsible for the production of the new antibacterial and antifungal compounds 
produced by S. formicae and the S. formicae Dfor mutant by deleting whole BGCs 
across the genome and examining the effects on compound production in the 
resulting mutants.  To this end, the antiSMASH output from the S. formicae genome 
was manually examined and 8 candidate BGCs were identified that were predicted 
to encode for either antifungal or antibacterial compounds (Table 1.1).  These 
clusters, ranging from 59133 base pairs to 208356 base pairs, were deleted using the 
pCRISPomyces-2 system as described previously in this thesis.  Once the mutants 
were generated and confirmed, bioassays were run to compare the activity of the 
mutant strain to the controls.  During the generation of these mutants, it was noted 
that the deletion of large areas of DNA occurs with lower efficiency than smaller 
deletions like the targeting of individual genes presented earlier in this thesis.  This 
is predicted to be due to the homologous repair being more challenging and 
therefore less efficient over such large regions of DNA.  As a result of this lower 
efficiency, some of the experiments only resulted in a single, confirmed whole cluster 
deletion mutant.  For this work to be completed, a full repertoire of at least three 
biological replicates for each strain will need to be generated.  Nevertheless, the 
results of the initial bioactivity assays are shown below with the number of confirmed 
mutants generated for each cluster indicated (Figure 7.7).  Representative images of 
all of the bioassays conducted during this experiment are included in the appendix 
of this thesis (Chapter 8.4). 
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Figure 7.7: Summary of bioactivity results from whole cluster deletion mutants presented as a heat 
map of level of inhibition with the number of biological replicates of each strain indicated.  Each 
individual replicate was bioassayed at least 3 times on separate agar plates.  All plates were overlayed 
after 7 days of incubation at 30°C. 
In general, these results show that S. formicae Dfor has greater antibacterial activity 
against Gram-positive pathogens and stronger antifungal activity than the wild-type 
strain.  This is consistent with observations made during HPLC analysis of the 
formicamycin cluster deletion mutants conducted earlier in this thesis.  None of the 
strains generated showed any antibacterial activity against E. coli suggesting the 
antibacterials produced will not be effective against Gram-negative pathogens.  
Interestingly, deleting some of the clusters in the wild-type background seemed to 
increase antibacterial activity against Gram-positive pathogens.  This may be due to 
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increased carbon flux through the formicamycin BGC when other secondary 
metabolites are removed.  More significantly, deletion of clusters 6 and 31 reduces 
the bioactivity of S. formicae Dfor against Gram-positive pathogens, implying that 
both of these clusters produce antimicrobial compounds and the potent bioactivity 
of S. formicae Dfor noted above may be due to a mixture of molecules from both 
BGCs (Figure 7.8).  From these bioassays, it also appears that cluster number 6 is 
expressed in the wild-type strain under normal laboratory conditions, with the 
bioactivity of the wild-type strain consisting of a mixture of compounds from cluster 
6 and the formicamycin BGC.   
 
 
Figure 7.8: Deletion of cluster number 6 and cluster number 31 significantly reduced the antibacterial 
activity of S. formicae and S. formicae Dfor against both B. subtilis and MRSA.  This suggests that both 
of these clusters are responsible for producing compounds with antimicrobial activity and the potent 
bioactivity of S. formicae Dfor is due to a mixture of these secondary metabolites. 
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Although annotated as one large cluster by AntiSMASH, cluster number 6 is actually 
thought to consist of 4 smaller clusters in close proximity; two NRPS clusters, a 
terpene and an aminoglycoside.  The terpene synthase is predicted to make 2-
methylisoborneol, an odorous secondary metabolite like geosmin with no reported 
bioactivity (Komatsu et al., 2008).  Both non-ribosomal peptides and aminoglycosides 
have been reported to have antibacterial activity, therefore there is no way to 
determine which cluster(s) is/are responsible for the production of the antibacterial 
activity seen here.  Early results from Mellisa Davie (undergraduate student in the 
Wilkinson Laboratory) suggest that there may be low levels of a telomycin-like 
compound in extracts of S. formicae Dfor.  It is possible that cluster 6a is responsible 
for the synthesis of this molecule, however, further investigation is needed (personal 
communication with Professor Barrie Wilkinson, April 2019).  Deletion of cluster 31 
in the wild-type strain has little to no effect on the anti- Gram-positive activity, 
suggesting that this BGC is not expressed in the wild-type under formicamycin 
producing conditions.  However, deletion of cluster 31 in S. formicae Dfor 
significantly reduces the bioactivity, especially against MRSA, implying that the 
production of this molecule is induced by deletion of the formicamycin BGC.  Cluster 
31 also encodes for a predicted NRPS and is thought to be responsible for the 
production of a novel glycopeptide antibiotic as described above (Chapter 7.2).  If a 
new glycopeptide antibiotic could be identified from S. formicae this could be 
extremely valuable in the fight against drug-resistant infections.   Indeed, analysis of 
both clusters 6 and 31 shows they have low homology to other BGCs in the database, 
therefore these compounds are likely to have novel structures. Having identified two 
more BGCs within S. formicae that produce antibacterial compounds and having a 
strain where these BGCs are switched on, we can now conduct further work on the 
clusters to identify the compounds produced.  We can then use the genetic 
techniques developed in this thesis to study these BGCs in similar detail to the 
formicamycin cluster as presented in this thesis.  It would also be interesting to 
generate a S. formicae Dfor D6 D31 triple cluster deletion mutant as this strain may 
either have no antibacterial activity, or more cryptic clusters may be induced in the 
absence of all three antibiotics. 
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Deletion of clusters 30 and 31 also appears to reduce the antifungal activity of S. 
formicae although only moderately.  As we know what the antifungal peaks look like 
on an HPLC trace, the whole cluster deletion mutants generated from this work have 
been analysed by HPLC for comparative metabolomics by Johannes Rassbach (former 
undergraduate student, JIC) to identify which strains can and cannot produce the 
antifungal compounds, however, the results were inconclusive.  Production of the 
antifungals is not evident in S. formicae D30, however, S. formicae D29 and S. 
formicae D31 also had altered levels of production (personal communication with 
Johannes Rassbach and Prof Barrie Wilkinson, March 2019).  This could imply that 
cluster 30 is the BGC responsible for production of the antifungal, as predicted 
previously, and genetic manipulation of neighbouring clusters might affect 
production levels.  It is possible that a regulator encoded in one cluster affects the 
other neighbouring clusters or, if the borders of the clusters are not called accurately 
by AntiSMASH, deletion of these neighbouring regions may have removed one or 
more genes involved in the biosynthesis of the antifungal.  Nonetheless, there is only 
a single replicate for the deletion of cluster 30, therefore further work is needed to 
confirm that this is the BGC responsible for the biosynthesis of the antifungal 
compounds.   
Although these results are preliminary, this work shows that CRISPR can be used for 
much larger deletions than previously demonstrated.  However, using CRISPR in S. 
formicae to delete such large regions of DNA was less efficient than the generation 
of smaller deletions presented earlier in this thesis.  The Cas9 enzyme has been 
reported to have toxicity in some strains although this is predicted to be low in S. 
formicae as many CRISPR mutants have been generated in this thesis that have been 
genetically complemented with no detrimental effects evident in the resulting 
strains.  Genetic engineering with CRISPR can result in off target effects due to the 
ability of the protospacer to mis-match and allow double strand breaks elsewhere in 
the genome (Alberti and Corre, 2019).  It is not known whether these off target 
effects become more common when larger regions of DNA are targeted, however, if 
the homologous repair is less efficient across larger regions of DNA this might allow 
for more off target events to occur during these experiments.  With whole cluster 
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deletions of the extensive sizes described here it is difficult to genetically 
complement the deletion without using cosmid libraries or PAC clones which are 
expensive to generate and screen.  Without genetic complementation, it is difficult 
to identify any off target effects that may have occurred elsewhere in the genome as 
a result of the CRISPR editing.  Although the mutants generated do not display any 
obvious phenotypic differences to the wild-type controls, it will be necessary to 
sequence their genomes to confirm the desired edits have been made with no off 
target effects.  However, it is worth noting that off target effects are possible 
regardless of the method used to introduce genetic mutation and are not just a 
problem that is specific to CRISPR.  As eluded to above, deletion of one cluster may 
affect the production of a secondary metabolite encoded by another cluster due to 
the deletion of a cross-cluster regulator, causing complications when applying this 
method of genome mining.  An alternative approach to identifying BGCs using a 
CRISPR-guided genome mining approach would be to target just the core PKS or NRPS 
genes or modules.  Deleting these core, essential genes would also prevent 
compound production, without the need for such large genetic deletions and without 
removing CSRs that may affect other BGCs in the genome.  However, the challenge 
with this approach is that these regions of DNA tend to be highly repetitive, therefore 
designing unique guide RNAs for this work would be difficult and PCR amplifying DNA 
regions for the homologous repair template in these regions would likely also be a 
challenge.  A recent study showed that CRISPR systems that utilise the pSG5 replicon, 
like pCRISPomyces2, are more likely to result in undesired recombination events in 
repetitive regions such as modular PKS genes.  To overcome this problem, the 
authors of the study developed a new CRISPR system, pMWCas9, using the pIJ101 
replicon along with an inducible Cas9, that showed much higher efficiency in the 
genetic manipulation of challenging DNA sequences (Mo et al., 2019).  This system 
may therefore be more appropriate for this type of genome editing in the future. 
Overall however, this preliminary work shows that CRISPR/Cas9 can be used to mine 
the genomes of talented secondary metabolite producers.  Similar approaches could 
potentially be used in other novel actinomycetes to delete BGCs for known molecules 
and thus identify novel natural products with clinically relevant bioactivities.  Using 
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these new whole-cluster deletion mutants, we will apply further bioactivity guided 
metabolomics approaches to identify further new molecules from S. formicae in the 
future.  In addition to the antibacterial and antifungal gene clusters identified here, 
there remain other cryptic BGCs in the S. formicae genome.  We plan to capture these 
BGCs and heterologously express them in engineered hosts with less complex 
secondary metabolite profiles.  We also plan to de-repress or activate the BGCs using 
genetic manipulation of the putative regulatory elements as has been presented in 
this thesis and elsewhere (Alberti et al., 2019).  The majority of potential novel 
biochemistry encoded in S. formicae remains to be discovered.  Continued genome 
mining efforts will be conducted to explore the full potential for secondary 
metabolite production in this strain.  Once novel compounds of interest are 
identified, their BGCs can be investigated in detail as we have done for the 
formicamycin gene cluster.  
7.4 Final conclusions 
 
S. formicae is a talented strain that is capable of producing multiple novel 
antimicrobial compounds of clinical interest.  The work presented in this thesis shows 
an in depth characterisation of a T2PKS BGC in S. formicae that is responsible for the 
production of a novel family of polyketides, the formicamycins.  We have shown how 
the formicamycins are biosynthesised by the host, how the pathway is regulated and 
what the mechanisms of host-resistance are, as well as beginning to define the 
mechanism of action of these promising new antibiotics.  The molecular genetic 
techniques developed over the course of this project will allow further work to be 
conducted in order to characterise the additional natural products encoded by this 
strain.  In addition to characterising formicamycin biosynthesis, we have already 
begun to characterise the products of other BGCs encoded within the genome of S. 
formicae.  Our results imply that both clusters 6 and clusters 31 are involved in the 
production of potent antimicrobials.  The peptide produced by cluster 31 seems to 
have particularly potent inhibitory activity against MRSA and is therefore a priority 
for further investigation.  We also know that S. formicae produces antifungal 
compounds with potent activity against the drug-resistant L. prolificans.  Confirming 
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the producing BGC and identifying the chemical structure(s) of the antifungal 
compound(s) will be the priority for future work.  Furthermore, there remains 
numerous other putative BGCs encoded within the genome of S. formicae that 
appear novel and could be a source of further interesting biochemistry.  Now that 
we have tools available for the genetic manipulation of S. formicae, we can 
investigate these silent clusters either in the host or in a heterologous producer.  We 
predict that S. formicae will continue to be a source of novel antibacterials and 
antifungals in the future.  Importantly, this work shows that searching novel 
environments such as the Tetraponera ant nests is a valid method for finding new 
species with prolific biosynthetic potential.  In addition, identifying novel strains 
increases the likelihood of identifying BGCs with low homology to other known 
clusters and therefore increases the chances of identifying new antimicrobials like 
the formicamycins that might eventually be used to treat drug-resistant infections.
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8 Appendix 
8.1 Strains used and generated during this thesis 
 
Strain Description Plasmid Resistance Source/Reference 
E. coli     
Top10 
F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara leu) 7697 galU galK rpsL (StrR) 
endA1 nupG 
  InvitrogenTM 
BW25113 
λ-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-4), lacIp-
4000(lacIQ), rpoS369(Am), rph-1, Δ(rhaD-rhaB)568, 
hsdR514 
pIJ790 CmlR (Datsenko and Wanner, 2000) 
DH10b 
F– mcrA Δ(mrr-hsdRMSmcrBC)  
Φ80lacZΔM15  
ΔlacX74 recA1 endA1  
araD139 Δ(ara leu) 7697  
galU galK rpsL nupG λ– 
  InvitrogenTM 
ET12567 dam- dcm- hsdS- pUZ8002 CmlR/TetR (MacNeil et al., 1992) 
BL21 
fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdSλ DE3 = λ 
sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 
∆nin5 
  (Studier and Moffattf, 1986) 
S. coelicolor     
M1146 Superhost strain: M145 ∆act ∆red ∆cpk ∆cda   (Gomez-Escribano and Bibb, 2011) 
Bioassay strains     
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Bacillus subtilis Wild-type strain 168   
Gift from Nicola Stanley Wall, 
University of Dundee 
E. coli Wild-type   Lab stock 
E. coli NR698 Membrane permeabilised via imp deletion   
(Ruiz, Kahne and Silhavy, 
2006) 
From Barrie Wilkinson 
Candida albicans Clinical isolate   
Gift from Prof Neil Gow, U. 
Exeter 
MRSA Clinical isolate   
Norfolk and Norwich 
University Hospital (UK) 
VRE Clinical isolate   
Norfolk and Norwich 
University Hospital (UK) 
Lamentospora 
prolificans 
Environmental isolate 
   
ATCC Culture collection 
Bacillus subtilis 
PL39 
gyrA::pMUTIN4 
ermC gryA’-lacZ 
pSPACgyrA+ 
DNA Gyrase inhibition reporter  ErmR 
Gift from Prof Jeff Errington, 
University of Newcastle 
Bacillus subtilis 
ypuA::pMUTIN4 
ermC ypuA’’-lacZ  
Cell wall damage reporter  ErmR 
Gift from Prof Jeff Errington, 
University of Newcastle 
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Bacillus subtilis 
fabHA::pMUTIN4 
ermC fabHA’-lacZ 
pSPAC-fabHA+ 
Fatty acid synthesis inhibition reporter  ErmR 
Gift from Prof Jeff Errington, 
University of Newcastle 
Bacillus subtilis 
ɸ105 (lacZ fusion 
to a late promoter 
in a ɸ105 
prophage) 
DNA damage reporter  CmlR 
Gift from Prof Jeff Errington, 
University of Newcastle 
Bacillus subtilis 
helD::pMUTIN4 
helD-lacZ ermC  
RNA polymerase inhibition reporter  ErmR 
Gift from Prof Jeff Errington, 
University of Newcastle 
Bacillus subtilis 
lial::pMUTIN4 lial-
lacZ ermC 
Cell envelope reporter  ErmR 
Gift from Prof Jeff Errington, 
University of Newcastle 
S. Kanamyceticus     
NRRL B2535 ATTC wild-type   Professor Barrie Wilkinson 
S. formicae KY5     
Wild-type    Lab stock 
KY5001-003 S. formicae ∆for   This work and Qin et al., 2017 
KY5004-006 S. formicae ∆for: ΦC31 for 215-G pESAC-13 215-G KanR/Tsr This work and Qin et al., 2017 
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KY5007-010 S. formicae ∆forV   This work and Qin et al., 2017 
KY5011-013 S. formicae ∆forX   This work 
KY5014-016 S. formicae ∆forY   This work 
KY5017-019 S. formicae ∆forV: ΦBT1 forV pforU pRD004 HygR This work and Qin et al., 2017 
KY5020-022 S. formicae ∆forX: ΦBT1 forX pforU pRD005 HygR This work 
KY5023-025 S. formicae ∆forY: ΦBT1 forY pforU pRD006 HygR This work and GenScript 
KY5026-028 S. formicae ∆forD   This work 
KY5029-031 S. formicae ∆forL   This work 
KY5032-034 S. formicae ∆forR   This work 
KY5035-037 S. formicae ∆forS   This work 
KY5038-040 S. formicae ∆forU   This work 
KY5041-043 S. formicae ∆forD: ΦBT1 forD pforT pRD012 HygR This work 
KY5044-046 S. formicae ∆forL: ΦBT1 forL pforM pRD013 HygR This work 
KY5047-049 S. formicae ∆forR: ΦBT1 forR pRD014 HygR This work 
KY5050-052 S. formicae ∆forR: ΦBT1 forRA permE* pRD015 HygR This work 
KY5053-055 S. formicae ∆forS: ΦBT1 forS  pRD016 HygR This work 
KY5056-058 S. formicae ∆forS: ΦBT1 forS permE*  pRD017 HygR This work 
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KY5059-061 S. formicae ∆forU: ΦBT1 forU pRD018 HygR  
KY5062-064 S. formicae ∆forU: ΦBT1 forUV permE* pRD019 HygR This work 
KY5065-067 S. formicae ∆forM   This work 
KY5068-070 S. formicae ∆forT   This work 
KY5071-073 S. formicae ∆forW   This work 
KY5074-076 S. formicae ∆forM: ΦBT1 forM pforM pRD023 HygR This work 
KY5077-079 S. formicae ∆forT: ΦBT1 forT pforT pRD023 HygR This work 
KY5080-082 S. formicae ∆forT: ΦBT1 forT permE*    
KY5083-085 S. formicae ∆forW: ΦBT1 forW pforU pRD025 HygR This work 
KY5086-088 S. formicae ∆forJ   This work 
KY5089-091 S. formicae ∆forGF   This work 
KY5092-094 S. formicae ∆forZ   This work 
KY595-097 S. formicae ∆forBBCC   This work 
KY5098-100 S. formicae ∆forJ: ΦBT1 forJ pforM pRD030 HygR This work 
KY5101-103 S. formicae ∆forGF: ΦBT1 forGF pforG pRD031 HygR This work 
KY5104-106 S. formicae ∆forZ: ΦBT1 forZ pforZ pRD032 HygR This work 
KY5107-109 S. formicae ∆forBBCC: ΦBT1 forBBCC pforBB pRD033 HygR This work 
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KY5110-112 S. formicae ∆forJ: ΦBT1 forJ 3x Flag pRD034 HygR This work 
KY5113-115 S. formicae ∆forGF: ΦBT1 forGF 3x Flag pRD035 HygR This work 
KY5116-118 S. formicae ∆forZ: ΦBT1 forZ 3x Flag pRD036 HygR This work 
KY5119-121 S. formicae ∆for: ΦC31 for 1-4 aac(3)IV pRD037 AprR This work 
KY5122-124 S. formicae ∆for: ΦC31 for 1-7 aac(3)IV pRD038 AprR This work 
KY5125-127 S. formicae ∆for: ΦC31 for 32-43 aac(3)IV pRD039 AprR This work 
KY5128-130 S. formicae ∆ for: ΦC31 for 36-43 aac(3)IV pRD040 AprR This work 
KY5131-133 S. formicae ∆forAA   This work 
KY5134-136 S. formicae ∆forK   This work 
KY5137-139 S. formicae ∆forAA: ΦC31 forAA pforAA pRD043 HygR This work 
KY5140-142 S. formicae ∆forK: ΦC31 forK pforM pRD044 HygR This work 
KY5143-145 S. formicae ∆forAA, ∆forK   This work 
KY5146-148 S. formicae ∆forJ: ΦC31 forK pforM pRD046 HygR This work 
KY5149-151 S. formicae ∆forJ: ΦC31 forAA pforAA pRD047 HygR This work 
KY5152-154 S. formicae ∆forJ, ∆forX   This work 
KY5155-157 S. formicae ∆forJ, ∆forV   This work 
KY5158-160 S. formicae ∆forJ, ∆forY   This work 
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KY5161-163 S. formicae ∆forJ, ∆forS   This work 
KY5164-165 S. formicae ∆5   This work 
KY5166-168 S. formicae ∆for ∆5   This work 
KY5169-171 S. formicae ∆6   This work 
KY5172-173 S. formicae ∆for ∆6   This work 
KY5174-176 S. formicae ∆8   This work 
KY5177-179 S. formicae ∆for ∆8   This work 
KY5180-183 S. formicae ∆27   This work 
KY5184-185 S. formicae ∆for ∆27   This work 
KY5186-187 S. formicae ∆29   This work 
KY5188-189 S. formicae ∆for ∆29   This work 
KY5190 S. formicae ∆30   This work 
KY5191 S. formicae ∆for ∆30   This work 
KY5192-KY5193 S. formicae ∆31   This work 
KY5194 S. formicae ∆for ∆31   This work 
KY5195-KY5197 S. formicae ∆34   This work 
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8.2 Plasmids used and generated during this thesis 
 
Plasmid Description Resistance Reference 
pUZ8002 RK2 derivative with a mutation in oriT KanR (Keiser et al., 2000) 
pMS82 ori, pUC18, hyg, oriT, RK2, int ΦBT1 HygR (Gregory & Smith, 2003) 
pIJ773 - aac(3)IV oriT bla AprR (Gust et al., 2004) 
pIJ790 araC-Parab,Υ, β, exo, cat, repA1001ts, oriR101 CmlR (Gust et al., 2004) 
pR9604 pUB307 derivative CarbR (Piffaretti, Arini and Frey, 1988) 
pIJ10257 oriT, ΦBT1 attB-int, Hygr, ermEp*, pMS81 backbone HygR (Hong et al., 2005) 
pESAC-13 215-G aphII, tsr KanR/TsrR BioS&T and Qin et al., 2017 
pCRISPomyces-2 Apr
R, oriT, reppSG5(ts), oriColE1, sSpcas9, synthetic guide RNA cassette AprR (Cobb et al., 2015) 
pIJ12900 pGM1190 with kan resistance marker KanR Professor Mervyn Bibb 
BCG30 pCRISPomyces-2 BCG30 flanking DNA and gRNA AprR This work and Qin et al., 2017 
pGS-21a forV pGS-21a with codon optimised forV cloned between NcoI and XhoI AmpR GenScriptÒ 
pRD001 pCRISPomyces-2 forV flanking DNA and gRNA AprR This work and Qin et al., 2017 
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pRD002 pCRISPomyces-2 forX flanking DNA and gRNA AprR This work 
pRD003 pCRISPomyces-2 forY flanking DNA and gRNA AprR This work 
pRD004 pMS82 pforU forV HygR This work 
pRD005 pMS82 pforU forX HygR This work 
pRD006 pMS82 pforU forY HygR This work, GenScriptÒ 
pRD007 pCRISPomyces-2 forD flanking DNA and gRNA AprR This work 
pRD008 pCRISPomyces-2 forL flanking DNA and gRNA AprR This work 
pRD009 pCRISPomyces-2 forR flanking DNA and gRNA AprR This work 
pRD010 pCRISPomyces-2 forS flanking DNA and gRNA AprR This work 
pRD011 pCRISPomyces-2 forU flanking DNA and gRNA AprR This work 
pRD012 pMS82 pforT forD HygR This work 
pRD013 pMS82 pforM forL HygR This work 
pRD014 pMS82 pforT forR HygR This work 
pRD015 pIJ10257 forR-forA HygR This work 
pRD016 pMS82 pforT forS HygR This work 
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pRD017 pIJ10257 forS HygR This work 
pRD018 pMS82 pforU forU HygR This work 
pRD019 pIJ10257 forU-forV HygR This work 
pRD020 pCRISPomyces-2 forM flanking DNA and gRNA AprR This work 
pRD021 pCRISPomyces-2 forT flanking DNA and gRNA AprR This work 
pRD022 pCRISPomyces-2 forW flanking DNA and gRNA AprR This work 
pRD023 pMS82 pforM forM HygR This work 
pRD024 pMS82 pforT forT HygR This work 
pRD025 pMS82 pforU forW HygR This work 
pRD026 pCRISPomyces-2 forJ flanking DNA and gRNA AprR This work 
pRD027 pCRISPomyces-2 forGF flanking DNA and gRNA AprR This work 
pRD028 pCRISPomyces-2 ForZ flanking DNA and gRNA AprR This work 
pRD029 pCRISPomyces-2 forBBCC flanking DNA and gRNA AprR This work 
pRD030 pMS82 pforM forJ HygR This work 
pRD031 pMS82 pforG forGF HygR This work 
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pRD032 pMS82 pforZ forZ HygR This work 
pRD033 pMS82 pforBB forBBCC HygR This work 
pRD034 pMS82 pforM forJ 3x Flag HygR This work 
pRD035 pMS82 pforG forGF 3x Flag HygR This work 
pRD036 pMS82 pforZ forZ 3x Flag HygR This work 
pRD037 pESAC-13 215-G 1-4 aac(3)IV oriT KanR/TsrR This work 
pRD038 pESAC-13 215-G 1-7 aac(3)IV oriT KanR/TsrR This work 
pRD039 pESAC-13 215-G 32-43 aac(3)IV oriT KanR/TsrR This work 
pRD040 pESAC-13 215-G 36-43 aac(3)IV oriT KanR/TsrR This work 
pRD041 pCRISPomyces-2 forK flanking DNA and gRNA AprR This work 
pRD042 pCRISPomyces-2 forAA flanking DNA and gRNA AprR This work 
pRD043 pMS82 pForAA forAA  HygR This work 
pRD044 pMS82 pForM forK  HygR This work 
pRD045 pCRISPomyces-2 Cluster 5 flanking DNA and gRNA AprR This work 
pRD046 pCRISPomyces-2 Cluster 6 flanking DNA and gRNA AprR This work 
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pRD047 pCRISPomyces-2 Cluster 8 flanking DNA and gRNA AprR This work 
pRD048 pCRISPomyces-2 Cluster 27 flanking DNA and gRNA AprR This work 
pRD049 pCRISPomyces-2 Cluster 29 flanking DNA and gRNA AprR This work 
pRD050 pCRISPomyces-2 Cluster 30 flanking DNA and gRNA AprR This work 
pRD051 pCRISPomyces-2 Cluster 31 flanking DNA and gRNA AprR This work 
pRD052 pCRISPomyces-2 Cluster 34 flanking DNA and gRNA AprR This work 
pRD053 pMF96 pforM GUS HygR This work 
pRD054 pMF96 pforH-GF GUS HygR This work 
pRD055 pMF96 pforGF-H GUS HygR This work 
pRD056 pMF96 pforT-U GUS HygR This work 
pRD057 pMF96 pforU-T GUS HygR This work 
pRD058 pMF96 pforZ-AA GUS HygR This work 
pRD059 pMF96 pforAA-Z GUS HygR This work 
pRD060 pCRISPomyces-2 ForJ S. Kanamyceticus flanking DNA and gRNA AprR This work 
pRD061 pIJ12900 ForJ:Apr in S. Kanamyceticus KanR, AprR This work 
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8.3 Primers used and generated during this thesis 
   
Name Description Sequence 
pCRISP Test F Test XbaI site pCRISP2 For AGGCTAGTCCGTTATCAACTTGAAA 
pCRISP Test R Test XbaI site pCRISP2 Rev TCGCCACCTCTGACTTGAGCGTCGA 
Spacer test Test BbsI site of pCRISP2 ATACGGCTGCCAGATAAGGC 
pIJ10257 TEST F Test MCS in pIJ10257 For GATCTTGACGGCTGGCGAGAG 
pIJ10257 TEST R Test MCS in pIJ10257 Rev GCGTCAGCATATCATCAGCGAGC 
KY5001 35KOFor1 pCRISPomyces-2 left flank BGC 
Template For 
ATCATCTAGAAAGGACATTCGC CTCGTCAGCCGCAAG  
KY5002 35KORev1 pCRISPomyces-2 left flank BGC 
Template Rev 
GCTGCTGCGACCAGGCGAGCTCGCGTCGAGACGCAACTCAGTGAAACCTTG  
KY5003 35KOFor2 pCRISPomyces-2 right flank BGC 
Template For 
GCGAGCTCGCCTGGTCGCAGCAGCGTACTGACAGACAATTTCTCACGTTCGGC  
KY5004 35KORev2 pCRISPoyces-2 right flank BGC 
Template Rev 
ACGTTCTAGAGAGGAACTCCTCATAGGTGATCAGATAACC 
KY5005 gRNA35 For BGC gRNA For ACGCGCGCCATGAAGCTAAGG AGG  
KY5006 gRNA35 Rev BGC gRNA Rev AAACCCTCCTTAGCTTCATGGC GC 
KY5007 BGC_Left_Fwd  pESAC13 5' edge forward test primer 
for BGC 
ACAGGTACGACGGGTCC 
KY5008 BGC_Left_Rev  pESAC13 5' edge reverse test primer 
for BGC 
CCCAACCAGTACGCGAAG  
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KY5009 
BGC_Right_Fwd  
pESAC13 3' edge forward test primer 
for BGC  
GCATGGGATGTGAGCACC  
KY5010 
BGC_Right_Rev  
pESAC13 3' edge reverse test primer 
for BGC  
AAGAGGCGATGAGCGAGG  
KY5011 BGC_Mid_Fwd  pESAC13 forward test primer for 
BGC centre  
TACCACATCGGCGAGTCC  
KY5012 BGC_Mid_Rev  pESAC13 reverse test primer for BGC 
centre  
CGCTCCAGGTTGTACGAC  
KY5013_6548  Confirmation of cluster deletion  ATCGGTGAGATCACCATGACTA CGG  
KY5014_6507  Confirmation of cluster deletion  GTTCGACGGTGCCGA TGAAGC 
KY5015_6505  Confirmation of cluster deletion  CTGTACGCTGACAGCCGGAAC 
KY5016_6514  Detection of cluster edge  GGCGAAGAGGCGGGCGATCTCG  
KY5017_6512  Detection of cluster edge  CACGACAGACCCCTCCCGCGT  
KY5018_6538  Detection of cluster edge  CATTCCCGGGGCCCGGGTGT  
KY5019_6537  Detection of cluster edge  AGCCGACGGCGTATCGGCTGA CG  
RD125 ForV deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgacgagcacggatacgtgatcgg 
RD126 ForV deletion Rev 1 GCGAGCTCGCCTGGTCGCAGCAGCgtgacggcacaggagcagagc 
RD127 ForV deletion For 2 GCTGCTGCGACCAGGCGAGCTCGCtcactcatcgccgttcccttcc 
RD128 ForV deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgacgtgatgcggctcgactg 
RD129 ForV gRNA F ACGCacgaccagtccttgatggta 
RD130 ForV gRNA R AAACtaccatcaaggactggtcgt 
RD037 ForV Test 1F gcgcgaacgcctggagaacatgg 
RD038 ForV Test 2R gccgtcgccgagcgggatgaa 
RD059 ForV Test 2F gtcaaggcgcacgaggagctg 
RD060 ForV Test 1R gactcgttcagggcgaagtgcc 
JTM431 ForX deletion For 1 gctcggttgccgccgggcgttttttatctagagccggtgacggcacaggagc 
JTM432 ForX deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcatcgtgcttcctcactcctgggtg 
RD019 ForX deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgacgagcccctctgttctcgtcgccc 
RD020 ForX deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAgccctcggcccgcaaggacttca 
RD131 ForX gRNA For ACGCctcgccctgttcgggccggta 
RD132 ForX gRNA Rev AAACtaccggcccgaacagggcgag 
RD049 ForX Test 1F ggtccgctggaacgtcgaacc 
RD050 ForX Test 2R gcagcgctcaggcgtgaagtc 
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RD053 ForX Test 2F gcccgctgtctgcacaactg 
RD054 ForX Test 1R cgatccgtccgcctcggtac 
RD133 ForY deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAggtgccgaagcgttccacggcc 
RD134 ForY deletion Rev 1 GCGAGCTCGCCTGGTCGCAGCAGCtcaccgctcgcacgccgcca 
RD135 ForY deletion For 2 GCTGCTGCGACCAGGCGAGCTCGCggtcgtacacgccgctcgga 
RD136 ForY deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcctggaagatggccgcggtcc 
RD137 ForY gRNA For ACGCggctcctcgcggcgccggta 
RD138 ForY gRNA Rev AAACtaccggcgccgcgaggagcc 
RD139 ForY Test 1F cgaagaaggtgagggagagcagcc 
RD140 ForY Test 2R cgcgatccaggacgcccacaacc 
RD055 ForY Test 2F gacgccttgcgcaggctgcac 
RD056 ForY Test 1R ctggccgagcggctctcgctc 
RD079 ForJ deletion For1 gctcggttgccgccgggcgttttttaTCTAGAggtgtgcgcgaagaacggcc 
RD080 ForJ deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcactgacgcggtcgttcccg 
RD081 ForJ deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgacgtgcttcgagaccgcc 
RD082 ForJ deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcctcttcatgttcctggtgggcc 
RD167 ForJ gRNA For ACGCtgccgacaccttctccatga 
RD168 ForJ gRNA Rev AAACtcatggagaaggtgtcggca 
RD085 ForJ Test 1F cctcttcggtgagcgcttcgagg 
RD086 ForJ Test 2R cctgttggacttcgcgcaggc 
RD087 ForJ Test 2F gtacgccaggaggacgtgcg 
RD088 ForJ Test 1R gccgacgcggcacttctatcc 
RD089 ForZ deletion For1 gctcggttgccgccgggcgttttttaTCTAGAcgaacaggccgacgctgaacag 
RD090 ForZ deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcatggcttgaagtccagcacgtcc 
RD091 ForZ deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtcatccgtacctggcagctcgtcg 
RD092 ForZ deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAccgaggcggacggatcgcgtcc 
RD169 ForZ gRNA For ACGCgtcggcggtcaactcgactg 
RD170 ForZ gRNA Rev AAACcagtcgagttgaccgccgac 
RD095 ForZ Test 1F gccggtgccgaaccggacgc 
RD096 ForZ Test 2R cgcacgccgccacgacgagc 
RD097 ForZ Test 2F cgcacgccgccacgacgagc 
RD098 ForZ Test 1R cgcacgccgccacgacgagc 
RD099 ForGF deletion For1 gctcggttgccgccgggcgttttttaTCTAGAggagccggtcttggccatctgc 
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RD100 FoGF deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCggcagcctcgttcacagcagc 
RD101 ForGF deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgaggctcaggcgggttcgatgg 
RD102 ForGF deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgagatcgtcatccacgcgcc 
RD157  Cluster 8 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAggacatcgccaacgccatcgcc 
RD158 Cluster 8 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcacgcgcacgctcctcggtcg 
RD159 Cluster 8 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCggccgacgagagagggtttg 
RD160 Cluster 8 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgaaggcttcgttgacctcg 
RD161 Cluster 8 gRNA F ACGCtcgccgtccgcagaccgtta 
RD162 Cluster 8 gRNA R AAACtaacggtctgcggacggcga 
RD163 Cluster 8 Test 1F ggacttcgaggagttccaggc 
RD164 Cluster 8 Test 1R ggtcctgctaccagtgagtagg 
RD165 Cluster 8 Test 2F ggtcgatggcggcatcttcc 
RD166 Cluster 8 Test 2R gccgtgcacgttgaccttctc 
RD171 ForGF gRNA For ACGCtggcgaagatgttgcgcaga 
RD172 ForGF gRNA Rev AAACtctgcgcaacatcttcgcca 
RD105 ForGF Test 1F gcagttcctggacgatgcgc 
RD106 ForGF Test 1R cgagggtctggagaacgcgc 
RD107 ForGF Test 2F cgtcggcaccttctaccaccg 
RD108 ForGF Test 2R gcctgcgtgattcatcggctg 
RD109 ForBBCC deletion For1 gctcggttgccgccgggcgttttttaTCTAGAgcgcagcgagcggatcttgatcc 
RD110 ForBBCC deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcacggacgggcgctcgacac 
RD111 ForBBCC deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgacgccgggcgtcaccacc 
RD112 ForBBCC deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAgctcgtcggcgtcgactggcg 
RD173 ForBBCC gRNA For ACGCtgatcgactcctggatgata 
RD174 ForBBCC gRNA Rev AAACtatcatccaggagtcgatca 
RD115 ForBBCC Test 1F cacaccatcgacaccagctggac 
RD116 ForBBCC Test 1R cggcgtatcggctgacgtcg 
RD117 ForBBCC Test 2F cgagtccgaggagcatgcgc 
RD118 ForBBCC Test 2R ctggacggcgttcggactcg 
RD187 pMS82-formicamycin promoter For gccgagaaccTAGGATCCAAGCTTcatggtgaggtgctcctcctg 
RD188 Formicamycin promoter-ForV Rev ggcgctgctggtcactcatgtggagctgccctcactc 
RD189 Formicamycin promoter-ForV For gagtgagggcagctccacatgagtgaccagcagcgcc 
RD190 ForV-pMS82 Rev CTGGTACCATGCATAGATCTAAGCTTtcaccggccccgctccacgg 
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RD191 Formicamycin promoter-ForX Rev gcacggatacgtgatcggtcatgtggagctgccctcactc 
RD192 Formicamycin promoter-ForX For gagtgagggcagctccacatgaccgatcacgtatccgtgc 
RD193 ForX-pMS82 Rev CTGGTACCATGCATAGATCTAAGCTTtcacggccgcctcccgttcc 
pMS82 TEST For Test HindIII site pMS82 For gcaacagtgccgttgatcgtgctatg 
pMS82 TEST Rev Test HindIII site pMS82 Rev gccagtggtatttatgtcaacaccgcc 
RD175 ReDirect - oriT 1F accacccgcaccgcccacctcaaggagagcagccccatgGCTCACGGTAACTGATGCCG 
RD176 ReDirect 4R ctgacccagcagtggcaggccgaccacaccgccttcatgTGTAGGCTGGAGCTGCTTC 
RD177 ReDirect 8R gctaagtcggtcgatctgcgcctcttggcgcggtgatcaTGTAGGCTGGAGCTGCTTC 
RD178 ReDirect - oriT 34F ggccgtacaaccagggtcgacacccgggccccgggaatgGCTCACGGTAACTGATGCCG 
RD179 ReDirect – oriT 36F tgtccgccgccgggcggcggggagtgaggagagagcgtgGCTCACGGTAACTGATGCCG 
RD180 ReDirect 43R ccgtcgtacctgtccgtcccgctgcgcgagcagtgatcaTGTAGGCTGGAGCTGCTTC 
RD205 ForD deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAccagttcggccacggactgc 
RD206 ForD deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcacggtcaggctcccttcg 
RD207 ForD deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCgtatgagcgccaccgaggcc 
RD208 ForD deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAccaacggccagacggcgcgtc 
RD209 ForD gRNA For ACGCtggatgcgcatgaacgcgaa 
RD210 ForD gRNA Rev ACGCtggatgcgcatgaacgcgaa 
RD211 ForD Test 1F ccacgctggtcgaacagtgc 
RD212 ForD Test 1R gcgagtctgaccaggcgctc 
RD213 ForD Test 2F cgtcctggtcaccgacgagg 
RD214 ForD Test 2R gcatggcgcaggtgcacacc 
RD215 ForL deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgcagcacgccgaccagcacg 
RD216 ForL deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCtagtcccgccatggcggacc 
RD217 ForL deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcatggacgaactccctttcgcc 
RD218 ForL deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAgctaaggaggtggccgagg 
RD219 ForL gRNA For ACGCgagccccaactgccttggta 
RD220 ForL gRNA Rev AAACtaccaaggcagttggggctc 
RD221 ForL Test 1F cgagggcgagcagcaggcg 
RD222 ForL Test 1R cggcacgcgagttcggtggc 
RD223 ForL Test 2F cgctcggtcgccacggcc 
RD224 ForL Test 2R ccgcgtgatgacagatgcgcc 
RD225  For M deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAggtcacgctcatggcgacgc 
RD226 ForM deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCtaacgcgagattccgcaaggcg 
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RD227 ForM deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcacaccggctcccatcggttg 
RD228 ForM deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgaaggtgttgtcgagcctgatcc 
RD229 ForM gRNA For ACGCgtcgaactccccgtcttcgta 
RD230 ForM gRNA Rev AAACtacgaagacggggagttcgac 
RD231 ForM Test 1F cgtcgtggaaggtgaagagc 
RD232 ForM Test 1R ccgaggcgcgtcaatgagc 
RD233 ForM Test 2F cgagcaccgcgagtgatccg 
RD234 ForM Test 2R cacggtcgcgccgccgatcc 
RD235 ForR deletion For 1 gctcggttgccgccgggcgttttttaTCTAGActtcggcaagcagttcttcg 
RD236 ForR deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCggtcatggttctccttgtcc 
RD237 ForR deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCacatgacccggcaggtcgcc 
RD238 ForR deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAccgagccgtgcgcgttgacg 
RD239 ForR gRNA For ACGCcgtagaggaactcctcggagta 
RD240 ForR gRNA Rev AAACtactccgaggagttcctctacg 
RD241  ForR Test 1F gcacatacgccatcaggtcgc 
RD242  ForR Test 1R ggtccatgcgttgggcctcg 
RD243  ForR Test 2F cggcgagcgggtcttcgac 
RD244  ForR Test 2R cgtgccggtcgttctgcttgg 
RD245  ForS deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgaggagcacctcaccatgacg 
RD246  ForS deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCgctcatacggtgccctccac 
RD247  ForS deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgatccgacccaacggggac 
RD248  ForS deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAgaagcgccggtgatcatgacg 
RD249  ForS gRNA For ACGCgggtttgtggacgtaggtga 
RD250  ForS gRNA Rev AAACtcacctacgtccacaaaccc 
RD251  ForS Test 1F cctcgtcgaggacagcacgg 
RD252  ForS Test 1R cgatgcgtacgtcgacgttgc 
RD253  ForS Test 2F gcctcttgcgcggcttgagc 
RD254  ForS Test 2R cgcgtcgaagcaggagacgg 
RD255  ForT deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAcctggaagtacgcccagacg 
RD256  ForT deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcatggtgaggtgctcctcctg 
RD257  ForT deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCgtatgagccaggaggagccg 
RD258  ForT deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcggatcgaagtcgcactcgg 
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RD259  ForT gRNA For  ACGCcgcagcaggcgctccaacgt 
RD260  ForT gRNA Rev AAACacgttggagcgcctgctgcg 
RD261  ForT Test 1F gctcctcgtgcgccttgacg 
RD262  ForT Test 1R cgctggtgatgagccattcg 
RD263  ForT Test 2F ctcgatcaggacgttgccgc 
RD264  ForT Test 2R ctgcacgtagcggtccatgcg 
RD265  ForU deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAcgtagtactcgccgcggttc 
RD266  ForU deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCgatgagtgaccagcagcgcc 
RD267  ForU deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcatgtggagctgccctcactc 
RD268  ForU deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAgcttcttgccgccgacgttg 
RD269  ForU gRNA For ACGCgtggccctcttgagctacgt 
RD270  ForU gRNA Rev AAACacgtagctcaagagggccac 
RD271  ForU Test 1F ggtccactgcggcaggtcg 
RD272  ForU Test 1R gcgcggttcctcgtcgagcg 
RD273  ForU Test 2F ggtcacgaagtcgacgtcgg 
RD274  ForU Test 2R cggtagccgtggtaggtgagg 
RD275 ForW deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAcgtcggcggcatcacatgg 
RD276 ForW deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCtgaggaagcacgatgaccgatc 
RD278 ForW deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCctcctgtgccgtcaccggcc 
RD279  ForW deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAccttctccttcgccgacggc 
RD279  ForW gRNA For ACGCtggtcgaggtagtcgaagta 
RD280  ForW gRNA Rev AAACtacttcgactacctcgacca 
RD281  ForW Test 1F gcagcacttccatcgagcgg 
RD282 ForW Test 1R cgctacgaggagagctaccg 
RD283 ForW Test 2F ggccatcttccaggcgagg 
RD284 ForW Test 2R gctcgtgcggaagtacggc 
RD297 ForJ compl pMS82 prom F gccgagaaccTAGGATCCAAGCTTgatgccggtgagcagggcgag 
RD298  ForJ compl prom-gene R ggcgccgtggtcgtggtcataccggctcccatcggttgctg 
RD299 ForJ compl prom-gene F cagcaaccgatgggagccggtatgaccacgaccacggcgcc 
RD300 ForJ compl gene-pMS82 R CTGGTACCATGCATAGATCTAAGCTTgcggaggcggaccgtgcctag 
RD301 ForZ compl pMS82 F gccgagaaccTAGGATCCAAGCTTccggtcaccacccattggag 
RD302 ForZ compl pMS82 R CTGGTACCATGCATAGATCTAAGCTTaggagttgtgcgccctcgc 
RD303 ForGF compl pMS82 F gccgagaaccTAGGATCCAAGCTTcgtgtaccccctgtgcacg 
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RD304 ForGF compl pMS82 R CTGGTACCATGCATAGATCTAAGCTTccgctgctcgccatcgaac 
RD305 ForBBCC compl pMS82 F gccgagaaccTAGGATCCAAGCTTtcgtcttgcccgcgccgttc 
RD306 ForBBCC compl pMS82 R CTGGTACCATGCATAGATCTAAGCTTtcagcggtccgcggagaccag 
RD307 ForD pMS82 pF gccgagaaccTAGGATCCAAGCTTgtggagctgccctcactctc 
RD308 ForD pMS82 pR cgttctcggtgagctcgggcacggtgaggtgctcctcctg 
RD309 ForD pMS82 gF caggaggagcacctcaccgtgcccgagctcaccgagaacg 
RD310 ForD pMS82 gR CTGGTACCATGCATAGATCTAAGCTTcctcggtggcgctcatacgg 
RD311 ForL pMS82 pF gccgagaaccTAGGATCCAAGCTTgattcttcggcgcacgacag 
RD312 ForL pMS82 pR cgacgatcaacgtggtgtgcataccggctcccatcggttgc 
RD313 ForL pMS82 gF gcaaccgatgggagccggtatgcacaccacgttgatcgtcg 
RD314 ForL pMS82 gR CTGGTACCATGCATAGATCTAAGCTTctactcgacggggactacgc 
RD315  ForM pMS82 pF gccgagaaccTAGGATCCAAGCTTgattcttcggcgcacgacag 
RD316  ForM pMS82 gR CTGGTACCATGCATAGATCTAAGCTTttatggaactcgggcgatcgc 
RD317  ForR pMS82 pF gccgagaaccTAGGATCCAAGCTTgtggagctgccctcactctc 
RD318  ForR pMS82 pR CGCACGGTGTGCGTGGTCATggtgaggtgctcctcctgt 
RD319  ForR pMS82 gF acaggaggagcacctcaccATGACCACGCACACCGTGCG 
RD320  ForR pMS82 gR CTGGTACCATGCATAGATCTAAGCTTTCATGTCCCGTACCGCTCTTCGG 
RD321   ForS pMS82 pF gccgagaaccTAGGATCCAAGCTTgtggagctgccctcactctc 
RD322  ForS pMS82 pR cggctcctcctggctcatggtgaggtgctcctcctgta 
RD323  ForS pMS82 gF tacaggaggagcacctcaccatgagccaggaggagccg 
RD324  ForS pMS82 gR CTGGTACCATGCATAGATCTAAGCTTcgttgggtcggatcagagg 
RD325  ForT pMS82 pF gccgagaaccTAGGATCCAAGCTTgtggagctgccctcactctc 
RD326  ForT pMS82 pR CTGGTACCATGCATAGATCTAAGCTTtcatacggtgccctccacc 
RD327  ForU pMS82 pF gccgagaaccTAGGATCCAAGCTTggtgaggtgctcctcctgtaaag 
RD328  ForU pMS82 gR CTGGTACCATGCATAGATCTAAGCTTtcactcatcgccgttcccttc 
RD329  ForW pMS82 pF gccgagaaccTAGGATCCAAGCTTggtgaggtgctcctcctgtaaag 
RD330  ForW pMS82 pR ctctgctcctgtgccgtcacgtggagctgccctcactc 
RD331  ForW pMS82 gF gagtgagggcagctccacgtgacggcacaggagcagag 
RD332  ForW pMS82 gR CTGGTACCATGCATAGATCTAAGCTTgcttcctcactcctgggtgac 
RD337  ForJ-FLAG Rev gcctgaaccgcctccaccgtgccccgcgggcacctg 
RD338  ForJ-FLAG For caggtgcccgcggggcacggtggaggcggttcaggc 
RD339  FLAG-pMS82 R CTGGTACCATGCATAGATCTAAGCTTtcaCTTGTCGTCATCGTCCTTG 
RD340  pMS82 ForF prom F gccgagaaccTAGGATCCAAGCTTtcgtgtaccccctgtgcacg 
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RD341   ForF-prom R ggtcaccacggtctgcatagcagcctccccggttcg 
RD342  ForF F cgaaccggggaggctgctatgcagaccgtggtgacc 
RD343  ForF-FLAG R gcctgaaccgcctccaccgccccggtcgccctgcg 
RD344  FLAG-pMS82 For cgcagggcgaccggggcggtggaggcggttcaggc 
RD345  ForZ-FLAG Rev gcctgaaccgcctccaccccgctcgcacgccgccacg 
RD346  ForZ-FLAG For cgtggcggcgtgcgagcggggtggaggcggttcaggc 
RD347  Prom-ForA Rev cgttcacgccttgggcacccatgtggagctgccctcactc 
RD350 ForAA deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgctgttgcgcaggctgtgg 
RD351 ForAA deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcatgacggcctcccggattgc 
RD352 ForAA deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgacgcccggcgtcagcg 
RD353 ForAA deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgacctcgacaggatcgcc 
RD354  ForAA gRNA F ACGCccggtaactcgttcacgcctt 
RD355  ForAA gRNA R AAACaaggcgtgaacgagttaccgg 
RD356  ForAA Test 1F cggcggcaggctcaccgtcg 
RD357 ForAA Test 1R cgagtacgtctatgccgcgc 
RD358 ForAA Test 2F cgagctgactggtggtcgtcg 
RD359 ForAA Test 2R gtcagccgatacgccgtcgg 
RD360 Cluster 31 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgctcgaccgcggctatctgg 
RD361 Cluster 31 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcatgactaatccgtcgcatggc 
RD362 Cluster 31 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcatgtgcggatcatcgatggaagc 
RD363 Cluster 31 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgtcctggtaccagaccgtcc 
RD364 Cluster 31 gRNA F ACGCggtgaggacggaacgggtta 
RD365 Cluster 31 gRNA R AAACtaacccgttccgtcctcacc 
RD366  Cluster 31 Test 1F cgctacctcgacctggtcgc 
RD367  Cluster 31 Test 1R gtgtgtgtcgaagcggcatg 
RD368 Cluster 31 Test 2F cgacgaggacttcctcgacg 
RD369 Cluster 31 Test 2R cgatcagcgctggtacgagc 
RD381 Cluster 5 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAggacctggatcgccgagatcg 
RD382 Cluster 5 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCgacaaggagagcacaggccg 
RD383 Cluster 5 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCccaggtgccgaacgtgctg 
RD384 Cluster 5 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGActctcgtgcttgctccgcac 
RD385 Cluster 5 gRNA F ACGCacacaccaccaccacacgaa 
RD386 Cluster 5 gRNA R AAACttcgtgtggtggtggtgtgt 
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RD387 Cluster 5 Test 1F gacgaccgcgatcatcaggag 
RD388 Cluster 5 Test 1R gatcgtcgaccgcaacctcgtc 
RD389 Cluster 5 Test 2F gtggtgcaagcggtggtgac 
RD390 Cluster 5 Test 2R ggtaccggtccgctcactcc 
RD391 Cluster 6 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgcaggtccgtctcaccgacc 
RD392 Cluster 6 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcacatcgagcggtacctctagc 
RD393 Cluster 6 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCgacgcgggcatgaactgaag 
RD394 Cluster 6 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAggcggtgagcagcacgagg 
RD395 Cluster 6 gRNA F ACGCcggagccggacatcgtggtaa 
RD396 Cluster 6 gRNA R AAACttaccacgatgtccggctccg 
RD397 Cluster 6 Test 1F ccggcgtggccgagaagg 
RD398 Cluster 6 Test 1R ccacctccgcggaggtcag 
RD399 Cluster 6 Test 2F ccacgctcaccgtcgacgg 
RD400 Cluster 6 Test 2R cggcagctcctgcaccagg 
RD441 Cluster 27 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAtcgccgaggcacaggacgtg 
RD442 Cluster 27 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcgtggcgaagtcctggatgg 
RD443 Cluster 27 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCtgacgccttgatcaccgcgc 
RD444 Cluster 27 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAggagcgcatgttgatcgtgc 
RD445 Cluster 27 gRNA F ACGCaggcgtcgccgagggaataa 
RD446 Cluster 27 gRNA R AAACttattccctcggcgacgcct 
RD447 Cluster 27 Test 1F ggtgccgcacgtcaagacg 
RD448 Cluster 27 Test 1R gtgcgaatgtcgatctgcacg 
RD449 Cluster 27 Test 2F gcactcgacgtggccgacg 
RD450 Cluster 27 Test 2R cgaccaggtcaggcgcatc 
RD451 Cluster 29 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAcgtacacggcggtgacctcc 
RD452 Cluster 29 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcggctcgaaggcttccgtg 
RD453 Cluster 29 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCgacggcgatgacggtgtgg 
RD454 Cluster 29 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAcgacttcctcggctgcgacg 
RD455 Cluster 29 gRNA F ACGCgcgcctcggatcaggcttaa 
RD456 Cluster 29 gRNA R AAACttaagcctgatccgaggcg 
RD457 Cluster 29 Test 1F ggtagtcgtcgtgctcggtgg 
RD458 Cluster 29 Test 1R ccttgacctcaccatcgagcg 
RD459 Cluster 29 Test 2F cgacgacggtcacgtcgtacg 
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RD460 Cluster 29 Test 2R gcacatctacctcctgcacgc 
RD461 Cluster 30 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAtgccatcggcatcggcag 
RD462 Cluster 30 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcggagtccgctgagcctgtg 
RD463 Cluster 30 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcgaatgcattctcgtccttcaatgg 
RD464 Cluster 30 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAccacacggtcacgtgcacg 
RD465 Cluster 30 gRNA F ACGCtgaacaacggccatgccctaa 
RD466 Cluster 30 gRNA R AAACttagggcatggccgttgttca 
RD467 Cluster 30 Test 1F ggacgcggtccgaaccagg 
RD468 Cluster 30 Test 1R ggccgtattggagcaatccgg 
RD469 Cluster 30 Test 2F cggagtccacttcggtgtgc 
RD480 Cluster 30 Test 2R cgtacgtggagtcgctgcc 
RD481 Cluster 34 deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAggtgtcgctctcggtgagc 
RD482 Cluster 34 deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCccgtctccgtcgtccgaac 
RD483 Cluster 34 deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcatgcggcgtcgacggatac 
RD484 Cluster 34 deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAgcgatgctgcacgtgctcg 
RD485 Cluster 34 gRNA F ACGCgcgttccgccacgagagaat 
RD486 Cluster 34 gRNA R AAACattctctcgtggcggaacgc 
RD487 Cluster 34 Test 1F ccgtcggcagcccgttgag 
RD488 Cluster 34 Test 1R gcccgacgtgacgtcactg 
RD489 Cluster 34 Test 2F cgacagatcgccgacaccg 
RD490 Cluster 34 Test 2R cgttgcggttcgccgcctc 
RD491  ForJ F gcaaggcggcgcagagcg 
RD492 ForJ R gccgacaccttctccatgagg 
RD493 ForZ F gaaccggacgcagccgcag 
RD394 ForZ R cctcgacgcgtgccacgag 
RD495 ForF F cctcgacgcgtgccacgag 
RD496 ForF R gcgaccagggtcatgacctcg 
RD497 ForK deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAgcatccggtcaccgagatgg 
RD498 ForK deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCcactgacttctgcaatgattgacc 
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RD499 ForK deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCcatggcgggactactcgacg 
RD500 ForK deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGAccagttccagtcgtccttcgagg 
RD501 ForK gRNA F ACGCtccgcatccggcatcccttg 
RD502 ForK gRNA R AAACcaagggatgccggatgcgga 
RD503 ForK Test 1F gaggtcaactgccgtatccagg 
RD504 ForK Test 1R cgtcggcgacgcagttctacc 
RD505 ForK Test 2F ctgtgacgtgcttcgagaccg 
RD506 ForK Test 2R gccggttatgggaccaaggc 
RD522 ForAA permE* pIJ10257 F AAAAAcatatgcgtccggtgctgtactgcaag 
RD508 ForAA permE* pIJ10257 R AAAAAaagctttcaccacccttgcgcatgttcacg 
RD509 ForK permE* pIJ10257 F AAAAAcatatgatggcggaccacaagggatgc 
RD510 ForK permE* pIJ10257 R AAAAAaagctttcagtggtggatggatagaagtgcc 
RD512 ForR-ForA ErmE* F AAAAAcatatgatgaccacgcacaccgtgc 
RD513 ForR-ForA ErmE* R AAAAAaagctttcacctcagctccctccggtc 
RD514 ForT ErmE* F  AAAAAcatatgatgacgtcaactcccttgcg 
RD515 ForT ErmE* R AAAAAaagctttcatacggtgccctccacc 
RD516 ForS ErmE* F AAAAAcatatgatgagccaggaggagccgc 
RD517 ForS ErmE* R AAAAAaagctttcagaggggtgctgccgtg 
RD518 ForU-ForV ErmE* F AAAAAcatatgatggccgagatctccgccg 
RD519 ForU-ForV ErmE* R AAAAAaagcttcgctctgctcctgtgccgtc 
RD520 ForW ErmE* F AAAAAcatatggtgacggcacaggagcagag 
RD521 ForW ErmE* R AAAAAaagcttcgtgcttcctcactcctggg 
RD523 S. Kan ForJ deletion For 1 gctcggttgccgccgggcgttttttaTCTAGAGCGATGTACCGGACGCTCGC 
RD524 S. Kan ForJ deletion Rev 1 GCTGCTGCGACCAGGCGAGCTCGCCATGTTCGCTCACCTCTGCTGTG 
RD525 S. Kan ForJ deletion For 2 GCGAGCTCGCCTGGTCGCAGCAGCCGCTGACGCGGTCGTTCC 
RD526 S. Kan ForJ deletion Rev 2 gcaacgcggcctttttacggttcctggccTCTAGACGAGCGGCTCGGCGACAAGC 
RD527 S. Kan ForJ gRNA F ACGCccaccttcgtgtgcatgcga 
RD528 S. Kan ForJ gRNA R AAACtcgcatgcacacgaaggtgg 
RD529 S. Kan ForJ Test 1F CTCGGCATCGGGCTCGGCTG 
RD530 S. Kan ForJ Test 1R GACGCGTCCGTTCCTGCTCC 
RD531 S. Kan ForJ Test 2F GCGGACGCGGCACTTCTATCC 
RD532 S. Kan ForJ Test 2R CGAAGAACGGCCTCGCCTTCG 
RD543 pMF96 HindIII Test For GCTCAATCAATCACCGGATCC 
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RD544 pMF96 HindIII Test Rev CATGTCCGTACCTCCGTTG 
RD545 pforM For AAAAAcatatgtcttcggcgcacgacagacc 
RD546 pforM Rev AAAAActcgagaccggctcccatcggttgc 
RD547 pforH-GF For AAAAAcatatggcgctgctcacggtcatcg 
RD548 pforH-GF Rev AAAAActcgaggcagcctcgttcacagcag 
RD549 pforGF-H For AAAAAcatatggcagcctcgttcacagcagc 
RD550 pforGF-H Rev AAAAActcgaggcgctgctcacggtcatcg 
RD551 pforT-U For AAAAAcatatgggcgaagccgaggctcatgc 
RD552 pforT-U Rev AAAAActcgagcagatcgaccagcttctgctggtcc 
RD553 pforU-T For AAAAAcatatgcagatcgaccagcttctgctggtcc 
RD554 pforU-T Rev AAAAActcgagggcgaagccgaggctcatgc 
RD559 pforZ-AA For AAAAAcatatggaatccctgacgcgccgcg 
RD560 pforZ-AA Rev AAAAActcgaggacgatggtggtgtcgagcac 
RD561 pforAA-Z For AAAAAcatatggacgatggtggtgtcgagcacc 
RD562 pforAA-Z Rev AAAAActcgaggaatccctgacgcgccgcg 
RD575 ForK pForM R catcccttgtggtccgccataccggctcccatcggttgc 
RD576 ForK F gcaaccgatgggagccggtatggcggaccacaagggatg 
RD577 ForK R pMS82 CTGGTACCATGCATAGATCTAAGCTTtcagtggtggatggatagaagtgcc 
RD578 pForAA-ForAA F pMS82 gccgagaaccTAGGATCCAAGCTTggcttgaagtccagcacgtcc 
RD579 pForAA-ForAA R pMS82 CTGGTACCATGCATAGATCTAAGCTTtcaccacccttgcgcatgttc 
RD596 S. Kan ForJ 1.1 For gaagggagcggacatatgaagcttGTGATGACGGATGCGCCATG 
RD597 S. Kan ForJ 1.2 Rev CGGCATCAGTTACCGTGAGCCATGTTCGCTCACCTCTGCTGTG 
RD598 S. Kan ForJ Apr For CACAGCAGAGGTGAGCGAACATGGCTCACGGTAACTGATGCCG 
RD599 S. Kan ForJ Apr Rev GACACCTTCTCCAGGAGCGCGTGTAGGCTGGAGCTGCTTC 
RD600 S. Kan ForJ 2.1 For GAAGCAGCTCCAGCCTACACGCGCTCCTGGAGAAGGTGTC 
RD601 S. Kan ForJ 2.2 Rev ctcggtacccggggatcctctagaGCAGATGGCCAAGACCGGCTC 
RD602 pGM1190 Apr ForJ Test For CCTGACCGAACTGGTCATCC 
RD603 pGM1190 Apr ForJ Test Rev CGGATCCGTGCTTCAGGTCG 
RD607 Apr-oriT ForM For atgaacaccctgcaataccgctttgacgggccggaagacGCTCACGGTAACTGATGCCG 
RD608 Apr-oriT ForX Rev ctcctgggtgacgggggcggcttcgacgaggtggagccgTGTAGGCTGGAGCTGCTTC 
RD611 ForM-X Apr Test For catcagtcacgagatgtcac 
RD612 ForM-X Apr Test Rev cgatgaccgatcacgtatcc 
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8.4 Phylogenetic analysis of ForS and similar ABM domain containing proteins  
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8.5 Bioassay images  from CRISPR/Cas9 genome mining project 
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Figure 8.1: Bioassays of whole-cluster deletion mutants were set up against B. subtilis, MRSA, E. coli, C. albicans and L. prolificans.    At least three replicates f each 
assay were set up.  The images presented here are a representative summary of the result for each strain.
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